data_2kxs_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kxs _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.777 0.323 . . . . 0.0 110.751 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 73.5 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.609 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.426 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.41 ' O ' ' N ' ' A' ' 37' ' ' GLY . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.429 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.437 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.435 HG22 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 47' ' ' ILE . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.407 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.609 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 15' ' ' THR . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . 0.413 ' CG2' ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.48 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.458 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.435 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.438 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.591 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.493 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.439 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.418 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.4 ' HG ' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.429 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 16.5 t-160 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.865 0.364 . . . . 0.0 110.955 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.591 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.456 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.5 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.1 m . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.435 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.728 0.299 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.581 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.469 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.41 HG22 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.411 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.401 HG13 ' CG1' ' A' ' 30' ' ' VAL . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.438 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 47' ' ' ILE . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.41 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.581 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 80' ' ' PRO . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 15' ' ' THR . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.427 ' CB ' ' CG1' ' A' ' 142' ' ' VAL . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HB2' HG13 ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.409 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.403 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.436 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.596 ' HG2' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.534 ' N ' ' O ' ' A' ' 130' ' ' ASP . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.452 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.42 ' HG ' ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.411 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.87 0.367 . . . . 0.0 111.071 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.452 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.43 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.44 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.596 ' HB2' ' HG2' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.44 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 3.9 m-85 . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.403 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.427 ' CG1' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.437 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.712 0.291 . . . . 0.0 110.779 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.401 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.402 ' CG2' ' HG2' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.593 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.502 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.449 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' HG22 ' A' ' 34' ' ' ILE . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.402 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.449 ' O ' ' HB3' ' A' ' 26' ' ' SER . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.484 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.593 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.439 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.411 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 80' ' ' PRO . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 15' ' ' THR . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.402 ' HG2' ' CG2' ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.42 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.42 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.466 ' CB ' ' CG1' ' A' ' 142' ' ' VAL . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.446 ' HB2' HG11 ' A' ' 59' ' ' VAL . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.405 ' CD1' ' CG2' ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.436 ' O ' ' N ' ' A' ' 132' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 130' ' ' ASP . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.413 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.451 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.41 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 13.6 t60 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.912 0.386 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.401 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.413 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.442 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.442 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.0 m . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.466 ' CG1' ' CB ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.792 0.329 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.413 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.43 ' CG2' ' HG2' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.434 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.537 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.438 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.418 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.425 HG21 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.472 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.472 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.409 ' HG3' ' O ' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.502 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.48 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 15' ' ' THR . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.43 ' HG2' ' CG2' ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . 0.416 ' ND2' ' N ' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.43 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.429 ' HG ' ' HB2' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.448 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.402 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.442 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.436 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.422 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.418 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 52.7 t-80 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.456 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.2 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.413 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 28.8 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.436 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.429 ' HB2' ' HG ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.417 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.5 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.415 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.425 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.419 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.415 HG13 ' CG1' ' A' ' 30' ' ' VAL . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.431 HG22 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.431 ' HD2' HG22 ' A' ' 47' ' ' ILE . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.5 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.436 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.425 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.407 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . 0.407 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.408 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 146' ' ' SER . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.452 ' HG ' ' HB2' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.473 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.424 ' HB2' HG13 ' A' ' 59' ' ' VAL . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.408 ' HG ' ' CG2' ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.436 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.0 p-80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.444 HD21 ' CZ ' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 130' ' ' ASP . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.424 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.419 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . 0.4 ' CE1' HG23 ' A' ' 142' ' ' VAL . 14.7 t-160 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.919 0.39 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.424 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.469 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.469 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 7.5 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.417 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 5.3 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.473 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 3' ' ' SER . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.452 ' HB2' ' HG ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.407 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.671 0.272 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.423 ' CZ ' HG11 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.426 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.439 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.42 HG21 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.43 ' CG2' HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.419 HG21 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.438 ' O ' ' HB3' ' A' ' 26' ' ' SER . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.478 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.565 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.476 HG11 ' HB2' ' A' ' 80' ' ' PRO . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 15' ' ' THR . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.428 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.428 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.405 ' CD1' ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.476 ' HB2' HG11 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.434 HD11 ' CE1' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.593 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.497 ' N ' ' O ' ' A' ' 130' ' ' ASP . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 37.1 t60 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.827 0.346 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.472 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.593 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.423 HG11 ' CZ ' ' A' ' 9' ' ' PHE . 28.9 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.445 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.407 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.686 0.279 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.422 HD12 ' CD2' ' A' ' 140' ' ' TYR . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.434 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.639 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.417 HG12 ' HG3' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 47' ' ' ILE . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.445 HG21 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.445 ' HD2' HG21 ' A' ' 47' ' ' ILE . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HG3' HG12 ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.443 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' O ' ' A' ' 57' ' ' PHE . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.401 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.466 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.43 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.409 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.451 ' HG2' ' CD1' ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.451 ' CD1' ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.59 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.425 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.453 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.431 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 29.8 t-80 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.844 0.354 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.425 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.469 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.59 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.469 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.8 m-85 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.409 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.422 ' CD2' HD12 ' A' ' 5' ' ' LEU . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' SER . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.417 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.801 0.334 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.444 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.533 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.406 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.438 HG22 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.43 ' CG2' HG13 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.406 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.455 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.405 HG13 ' CG1' ' A' ' 30' ' ' VAL . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.422 HG21 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.422 ' HD2' HG21 ' A' ' 47' ' ' ILE . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.533 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.468 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.417 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.483 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.449 ' O ' ' N ' ' A' ' 132' ' ' PHE . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.441 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.439 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.406 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.439 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.475 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.475 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 5.9 m-85 . . . . . 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.8 m . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.483 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.774 0.321 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.413 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.403 ' HB1' ' CZ ' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.584 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.407 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.458 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.42 HG22 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.42 ' HD2' HG22 ' A' ' 47' ' ' ILE . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.4 ' CG2' ' N ' ' A' ' 52' ' ' GLU . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.472 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.584 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 15' ' ' THR . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.409 ' CD1' HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.41 ' HG2' ' N ' ' A' ' 146' ' ' SER . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.444 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.511 ' HB2' ' HB ' ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.417 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 132' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.601 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.411 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.422 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.407 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.411 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.601 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.511 ' HB ' ' HB2' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.402 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.41 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.842 0.353 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . 0.403 ' HG2' ' CG1' ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.455 ' HB2' HD12 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.616 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.435 ' HA3' HD22 ' A' ' 31' ' ' LEU . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.494 ' CE2' ' HB ' ' A' ' 55' ' ' ILE . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.436 HG22 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 26' ' ' SER . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.415 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.494 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.616 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.521 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' HB2' ' A' ' 80' ' ' PRO . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.436 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.459 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.443 ' HB2' HG13 ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.521 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.433 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.45 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.591 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.519 ' N ' ' O ' ' A' ' 130' ' ' ASP . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.445 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.434 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p . . . . . 0 CA--C 1.523 -0.067 0 CA-C-O 120.975 0.417 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.445 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.442 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.591 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.442 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.2 m-85 . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 N--CA 1.455 -0.189 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.458 HG22 ' N ' ' A' ' 140' ' ' TYR . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.458 ' N ' HG22 ' A' ' 139' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.459 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.436 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.4 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.749 0.309 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' CB ' ' A' ' 35' ' ' GLU . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.469 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.526 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.526 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 37' ' ' GLY . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.401 ' CB ' ' HB3' ' A' ' 18' ' ' ALA . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.409 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.404 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.451 ' HD2' HG23 ' A' ' 47' ' ' ILE . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.469 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.409 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' THR . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.434 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.402 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.415 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.433 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.405 ' CG ' HD11 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.463 HD12 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.722 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.463 ' CE1' HD12 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.425 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.404 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.346 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.48 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.722 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.48 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.1 m-85 . . . . . 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 23.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.434 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.429 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.735 0.302 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.416 ' CZ ' HG13 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.425 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.633 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 47' ' ' ILE . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 37' ' ' GLY . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.419 ' CG2' HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.421 ' N ' ' O ' ' A' ' 96' ' ' GLU . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.412 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.421 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.421 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.633 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.425 ' CE2' ' HB3' ' A' ' 20' ' ' ALA . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.429 HG11 ' HB2' ' A' ' 80' ' ' PRO . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.41 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.429 ' HB2' HG11 ' A' ' 59' ' ' VAL . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.422 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.407 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.596 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.522 ' N ' ' O ' ' A' ' 130' ' ' ASP . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.402 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.423 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.455 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.596 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.455 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.8 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.416 HG13 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.407 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.684 0.278 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.407 HD12 ' CE2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.56 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.509 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.509 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.405 ' CG2' HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.43 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.9 tm0? -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.409 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 26' ' ' SER . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.412 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.491 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.56 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.448 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' PRO . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 15' ' ' THR . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.439 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.425 ' HB2' ' CE1' ' A' ' 101' ' ' HIS . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.439 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HB2' HG11 ' A' ' 59' ' ' VAL . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 15.3 p80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.433 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.429 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.471 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.424 ' HG ' HD22 ' A' ' 97' ' ' LEU . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.43 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.884 0.373 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.452 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.452 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.1 m-85 . . . . . 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 33.4 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.407 ' CE2' HD12 ' A' ' 5' ' ' LEU . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.439 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.409 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.838 0.351 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.431 HD12 ' CD1' ' A' ' 140' ' ' TYR . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.495 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.403 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.434 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.493 ' CD1' ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.424 HG22 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' SER . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.416 ' CG1' ' O ' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.495 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.487 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.417 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.443 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.417 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.458 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.467 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 130' ' ' ASP . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.413 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.434 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . 0.425 ' CD2' HG22 ' A' ' 142' ' ' VAL . 23.0 t-80 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.434 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' N ' ' O ' ' A' ' 89' ' ' LEU . 3.6 m-85 . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.412 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 3.9 m . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.431 ' CD1' HD12 ' A' ' 5' ' ' LEU . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.443 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.426 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 87.4 p . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.764 0.316 . . . . 0.0 111.019 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.401 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.603 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.428 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.418 HG21 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.42 HG22 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.454 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.454 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.471 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.603 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.403 ' N ' ' O ' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 15' ' ' THR . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.434 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.449 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.442 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.429 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.437 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.544 ' N ' ' O ' ' A' ' 130' ' ' ASP . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.6 t60 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.965 0.412 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.401 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.428 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 3.0 m-85 . . . . . 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.449 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.441 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.862 0.363 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.46 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.553 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.406 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.409 HG21 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.401 ' CG2' HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.422 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.456 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.438 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 47' ' ' ILE . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.437 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.553 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.46 ' CE1' ' CB ' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.43 HG11 ' HB2' ' A' ' 80' ' ' PRO . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 15' ' ' THR . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.486 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.43 ' HB2' HG11 ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.404 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.454 ' O ' ' N ' ' A' ' 132' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.494 ' N ' ' O ' ' A' ' 130' ' ' ASP . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.439 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.424 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.405 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.422 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.937 0.398 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' N ' ' O ' ' A' ' 89' ' ' LEU . 8.6 m-85 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.406 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.635 0.255 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.447 HD21 HG13 ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.438 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.591 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.401 ' O ' ' N ' ' A' ' 37' ' ' GLY . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.43 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.437 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.4 HG13 ' CG1' ' A' ' 30' ' ' VAL . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.47 HG21 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.47 ' HD2' HG21 ' A' ' 47' ' ' ILE . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.591 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.438 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.464 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.439 ' N ' ' CG1' ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.2 p80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.433 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.52 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.466 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.449 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.402 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.43 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . 0.404 ' CD2' HG23 ' A' ' 142' ' ' VAL . 50.5 t-80 . . . . . 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.93 0.395 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.466 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.52 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 9.4 m-85 . . . . . 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.464 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.444 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.821 0.343 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.594 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.525 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.525 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.411 ' N ' HG22 ' A' ' 34' ' ' ILE . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.435 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.411 ' CD1' ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.431 HG21 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.431 ' HD2' HG21 ' A' ' 47' ' ' ILE . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' N ' ' A' ' 52' ' ' GLU . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.404 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.594 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.459 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.428 HG13 ' HB2' ' A' ' 80' ' ' PRO . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 15' ' ' THR . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 142' ' ' VAL . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.428 ' HB2' HG13 ' A' ' 59' ' ' VAL . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.435 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.407 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.402 ' CA ' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.454 ' N ' ' CD2' ' A' ' 87' ' ' HIS . 2.6 m170 -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.45 ' CD2' ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.601 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.523 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.445 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.899 0.38 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.414 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.449 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.523 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.601 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 10.7 m . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.407 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.411 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.81 0.338 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.421 ' CE2' HG13 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.443 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.576 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.412 HG23 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.412 ' N ' HG23 ' A' ' 34' ' ' ILE . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.461 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.427 ' N ' ' O ' ' A' ' 96' ' ' GLU . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.442 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 47' ' ' ILE . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.409 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.463 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.576 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.461 ' CD2' ' CD1' ' A' ' 40' ' ' ILE . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 15' ' ' THR . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.485 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.414 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.426 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.438 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.404 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.911 0.386 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.438 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . 0.426 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.451 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.5 m-85 . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . 0.421 HG13 ' CE2' ' A' ' 9' ' ' PHE . 30.0 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.485 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' SER . . . . . 0.409 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.73 0.3 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.403 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.448 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.456 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LEU . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.407 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.419 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.447 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . 0.421 HG21 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 26' ' ' SER . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.415 ' CG1' ' O ' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . 0.401 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.474 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.456 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.447 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.445 HG12 ' HB2' ' A' ' 80' ' ' PRO . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ARG . . . . . 0.448 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.426 ' CD1' ' CD1' ' A' ' 77' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' SER . . . . . 0.433 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . 0.445 ' HB2' HG12 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.437 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' MET . . . . . 0.415 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.455 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.44 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.479 ' N ' ' O ' ' A' ' 130' ' ' ASP . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.452 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.419 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.853 0.359 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.457 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.457 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.4 m-85 . . . . . 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 14.9 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.415 HG12 ' HG2' ' A' ' 83' ' ' MET . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' SER . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.768 0.318 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.6 t -170.89 162.52 7.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p -119.27 154.41 33.5 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.751 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 73.5 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.433 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.609 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.426 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.41 ' O ' ' N ' ' A' ' 37' ' ' GLY . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.429 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.437 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.435 HG22 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.435 ' HD2' HG22 ' A' ' 47' ' ' ILE . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.407 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.426 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.609 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.433 ' HA ' ' O ' ' A' ' 15' ' ' THR . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.413 ' CG2' ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.48 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.458 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.435 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.438 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.591 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.493 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.439 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.418 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.4 ' HG ' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.429 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 16.5 t-160 -109.31 117.71 34.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 13.0 p -95.31 171.81 8.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.986 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.78 161.76 42.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.821 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.425 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 67.2 Cg_endo -73.97 -8.77 21.59 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.62 2.213 . . . . 0.0 112.768 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 3.0 mmmt -65.68 -38.21 88.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.78 0.324 . . . . 0.0 110.937 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 2.0 t -89.3 8.21 31.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.424 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.425 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -48.0 -27.56 2.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.77 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -144.91 16.52 1.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -82.2 142.99 31.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.936 0.398 . . . . 0.0 110.903 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.441 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.8 mtpt -57.64 -21.86 42.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.181 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.441 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 82.85 111.3 0.06 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.102 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.83 151.19 38.84 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.129 -179.25 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.37 -12.36 31.61 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.727 2.285 . . . . 0.0 112.254 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.32 -39.13 96.73 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 17.2 p30 -165.72 59.44 0.6 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 95.8 Cg_endo -80.23 -1.11 11.14 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.468 2.112 . . . . 0.0 112.589 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.436 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 13.3 m-80 -131.12 12.81 5.15 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.097 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.3 -79.97 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.615 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.465 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -87.25 -4.67 59.09 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.851 -179.752 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.436 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 79.2 t -51.12 -28.99 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.96 0.409 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.74 -9.86 9.72 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.283 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.8 -64.39 1.16 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.875 0.369 . . . . 0.0 111.064 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 6.0 m-80 -79.48 58.43 2.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m -81.18 150.45 28.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.955 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.418 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.591 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.456 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.5 m-85 -96.71 120.52 37.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.84 172.92 0.37 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 115.888 -0.596 . . . . 0.0 113.427 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.5 t -131.58 99.66 4.88 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.607 0.241 . . . . 0.0 110.621 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -137.71 174.67 21.71 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.704 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.2 t -59.09 -25.6 63.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.136 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -168.74 46.05 0.22 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.573 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 20.1 m -61.6 87.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.435 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 . . . . . 0 N--CA 1.488 1.43 0 CA-C-O 120.846 0.355 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.42 179.55 4.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.945 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -136.14 161.01 36.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.437 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.581 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.469 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.512 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.512 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.41 HG22 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.411 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.401 HG13 ' CG1' ' A' ' 30' ' ' VAL . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.438 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 47' ' ' ILE . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.41 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.581 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.444 HG13 ' HB2' ' A' ' 80' ' ' PRO . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 15' ' ' THR . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.437 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.427 ' CB ' ' CG1' ' A' ' 142' ' ' VAL . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HB2' HG13 ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.409 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.403 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.417 ' N ' ' HB2' ' A' ' 134' ' ' SER . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.436 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.596 ' HG2' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.534 ' N ' ' O ' ' A' ' 130' ' ' ASP . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.43 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.452 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.42 ' HG ' ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.411 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -134.36 127.5 31.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 17.0 p -93.85 171.75 8.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.21 163.53 67.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.929 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 40.5 Cg_endo -67.03 -14.0 41.94 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.546 2.164 . . . . 0.0 112.588 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 19.0 mmtt -61.58 -38.02 86.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.778 0.323 . . . . 0.0 110.974 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -88.98 8.09 31.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.338 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.434 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.19 -29.24 1.49 Allowed 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.776 0.322 . . . . 0.0 111.508 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.434 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.8 mt-30 -121.09 -30.46 4.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.041 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -49.82 138.9 14.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.07 0.462 . . . . 0.0 111.375 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mtpp -72.95 -21.57 60.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.111 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 14.0 m 88.15 111.02 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.956 -179.148 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.446 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.96 154.55 45.26 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.33 -179.13 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 -11.47 30.76 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.668 2.246 . . . . 0.0 112.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.15 -32.38 82.11 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.528 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.419 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 7.5 t0 -163.78 62.71 1.11 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -83.31 7.77 5.01 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.744 2.296 . . . . 0.0 112.798 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.411 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.9 m-80 -132.61 12.46 4.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.686 0.279 . . . . 0.0 111.233 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.571 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.1 -79.55 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.228 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.469 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -91.8 -2.17 57.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.73 -179.8 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.411 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 83.5 t -51.84 -28.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.91 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -113.68 -10.78 13.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.354 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.42 -71.73 0.39 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.867 0.365 . . . . 0.0 111.24 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -71.4 63.49 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m -88.26 144.74 26.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.071 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.452 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.43 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.44 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.596 ' HB2' ' HG2' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.44 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 3.9 m-85 -96.87 123.3 40.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.19 172.55 0.31 Allowed Glycine 0 C--N 1.331 0.258 0 CA-C-N 115.857 -0.61 . . . . 0.0 113.512 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.417 ' HB2' ' N ' ' A' ' 88' ' ' GLY . 12.2 t -130.06 74.71 1.61 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.838 0.351 . . . . 0.0 110.688 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -113.76 169.86 13.09 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.6 t -69.6 -20.94 63.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.648 0.261 . . . . 0.0 111.128 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -156.23 31.26 0.59 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.003 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 27.3 m -61.08 98.65 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.403 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.427 ' CG1' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.437 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 120.73 0.3 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.2 -168.56 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 110.962 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p -141.22 164.09 31.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.401 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.449 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.402 ' CG2' ' HG2' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.593 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.502 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.449 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.502 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.409 HG22 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.409 ' N ' HG22 ' A' ' 34' ' ' ILE . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.402 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.422 HG22 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.449 ' O ' ' HB3' ' A' ' 26' ' ' SER . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.484 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.593 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.439 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.411 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.446 HG11 ' HB2' ' A' ' 80' ' ' PRO . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.449 ' HA ' ' O ' ' A' ' 15' ' ' THR . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.402 ' HG2' ' CG2' ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.405 ' CG2' ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.42 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.42 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.419 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.466 ' CB ' ' CG1' ' A' ' 142' ' ' VAL . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.446 ' HB2' HG11 ' A' ' 59' ' ' VAL . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.405 ' CD1' ' CG2' ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.4 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.436 ' O ' ' N ' ' A' ' 132' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 130' ' ' ASP . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.413 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.451 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.41 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -140.04 107.77 5.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 9.8 m -75.41 171.88 13.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.122 0.486 . . . . 0.0 111.382 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -65.9 158.39 75.74 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.094 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.407 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 54.0 Cg_endo -69.63 -19.43 36.76 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.173 . . . . 0.0 112.418 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.85 -31.6 72.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 2.8 t -88.84 7.25 35.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.085 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.407 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.3 OUTLIER -50.18 -27.75 6.36 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.554 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -128.48 -21.53 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.541 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -46.21 139.07 4.9 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.959 0.409 . . . . 0.0 111.445 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -62.95 -21.95 66.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.123 179.946 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 82.07 112.38 0.06 Allowed 'General case' 0 N--CA 1.462 0.172 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.015 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.473 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.61 147.0 32.47 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.117 0.484 . . . . 0.0 111.547 -178.799 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -73.88 -6.06 18.0 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 123.03 2.487 . . . . 0.0 112.533 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.33 -26.25 40.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.56 -0.828 . . . . 0.0 112.754 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.453 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.7 p-10 -148.67 57.64 3.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-O 120.764 0.316 . . . . 0.0 111.288 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -83.49 8.27 4.72 Favored 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.575 2.183 . . . . 0.0 112.753 179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -129.57 7.72 5.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.945 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.543 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.86 -24.82 2.67 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.863 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.475 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -167.29 18.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.668 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 9.0 t -63.98 -25.53 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.936 0.398 . . . . 0.0 110.375 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -129.64 8.6 6.16 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.016 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.7 -50.86 5.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.897 0.38 . . . . 0.0 111.288 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -91.16 42.58 1.11 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.02 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m -66.68 162.34 21.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.914 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.401 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.451 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.413 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.442 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.442 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 2.5 m-85 -96.7 136.86 36.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.67 -168.39 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.22 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.456 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.4 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.7 m -91.09 22.21 3.86 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.43 ' HA2' HG23 ' A' ' 138' ' ' VAL . . . 47.79 -151.3 2.4 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.924 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.89 19.61 8.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.624 0.249 . . . . 0.0 111.355 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 166.72 -43.23 0.26 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.529 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.43 HG23 ' HA2' ' A' ' 135' ' ' GLY . 8.0 m -57.03 122.02 5.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.466 ' CG1' ' CB ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.419 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 36.1 m-70 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.808 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -169.66 144.97 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p -103.81 149.45 25.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.826 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.413 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.48 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.43 ' CG2' ' HG2' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.434 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.48 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.502 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.537 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.537 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.438 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.418 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.425 HG21 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.472 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.472 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.409 ' HG3' ' O ' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.502 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.489 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.48 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.41 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.48 ' HA ' ' O ' ' A' ' 15' ' ' THR . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.43 ' HG2' ' CG2' ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.416 ' ND2' ' N ' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.43 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.429 ' HG ' ' HB2' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.448 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.402 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.442 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.436 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.49 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.422 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.418 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 52.7 t-80 -123.06 118.69 28.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.409 ' HB3' ' CD2' ' A' ' 119' ' ' LEU . 14.3 m -97.49 171.8 8.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.07 163.56 60.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.76 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.2 Cg_endo -68.07 -13.23 37.58 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.458 2.105 . . . . 0.0 112.625 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -66.28 -37.06 84.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -89.09 7.95 32.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.38 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.413 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -47.17 -29.86 2.56 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.78 0.324 . . . . 0.0 111.595 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.408 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 23.9 mt-30 -123.48 -27.2 4.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.351 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -46.42 138.81 5.38 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 121.036 0.446 . . . . 0.0 111.469 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.442 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.3 mtpt -69.78 -21.81 63.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.108 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 11.2 m 85.03 107.94 0.05 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.904 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.473 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -88.31 152.07 49.57 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.463 -178.89 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.45 -12.45 31.6 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.867 2.378 . . . . 0.0 112.557 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.61 -35.55 74.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.535 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 30.6 m-20 -155.42 60.91 2.71 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.92 6.84 5.56 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.824 2.35 . . . . 0.0 112.742 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.418 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.4 m-80 -132.36 11.76 4.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.601 0.239 . . . . 0.0 111.291 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.03 -79.77 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.812 0.339 . . . . 0.0 111.304 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.455 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -91.12 -0.71 57.77 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.655 -179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.418 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 91.9 t -54.69 -27.45 18.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.358 . . . . 0.0 110.819 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.94 -3.04 20.18 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.311 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.53 -49.74 6.72 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.881 0.372 . . . . 0.0 111.233 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -93.97 29.69 2.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.253 -179.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.19 158.57 25.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.439 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.456 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.49 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.456 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.2 m-85 -98.27 120.53 38.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.92 170.3 0.04 OUTLIER Glycine 0 C--N 1.332 0.351 0 CA-C-N 115.891 -0.595 . . . . 0.0 113.473 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.57 32.71 4.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.743 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -62.34 -172.85 1.61 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.7 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.3 t -78.37 -27.01 46.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.745 0.307 . . . . 0.0 111.016 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -161.61 41.8 0.39 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.61 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.413 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 28.8 m -57.15 116.69 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.436 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.429 ' HB2' ' HG ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 120.774 0.321 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 p -71.31 -177.02 1.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER -129.67 173.12 10.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.931 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.417 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.5 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.415 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.425 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.419 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.415 HG13 ' CG1' ' A' ' 30' ' ' VAL . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.431 HG22 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.431 ' HD2' HG22 ' A' ' 47' ' ' ILE . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.504 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.5 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.436 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.425 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.409 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.407 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . 0.407 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.408 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.407 ' HG2' ' N ' ' A' ' 146' ' ' SER . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.452 ' HG ' ' HB2' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.473 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.424 ' HB2' HG13 ' A' ' 59' ' ' VAL . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.408 ' HG ' ' CG2' ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.436 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.0 p-80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.43 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.444 HD21 ' CZ ' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 130' ' ' ASP . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.424 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.419 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' O ' ' A' ' 102' ' ' CYS . 14.7 t-160 -129.43 112.51 13.88 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.405 ' O ' ' CD2' ' A' ' 101' ' ' HIS . 24.6 p -79.88 171.91 14.49 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.24 163.38 66.76 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.893 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 41.4 Cg_endo -67.45 -14.74 43.48 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.564 2.176 . . . . 0.0 112.483 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.1 mmtt -60.63 -36.94 79.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.81 0.338 . . . . 0.0 110.818 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.6 t -89.69 8.21 32.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.377 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.419 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.7 OUTLIER -46.5 -29.91 1.98 Allowed 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 120.754 0.311 . . . . 0.0 111.421 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 14.4 mt-30 -126.78 -22.9 3.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.516 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -47.53 138.8 7.51 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.011 0.434 . . . . 0.0 111.456 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.447 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -68.26 -21.58 64.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.066 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.447 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 11.9 m 85.82 110.41 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.109 -179.2 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.438 ' N ' ' CD1' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.92 150.42 40.63 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.28 -179.146 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.31 -10.3 26.87 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.809 2.339 . . . . 0.0 112.516 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -72.06 -40.72 56.1 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.718 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 18.2 m-20 -150.47 58.42 3.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 111.073 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -82.87 5.13 6.61 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.702 2.268 . . . . 0.0 112.695 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.417 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 10.6 m-80 -131.25 12.5 5.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.708 0.289 . . . . 0.0 111.154 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -48.96 -79.82 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.281 -179.737 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.457 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -90.36 -3.45 57.72 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.735 -179.878 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.417 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 89.6 t -51.77 -28.29 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.968 0.413 . . . . 0.0 110.887 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -116.19 -10.13 11.14 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.302 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.17 -68.46 0.61 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.87 0.367 . . . . 0.0 111.299 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.25 59.42 1.01 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.063 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m -82.19 157.43 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.114 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.424 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.469 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.469 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 7.5 m-85 -96.72 135.71 38.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.51 -173.1 0.05 OUTLIER Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.081 -0.58 . . . . 0.0 113.125 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.43 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 0.5 OUTLIER -102.07 45.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.752 0.311 . . . . 0.0 111.336 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 47.44 -132.73 15.12 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.811 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m 68.85 9.87 7.61 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 139.22 -26.82 2.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.57 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.417 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 5.3 m -46.59 122.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.473 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 3' ' ' SER . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.452 ' HB2' ' HG ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.407 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . 0.412 ' O ' ' CD2' ' A' ' 1' ' ' HIS . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.426 0 CA-C-O 121.009 0.433 . . . . 0.0 111.266 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.0 p -88.86 -178.1 5.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.012 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -137.22 165.7 25.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.423 ' CZ ' HG11 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.426 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.439 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.438 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.42 HG21 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.43 ' CG2' HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.419 HG21 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.438 ' O ' ' HB3' ' A' ' 26' ' ' SER . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.448 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.478 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.565 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.476 HG11 ' HB2' ' A' ' 80' ' ' PRO . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.411 ' HA ' ' O ' ' A' ' 15' ' ' THR . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.428 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.428 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.405 ' CD1' ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.445 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.476 ' HB2' HG11 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.434 HD11 ' CE1' ' A' ' 91' ' ' PHE . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.593 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.497 ' N ' ' O ' ' A' ' 130' ' ' ASP . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.435 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 37.1 t60 -128.54 101.35 6.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 6.7 m -68.62 171.88 7.04 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.042 0.449 . . . . 0.0 111.166 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . 0.411 ' HB3' ' HD2' ' A' ' 105' ' ' LYS . 10.2 m-20 -73.35 157.53 87.92 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.075 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.41 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 46.5 Cg_endo -67.95 -12.48 35.42 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.485 2.124 . . . . 0.0 112.113 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . 0.411 ' HD2' ' HB3' ' A' ' 103' ' ' ASP . 10.4 mttt -61.84 -36.5 81.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.932 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 t -89.56 7.95 33.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.15 179.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.416 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.18 -30.35 1.15 Allowed 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.658 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.6 mt-30 -118.56 -31.16 4.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.935 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -49.9 138.27 15.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.09 0.471 . . . . 0.0 111.225 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -68.13 -21.62 64.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.078 179.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 10.8 m 84.69 109.25 0.05 Allowed 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.887 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.478 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -89.84 148.28 39.43 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.418 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -71.82 -9.11 24.29 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.833 2.355 . . . . 0.0 112.449 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.8 -39.61 28.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.693 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.445 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.3 t0 -138.05 57.24 12.46 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.414 ' O ' ' CG2' ' A' ' 120' ' ' VAL . 82.4 Cg_endo -85.39 15.7 2.15 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.602 2.201 . . . . 0.0 112.804 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -129.99 8.06 5.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.024 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.534 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.77 -24.93 2.62 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.714 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.5 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.37 19.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -179.961 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.414 ' CG2' ' O ' ' A' ' 116' ' ' PRO . 44.9 t -68.47 -24.06 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.97 0.414 . . . . 0.0 110.474 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -119.91 -2.59 12.6 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.273 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.65 -68.44 0.69 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.902 0.382 . . . . 0.0 111.024 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.64 61.39 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.891 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p -81.67 146.11 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.086 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.435 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.472 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.593 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.0 m-85 -96.68 115.31 27.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.37 169.59 0.39 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.792 -0.64 . . . . 0.0 113.426 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.46 106.63 7.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.715 0.293 . . . . 0.0 110.437 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.89 -166.66 11.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.699 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -63.84 -27.96 69.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.765 0.316 . . . . 0.0 111.02 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.42 50.47 0.1 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.759 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.423 HG11 ' CZ ' ' A' ' 9' ' ' PHE . 28.9 m -61.41 101.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.445 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.407 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.732 0.301 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.97 -172.48 3.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.894 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p -143.93 147.04 33.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.843 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.422 HD12 ' CD2' ' A' ' 140' ' ' TYR . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.446 ' CZ ' ' CG1' ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.434 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.639 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.417 HG12 ' HG3' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.493 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 47' ' ' ILE . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.493 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.431 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.445 HG21 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.445 ' HD2' HG21 ' A' ' 47' ' ' ILE . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.417 ' HG3' HG12 ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.443 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' O ' ' A' ' 57' ' ' PHE . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.401 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.411 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.466 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.43 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.409 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.451 ' HG2' ' CD1' ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.4 ' CA ' ' HB2' ' A' ' 134' ' ' SER . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.451 ' CD1' ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.59 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.425 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.453 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.431 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 29.8 t-80 -94.38 136.41 34.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 26.0 p -101.19 171.86 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.095 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.43 163.63 60.56 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.027 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.444 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 33.1 Cg_endo -63.97 -14.56 44.05 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.672 2.248 . . . . 0.0 112.622 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.6 mmmt -63.35 -42.9 98.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.918 0.39 . . . . 0.0 110.883 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.43 8.24 31.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.309 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -44.83 -29.66 0.84 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.754 -179.738 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.422 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 26.4 mt-30 -123.15 -28.86 3.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.306 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -47.22 138.4 7.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.947 0.403 . . . . 0.0 111.5 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.465 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.9 mttt -69.74 -21.91 63.42 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.054 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.465 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 4.1 t 86.4 109.36 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.028 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.463 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.52 149.7 41.31 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.41 -179.043 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.31 -10.8 27.75 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.824 2.349 . . . . 0.0 112.444 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.86 -27.36 60.73 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.646 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.7 OUTLIER -153.33 58.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.82 0.343 . . . . 0.0 111.077 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.403 ' O ' ' CG2' ' A' ' 120' ' ' VAL . 93.1 Cg_endo -84.73 14.39 2.48 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.625 2.216 . . . . 0.0 112.853 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -129.12 8.27 5.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.951 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.51 ' CD1' HD12 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.91 -24.6 2.6 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.735 -179.801 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.51 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.87 20.07 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.403 ' CG2' ' O ' ' A' ' 116' ' ' PRO . 48.4 t -69.91 -23.47 25.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.96 0.409 . . . . 0.0 110.485 179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.59 5.05 8.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.254 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.63 -64.54 1.13 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.922 0.391 . . . . 0.0 111.037 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.13 59.52 3.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.722 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.23 148.53 29.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.96 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.453 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.425 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.469 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.59 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.469 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.8 m-85 -96.79 122.49 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.3 171.18 0.03 OUTLIER Glycine 0 C--N 1.331 0.276 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.521 -179.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.4 ' HB2' ' CA ' ' A' ' 88' ' ' GLY . 0.9 OUTLIER -129.82 90.26 2.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.785 0.326 . . . . 0.0 110.818 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -158.77 143.84 9.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.534 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 20.7 p -75.62 62.97 1.5 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.933 0.397 . . . . 0.0 110.691 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 173.18 -33.92 0.12 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.576 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.446 ' CG1' ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m -48.75 103.03 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.409 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.422 ' CD2' HD12 ' A' ' 5' ' ' LEU . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.466 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 3' ' ' SER . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.417 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.778 0.323 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -132.3 160.05 37.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.819 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.31 163.88 16.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.88 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.444 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.438 ' HB2' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.533 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.406 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.48 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.438 HG22 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.43 ' CG2' HG13 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.406 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.455 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.405 HG13 ' CG1' ' A' ' 30' ' ' VAL . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.422 HG21 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.422 ' HD2' HG21 ' A' ' 47' ' ' ILE . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.447 ' HB ' ' CD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.533 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.468 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.417 ' CG2' ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.42 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.483 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.465 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.468 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.449 ' O ' ' N ' ' A' ' 132' ' ' PHE . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.441 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.439 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.406 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -128.39 107.79 10.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 19.5 m -85.93 171.9 11.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.039 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.97 163.48 56.16 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.137 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.422 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 57.1 Cg_endo -70.35 -9.09 25.14 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.661 2.241 . . . . 0.0 112.669 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -68.23 -39.84 82.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.882 0.372 . . . . 0.0 110.983 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 2.0 t -89.33 8.05 32.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.374 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.422 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -47.21 -28.98 2.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.811 0.339 . . . . 0.0 111.443 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -123.49 -29.58 3.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.238 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -47.31 138.34 7.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.008 0.432 . . . . 0.0 111.389 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.468 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -65.98 -21.88 66.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.144 179.831 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.468 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 86.04 112.19 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.125 -179.263 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.429 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.06 149.45 36.9 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.446 -179.182 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.63 -10.41 26.59 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.899 2.399 . . . . 0.0 112.475 179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.94 -36.71 60.94 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.68 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.443 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.1 m-20 -146.33 60.66 6.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 111.151 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -84.05 11.46 3.32 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.554 2.169 . . . . 0.0 112.818 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -131.04 7.89 4.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.013 179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.522 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.03 -25.21 3.17 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.702 -179.768 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.464 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.92 18.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.84 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 25.6 t -68.03 -24.17 29.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 110.4 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.05 5.37 8.32 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.948 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.76 -54.7 3.94 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.99 0.424 . . . . 0.0 111.172 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -91.35 41.61 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.217 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -73.44 157.41 36.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.439 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.441 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.475 ' CG2' ' CE1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.475 ' CE1' ' CG2' ' A' ' 129' ' ' ILE . 5.9 m-85 -96.62 138.24 34.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.04 -164.66 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.436 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.7 t -71.95 -7.24 47.46 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 61.77 15.83 49.47 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.713 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.2 t -98.78 32.2 2.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.029 0.442 . . . . 0.0 110.319 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 151.44 -30.35 0.95 Allowed Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.766 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 8.8 m -55.76 121.76 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.483 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 2.0 p-80 . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.813 0.34 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.2 t -115.84 179.38 4.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.95 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -103.82 148.35 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.952 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.413 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.403 ' HB1' ' CZ ' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.584 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.468 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.407 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.458 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.42 HG22 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.42 ' HD2' HG22 ' A' ' 47' ' ' ILE . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.4 ' CG2' ' N ' ' A' ' 52' ' ' GLU . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.468 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.472 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.584 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.43 ' HA ' ' O ' ' A' ' 15' ' ' THR . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.409 ' CD1' HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.41 ' HG2' ' N ' ' A' ' 146' ' ' SER . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.444 ' CD1' ' N ' ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.511 ' HB2' ' HB ' ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.417 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.445 ' O ' ' N ' ' A' ' 132' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.601 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.411 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.422 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.407 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -123.01 138.48 54.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.7 p -114.05 171.83 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.963 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.72 162.73 71.59 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.438 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 73.4 Cg_endo -75.51 -5.27 16.36 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.581 2.188 . . . . 0.0 112.612 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -65.7 -35.46 80.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.88 8.17 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.221 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.438 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -49.48 -27.58 4.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.787 0.327 . . . . 0.0 111.511 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.01 -23.65 3.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.648 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.0 138.13 6.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.961 0.41 . . . . 0.0 111.484 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -60.44 -21.85 62.77 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.153 179.718 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.412 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 8.3 m 82.45 110.85 0.06 Allowed 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.81 147.89 34.34 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.436 -178.94 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.05 -6.63 19.31 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.986 2.457 . . . . 0.0 112.489 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.88 -37.49 22.39 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.782 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 25.7 p30 -136.84 54.95 9.64 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.702 0.287 . . . . 0.0 111.32 -179.739 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -80.36 -0.46 10.66 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.51 2.14 . . . . 0.0 112.59 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.415 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.7 m-80 -130.84 12.54 5.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.102 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.546 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.1 -79.89 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.521 -179.664 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.47 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -89.0 -2.97 58.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.839 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.415 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 77.0 t -52.86 -28.2 13.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.856 0.36 . . . . 0.0 110.736 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -109.41 -20.88 7.55 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.056 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.67 -64.57 0.86 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.913 0.387 . . . . 0.0 111.109 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.23 61.84 1.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.959 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p -84.77 132.82 34.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.861 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.413 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.422 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.411 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.601 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.5 m-85 -96.84 135.15 39.21 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.57 -173.06 0.07 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 98.4 p -106.98 55.13 0.66 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.367 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 46.38 -128.9 10.74 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.894 179.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 67.69 9.49 7.11 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.534 0.198 . . . . 0.0 111.534 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 129.86 -18.91 5.31 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.379 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 16.6 m -49.55 119.15 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.511 ' HB ' ' HB2' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.402 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.41 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 120.776 0.322 . . . . 0.0 111.364 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.9 m -55.08 173.18 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.147 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p -118.57 174.69 6.11 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.833 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.403 ' HG2' ' CG1' ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.455 ' HB2' HD12 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.616 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.435 ' HA3' HD22 ' A' ' 31' ' ' LEU . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.494 ' CE2' ' HB ' ' A' ' 55' ' ' ILE . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.436 HG22 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.436 ' O ' ' HB3' ' A' ' 26' ' ' SER . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.415 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.494 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.616 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.521 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' HB2' ' A' ' 80' ' ' PRO . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.436 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.459 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.443 ' HB2' HG13 ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.521 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.433 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.45 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.591 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.519 ' N ' ' O ' ' A' ' 130' ' ' ASP . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.445 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.434 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -118.24 128.81 55.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 16.1 m -98.54 171.91 7.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.882 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -72.85 163.45 68.14 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.972 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 55.2 Cg_endo -69.87 -11.57 30.95 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.577 2.184 . . . . 0.0 112.541 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -67.18 -37.11 83.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.921 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.71 8.05 33.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.315 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.43 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -47.81 -28.81 2.75 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 120.797 0.332 . . . . 0.0 111.391 179.977 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.43 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 23.1 mt-30 -126.23 -24.93 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.383 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -46.69 138.77 5.78 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.001 0.429 . . . . 0.0 111.437 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 18.8 mtpt -66.78 -21.79 66.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.07 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.448 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 84.39 109.84 0.06 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.115 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.47 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.91 148.39 36.9 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.398 -178.96 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -72.95 -8.38 22.17 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.97 2.447 . . . . 0.0 112.573 179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.88 -29.03 39.81 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.764 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.7 m-20 -146.3 56.15 3.04 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 120.76 0.314 . . . . 0.0 111.236 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -81.81 6.51 5.62 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.543 2.162 . . . . 0.0 112.643 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -127.8 9.46 6.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.874 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.512 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.87 -25.28 3.04 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.844 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.457 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -164.67 18.03 0.05 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 111.904 0.335 . . . . 0.0 111.904 -179.88 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 24.8 t -68.44 -23.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.962 0.411 . . . . 0.0 110.324 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.91 -0.61 9.8 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.229 179.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.07 -66.16 0.93 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.916 0.388 . . . . 0.0 110.972 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.02 59.14 2.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.705 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p -82.86 148.47 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.434 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.445 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.442 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.591 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.442 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.2 m-85 -96.74 138.13 34.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 -167.79 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.522 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.2 m -88.01 22.1 2.5 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 46.38 -152.57 1.15 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.936 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.8 m 56.74 21.87 6.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 111.29 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 169.61 -46.17 0.21 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.544 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 14.1 m -56.13 125.04 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.458 HG22 ' N ' ' A' ' 140' ' ' TYR . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.458 ' N ' HG22 ' A' ' 139' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.459 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.436 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.4 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 53.3 p-80 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.873 0.368 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -144.09 175.45 10.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.78 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p -135.08 153.71 51.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' CB ' ' A' ' 35' ' ' GLU . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.432 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.469 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.457 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.526 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.526 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 37' ' ' GLY . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.401 ' CB ' ' HB3' ' A' ' 18' ' ' ALA . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.409 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.404 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.451 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.451 ' HD2' HG23 ' A' ' 47' ' ' ILE . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.48 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.469 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.409 ' CG1' ' CG2' ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' THR . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.434 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.402 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.415 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.433 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.405 ' CG ' HD11 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.463 HD12 ' CE1' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.722 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.463 ' CE1' HD12 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.425 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.404 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 -107.27 118.4 36.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 18.5 p -95.38 171.91 8.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.86 163.36 50.46 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.096 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.424 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 60.8 Cg_endo -72.56 -14.51 27.56 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.668 2.246 . . . . 0.0 112.441 179.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.2 mmmt -57.84 -35.6 71.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.831 0.348 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.27 8.16 31.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.254 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.438 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.03 -28.81 1.8 Allowed 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.775 0.321 . . . . 0.0 111.555 -179.851 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.438 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 17.0 mt-30 -121.52 -31.84 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.996 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -48.69 138.12 11.27 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 111.439 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.456 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 3.8 mptt -68.1 -21.57 64.94 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.956 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.456 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 85.18 109.97 0.05 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.788 -179.08 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.455 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.44 148.44 36.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 121.118 0.485 . . . . 0.0 111.436 -178.792 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.22 -8.69 23.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.904 2.403 . . . . 0.0 112.311 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.76 -39.54 33.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.679 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 38.4 p30 -142.8 56.42 4.98 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 120.699 0.285 . . . . 0.0 111.339 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.421 ' HD3' ' N ' ' A' ' 115' ' ' ASP . 69.0 Cg_endo -86.52 18.33 1.59 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.717 2.278 . . . . 0.0 112.781 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.36 8.61 6.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.908 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.546 ' CD1' HD12 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.9 -23.94 2.22 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.621 -179.771 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.546 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -170.84 21.93 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.55 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 116' ' ' PRO . 15.5 t -66.77 -25.92 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.939 0.399 . . . . 0.0 110.382 179.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -123.34 4.64 9.49 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.257 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.82 -42.73 11.1 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.842 0.353 . . . . 0.0 111.076 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -94.65 34.13 1.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.051 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p -59.75 137.56 58.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.044 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.425 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.48 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.722 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.48 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 1.1 m-85 -96.44 107.39 19.78 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.36 168.3 0.02 OUTLIER Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.927 -0.578 . . . . 0.0 113.51 -178.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.4 25.11 11.82 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.612 0.244 . . . . 0.0 111.286 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.433 ' HA3' ' CG1' ' A' ' 138' ' ' VAL . . . -59.92 167.57 8.9 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.45 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 53.0 p -80.83 -20.78 41.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.677 0.275 . . . . 0.0 111.158 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.95 22.13 2.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.979 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.433 ' CG1' ' HA3' ' A' ' 135' ' ' GLY . 23.3 m -58.4 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.434 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.429 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.1 p80 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.844 0.354 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -174.22 150.18 1.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p -128.69 168.04 16.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.416 ' CZ ' HG13 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.474 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.425 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.633 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 47' ' ' ILE . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.406 ' O ' ' N ' ' A' ' 37' ' ' GLY . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.419 ' CG2' HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.406 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.425 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.421 ' N ' ' O ' ' A' ' 96' ' ' GLU . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.412 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.421 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.421 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.487 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.633 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.425 ' CE2' ' HB3' ' A' ' 20' ' ' ALA . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.429 HG11 ' HB2' ' A' ' 80' ' ' PRO . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.41 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.429 ' HB2' HG11 ' A' ' 59' ' ' VAL . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.422 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.407 ' CG ' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.408 ' N ' ' HB3' ' A' ' 134' ' ' SER . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.445 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.596 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.522 ' N ' ' O ' ' A' ' 130' ' ' ASP . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.42 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.423 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.402 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -128.71 131.71 47.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 17.3 p -105.18 171.85 7.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.068 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.38 163.39 58.84 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 62.3 Cg_endo -73.26 -14.72 25.58 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.553 2.168 . . . . 0.0 112.441 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -35.6 72.9 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.2 8.17 31.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.29 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.456 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.68 -28.44 2.41 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.568 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.456 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 14.0 mt-30 -123.43 -30.42 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.28 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.05 138.21 6.86 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.973 0.416 . . . . 0.0 111.352 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.451 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -65.55 -21.8 66.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.07 179.711 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.451 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.9 OUTLIER 84.64 110.79 0.05 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.983 -179.17 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.473 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.7 147.81 34.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.471 -178.972 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.46 -7.9 21.68 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.913 2.409 . . . . 0.0 112.471 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.0 -40.06 22.1 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.859 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.458 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.2 t0 -138.66 55.93 8.9 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.618 0.247 . . . . 0.0 111.342 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.4 ' HD3' ' N ' ' A' ' 115' ' ' ASP . 94.7 Cg_endo -84.44 12.32 3.08 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.595 2.197 . . . . 0.0 112.797 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -128.79 8.24 5.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.758 0.313 . . . . 0.0 111.005 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.83 -24.59 2.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.666 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.496 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.56 20.23 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -179.839 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 20.5 t -67.44 -24.29 31.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.88 0.372 . . . . 0.0 110.48 179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -126.21 4.16 7.79 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.253 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.6 -44.35 10.14 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.945 0.403 . . . . 0.0 111.284 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -95.12 35.64 1.27 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.084 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m -59.84 158.62 10.24 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.09 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.423 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.42 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.455 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.522 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.596 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.455 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.8 m-85 -96.72 116.25 28.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 177.96 0.17 Allowed Glycine 0 C--N 1.33 0.219 0 C-N-CA 121.061 -0.59 . . . . 0.0 113.12 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.408 ' HB3' ' N ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -143.39 96.56 2.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.78 0.324 . . . . 0.0 110.705 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -128.22 -174.11 13.65 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.517 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.7 m -57.78 -27.74 63.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.939 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -169.84 43.9 0.21 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.494 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.416 HG13 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m -57.5 92.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.407 ' CG1' ' CG ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.439 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 38.6 m80 . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.768 0.318 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 78.0 p -161.15 177.95 9.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p -134.62 150.71 50.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.922 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.407 HD12 ' CE2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.56 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.509 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.509 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.405 ' CG2' HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.43 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.9 tm0? -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.409 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.445 ' O ' ' HB3' ' A' ' 26' ' ' SER . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.412 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.491 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.56 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.448 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.444 HG11 ' HB2' ' A' ' 80' ' ' PRO . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 15' ' ' THR . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.439 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.425 ' HB2' ' CE1' ' A' ' 101' ' ' HIS . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.439 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.444 ' HB2' HG11 ' A' ' 59' ' ' VAL . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.448 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.42 ' HA ' ' O ' ' A' ' 134' ' ' SER . 15.3 p80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.433 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.429 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.471 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.424 ' HG ' HD22 ' A' ' 97' ' ' LEU . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.43 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 -106.68 119.33 39.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.407 ' HA ' HD23 ' A' ' 119' ' ' LEU . 72.3 m -85.52 171.8 11.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.009 0.433 . . . . 0.0 111.183 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.56 163.52 67.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.924 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 29.1 Cg_endo -62.69 -16.29 51.99 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.679 2.253 . . . . 0.0 112.555 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 28.9 mmtt -59.84 -37.31 78.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.999 0.428 . . . . 0.0 110.892 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.29 8.12 32.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.254 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.419 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.59 -30.04 1.38 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.753 0.311 . . . . 0.0 111.495 -179.81 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.419 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 2.7 mt-30 -119.44 -31.05 4.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.976 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -50.94 138.23 19.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.028 0.442 . . . . 0.0 111.444 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 15.0 mttt -74.97 -21.6 59.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.031 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.499 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 5.3 t 89.96 109.03 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.886 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.445 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.75 150.68 39.09 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.428 -179.033 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -70.7 -11.68 29.98 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.799 2.333 . . . . 0.0 112.51 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.38 -31.63 71.46 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.661 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.449 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.2 t0 -157.7 60.99 2.1 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.231 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -86.91 20.04 1.29 Allowed 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.753 2.302 . . . . 0.0 112.738 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -127.16 7.8 6.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.825 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.541 ' CD1' HD12 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.86 -23.28 1.83 Allowed 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.689 -179.676 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.541 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -174.78 24.6 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 179.614 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 28.9 t -69.3 -25.01 28.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.761 0.315 . . . . 0.0 110.492 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -114.87 -14.44 8.6 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.28 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.54 -70.17 0.32 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -71.49 63.93 0.41 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -83.54 134.24 34.84 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.105 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.471 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.452 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.452 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.1 m-85 -96.75 133.31 41.48 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.92 -165.48 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.776 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.42 ' O ' ' HA ' ' A' ' 87' ' ' HIS . 28.3 t -62.06 -115.65 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 O-C-N 123.01 -0.112 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.411 ' HA2' ' CG2' ' A' ' 138' ' ' VAL . . . -179.05 -31.05 0.05 OUTLIER Glycine 0 C--N 1.335 0.504 0 C-N-CA 120.226 -0.988 . . . . 0.0 112.864 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.0 p -75.97 57.47 1.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.686 0.279 . . . . 0.0 111.6 -179.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 127.43 27.26 0.99 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.97 179.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.411 ' CG2' ' HA2' ' A' ' 135' ' ' GLY . 33.4 m -129.53 110.91 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.407 ' CE2' HD12 ' A' ' 5' ' ' LEU . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.439 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.409 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.1 p80 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.795 0.331 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.95 -174.51 4.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.87 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p -138.58 148.76 44.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.431 HD12 ' CD1' ' A' ' 140' ' ' TYR . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.412 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.417 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.495 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.532 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.438 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.532 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.403 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.434 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 ' O ' ' HA ' ' A' ' 30' ' ' VAL . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.493 ' CD1' ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.424 HG22 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' SER . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.416 ' CG1' ' O ' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.4 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.495 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.476 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.487 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.417 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.443 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.426 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.417 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.458 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.467 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.505 ' N ' ' O ' ' A' ' 130' ' ' ASP . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.413 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.434 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . 0.425 ' CD2' HG22 ' A' ' 142' ' ' VAL . 23.0 t-80 -120.93 116.08 24.44 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.402 ' HB3' ' CD2' ' A' ' 119' ' ' LEU . 37.3 m -94.5 171.93 8.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -72.58 163.52 67.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.853 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.415 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.9 Cg_endo -64.64 -14.74 46.32 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.687 2.258 . . . . 0.0 112.544 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.5 mmmt -64.35 -40.0 95.01 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 110.912 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -89.27 8.31 31.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.362 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.415 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.75 -28.09 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.831 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -147.1 18.66 1.24 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.824 0.305 . . . . 0.0 111.824 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -79.07 136.87 37.29 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.901 0.382 . . . . 0.0 111.048 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.462 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.5 mttt -59.66 -21.91 61.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.103 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.462 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 85.35 113.12 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.993 -179.242 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.78 154.18 39.93 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.267 -179.211 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.83 -14.39 35.81 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.62 2.214 . . . . 0.0 112.076 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.5 95.09 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.516 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.407 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 33.3 p-10 -174.93 73.91 0.3 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.698 0.285 . . . . 0.0 111.324 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -84.6 9.81 3.99 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.731 2.287 . . . . 0.0 112.68 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.46 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 6.0 m-80 -129.78 15.57 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.113 0.482 . . . . 0.0 110.851 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.575 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.05 -79.73 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.572 -179.681 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.46 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -91.57 2.83 56.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.914 -179.807 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 42.7 t -52.38 -28.98 12.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.802 0.334 . . . . 0.0 110.739 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.03 3.88 10.62 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.35 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.61 -46.22 8.8 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.933 0.397 . . . . 0.0 111.124 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . 0.402 ' O ' ' HB3' ' A' ' 101' ' ' HIS . 1.2 m-80 -92.17 25.14 3.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.356 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p -53.69 157.78 2.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.434 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' N ' ' O ' ' A' ' 89' ' ' LEU . 3.6 m-85 -96.74 134.64 39.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.03 -171.35 0.05 OUTLIER Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.979 -0.555 . . . . 0.0 113.295 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 2.3 m -95.74 32.34 1.87 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.581 0.229 . . . . 0.0 111.534 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.434 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.44 -143.87 5.76 Favored Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.853 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.43 14.26 9.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.578 0.228 . . . . 0.0 111.562 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 157.6 -40.55 0.53 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.577 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.434 HG22 ' HA2' ' A' ' 135' ' ' GLY . 3.9 m -49.68 123.02 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.431 ' CD1' HD12 ' A' ' 5' ' ' LEU . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.443 ' CG1' ' HB2' ' A' ' 79' ' ' SER . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.426 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 3.4 p80 . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.868 0.366 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.5 m -165.76 139.39 4.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.798 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 87.4 p -104.35 143.12 33.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.019 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.401 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.403 ' O ' ' N ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.452 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.603 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.48 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.428 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.418 HG21 HD11 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.42 HG22 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.454 ' HG2' ' CG1' ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.454 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.422 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.48 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.471 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.603 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.403 ' N ' ' O ' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.417 ' HA ' ' O ' ' A' ' 15' ' ' THR . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.434 ' O ' ' HD3' ' A' ' 67' ' ' PRO . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.434 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.449 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.442 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.429 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.437 HD22 ' CZ ' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.544 ' N ' ' O ' ' A' ' 130' ' ' ASP . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.428 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.6 t60 -91.02 127.77 36.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 37.9 m -85.33 171.82 11.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.995 0.426 . . . . 0.0 111.254 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.06 163.6 54.56 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.973 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 32.7 Cg_endo -63.85 -14.83 45.45 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.662 2.241 . . . . 0.0 112.54 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.3 mttt -61.88 -39.61 92.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.916 0.389 . . . . 0.0 110.958 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.35 8.14 32.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.275 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.429 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.53 -28.67 1.49 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.66 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.416 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 11.6 mt-30 -126.13 -26.79 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.537 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -46.98 138.12 6.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.029 0.442 . . . . 0.0 111.405 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.446 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -63.79 -21.83 66.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.033 179.737 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.446 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 5.2 t 83.89 109.82 0.06 Allowed 'General case' 0 N--CA 1.462 0.14 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.061 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.457 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.18 147.51 34.8 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.553 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.75 -6.39 18.56 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 123.055 2.503 . . . . 0.0 112.597 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.35 -31.17 20.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.768 -179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.447 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.3 m-20 -130.74 53.9 13.14 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.732 0.301 . . . . 0.0 111.306 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.414 ' HD3' ' N ' ' A' ' 115' ' ' ASP . 89.6 Cg_endo -82.45 9.51 3.98 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.489 2.126 . . . . 0.0 112.716 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -129.88 6.83 5.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.106 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.533 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.13 -23.93 2.45 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.819 -179.792 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.465 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.05 20.53 0.03 OUTLIER 'General case' 0 C--O 1.233 0.212 0 N-CA-C 111.826 0.306 . . . . 0.0 111.826 179.877 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 13.2 t -68.43 -24.35 29.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.985 0.421 . . . . 0.0 110.472 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -118.3 4.63 15.59 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.104 179.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.67 -70.73 0.65 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.89 0.376 . . . . 0.0 111.13 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.94 61.41 2.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.812 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -77.04 155.82 32.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.173 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.401 ' CG1' ' HB2' ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.428 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 3.0 m-85 -96.73 138.55 34.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.92 -168.21 0.02 OUTLIER Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.586 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 74.5 p -89.73 23.45 2.68 Favored 'General case' 0 C--N 1.333 -0.126 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.443 ' HA2' HG23 ' A' ' 138' ' ' VAL . . . 46.57 -153.85 0.95 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.96 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 58.82 19.97 7.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 111.427 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.77 -46.06 0.24 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.451 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.443 HG23 ' HA2' ' A' ' 135' ' ' GLY . 16.2 m -56.88 119.95 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.449 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.441 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.815 0.341 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -107.99 -169.03 1.45 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.839 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -136.54 152.61 50.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.822 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.424 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.413 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.46 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.553 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.416 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.406 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.409 HG21 HD12 ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.401 ' CG2' HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.422 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.456 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.438 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 47' ' ' ILE . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.437 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.553 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.46 ' CE1' ' CB ' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.413 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.43 HG11 ' HB2' ' A' ' 80' ' ' PRO . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 15' ' ' THR . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.486 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.43 ' HB2' HG11 ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.404 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.454 ' O ' ' N ' ' A' ' 132' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.494 ' N ' ' O ' ' A' ' 130' ' ' ASP . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.439 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.424 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.405 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.422 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 -129.86 99.93 5.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.411 ' HA ' HD22 ' A' ' 119' ' ' LEU . 24.9 p -66.62 171.81 4.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.427 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -75.85 163.65 65.59 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.023 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.449 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 36.6 Cg_endo -64.95 -10.98 27.46 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.663 2.242 . . . . 0.0 112.771 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 14.1 mmtt -71.43 -40.5 70.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 110.981 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -97.12 8.31 44.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.295 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.449 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -45.32 -28.64 0.87 Allowed 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.715 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 -125.98 -26.23 3.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.412 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -46.86 138.35 6.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.048 0.451 . . . . 0.0 111.475 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -62.12 -21.94 65.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 179.878 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.448 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.5 OUTLIER 84.9 111.9 0.05 Allowed 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.182 -179.275 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.44 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.69 152.4 39.8 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.269 -179.212 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.77 -13.2 31.94 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.72 2.28 . . . . 0.0 112.333 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.31 -31.0 77.71 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.549 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.446 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.1 m-20 -165.51 62.21 0.81 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.84 0.353 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -83.92 11.68 3.24 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.6 2.2 . . . . 0.0 112.825 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -128.97 9.04 5.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.92 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.508 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.84 -25.35 3.05 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.757 -179.821 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.468 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -166.1 17.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.872 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 52.3 t -69.09 -23.91 27.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 121.008 0.432 . . . . 0.0 110.175 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -124.16 -1.11 8.76 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.26 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.02 -65.43 1.01 Allowed 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.931 0.396 . . . . 0.0 110.984 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.82 59.8 1.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.679 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m -82.87 150.08 26.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.439 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' N ' ' O ' ' A' ' 89' ' ' LEU . 8.6 m-85 -96.75 133.93 40.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -60.94 -151.76 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.782 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -75.69 -24.17 56.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.794 0.33 . . . . 0.0 111.41 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.489 ' HA2' HG23 ' A' ' 138' ' ' VAL . . . 82.46 -53.93 4.85 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.803 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 12.4 t -52.67 -24.3 8.26 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -124.29 -9.63 5.45 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.419 -0.896 . . . . 0.0 113.109 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.489 HG23 ' HA2' ' A' ' 135' ' ' GLY . 2.4 m -110.99 126.84 68.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.938 0.369 . . . . 0.0 111.018 -179.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.486 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.406 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.636 0.255 . . . . 0.0 111.458 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.8 p -113.32 178.33 4.32 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.804 0.335 . . . . 0.0 110.998 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p -136.42 158.11 45.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.447 HD21 HG13 ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.438 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.591 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.447 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.531 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.401 ' O ' ' N ' ' A' ' 37' ' ' GLY . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.43 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.437 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.4 HG13 ' CG1' ' A' ' 30' ' ' VAL . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.47 HG21 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.47 ' HD2' HG21 ' A' ' 47' ' ' ILE . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.591 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.438 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.435 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 81' ' ' LEU . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.464 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.439 ' N ' ' CG1' ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.413 ' O ' ' HA ' ' A' ' 59' ' ' VAL . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.427 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.2 p80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.433 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.52 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.466 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.449 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.402 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.43 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . 0.404 ' CD2' HG23 ' A' ' 142' ' ' VAL . 50.5 t-80 -112.26 128.74 56.35 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.3 m -99.74 171.83 7.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.011 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.3 163.54 66.6 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.3 Cg_endo -64.58 -13.08 36.78 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.61 2.206 . . . . 0.0 112.677 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.91 -42.25 63.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.842 0.353 . . . . 0.0 110.984 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.416 ' HA ' ' HB2' ' A' ' 109' ' ' ASN . 1.8 t -94.76 8.31 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.329 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.06 -28.22 1.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.869 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.427 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 8.2 mt-30 -147.04 17.76 1.23 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.636 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.416 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 3.8 t-20 -76.13 142.49 41.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.933 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.415 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -56.99 -22.0 35.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.195 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 8.1 m 82.15 111.82 0.06 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.118 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.457 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.71 154.83 39.88 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.265 -179.244 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 -16.04 36.67 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.642 2.228 . . . . 0.0 112.281 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.78 -35.25 85.79 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.333 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.438 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 6.9 t0 -176.12 67.24 0.24 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.943 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -81.12 5.85 5.97 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.668 2.245 . . . . 0.0 112.879 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.451 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.4 m-80 -130.53 14.08 5.47 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.909 0.385 . . . . 0.0 111.007 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.08 -79.88 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.563 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.477 HD12 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -90.36 -1.88 57.94 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.929 -179.694 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.451 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 70.4 t -51.46 -29.2 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.963 0.411 . . . . 0.0 110.673 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.36 -9.32 10.5 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.34 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -76.44 -68.45 0.59 Allowed 'General case' 0 C--O 1.232 0.172 0 CA-C-O 120.835 0.35 . . . . 0.0 111.241 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -78.9 59.84 2.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.853 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m -80.11 160.6 25.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.105 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.449 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.466 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.52 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.446 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 9.4 m-85 -96.86 139.1 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.44 -167.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 116.0 -0.546 . . . . 0.0 113.497 -179.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 87.0 p -87.58 21.38 2.57 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.447 ' HA2' HG23 ' A' ' 138' ' ' VAL . . . 47.28 -154.12 1.18 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.934 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.5 p 58.85 20.14 7.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.626 0.25 . . . . 0.0 111.429 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.72 -43.92 0.24 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.525 -0.845 . . . . 0.0 112.304 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.447 HG23 ' HA2' ' A' ' 135' ' ' GLY . 11.9 m -59.85 121.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.464 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.444 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.915 0.388 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.9 131.36 7.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.89 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -105.25 146.74 28.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.929 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.594 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.525 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.525 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.411 HG22 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.411 ' N ' HG22 ' A' ' 34' ' ' ILE . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.445 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.435 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.411 ' CD1' ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.431 HG21 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.431 ' HD2' HG21 ' A' ' 47' ' ' ILE . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.404 ' CG2' ' N ' ' A' ' 52' ' ' GLU . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.404 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.594 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' A' ' 20' ' ' ALA . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.459 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.428 HG13 ' HB2' ' A' ' 80' ' ' PRO . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 15' ' ' THR . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.437 ' HB3' ' CG1' ' A' ' 142' ' ' VAL . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.428 ' HB2' HG13 ' A' ' 59' ' ' VAL . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.435 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.407 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.402 ' CA ' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.454 ' N ' ' CD2' ' A' ' 87' ' ' HIS . 2.6 m170 -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.425 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.45 ' CD2' ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.601 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.523 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.455 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.445 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -101.29 100.02 10.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.411 ' HA ' HD21 ' A' ' 119' ' ' LEU . 14.6 p -75.83 171.85 13.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.007 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.32 163.44 58.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.949 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.421 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.2 Cg_endo -66.21 -13.05 38.14 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.653 2.236 . . . . 0.0 112.608 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.0 mmtt -66.98 -42.35 85.23 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.958 0.409 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.87 8.47 31.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.335 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.421 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.08 -28.18 1.13 Allowed 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.654 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.421 ' HG3' ' CG ' ' A' ' 107' ' ' TRP . 12.9 mt-30 -150.45 21.61 0.83 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -78.1 145.51 35.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.864 0.364 . . . . 0.0 110.999 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.429 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 73.4 mttt -58.64 -21.94 55.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.224 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.429 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 0.6 OUTLIER 82.24 111.43 0.06 Allowed 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.953 0.406 . . . . 0.0 109.988 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.432 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.82 153.66 39.99 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.263 -179.248 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.92 -14.35 35.48 Favored 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.615 2.21 . . . . 0.0 112.111 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.77 -41.13 95.8 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.543 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.413 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.2 OUTLIER -174.03 74.41 0.35 Allowed Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.89 0.376 . . . . 0.0 111.188 -179.916 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -82.74 4.27 7.21 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.644 2.23 . . . . 0.0 112.484 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . 0.44 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 10.7 m-80 -131.01 13.86 5.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.811 0.339 . . . . 0.0 111.007 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.577 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.18 -80.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.383 -179.686 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.456 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -88.41 -5.15 58.45 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.731 -179.987 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.44 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 94.9 t -51.52 -28.23 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.983 0.42 . . . . 0.0 110.756 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.22 -11.66 10.57 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.263 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.2 -58.7 3.13 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.921 0.391 . . . . 0.0 111.219 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.84 49.87 1.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.112 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m -72.85 171.83 11.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.275 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.414 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.449 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.523 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.601 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.449 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 2.0 m-85 -96.82 134.62 39.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.73 -173.46 0.06 OUTLIER Glycine 0 C--N 1.332 0.311 0 C-N-CA 121.021 -0.609 . . . . 0.0 113.225 -179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.425 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.5 p -102.54 50.38 0.83 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.349 . . . . 0.0 111.414 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.427 ' HA2' ' CG2' ' A' ' 138' ' ' VAL . . . 46.47 -128.86 10.91 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.818 -0.706 . . . . 0.0 113.024 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 133.65 -20.48 4.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.427 ' CG2' ' HA2' ' A' ' 135' ' ' GLY . 10.7 m -50.56 119.75 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.407 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.437 ' CG1' ' HB3' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.411 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.775 0.322 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.6 p -115.91 129.5 56.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.924 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p -89.93 154.08 20.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.825 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.421 ' CE2' HG13 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.443 ' CB ' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.576 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.45 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.412 HG23 ' N ' ' A' ' 35' ' ' GLU . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.412 ' N ' HG23 ' A' ' 34' ' ' ILE . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.461 ' CD1' ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.427 ' N ' ' O ' ' A' ' 96' ' ' GLU . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.442 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 47' ' ' ILE . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.409 ' CG1' ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.45 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.463 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.576 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.461 ' CD2' ' CD1' ' A' ' 40' ' ' ILE . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . 0.437 ' HA ' ' O ' ' A' ' 15' ' ' THR . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.428 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.485 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.414 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.412 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.404 ' N ' ' HB3' ' A' ' 134' ' ' SER . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.454 HD22 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.426 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.438 ' HB3' ' CG1' ' A' ' 127' ' ' VAL . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.404 ' CD1' ' CD2' ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.413 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -132.08 114.66 14.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 12.8 m -87.93 171.87 10.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.289 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -71.33 163.53 65.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.022 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.3 Cg_endo -67.96 -12.63 35.89 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.606 2.204 . . . . 0.0 112.618 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.9 mmtt -66.1 -38.66 88.8 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.809 0.338 . . . . 0.0 110.869 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.27 8.17 31.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.268 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -46.54 -29.66 1.89 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.871 0.367 . . . . 0.0 111.532 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -122.45 -28.91 4.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -47.24 138.17 7.41 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.112 0.482 . . . . 0.0 111.453 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.439 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -68.41 -21.59 64.67 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.048 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.439 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 10.6 m 84.69 113.24 0.05 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.473 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.6 149.53 36.66 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.461 -178.827 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.28 -11.45 28.7 Favored 'Trans proline' 0 N--CA 1.465 -0.193 0 C-N-CA 122.909 2.406 . . . . 0.0 112.21 179.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -68.96 -36.92 82.62 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.621 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.455 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.7 m-20 -156.37 65.12 3.86 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.711 0.291 . . . . 0.0 111.231 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.407 ' O ' ' CG2' ' A' ' 120' ' ' VAL . 86.8 Cg_endo -85.48 16.91 1.86 Allowed 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.728 2.285 . . . . 0.0 112.77 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -128.76 10.76 6.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.779 179.618 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.486 ' CD1' HD11 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.98 -25.2 3.1 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.612 -179.676 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.486 HD11 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.8 19.32 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.407 ' CG2' ' O ' ' A' ' 116' ' ' PRO . 10.3 t -64.81 -26.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.913 0.387 . . . . 0.0 110.286 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.37 2.56 10.44 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.18 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -86.63 -45.26 11.19 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.902 0.382 . . . . 0.0 111.067 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -95.08 30.81 2.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.041 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p -57.77 157.42 7.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.051 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.438 ' CG1' ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . 0.426 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.451 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.451 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 6.5 m-85 -96.78 118.87 34.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.71 174.49 0.66 Allowed Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.191 -179.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.404 ' HB3' ' N ' ' A' ' 88' ' ' GLY . 7.5 p -140.59 108.11 5.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.792 0.33 . . . . 0.0 110.626 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.12 -172.39 13.56 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.626 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.63 -27.43 66.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 110.987 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.74 48.19 0.17 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.56 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.421 HG13 ' CE2' ' A' ' 9' ' ' PHE . 30.0 m -61.24 93.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.485 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . . . . . . . . . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . 0.428 ' O ' ' HA ' ' A' ' 75' ' ' GLU . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' SER . . . . . 0.409 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.6 m80 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.785 0.326 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.79 179.45 8.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER -138.24 153.93 49.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.949 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.403 ' HB2' ' CG1' ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.448 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.456 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.51 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.422 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . 0.51 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.407 ' CG2' ' CG1' ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.419 ' CG2' ' CD ' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.447 ' CD1' ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . 0.421 HG21 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.422 ' O ' ' HB2' ' A' ' 26' ' ' SER . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.415 ' CG1' ' O ' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.401 ' N ' ' CG2' ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.474 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.456 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.447 ' CD1' ' CD1' ' A' ' 40' ' ' ILE . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.445 HG12 ' HB2' ' A' ' 80' ' ' PRO . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ARG . . . . . 0.448 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.426 ' CD1' ' CD1' ' A' ' 77' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 142' ' ' VAL . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.433 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . 0.445 ' HB2' HG12 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.437 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' MET . . . . . 0.415 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.407 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.455 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.44 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.479 ' N ' ' O ' ' A' ' 130' ' ' ASP . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.452 ' HB3' ' HB ' ' A' ' 127' ' ' VAL . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.419 ' CD ' ' CG2' ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 -117.33 111.67 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 87.8 m -94.73 171.87 8.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.953 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -66.34 163.49 39.25 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.986 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.7 Cg_endo -66.64 -11.65 32.68 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.551 2.167 . . . . 0.0 112.637 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -67.42 -37.13 82.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 110.922 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -94.05 8.25 42.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.355 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -46.21 -29.15 1.47 Allowed 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 120.723 0.296 . . . . 0.0 111.447 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLN . . . . . 0.407 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 26.9 mt-30 -122.81 -29.72 3.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.219 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -50.15 138.43 16.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.997 0.427 . . . . 0.0 111.366 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.45 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mttp -69.61 -21.63 63.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.064 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.45 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 14.0 m 87.39 111.9 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.904 -179.173 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.44 ' N ' ' CD1' ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.61 154.12 42.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.27 -179.181 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.32 -15.05 34.93 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.67 2.246 . . . . 0.0 112.44 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.84 -29.17 74.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.407 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ASP . . . . . 0.464 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 21.5 t0 -165.61 63.46 0.9 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.756 0.312 . . . . 0.0 111.039 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.41 ' O ' ' CG2' ' A' ' 120' ' ' VAL . 95.8 Cg_endo -86.24 12.84 2.9 Favored 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.655 2.237 . . . . 0.0 112.831 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -131.55 13.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.867 0.365 . . . . 0.0 110.784 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' TYR . . . . . 0.506 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.84 -26.55 4.12 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.505 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.45 ' CD1' ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -160.12 16.54 0.14 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.523 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . 0.41 ' CG2' ' O ' ' A' ' 116' ' ' PRO . 5.5 t -62.95 -26.78 41.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.318 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -111.1 -18.82 7.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.01 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.96 -73.59 0.13 Allowed 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.919 0.39 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -73.07 63.44 0.68 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.895 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m -86.21 133.69 33.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' VAL . . . . . 0.452 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.457 ' CD1' ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.457 ' CZ ' ' CD1' ' A' ' 129' ' ' ILE . 5.4 m-85 -96.65 130.61 43.84 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.34 -174.27 0.05 OUTLIER Glycine 0 C--N 1.331 0.262 0 C-N-CA 121.007 -0.616 . . . . 0.0 113.097 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.1 m -100.38 49.97 0.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.368 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.401 ' HA2' ' CG2' ' A' ' 138' ' ' VAL . . . 47.43 -132.44 15.12 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.819 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 67.26 9.86 7.28 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 138.08 -23.79 3.01 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.846 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' VAL . . . . . 0.401 ' CG2' ' HA2' ' A' ' 135' ' ' GLY . 14.9 m -49.29 118.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.415 HG12 ' HG2' ' A' ' 83' ' ' MET . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.437 ' O ' ' HG ' ' A' ' 77' ' ' LEU . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 3' ' ' SER . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' ARG . . . . . . . . . . . . . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.777 0.323 . . . . 0.0 110.751 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.808 HD13 ' N ' ' A' ' 6' ' ' GLU . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.808 ' N ' HD13 ' A' ' 5' ' ' LEU . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.472 ' OE1' HG11 ' A' ' 139' ' ' VAL . 23.1 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.684 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.565 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.892 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.852 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.463 ' HB2' ' HB2' ' A' ' 33' ' ' SER . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.65 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.581 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.94 HG21 HG11 ' A' ' 59' ' ' VAL . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.54 HG22 ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.543 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.581 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.428 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.588 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.864 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.864 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.482 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.581 HD12 ' HD2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.65 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.713 ' HB2' HG13 ' A' ' 82' ' ' VAL . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.852 ' HG3' HG23 ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.94 HG11 HG21 ' A' ' 36' ' ' THR . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.684 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.565 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.447 HD13 HD21 ' A' ' 81' ' ' LEU . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.688 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 8' ' ' LEU . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.681 HG23 ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.759 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.637 ' O ' HD23 ' A' ' 77' ' ' LEU . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 140' ' ' TYR . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.404 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . 0.531 ' SG ' HG23 ' A' ' 138' ' ' VAL . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.6 m80 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.481 HD21 ' CE1' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.5 ' HE1' HD11 ' A' ' 55' ' ' ILE . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.474 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.659 HG12 HG23 ' A' ' 42' ' ' ILE . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.609 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.515 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.54 ' CD ' HG22 ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' HB2' ' A' ' 78' ' ' LEU . 16.5 t-160 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.865 0.364 . . . . 0.0 110.955 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.542 HG11 HD23 ' A' ' 5' ' ' LEU . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.594 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.474 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.962 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.962 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.5 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.641 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 20.1 m . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 82' ' ' VAL . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.475 ' O ' HD23 ' A' ' 81' ' ' LEU . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 78' ' ' LEU . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.544 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.648 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.728 0.299 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.867 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.867 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.629 HD13 ' HA3' ' A' ' 141' ' ' GLY . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.704 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.698 HG22 ' SG ' ' A' ' 60' ' ' CYS . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.688 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.964 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.784 HG23 ' HG3' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.721 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.059 HG21 HG11 ' A' ' 59' ' ' VAL . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.614 ' CG2' HD23 ' A' ' 99' ' ' LEU . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.593 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.6 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.625 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.594 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.878 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.878 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.547 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.617 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.684 ' HB2' HG13 ' A' ' 82' ' ' VAL . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.784 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.059 HG11 HG21 ' A' ' 36' ' ' THR . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.698 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.688 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.45 ' OD1' HD11 ' A' ' 65' ' ' ILE . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASN . . . . . 0.537 HD22 ' HB2' ' A' ' 61' ' ' ARG . 1.2 p30 -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.83 HG21 HD22 ' A' ' 81' ' ' LEU . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.713 ' O ' HD23 ' A' ' 66' ' ' LEU . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.425 ' HA ' HD23 ' A' ' 8' ' ' LEU . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 76' ' ' THR . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.828 HG22 ' HD2' ' A' ' 144' ' ' ARG . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.923 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.723 ' O ' HD23 ' A' ' 77' ' ' LEU . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.407 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.83 HD22 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.684 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.537 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.54 HD21 ' CE1' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.547 ' HE1' HD11 ' A' ' 55' ' ' ILE . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.625 HG12 HG23 ' A' ' 42' ' ' ILE . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.617 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.432 ' HD2' HD13 ' A' ' 41' ' ' ILE . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.614 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 142' ' ' VAL . 44.4 t-80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.87 0.367 . . . . 0.0 111.071 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.619 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.61 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.937 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.937 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.9 m-85 . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.704 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.3 m . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.537 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.656 ' HD1' HD11 ' A' ' 5' ' ' LEU . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.629 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.431 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.923 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.712 0.291 . . . . 0.0 110.779 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.679 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.964 HD23 HG11 ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.688 ' N ' HD13 ' A' ' 5' ' ' LEU . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.526 HD23 ' HA ' ' A' ' 67' ' ' PRO . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.684 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.71 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.679 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.535 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.901 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 21' ' ' ARG . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.816 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.072 HG21 HG11 ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.596 HG22 ' HD2' ' A' ' 100' ' ' PRO . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.58 HD12 ' CD1' ' A' ' 57' ' ' PHE . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.679 HG23 HG12 ' A' ' 95' ' ' VAL . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.589 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.799 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.799 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.623 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.637 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.777 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.072 HG11 HG21 ' A' ' 36' ' ' THR . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.679 ' SG ' HG22 ' A' ' 16' ' ' VAL . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.535 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.85 HG21 ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.71 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.526 ' HA ' HD23 ' A' ' 8' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.488 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.478 HG22 ' NE ' ' A' ' 144' ' ' ARG . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.881 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.737 ' O ' HD23 ' A' ' 77' ' ' LEU . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.85 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG13 ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.2 p-80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.605 HD21 ' CE1' ' A' ' 91' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.605 ' CE1' HD21 ' A' ' 89' ' ' LEU . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.679 HG12 HG23 ' A' ' 42' ' ' ILE . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 41' ' ' ILE . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.637 ' C ' HD23 ' A' ' 97' ' ' LEU . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.635 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HD2' HG22 ' A' ' 38' ' ' VAL . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.5 ' CE1' HG21 ' A' ' 142' ' ' VAL . 13.6 t60 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.912 0.386 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.964 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.592 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.932 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.684 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 8.0 m . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.603 HG12 ' O ' ' A' ' 82' ' ' VAL . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.406 ' OH ' HG12 ' A' ' 129' ' ' ILE . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.488 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.501 HG12 ' N ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.881 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.792 0.329 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.622 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.799 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.599 HD12 ' N ' ' A' ' 8' ' ' LEU . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.833 ' OE1' HG22 ' A' ' 65' ' ' ILE . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.631 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.742 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.818 HG23 ' HG3' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.467 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.497 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.531 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.607 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.648 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.052 HG21 HG11 ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.576 HG22 ' HD2' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.522 HD12 ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.549 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.661 HG23 HG12 ' A' ' 95' ' ' VAL . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.618 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.78 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.78 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.418 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.497 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.607 ' CE1' HD23 ' A' ' 31' ' ' LEU . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.818 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.052 HG11 HG21 ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.631 ' SG ' HG22 ' A' ' 16' ' ' VAL . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.742 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASN . . . . . 0.711 HD22 ' HB2' ' A' ' 61' ' ' ARG . 0.1 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.867 HG21 ' HG ' ' A' ' 81' ' ' LEU . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.415 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.686 HG22 ' HD2' ' A' ' 144' ' ' ARG . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.487 HD13 HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.738 HD11 ' HG3' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.452 ' HB2' HG12 ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.468 ' HB2' HG13 ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.867 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.457 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.481 ' HG2' HD23 ' A' ' 89' ' ' LEU . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.482 ' C ' HD12 ' A' ' 89' ' ' LEU . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.463 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.661 HG12 HG23 ' A' ' 42' ' ' ILE . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.587 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.514 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.44 ' HB2' HG23 ' A' ' 125' ' ' VAL . 83.0 t60 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.715 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.961 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.961 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.2 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.8 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.457 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.715 ' HE2' HG21 ' A' ' 127' ' ' VAL . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.452 HG12 ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.622 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.738 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.695 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.679 HD23 HG11 ' A' ' 125' ' ' VAL . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.582 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.578 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.619 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.539 ' CG ' HG11 ' A' ' 139' ' ' VAL . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.525 HG22 ' SG ' ' A' ' 60' ' ' CYS . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.851 HG23 ' HG3' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.513 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.562 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.037 HG21 HG11 ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.575 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.609 HG12 HD12 ' A' ' 97' ' ' LEU . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.615 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.674 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.547 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.853 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.853 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.552 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' HD12 ' A' ' 40' ' ' ILE . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.851 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.037 HG11 HG21 ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.525 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.864 HG21 ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.578 ' HA ' HD23 ' A' ' 8' ' ' LEU . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.433 HD13 ' N ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.43 ' O ' ' HB ' ' A' ' 76' ' ' THR . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.622 HG22 ' HE ' ' A' ' 144' ' ' ARG . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.721 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.836 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.48 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.864 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.518 ' O ' HG12 ' A' ' 139' ' ' VAL . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.4 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 22.5 p80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.526 HD21 ' CE1' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.552 ' HE1' HD11 ' A' ' 55' ' ' ILE . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.674 HG12 HG23 ' A' ' 42' ' ' ILE . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.609 HD12 HG12 ' A' ' 40' ' ' ILE . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.509 ' CD2' HG21 ' A' ' 142' ' ' VAL . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.919 0.39 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.679 HG11 HD23 ' A' ' 5' ' ' LEU . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.956 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.956 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 7.5 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 5.3 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.539 HG11 ' CG ' ' A' ' 10' ' ' GLN . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.617 ' HD1' HD11 ' A' ' 5' ' ' LEU . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.509 HG21 ' CD2' ' A' ' 101' ' ' HIS . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.695 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.836 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.419 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.671 0.272 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.733 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.895 HD23 HG11 ' A' ' 125' ' ' VAL . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.467 ' N ' HD13 ' A' ' 5' ' ' LEU . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.586 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.575 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.491 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.95 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.809 HG22 ' HD2' ' A' ' 21' ' ' ARG . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.809 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.531 HD23 ' CE1' ' A' ' 57' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.085 HG21 HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.58 HG22 ' HD2' ' A' ' 100' ' ' PRO . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.51 HD12 ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.566 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.795 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.603 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.743 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.743 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.608 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.751 ' HB2' HG13 ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.734 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.085 HG11 HG21 ' A' ' 36' ' ' THR . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.491 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.1 p-10 -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.63 HD13 HD11 ' A' ' 81' ' ' LEU . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.73 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.586 ' HA ' HD23 ' A' ' 8' ' ' LEU . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.472 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.444 ' O ' ' HB ' ' A' ' 76' ' ' THR . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.527 HG22 ' NE ' ' A' ' 144' ' ' ARG . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.902 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.768 ' O ' HD23 ' A' ' 77' ' ' LEU . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.458 ' HB2' HG13 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.63 HD11 HD13 ' A' ' 65' ' ' ILE . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.881 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.875 ' HG2' HD12 ' A' ' 89' ' ' LEU . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.875 HD12 ' HG2' ' A' ' 86' ' ' PRO . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.513 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.795 HG12 HG23 ' A' ' 42' ' ' ILE . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.757 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.757 ' N ' HD23 ' A' ' 97' ' ' LEU . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.559 HD21 HG21 ' A' ' 82' ' ' VAL . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' HG22 ' A' ' 38' ' ' VAL . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.78 ' ND1' HG21 ' A' ' 142' ' ' VAL . 37.1 t60 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.827 0.346 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.895 HG11 HD23 ' A' ' 5' ' ' LEU . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.927 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.593 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.9 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.881 HG12 ' HA ' ' A' ' 83' ' ' MET . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.441 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.78 HG21 ' ND1' ' A' ' 101' ' ' HIS . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.902 ' HG3' HD11 ' A' ' 78' ' ' LEU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.686 0.279 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.668 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.764 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.711 HD23 ' HD2' ' A' ' 68' ' ' PRO . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.774 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.473 HG22 ' SG ' ' A' ' 60' ' ' CYS . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.556 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.82 HG22 ' HD2' ' A' ' 21' ' ' ARG . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.537 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.82 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.538 ' HD2' HD12 ' A' ' 55' ' ' ILE . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.748 HD23 ' CD2' ' A' ' 57' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.464 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.875 HG21 HG11 ' A' ' 59' ' ' VAL . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.572 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.665 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.659 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.859 ' HG2' HG11 ' A' ' 51' ' ' VAL . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.859 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.496 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.538 HD12 ' HD2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.748 ' CD2' HD23 ' A' ' 31' ' ' LEU . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.732 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.941 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.473 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.556 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.1 p-10 -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.92 HG21 ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.711 ' HD2' HD23 ' A' ' 8' ' ' LEU . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.628 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.539 HD22 HD22 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.84 HD11 ' HG3' ' A' ' 144' ' ' ARG . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.464 ' HB2' HG12 ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.452 ' HB2' HG13 ' A' ' 59' ' ' VAL . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.92 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.581 HG22 HG22 ' A' ' 59' ' ' VAL . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.443 ' CG ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.869 ' HG2' HD12 ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.869 HD12 ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.664 ' N ' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 129' ' ' ILE . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' HA ' HD23 ' A' ' 128' ' ' LEU . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.629 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HD2' HD13 ' A' ' 41' ' ' ILE . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.59 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.559 ' CD ' HG22 ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 77.5 t60 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.844 0.354 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.629 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.939 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.597 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.939 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.8 m-85 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.774 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.443 HG12 ' CG ' ' A' ' 83' ' ' MET . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.488 ' HE2' HG11 ' A' ' 127' ' ' VAL . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.464 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.84 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.801 0.334 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.044 HD23 HG11 ' A' ' 125' ' ' VAL . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.686 ' N ' HD13 ' A' ' 5' ' ' LEU . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.406 ' CG ' HG11 ' A' ' 139' ' ' VAL . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.406 HG13 ' HB3' ' A' ' 58' ' ' LYS . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.447 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.779 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.601 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.563 ' HB3' ' HB2' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.475 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.673 ' HD2' HD12 ' A' ' 55' ' ' ILE . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.701 HD23 ' CD2' ' A' ' 57' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.612 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.776 HG21 HG11 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HD2' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.61 HD12 ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.618 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.588 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.643 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.874 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.874 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.673 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.563 ' HB2' ' HB3' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.701 ' CD2' HD23 ' A' ' 31' ' ' LEU . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.779 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 82' ' ' VAL . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.447 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.992 HG21 ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.512 ' HA ' HD23 ' A' ' 8' ' ' LEU . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 8' ' ' LEU . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.453 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.703 HG23 ' CD1' ' A' ' 78' ' ' LEU . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.703 ' CD1' HG23 ' A' ' 76' ' ' THR . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.548 ' HB2' HG12 ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.405 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.992 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 59' ' ' VAL . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.456 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.871 ' CG ' HD12 ' A' ' 89' ' ' LEU . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.6 p-80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.871 HD12 ' CG ' ' A' ' 86' ' ' PRO . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.651 ' N ' HD23 ' A' ' 89' ' ' LEU . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 129' ' ' ILE . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.455 ' HA ' HD23 ' A' ' 128' ' ' LEU . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.614 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.581 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.592 ' HD2' HG22 ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 1.044 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.785 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.96 HG21 ' CD1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.6 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.96 ' CD1' HG21 ' A' ' 129' ' ' ILE . 5.9 m-85 . . . . . 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.507 ' O ' HG23 ' A' ' 138' ' ' VAL . 8.8 m . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 82' ' ' VAL . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.785 ' HE2' HG21 ' A' ' 127' ' ' VAL . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.548 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.478 HG21 HH21 ' A' ' 145' ' ' ARG . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.672 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ARG . . . . . 0.478 HH21 HG21 ' A' ' 143' ' ' VAL . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.774 0.321 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.75 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.915 HD23 HG11 ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.748 HD12 ' HA3' ' A' ' 141' ' ' GLY . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.551 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.66 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.452 HG11 ' NE ' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.803 HG22 ' HD2' ' A' ' 21' ' ' ARG . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.424 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.803 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.556 ' HD2' HD12 ' A' ' 55' ' ' ILE . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.518 HD22 ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.956 HG21 HG11 ' A' ' 59' ' ' VAL . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.594 HG22 ' HD2' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.574 HD12 ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.558 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.771 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.771 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.556 HD12 ' HD2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.705 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.792 ' HG3' HG23 ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.956 HG11 HG21 ' A' ' 36' ' ' THR . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.66 ' SG ' HG22 ' A' ' 16' ' ' VAL . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.452 ' NE ' HG11 ' A' ' 17' ' ' VAL . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.837 HG21 HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.575 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.434 ' O ' ' HB ' ' A' ' 76' ' ' THR . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.647 HG23 ' CD1' ' A' ' 78' ' ' LEU . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.679 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.711 ' N ' HD13 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.569 ' H ' HG12 ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.837 HD13 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.705 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.424 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.523 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.624 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.593 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.594 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.603 ' HE1' HD23 ' A' ' 78' ' ' LEU . 81.4 t60 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.915 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.562 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.954 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.954 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.551 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 16.6 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.424 HG12 ' HA ' ' A' ' 83' ' ' MET . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.748 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.75 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.628 ' CG ' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.425 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.842 0.353 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.061 HD23 HG11 ' A' ' 125' ' ' VAL . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.66 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.734 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.696 ' HG2' HG11 ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.436 HG22 ' SG ' ' A' ' 60' ' ' CYS . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.918 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.667 HG23 ' CG ' ' A' ' 58' ' ' LYS . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.775 ' HB1' HD11 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.658 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.696 ' HZ ' HD23 ' A' ' 31' ' ' LEU . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.97 HD12 ' CE2' ' A' ' 57' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.432 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.647 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.105 HG21 HG11 ' A' ' 59' ' ' VAL . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.589 HG22 ' HD2' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.48 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.621 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.815 ' HG2' HG11 ' A' ' 51' ' ' VAL . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 26' ' ' SER . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.815 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.497 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.97 ' CE2' HD12 ' A' ' 31' ' ' LEU . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.667 ' CG ' HG23 ' A' ' 19' ' ' THR . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.105 HG11 HG21 ' A' ' 36' ' ' THR . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.436 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.899 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.571 ' HA ' HD23 ' A' ' 8' ' ' LEU . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.563 ' HD3' HD23 ' A' ' 8' ' ' LEU . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.467 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.579 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.643 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.513 ' HB2' HG12 ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.899 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.791 ' O ' HG23 ' A' ' 139' ' ' VAL . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.534 HD21 ' CE1' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.534 ' CE1' HD21 ' A' ' 89' ' ' LEU . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 129' ' ' ILE . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.421 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.605 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.559 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.589 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p . . . . . 0 CA--C 1.523 -0.067 0 CA-C-O 120.975 0.417 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 1.061 HG11 HD23 ' A' ' 5' ' ' LEU . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.722 HG21 ' HE2' ' A' ' 140' ' ' TYR . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.477 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.94 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.94 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.2 m-85 . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.734 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 14.1 m . . . . . 0 N--CA 1.455 -0.189 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 82' ' ' VAL . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.722 ' HE2' HG21 ' A' ' 127' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.643 ' CG ' HD11 ' A' ' 78' ' ' LEU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.749 0.309 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.898 HD23 HG11 ' A' ' 125' ' ' VAL . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.695 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.613 HG22 ' CE1' ' A' ' 140' ' ' TYR . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.599 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.722 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.722 HG22 ' SG ' ' A' ' 60' ' ' CYS . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.811 HG23 ' HG3' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD3' ' CD2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.487 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.535 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.535 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.116 HG21 HG11 ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.622 ' CG2' HD23 ' A' ' 99' ' ' LEU . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.609 HD12 ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.655 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.503 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.814 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.814 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.442 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.564 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.482 ' CD2' ' HD3' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.609 ' CD1' HD12 ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.811 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.116 HG11 HG21 ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.722 ' SG ' HG22 ' A' ' 16' ' ' VAL . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.3 p-10 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.708 HD13 HD11 ' A' ' 81' ' ' LEU . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.599 ' HA ' HD23 ' A' ' 8' ' ' LEU . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.531 HG22 ' CD ' ' A' ' 144' ' ' ARG . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.802 HD11 ' HG3' ' A' ' 144' ' ' ARG . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.575 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.437 ' HB2' HG13 ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.708 HD11 HD13 ' A' ' 65' ' ' ILE . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.564 HG13 ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.451 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.524 ' HG2' HD12 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.823 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.738 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.823 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.467 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.696 HG22 ' O ' ' A' ' 129' ' ' ILE . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 41' ' ' ILE . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.611 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.622 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.346 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.898 HG11 HD23 ' A' ' 5' ' ' LEU . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.535 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.915 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.738 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.8 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.915 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.1 m-85 . . . . . 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.722 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 23.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.613 ' CE1' HG22 ' A' ' 7' ' ' VAL . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.447 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.802 ' HG3' HD11 ' A' ' 78' ' ' LEU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.735 0.302 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.796 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.796 ' N ' HD13 ' A' ' 5' ' ' LEU . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.47 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.781 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.834 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.678 HG22 ' SG ' ' A' ' 60' ' ' CYS . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.954 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.919 HG22 ' HD2' ' A' ' 21' ' ' ARG . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.416 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.919 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.595 ' HD2' HD12 ' A' ' 55' ' ' ILE . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.416 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.663 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.017 HG21 HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.566 HG22 ' HD2' ' A' ' 100' ' ' PRO . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.499 HD12 ' CD1' ' A' ' 57' ' ' PHE . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.893 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.893 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.595 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.687 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.683 ' HB2' HG13 ' A' ' 82' ' ' VAL . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.717 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.017 HG11 HG21 ' A' ' 36' ' ' THR . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.678 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.835 HG21 ' CD1' ' A' ' 81' ' ' LEU . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.718 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.47 ' HA ' HD23 ' A' ' 8' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 76' ' ' THR . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 69' ' ' LEU . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 79' ' ' SER . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.912 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.745 ' O ' HD23 ' A' ' 77' ' ' LEU . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.835 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.683 HG13 ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.696 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.507 HD21 ' CE1' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.507 ' CE1' HD21 ' A' ' 89' ' ' LEU . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.452 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.713 HG12 HG23 ' A' ' 42' ' ' ILE . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.597 ' C ' HD23 ' A' ' 97' ' ' LEU . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.578 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HD2' HG22 ' A' ' 38' ' ' VAL . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.789 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.565 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.964 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.604 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.964 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.8 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.781 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.696 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.634 ' CD2' HD11 ' A' ' 5' ' ' LEU . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.912 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.684 0.278 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.595 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.638 HD11 ' CD2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.603 ' N ' HD13 ' A' ' 5' ' ' LEU . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 77' ' ' LEU . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.694 HG22 ' SG ' ' A' ' 60' ' ' CYS . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.956 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.742 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.501 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.637 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.664 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.081 HG21 HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.545 ' CG2' HD23 ' A' ' 99' ' ' LEU . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.546 HD12 ' CD1' ' A' ' 57' ' ' PHE . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.708 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.783 ' HG2' HG11 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.783 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.494 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.595 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.676 ' HB2' HG13 ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.742 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.081 HG11 HG21 ' A' ' 36' ' ' THR . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.694 ' SG ' HG22 ' A' ' 16' ' ' VAL . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.525 HG21 HD22 ' A' ' 81' ' ' LEU . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.703 ' O ' HD23 ' A' ' 66' ' ' LEU . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' O ' ' HB ' ' A' ' 76' ' ' THR . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.508 HG22 ' CD ' ' A' ' 144' ' ' ARG . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 8' ' ' LEU . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.728 HD21 ' HD2' ' A' ' 144' ' ' ARG . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.513 ' O ' HD23 ' A' ' 77' ' ' LEU . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.525 HD22 HG21 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.676 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.482 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.525 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.708 HG12 HG23 ' A' ' 42' ' ' ILE . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.406 ' HA ' HD23 ' A' ' 128' ' ' LEU . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.77 HD22 ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 38' ' ' VAL . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.545 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.545 ' CD ' HG22 ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.44 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.884 0.373 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.77 ' CG1' HD22 ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.968 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.968 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.1 m-85 . . . . . 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 138' ' ' VAL . 33.4 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.687 ' HE2' HG21 ' A' ' 127' ' ' VAL . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.595 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.728 ' HD2' HD21 ' A' ' 78' ' ' LEU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.403 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.838 0.351 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.772 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.528 ' HB2' HG11 ' A' ' 125' ' ' VAL . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.611 HD12 ' N ' ' A' ' 8' ' ' LEU . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.477 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.496 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' SG ' ' A' ' 60' ' ' CYS . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.584 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.619 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.799 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.502 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.54 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.491 ' HB2' ' HB1' ' A' ' 18' ' ' ALA . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.033 HG21 HG11 ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.565 HG22 ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.822 HG12 HD12 ' A' ' 97' ' ' LEU . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.564 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.782 ' HG2' HG11 ' A' ' 51' ' ' VAL . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.782 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.493 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.55 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.502 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.438 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.799 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.033 HG11 HG21 ' A' ' 36' ' ' THR . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.448 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.584 ' HD3' HG11 ' A' ' 17' ' ' VAL . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.914 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.697 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.475 ' HA ' HD23 ' A' ' 8' ' ' LEU . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.455 HD22 ' CA ' ' A' ' 76' ' ' THR . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.488 HG22 ' CD ' ' A' ' 144' ' ' ARG . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.533 HD11 ' CG ' ' A' ' 144' ' ' ARG . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.914 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 139' ' ' VAL . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.635 HD21 ' CE1' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.635 ' CE1' HD21 ' A' ' 89' ' ' LEU . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.683 HG12 HG23 ' A' ' 42' ' ' ILE . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.822 HD12 HG12 ' A' ' 40' ' ' ILE . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.654 ' HG3' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.657 HD12 ' HB ' ' A' ' 125' ' ' VAL . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.565 ' CD ' HG22 ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.563 ' ND1' HG21 ' A' ' 142' ' ' VAL . 4.1 t60 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.657 ' HB ' HD12 ' A' ' 99' ' ' LEU . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.897 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.897 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.6 m-85 . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.477 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 3.9 m . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 82' ' ' VAL . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.563 HG21 ' ND1' ' A' ' 101' ' ' HIS . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.772 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.533 ' CG ' HD11 ' A' ' 78' ' ' LEU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.416 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 87.4 p . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.764 0.316 . . . . 0.0 111.019 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.714 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.885 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.674 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.514 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.705 ' OE1' HG22 ' A' ' 65' ' ' ILE . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.67 HG22 ' SG ' ' A' ' 60' ' ' CYS . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.465 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.865 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.827 HG23 ' HG3' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.419 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.546 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.4 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.676 HG21 HG11 ' A' ' 59' ' ' VAL . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.599 HG22 ' HD2' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.596 HD12 ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.559 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.639 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.767 ' HG2' HG11 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.767 HG11 ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.486 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.596 ' CD1' HD12 ' A' ' 40' ' ' ILE . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.827 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.865 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.67 ' SG ' HG22 ' A' ' 16' ' ' VAL . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.465 ' HD3' HG11 ' A' ' 17' ' ' VAL . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.1 p-10 -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.78 HD13 HD11 ' A' ' 81' ' ' LEU . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HA ' HD23 ' A' ' 8' ' ' LEU . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.55 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.82 HD11 ' HG3' ' A' ' 144' ' ' ARG . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.477 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.78 HD11 HD13 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 59' ' ' VAL . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.402 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.612 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.551 ' CE1' HD21 ' A' ' 89' ' ' LEU . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.459 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.639 HG12 HG23 ' A' ' 42' ' ' ILE . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.469 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.669 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.669 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' HG22 ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 125' ' ' VAL . 12.6 t60 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.965 0.412 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.885 HG11 HD23 ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.768 HG21 ' HE2' ' A' ' 140' ' ' TYR . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 96' ' ' GLU . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.612 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.0 m-85 . . . . . 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.518 ' O ' HG23 ' A' ' 138' ' ' VAL . 16.2 m . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 10' ' ' GLN . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.768 ' HE2' HG21 ' A' ' 127' ' ' VAL . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.453 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.82 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.862 0.363 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.82 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.82 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.476 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.656 HG22 ' SG ' ' A' ' 60' ' ' CYS . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.935 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.657 HG23 ' HG3' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.58 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.451 HD13 ' CA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.68 ' HD2' HD12 ' A' ' 55' ' ' ILE . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.61 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.854 HG21 HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.57 HG22 ' HD2' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.604 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.675 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.638 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.8 ' HG2' HG11 ' A' ' 51' ' ' VAL . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.8 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.451 ' CA ' HD13 ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.68 HD12 ' HD2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.58 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.657 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.935 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.656 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.8 p-10 -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.794 HD13 HD11 ' A' ' 81' ' ' LEU . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.541 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.476 ' HA ' HD23 ' A' ' 8' ' ' LEU . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.552 HG23 ' CD2' ' A' ' 78' ' ' LEU . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.878 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.726 ' O ' HD23 ' A' ' 77' ' ' LEU . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.406 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.794 HD11 HD13 ' A' ' 65' ' ' ILE . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.651 ' O ' HG12 ' A' ' 139' ' ' VAL . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.606 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.606 ' CE1' HD21 ' A' ' 89' ' ' LEU . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.472 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.675 HG12 HG23 ' A' ' 42' ' ' ILE . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.606 HD21 ' HG ' ' A' ' 99' ' ' LEU . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.606 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 6.1 t60 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.937 0.398 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.725 HG11 HD23 ' A' ' 5' ' ' LEU . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.472 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 8.6 m-85 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 82' ' ' VAL . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.461 ' HD2' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.505 HG12 ' N ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.878 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.635 0.255 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.821 HD23 ' HB ' ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.645 HD22 ' HD3' ' A' ' 68' ' ' PRO . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.645 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.534 ' HG2' HG21 ' A' ' 139' ' ' VAL . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.612 HG11 HH11 ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.884 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.802 HG23 ' HG3' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.44 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.669 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.583 HD23 ' CE1' ' A' ' 57' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.412 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.88 HG21 HG11 ' A' ' 59' ' ' VAL . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.553 HG22 ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.576 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.587 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.486 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.866 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.866 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.631 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.583 ' CE1' HD23 ' A' ' 31' ' ' LEU . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.802 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.884 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 15' ' ' THR . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.612 HH11 HG11 ' A' ' 17' ' ' VAL . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.7 p-10 -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.936 HG21 ' HG ' ' A' ' 81' ' ' LEU . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.645 ' HD3' HD22 ' A' ' 8' ' ' LEU . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.491 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HE2' HD11 ' A' ' 69' ' ' LEU . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.491 ' N ' HD13 ' A' ' 69' ' ' LEU . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.81 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.48 ' N ' HG11 ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.936 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.601 ' O ' HG12 ' A' ' 139' ' ' VAL . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.636 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.487 HD21 ' CE1' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.498 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 129' ' ' ILE . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.603 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.567 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.553 ' CD ' HG22 ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.456 ' HB2' HG23 ' A' ' 125' ' ' VAL . 50.5 t-80 . . . . . 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.93 0.395 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.821 ' HB ' HD23 ' A' ' 5' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.955 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.491 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.955 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 9.4 m-85 . . . . . 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.645 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 11.9 m . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 83' ' ' MET . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.765 ' HE2' HG21 ' A' ' 127' ' ' VAL . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 79' ' ' SER . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 143' ' ' VAL . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.81 ' CG ' HD11 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.821 0.343 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.872 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.872 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.771 HD23 ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.608 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.487 ' HG2' HG21 ' A' ' 139' ' ' VAL . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.938 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.846 HG23 ' HG3' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.64 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.623 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.553 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.708 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.041 HG21 HG11 ' A' ' 59' ' ' VAL . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.548 HG22 ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.63 HD12 ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.625 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' HB1' ' HB3' ' A' ' 91' ' ' PHE . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.562 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.668 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.668 HG11 ' HG2' ' A' ' 48' ' ' PRO . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.623 HD12 ' HD2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.64 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.63 ' CD1' HD12 ' A' ' 40' ' ' ILE . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.846 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.041 HG11 HG21 ' A' ' 36' ' ' THR . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 81' ' ' LEU . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.607 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.771 ' HD2' HD23 ' A' ' 8' ' ' LEU . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.877 HG22 ' HD3' ' A' ' 144' ' ' ARG . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.645 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.65 HD21 ' HD2' ' A' ' 144' ' ' ARG . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.645 ' O ' HD23 ' A' ' 77' ' ' LEU . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.75 HD11 HD13 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG22 ' A' ' 59' ' ' VAL . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.419 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.462 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.653 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.653 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.548 ' CD ' HG22 ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 1.4 t60 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.899 0.38 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.649 HG11 HD23 ' A' ' 5' ' ' LEU . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.64 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.447 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.948 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.948 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.608 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 10.7 m . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.487 HG21 ' HG2' ' A' ' 10' ' ' GLN . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.64 ' HE2' HG21 ' A' ' 127' ' ' VAL . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.877 ' HD3' HG22 ' A' ' 76' ' ' THR . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.81 0.338 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.733 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 77' ' ' LEU . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.707 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.486 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.439 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.504 HG22 ' SG ' ' A' ' 60' ' ' CYS . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.45 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.872 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.661 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.65 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.602 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.578 ' HD2' HD12 ' A' ' 55' ' ' ILE . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.532 HD23 ' CD2' ' A' ' 57' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.978 HG21 HG11 ' A' ' 59' ' ' VAL . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.574 HG22 ' HD2' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.608 HD12 ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.573 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.629 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.581 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.882 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.882 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.578 HD12 ' HD2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.602 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.687 ' HB2' HG13 ' A' ' 82' ' ' VAL . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.661 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.978 HG11 HG21 ' A' ' 36' ' ' THR . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' CYS . . . . . 0.504 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.45 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.642 HG21 ' CD1' ' A' ' 81' ' ' LEU . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.722 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.829 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 8' ' ' LEU . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.742 HD11 ' HG3' ' A' ' 144' ' ' ARG . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 79' ' ' SER . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.642 ' CD1' HG21 ' A' ' 65' ' ' ILE . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.441 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.502 HD21 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.606 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.629 HG12 HG23 ' A' ' 42' ' ' ILE . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.617 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.617 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.911 0.386 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.587 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.967 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.606 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.967 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.5 m-85 . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.707 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 30.0 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.486 HG21 ' HG2' ' A' ' 10' ' ' GLN . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.505 ' HD2' HD11 ' A' ' 5' ' ' LEU . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.411 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.829 ' HD2' HG22 ' A' ' 76' ' ' THR . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.73 0.3 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.642 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 1.055 HD23 HG11 ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLU . . . . . 0.714 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.504 HD23 ' CD ' ' A' ' 68' ' ' PRO . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.598 ' NE2' HG11 ' A' ' 139' ' ' VAL . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.839 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' THR . . . . . 0.82 HG23 ' HG3' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.466 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.408 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.668 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . 1.103 HG21 HG11 ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.756 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.516 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.79 ' HG2' HG11 ' A' ' 51' ' ' VAL . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.79 HG11 ' HG2' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLU . . . . . 0.478 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' HG13 ' A' ' 82' ' ' VAL . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.82 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 1.103 HG11 HG21 ' A' ' 36' ' ' THR . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ARG . . . . . 0.422 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.9 HG21 ' HG ' ' A' ' 81' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.504 ' CD ' HD23 ' A' ' 8' ' ' LEU . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.512 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.585 HG22 ' CD ' ' A' ' 144' ' ' ARG . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.657 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.674 HD21 ' HD2' ' A' ' 144' ' ' ARG . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' HG12 ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PRO . . . . . 0.44 ' HB2' HG13 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.9 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG12 ' A' ' 139' ' ' VAL . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' MET . . . . . 0.513 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.639 HD21 ' CE1' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CE1' HD21 ' A' ' 89' ' ' LEU . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' PRO . . . . . 0.423 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 42' ' ' ILE . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLU . . . . . 0.418 ' HB3' ' HB ' ' A' ' 41' ' ' ILE . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.76 ' N ' HD23 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.569 ' CD1' HD22 ' A' ' 97' ' ' LEU . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.552 ' HD2' HG22 ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' HIS . . . . . 0.552 ' ND1' HG21 ' A' ' 142' ' ' VAL . 86.7 t60 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.853 0.359 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 1.055 HG11 HD23 ' A' ' 5' ' ' LEU . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 127' ' ' VAL . . . . . 0.88 HG11 ' CE1' ' A' ' 140' ' ' TYR . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' LEU . . . . . 0.423 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.95 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.95 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.4 m-85 . . . . . 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' VAL . . . . . 0.536 ' O ' HG23 ' A' ' 138' ' ' VAL . 14.9 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.598 HG11 ' NE2' ' A' ' 10' ' ' GLN . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.88 ' CE1' HG11 ' A' ' 127' ' ' VAL . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.552 HG21 ' ND1' ' A' ' 101' ' ' HIS . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' ARG . . . . . 0.674 ' HD2' HD21 ' A' ' 78' ' ' LEU . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.768 0.318 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.6 t -170.89 162.52 7.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p -119.27 154.41 33.5 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.751 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.808 HD13 ' N ' ' A' ' 6' ' ' GLU . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.808 ' N ' HD13 ' A' ' 5' ' ' LEU . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.472 ' OE1' HG11 ' A' ' 139' ' ' VAL . 23.1 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.684 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.565 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.892 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.852 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.463 ' HB2' ' HB2' ' A' ' 33' ' ' SER . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.65 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.581 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.94 HG21 HG11 ' A' ' 59' ' ' VAL . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.54 HG22 ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.543 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.581 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.428 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.588 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.864 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.864 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.482 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.581 HD12 ' HD2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.65 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.713 ' HB2' HG13 ' A' ' 82' ' ' VAL . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.852 ' HG3' HG23 ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.94 HG11 HG21 ' A' ' 36' ' ' THR . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.684 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.565 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.447 HD13 HD21 ' A' ' 81' ' ' LEU . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.688 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 8' ' ' LEU . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.681 HG23 ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.759 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.637 ' O ' HD23 ' A' ' 77' ' ' LEU . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 140' ' ' TYR . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.404 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.531 ' SG ' HG23 ' A' ' 138' ' ' VAL . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.403 ' CA ' ' HB2' ' A' ' 134' ' ' SER . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.481 HD21 ' CE1' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.5 ' HE1' HD11 ' A' ' 55' ' ' ILE . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.474 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.659 HG12 HG23 ' A' ' 42' ' ' ILE . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.609 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.515 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.54 ' CD ' HG22 ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' HB2' ' A' ' 78' ' ' LEU . 16.5 t-160 -109.31 117.71 34.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.464 ' CB ' HD23 ' A' ' 119' ' ' LEU . 13.0 p -95.31 171.81 8.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.986 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.78 161.76 42.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.821 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.425 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 67.2 Cg_endo -73.97 -8.77 21.59 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.62 2.213 . . . . 0.0 112.768 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 3.0 mmmt -65.68 -38.21 88.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.78 0.324 . . . . 0.0 110.937 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.417 ' HA ' ' HB2' ' A' ' 109' ' ' ASN . 2.0 t -89.3 8.21 31.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.424 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.425 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -48.0 -27.56 2.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.77 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -144.91 16.52 1.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.417 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.3 t-20 -82.2 142.99 31.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.936 0.398 . . . . 0.0 110.903 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.441 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.8 mtpt -57.64 -21.86 42.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.181 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.499 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 82.85 111.3 0.06 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.102 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.699 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.83 151.19 38.84 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.129 -179.25 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.37 -12.36 31.61 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.727 2.285 . . . . 0.0 112.254 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.32 -39.13 96.73 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 17.2 p30 -165.72 59.44 0.6 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.452 ' O ' HG21 ' A' ' 120' ' ' VAL . 95.8 Cg_endo -80.23 -1.11 11.14 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.468 2.112 . . . . 0.0 112.589 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.45 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.3 m120 -131.12 12.81 5.15 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.097 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.604 ' CG ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.3 -79.97 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.615 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -87.25 -4.67 59.09 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.851 -179.752 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.452 HG21 ' O ' ' A' ' 116' ' ' PRO . 79.2 t -51.12 -28.99 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.96 0.409 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.74 -9.86 9.72 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.283 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.8 -64.39 1.16 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.875 0.369 . . . . 0.0 111.064 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 6.0 m-80 -79.48 58.43 2.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m -81.18 150.45 28.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.955 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.542 HG11 HD23 ' A' ' 5' ' ' LEU . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.594 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.474 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.962 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.962 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.5 m-85 -96.71 120.52 37.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.84 172.92 0.37 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 115.888 -0.596 . . . . 0.0 113.427 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.403 ' HB2' ' CA ' ' A' ' 88' ' ' GLY . 22.5 t -131.58 99.66 4.88 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.607 0.241 . . . . 0.0 110.621 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -137.71 174.67 21.71 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.704 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.2 t -59.09 -25.6 63.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.136 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -168.74 46.05 0.22 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.573 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.641 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 20.1 m -61.6 87.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 82' ' ' VAL . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.475 ' O ' HD23 ' A' ' 81' ' ' LEU . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 78' ' ' LEU . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.544 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.648 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 . . . . . 0 N--CA 1.488 1.43 0 CA-C-O 120.846 0.355 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.42 179.55 4.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.945 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -136.14 161.01 36.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.867 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.867 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.629 HD13 ' HA3' ' A' ' 141' ' ' GLY . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.704 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.698 HG22 ' SG ' ' A' ' 60' ' ' CYS . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.688 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.964 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.784 HG23 ' HG3' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.721 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.059 HG21 HG11 ' A' ' 59' ' ' VAL . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.614 ' CG2' HD23 ' A' ' 99' ' ' LEU . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.593 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.6 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.625 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.594 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.878 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.878 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.547 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.617 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.684 ' HB2' HG13 ' A' ' 82' ' ' VAL . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.784 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.059 HG11 HG21 ' A' ' 36' ' ' THR . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.698 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.688 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.45 ' OD1' HD11 ' A' ' 65' ' ' ILE . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.537 HD22 ' HB2' ' A' ' 61' ' ' ARG . 1.2 p30 -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.83 HG21 HD22 ' A' ' 81' ' ' LEU . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.713 ' O ' HD23 ' A' ' 66' ' ' LEU . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.425 ' HA ' HD23 ' A' ' 8' ' ' LEU . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 76' ' ' THR . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.828 HG22 ' HD2' ' A' ' 144' ' ' ARG . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.923 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.723 ' O ' HD23 ' A' ' 77' ' ' LEU . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.407 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.83 HD22 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.684 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.537 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.42 ' CA ' ' HB2' ' A' ' 134' ' ' SER . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.54 HD21 ' CE1' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.547 ' HE1' HD11 ' A' ' 55' ' ' ILE . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.625 HG12 HG23 ' A' ' 42' ' ' ILE . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.617 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.432 ' HD2' HD13 ' A' ' 41' ' ' ILE . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.614 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 142' ' ' VAL . 44.4 t-80 -134.36 127.5 31.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' HD23 ' A' ' 119' ' ' LEU . 17.0 p -93.85 171.75 8.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.21 163.53 67.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.929 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 40.5 Cg_endo -67.03 -14.0 41.94 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.546 2.164 . . . . 0.0 112.588 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 19.0 mmtt -61.58 -38.02 86.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.778 0.323 . . . . 0.0 110.974 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -88.98 8.09 31.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.338 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.19 -29.24 1.49 Allowed 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.776 0.322 . . . . 0.0 111.508 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.8 mt-30 -121.09 -30.46 4.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.041 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -49.82 138.9 14.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.07 0.462 . . . . 0.0 111.375 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mtpp -72.95 -21.57 60.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.111 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 14.0 m 88.15 111.02 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.956 -179.148 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.713 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.96 154.55 45.26 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.33 -179.13 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 -11.47 30.76 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.668 2.246 . . . . 0.0 112.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.15 -32.38 82.11 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.528 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.419 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 7.5 t0 -163.78 62.71 1.11 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.615 ' O ' HG21 ' A' ' 120' ' ' VAL . 87.9 Cg_endo -83.31 7.77 5.01 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.744 2.296 . . . . 0.0 112.798 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.427 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.3 m120 -132.61 12.46 4.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.686 0.279 . . . . 0.0 111.233 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.571 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.1 -79.55 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.228 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.687 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.8 -2.17 57.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.73 -179.8 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.615 HG21 ' O ' ' A' ' 116' ' ' PRO . 83.5 t -51.84 -28.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.91 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -113.68 -10.78 13.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.354 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.42 -71.73 0.39 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.867 0.365 . . . . 0.0 111.24 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -71.4 63.49 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m -88.26 144.74 26.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.071 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.619 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.61 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.937 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.937 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.9 m-85 -96.87 123.3 40.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.19 172.55 0.31 Allowed Glycine 0 C--N 1.331 0.258 0 CA-C-N 115.857 -0.61 . . . . 0.0 113.512 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.42 ' HB2' ' CA ' ' A' ' 88' ' ' GLY . 12.2 t -130.06 74.71 1.61 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.838 0.351 . . . . 0.0 110.688 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.767 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -113.76 169.86 13.09 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.6 t -69.6 -20.94 63.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.648 0.261 . . . . 0.0 111.128 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -156.23 31.26 0.59 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.003 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.767 HG13 ' HA3' ' A' ' 135' ' ' GLY . 27.3 m -61.08 98.65 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.537 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.656 ' HD1' HD11 ' A' ' 5' ' ' LEU . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.629 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.431 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.923 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 120.73 0.3 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.2 -168.56 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 110.962 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p -141.22 164.09 31.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.679 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.964 HD23 HG11 ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.688 ' N ' HD13 ' A' ' 5' ' ' LEU . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.526 HD23 ' HA ' ' A' ' 67' ' ' PRO . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.684 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.71 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.679 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.535 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.901 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 21' ' ' ARG . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.816 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.072 HG21 HG11 ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.596 HG22 ' HD2' ' A' ' 100' ' ' PRO . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.58 HD12 ' CD1' ' A' ' 57' ' ' PHE . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.679 HG23 HG12 ' A' ' 95' ' ' VAL . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.589 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.799 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.799 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.623 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.637 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.777 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.072 HG11 HG21 ' A' ' 36' ' ' THR . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.679 ' SG ' HG22 ' A' ' 16' ' ' VAL . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.535 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.3 p30 -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.85 HG21 ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.71 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.526 ' HA ' HD23 ' A' ' 8' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.488 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.478 HG22 ' NE ' ' A' ' 144' ' ' ARG . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.881 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.737 ' O ' HD23 ' A' ' 77' ' ' LEU . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.85 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG13 ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.2 p-80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.415 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.605 HD21 ' CE1' ' A' ' 91' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.605 ' CE1' HD21 ' A' ' 89' ' ' LEU . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.679 HG12 HG23 ' A' ' 42' ' ' ILE . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 41' ' ' ILE . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.637 ' C ' HD23 ' A' ' 97' ' ' LEU . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.635 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HD2' HG22 ' A' ' 38' ' ' VAL . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.5 ' CE1' HG21 ' A' ' 142' ' ' VAL . 13.6 t60 -140.04 107.77 5.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 9.8 m -75.41 171.88 13.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.122 0.486 . . . . 0.0 111.382 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 106' ' ' THR . 11.7 p-10 -65.9 158.39 75.74 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.094 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 103' ' ' ASP . 54.0 Cg_endo -69.63 -19.43 36.76 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.173 . . . . 0.0 112.418 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.85 -31.6 72.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 103' ' ' ASP . 2.8 t -88.84 7.25 35.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.085 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.407 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.3 OUTLIER -50.18 -27.75 6.36 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.554 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 50.7 mt-30 -128.48 -21.53 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.541 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -46.21 139.07 4.9 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.959 0.409 . . . . 0.0 111.445 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -62.95 -21.95 66.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.123 179.946 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.518 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 82.07 112.38 0.06 Allowed 'General case' 0 N--CA 1.462 0.172 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.015 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.728 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.61 147.0 32.47 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.117 0.484 . . . . 0.0 111.547 -178.799 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -73.88 -6.06 18.0 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 123.03 2.487 . . . . 0.0 112.533 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.33 -26.25 40.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.56 -0.828 . . . . 0.0 112.754 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.453 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.7 p-10 -148.67 57.64 3.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-O 120.764 0.316 . . . . 0.0 111.288 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.489 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.1 Cg_endo -83.49 8.27 4.72 Favored 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.575 2.183 . . . . 0.0 112.753 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -129.57 7.72 5.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.945 179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.543 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.86 -24.82 2.67 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.863 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.467 HD13 ' CG ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -167.29 18.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.668 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.489 HG21 ' O ' ' A' ' 116' ' ' PRO . 9.0 t -63.98 -25.53 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.936 0.398 . . . . 0.0 110.375 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -129.64 8.6 6.16 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.016 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.413 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -89.7 -50.86 5.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.897 0.38 . . . . 0.0 111.288 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -91.16 42.58 1.11 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.02 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m -66.68 162.34 21.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.914 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.964 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.592 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.932 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 -96.7 136.86 36.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.67 -168.39 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.22 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.456 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.415 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.7 m -91.09 22.21 3.86 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.826 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.79 -151.3 2.4 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.924 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.89 19.61 8.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.624 0.249 . . . . 0.0 111.355 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 166.72 -43.23 0.26 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.529 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.826 HG22 ' HA2' ' A' ' 135' ' ' GLY . 8.0 m -57.03 122.02 5.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.603 HG12 ' O ' ' A' ' 82' ' ' VAL . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.406 ' OH ' HG12 ' A' ' 129' ' ' ILE . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.488 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.501 HG12 ' N ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.881 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 43.6 m80 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.808 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -169.66 144.97 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p -103.81 149.45 25.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.826 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.622 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.799 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.599 HD12 ' N ' ' A' ' 8' ' ' LEU . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.833 ' OE1' HG22 ' A' ' 65' ' ' ILE . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.631 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.742 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.818 HG23 ' HG3' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.467 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.497 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.531 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.607 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.648 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.052 HG21 HG11 ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.576 HG22 ' HD2' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.522 HD12 ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.549 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.661 HG23 HG12 ' A' ' 95' ' ' VAL . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.618 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.78 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.78 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.418 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.497 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.607 ' CE1' HD23 ' A' ' 31' ' ' LEU . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.818 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.052 HG11 HG21 ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.631 ' SG ' HG22 ' A' ' 16' ' ' VAL . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.742 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . 0.711 HD22 ' HB2' ' A' ' 61' ' ' ARG . 0.1 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.867 HG21 ' HG ' ' A' ' 81' ' ' LEU . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.415 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.686 HG22 ' HD2' ' A' ' 144' ' ' ARG . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.487 HD13 HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.738 HD11 ' HG3' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.452 ' HB2' HG12 ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.468 ' HB2' HG13 ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.867 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.457 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.481 ' HG2' HD23 ' A' ' 89' ' ' LEU . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.482 ' C ' HD12 ' A' ' 89' ' ' LEU . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.463 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.661 HG12 HG23 ' A' ' 42' ' ' ILE . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.587 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.514 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.44 ' HB2' HG23 ' A' ' 125' ' ' VAL . 52.7 t-80 -123.06 118.69 28.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.405 ' HB3' ' CD2' ' A' ' 119' ' ' LEU . 14.3 m -97.49 171.8 8.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.07 163.56 60.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.76 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.2 Cg_endo -68.07 -13.23 37.58 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.458 2.105 . . . . 0.0 112.625 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -66.28 -37.06 84.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -89.09 7.95 32.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.38 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.422 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -47.17 -29.86 2.56 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.78 0.324 . . . . 0.0 111.595 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.422 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 55.4 mt-30 -123.48 -27.2 4.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.351 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -46.42 138.81 5.38 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 121.036 0.446 . . . . 0.0 111.469 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.442 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.3 mtpt -69.78 -21.81 63.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.108 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 11.2 m 85.03 107.94 0.05 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.904 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.728 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -88.31 152.07 49.57 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.463 -178.89 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.45 -12.45 31.6 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.867 2.378 . . . . 0.0 112.557 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.61 -35.55 74.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.535 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 30.6 m-20 -155.42 60.91 2.71 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.639 ' O ' HG21 ' A' ' 120' ' ' VAL . 88.4 Cg_endo -82.92 6.84 5.56 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.824 2.35 . . . . 0.0 112.742 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.432 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.2 m120 -132.36 11.76 4.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.601 0.239 . . . . 0.0 111.291 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.03 -79.77 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.812 0.339 . . . . 0.0 111.304 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.659 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.12 -0.71 57.77 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.655 -179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.639 HG21 ' O ' ' A' ' 116' ' ' PRO . 91.9 t -54.69 -27.45 18.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.358 . . . . 0.0 110.819 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.94 -3.04 20.18 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.311 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.42 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -88.53 -49.74 6.72 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.881 0.372 . . . . 0.0 111.233 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -93.97 29.69 2.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.253 -179.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.19 158.57 25.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.715 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.961 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.961 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.2 m-85 -98.27 120.53 38.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.92 170.3 0.04 OUTLIER Glycine 0 C--N 1.332 0.351 0 CA-C-N 115.891 -0.595 . . . . 0.0 113.473 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.57 32.71 4.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.743 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.437 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -62.34 -172.85 1.61 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.7 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.3 t -78.37 -27.01 46.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.745 0.307 . . . . 0.0 111.016 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -161.61 41.8 0.39 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.61 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.8 m -57.15 116.69 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.457 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.715 ' HE2' HG21 ' A' ' 127' ' ' VAL . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.452 HG12 ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.622 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.738 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 120.774 0.321 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 p -71.31 -177.02 1.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER -129.67 173.12 10.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.931 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.695 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.679 HD23 HG11 ' A' ' 125' ' ' VAL . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.582 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.578 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.619 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.539 ' CG ' HG11 ' A' ' 139' ' ' VAL . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.525 HG22 ' SG ' ' A' ' 60' ' ' CYS . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.851 HG23 ' HG3' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.513 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.562 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.037 HG21 HG11 ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.575 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.609 HG12 HD12 ' A' ' 97' ' ' LEU . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.615 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.674 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.547 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.853 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.853 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.552 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' HD12 ' A' ' 40' ' ' ILE . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.851 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.037 HG11 HG21 ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.525 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.864 HG21 ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.578 ' HA ' HD23 ' A' ' 8' ' ' LEU . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.433 HD13 ' N ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.43 ' O ' ' HB ' ' A' ' 76' ' ' THR . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.622 HG22 ' HE ' ' A' ' 144' ' ' ARG . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.721 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.836 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.48 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.864 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.518 ' O ' HG12 ' A' ' 139' ' ' VAL . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.4 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 22.5 p80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.438 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.526 HD21 ' CE1' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.552 ' HE1' HD11 ' A' ' 55' ' ' ILE . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.674 HG12 HG23 ' A' ' 42' ' ' ILE . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.609 HD12 HG12 ' A' ' 40' ' ' ILE . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.509 ' CD2' HG21 ' A' ' 142' ' ' VAL . 0.4 OUTLIER -129.43 112.51 13.88 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.442 ' HA ' HD23 ' A' ' 119' ' ' LEU . 24.6 p -79.88 171.91 14.49 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.24 163.38 66.76 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.893 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 41.4 Cg_endo -67.45 -14.74 43.48 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.564 2.176 . . . . 0.0 112.483 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.1 mmtt -60.63 -36.94 79.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.81 0.338 . . . . 0.0 110.818 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.6 t -89.69 8.21 32.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.377 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.419 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.7 OUTLIER -46.5 -29.91 1.98 Allowed 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 120.754 0.311 . . . . 0.0 111.421 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -126.78 -22.9 3.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.516 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -47.53 138.8 7.51 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.011 0.434 . . . . 0.0 111.456 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.447 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -68.26 -21.58 64.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.066 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.464 ' C ' HD13 ' A' ' 112' ' ' LEU . 11.9 m 85.82 110.41 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.109 -179.2 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.685 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.92 150.42 40.63 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.28 -179.146 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.31 -10.3 26.87 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.809 2.339 . . . . 0.0 112.516 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -72.06 -40.72 56.1 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.718 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 18.2 m-20 -150.47 58.42 3.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 111.073 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.599 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.0 Cg_endo -82.87 5.13 6.61 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.702 2.268 . . . . 0.0 112.695 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.429 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.7 m120 -131.25 12.5 5.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.708 0.289 . . . . 0.0 111.154 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -48.96 -79.82 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.281 -179.737 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.677 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -90.36 -3.45 57.72 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.735 -179.878 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 116' ' ' PRO . 89.6 t -51.77 -28.29 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.968 0.413 . . . . 0.0 110.887 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -116.19 -10.13 11.14 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.302 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.17 -68.46 0.61 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.87 0.367 . . . . 0.0 111.299 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.25 59.42 1.01 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.063 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m -82.19 157.43 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.114 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.679 HG11 HD23 ' A' ' 5' ' ' LEU . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.956 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.956 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 7.5 m-85 -96.72 135.71 38.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.51 -173.1 0.05 OUTLIER Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.081 -0.58 . . . . 0.0 113.125 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.438 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 0.5 OUTLIER -102.07 45.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.752 0.311 . . . . 0.0 111.336 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.44 -132.73 15.12 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.811 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m 68.85 9.87 7.61 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 139.22 -26.82 2.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.57 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.794 HG22 ' HA2' ' A' ' 135' ' ' GLY . 5.3 m -46.59 122.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.539 HG11 ' CG ' ' A' ' 10' ' ' GLN . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.617 ' HD1' HD11 ' A' ' 5' ' ' LEU . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.509 HG21 ' CD2' ' A' ' 101' ' ' HIS . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.695 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.836 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.419 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.426 0 CA-C-O 121.009 0.433 . . . . 0.0 111.266 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.0 p -88.86 -178.1 5.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.012 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -137.22 165.7 25.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.733 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.895 HD23 HG11 ' A' ' 125' ' ' VAL . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.467 ' N ' HD13 ' A' ' 5' ' ' LEU . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.586 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.575 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.491 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.95 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.809 HG22 ' HD2' ' A' ' 21' ' ' ARG . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.809 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.531 HD23 ' CE1' ' A' ' 57' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.085 HG21 HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.58 HG22 ' HD2' ' A' ' 100' ' ' PRO . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.51 HD12 ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.566 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.795 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.603 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.743 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.743 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.608 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.751 ' HB2' HG13 ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.734 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.085 HG11 HG21 ' A' ' 36' ' ' THR . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.491 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.1 p-10 -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.63 HD13 HD11 ' A' ' 81' ' ' LEU . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.73 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.586 ' HA ' HD23 ' A' ' 8' ' ' LEU . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.472 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.444 ' O ' ' HB ' ' A' ' 76' ' ' THR . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.527 HG22 ' NE ' ' A' ' 144' ' ' ARG . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.902 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.768 ' O ' HD23 ' A' ' 77' ' ' LEU . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.458 ' HB2' HG13 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.63 HD11 HD13 ' A' ' 65' ' ' ILE . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.881 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.875 ' HG2' HD12 ' A' ' 89' ' ' LEU . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.875 HD12 ' HG2' ' A' ' 86' ' ' PRO . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.513 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.795 HG12 HG23 ' A' ' 42' ' ' ILE . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.757 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.757 ' N ' HD23 ' A' ' 97' ' ' LEU . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.559 HD21 HG21 ' A' ' 82' ' ' VAL . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' HG22 ' A' ' 38' ' ' VAL . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.78 ' ND1' HG21 ' A' ' 142' ' ' VAL . 37.1 t60 -128.54 101.35 6.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 6.7 m -68.62 171.88 7.04 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.042 0.449 . . . . 0.0 111.166 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . 0.432 ' HB3' ' HD2' ' A' ' 105' ' ' LYS . 10.2 m-20 -73.35 157.53 87.92 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.075 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.41 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 46.5 Cg_endo -67.95 -12.48 35.42 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.485 2.124 . . . . 0.0 112.113 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LYS . . . . . 0.432 ' HD2' ' HB3' ' A' ' 103' ' ' ASP . 10.4 mttt -61.84 -36.5 81.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.932 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 t -89.56 7.95 33.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.15 179.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.423 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.18 -30.35 1.15 Allowed 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.658 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.423 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.6 mt-30 -118.56 -31.16 4.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.935 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -49.9 138.27 15.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.09 0.471 . . . . 0.0 111.225 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -68.13 -21.62 64.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.078 179.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.44 ' C ' HD13 ' A' ' 112' ' ' LEU . 10.8 m 84.69 109.25 0.05 Allowed 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.887 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.727 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -89.84 148.28 39.43 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.418 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -71.82 -9.11 24.29 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.833 2.355 . . . . 0.0 112.449 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.8 -39.61 28.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.693 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.445 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.3 t0 -138.05 57.24 12.46 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.555 ' O ' HG21 ' A' ' 120' ' ' VAL . 82.4 Cg_endo -85.39 15.7 2.15 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.602 2.201 . . . . 0.0 112.804 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -129.99 8.06 5.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.024 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.534 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.77 -24.93 2.62 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.714 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.449 HD13 ' CB ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.37 19.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.555 HG21 ' O ' ' A' ' 116' ' ' PRO . 44.9 t -68.47 -24.06 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.97 0.414 . . . . 0.0 110.474 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -119.91 -2.59 12.6 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.273 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.65 -68.44 0.69 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.902 0.382 . . . . 0.0 111.024 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.64 61.39 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.891 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p -81.67 146.11 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.086 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.895 HG11 HD23 ' A' ' 5' ' ' LEU . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.927 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 -96.68 115.31 27.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.37 169.59 0.39 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.792 -0.64 . . . . 0.0 113.426 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.46 106.63 7.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.715 0.293 . . . . 0.0 110.437 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.89 -166.66 11.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.699 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -63.84 -27.96 69.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.765 0.316 . . . . 0.0 111.02 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.42 50.47 0.1 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.759 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.593 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.9 m -61.41 101.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.881 HG12 ' HA ' ' A' ' 83' ' ' MET . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.441 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.78 HG21 ' ND1' ' A' ' 101' ' ' HIS . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.902 ' HG3' HD11 ' A' ' 78' ' ' LEU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 12.8 m80 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.732 0.301 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.97 -172.48 3.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.894 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p -143.93 147.04 33.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.843 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.668 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.764 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.711 HD23 ' HD2' ' A' ' 68' ' ' PRO . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.774 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.473 HG22 ' SG ' ' A' ' 60' ' ' CYS . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.556 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.82 HG22 ' HD2' ' A' ' 21' ' ' ARG . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.537 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.82 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.538 ' HD2' HD12 ' A' ' 55' ' ' ILE . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.748 HD23 ' CD2' ' A' ' 57' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.464 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.875 HG21 HG11 ' A' ' 59' ' ' VAL . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.572 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.665 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.659 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.859 ' HG2' HG11 ' A' ' 51' ' ' VAL . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.859 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.496 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.538 HD12 ' HD2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.748 ' CD2' HD23 ' A' ' 31' ' ' LEU . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.732 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.941 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.473 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.556 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.1 p-10 -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.92 HG21 ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.711 ' HD2' HD23 ' A' ' 8' ' ' LEU . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.628 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.539 HD22 HD22 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.84 HD11 ' HG3' ' A' ' 144' ' ' ARG . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.464 ' HB2' HG12 ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.452 ' HB2' HG13 ' A' ' 59' ' ' VAL . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.92 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.581 HG22 HG22 ' A' ' 59' ' ' VAL . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.443 ' CG ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.869 ' HG2' HD12 ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.869 HD12 ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.664 ' N ' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 129' ' ' ILE . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' HA ' HD23 ' A' ' 128' ' ' LEU . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.629 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HD2' HD13 ' A' ' 41' ' ' ILE . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.59 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.559 ' CD ' HG22 ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -94.38 136.41 34.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.463 ' SG ' HG23 ' A' ' 106' ' ' THR . 26.0 p -101.19 171.86 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.095 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.43 163.63 60.56 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.027 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.444 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 33.1 Cg_endo -63.97 -14.56 44.05 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.672 2.248 . . . . 0.0 112.622 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.6 mmmt -63.35 -42.9 98.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.918 0.39 . . . . 0.0 110.883 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.463 HG23 ' SG ' ' A' ' 102' ' ' CYS . 1.8 t -89.43 8.24 31.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.309 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -44.83 -29.66 0.84 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.754 -179.738 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.434 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 54.3 mt-30 -123.15 -28.86 3.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.306 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -47.22 138.4 7.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.947 0.403 . . . . 0.0 111.5 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.465 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.9 mttt -69.74 -21.91 63.42 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.054 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.465 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 4.1 t 86.4 109.36 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.028 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.52 149.7 41.31 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.41 -179.043 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.31 -10.8 27.75 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.824 2.349 . . . . 0.0 112.444 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.86 -27.36 60.73 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.646 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.7 OUTLIER -153.33 58.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.82 0.343 . . . . 0.0 111.077 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.538 ' O ' HG21 ' A' ' 120' ' ' VAL . 93.1 Cg_endo -84.73 14.39 2.48 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.625 2.216 . . . . 0.0 112.853 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -129.12 8.27 5.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.951 179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.505 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.91 -24.6 2.6 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.735 -179.801 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.466 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.87 20.07 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.538 HG21 ' O ' ' A' ' 116' ' ' PRO . 48.4 t -69.91 -23.47 25.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.96 0.409 . . . . 0.0 110.485 179.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.59 5.05 8.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.254 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.63 -64.54 1.13 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.922 0.391 . . . . 0.0 111.037 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.13 59.52 3.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.722 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.23 148.53 29.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.96 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.629 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.939 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.597 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.939 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.8 m-85 -96.79 122.49 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.3 171.18 0.03 OUTLIER Glycine 0 C--N 1.331 0.276 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.521 -179.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -129.82 90.26 2.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.785 0.326 . . . . 0.0 110.818 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . . . -158.77 143.84 9.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.534 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 20.7 p -75.62 62.97 1.5 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.933 0.397 . . . . 0.0 110.691 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.448 ' O ' HG22 ' A' ' 139' ' ' VAL . . . 173.18 -33.92 0.12 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.576 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.774 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m -48.75 103.03 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 137' ' ' GLY . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.488 ' HE2' HG11 ' A' ' 127' ' ' VAL . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.464 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.84 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.778 0.323 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -132.3 160.05 37.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.819 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.31 163.88 16.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.88 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.044 HD23 HG11 ' A' ' 125' ' ' VAL . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.686 ' N ' HD13 ' A' ' 5' ' ' LEU . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.406 ' CG ' HG11 ' A' ' 139' ' ' VAL . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.406 HG13 ' HB3' ' A' ' 58' ' ' LYS . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.447 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.779 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.601 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.563 ' HB3' ' HB2' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.475 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.673 ' HD2' HD12 ' A' ' 55' ' ' ILE . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.701 HD23 ' CD2' ' A' ' 57' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.612 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.776 HG21 HG11 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HD2' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.61 HD12 ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.618 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.588 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.643 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.874 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.874 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.673 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.563 ' HB2' ' HB3' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.701 ' CD2' HD23 ' A' ' 31' ' ' LEU . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.779 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 82' ' ' VAL . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.447 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.992 HG21 ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.512 ' HA ' HD23 ' A' ' 8' ' ' LEU . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 8' ' ' LEU . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.453 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.703 HG23 ' CD1' ' A' ' 78' ' ' LEU . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.703 ' CD1' HG23 ' A' ' 76' ' ' THR . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.548 ' HB2' HG12 ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.405 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.992 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 59' ' ' VAL . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.456 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.871 ' CG ' HD12 ' A' ' 89' ' ' LEU . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.6 p-80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.871 HD12 ' CG ' ' A' ' 86' ' ' PRO . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.651 ' N ' HD23 ' A' ' 89' ' ' LEU . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 129' ' ' ILE . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.455 ' HA ' HD23 ' A' ' 128' ' ' LEU . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.614 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.581 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.592 ' HD2' HG22 ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -128.39 107.79 10.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 19.5 m -85.93 171.9 11.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.039 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.97 163.48 56.16 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.137 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.422 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 57.1 Cg_endo -70.35 -9.09 25.14 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.661 2.241 . . . . 0.0 112.669 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -68.23 -39.84 82.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.882 0.372 . . . . 0.0 110.983 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 2.0 t -89.33 8.05 32.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.374 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.422 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -47.21 -28.98 2.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.811 0.339 . . . . 0.0 111.443 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -123.49 -29.58 3.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.238 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -47.31 138.34 7.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.008 0.432 . . . . 0.0 111.389 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.468 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -65.98 -21.88 66.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.144 179.831 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.492 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 86.04 112.19 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.125 -179.263 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.706 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.06 149.45 36.9 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.446 -179.182 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.63 -10.41 26.59 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.899 2.399 . . . . 0.0 112.475 179.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.94 -36.71 60.94 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.68 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.443 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.1 m-20 -146.33 60.66 6.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 111.151 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.545 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.0 Cg_endo -84.05 11.46 3.32 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.554 2.169 . . . . 0.0 112.818 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -131.04 7.89 4.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.013 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.522 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.03 -25.21 3.17 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.702 -179.768 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.493 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.92 18.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.84 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.545 HG21 ' O ' ' A' ' 116' ' ' PRO . 25.6 t -68.03 -24.17 29.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 110.4 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.05 5.37 8.32 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.948 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.76 -54.7 3.94 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.99 0.424 . . . . 0.0 111.172 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -91.35 41.61 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.217 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -73.44 157.41 36.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 1.044 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.785 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.96 HG21 ' CD1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.6 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.96 ' CD1' HG21 ' A' ' 129' ' ' ILE . 5.9 m-85 -96.62 138.24 34.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.04 -164.66 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.436 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.7 t -71.95 -7.24 47.46 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 61.77 15.83 49.47 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.713 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.2 t -98.78 32.2 2.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.029 0.442 . . . . 0.0 110.319 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 151.44 -30.35 0.95 Allowed Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.766 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 135' ' ' GLY . 8.8 m -55.76 121.76 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 82' ' ' VAL . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.785 ' HE2' HG21 ' A' ' 127' ' ' VAL . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.548 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.478 HG21 HH21 ' A' ' 145' ' ' ARG . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.672 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ARG . . . . . 0.478 HH21 HG21 ' A' ' 143' ' ' VAL . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 2.2 p80 . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.813 0.34 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.2 t -115.84 179.38 4.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.95 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -103.82 148.35 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.952 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.75 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.915 HD23 HG11 ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.748 HD12 ' HA3' ' A' ' 141' ' ' GLY . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.551 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.66 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.452 HG11 ' NE ' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.803 HG22 ' HD2' ' A' ' 21' ' ' ARG . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.424 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.803 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.556 ' HD2' HD12 ' A' ' 55' ' ' ILE . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.518 HD22 ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.956 HG21 HG11 ' A' ' 59' ' ' VAL . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.594 HG22 ' HD2' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.574 HD12 ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.558 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.771 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.771 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.556 HD12 ' HD2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.705 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.792 ' HG3' HG23 ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.956 HG11 HG21 ' A' ' 36' ' ' THR . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.66 ' SG ' HG22 ' A' ' 16' ' ' VAL . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.452 ' NE ' HG11 ' A' ' 17' ' ' VAL . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.837 HG21 HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.575 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.434 ' O ' ' HB ' ' A' ' 76' ' ' THR . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.647 HG23 ' CD1' ' A' ' 78' ' ' LEU . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.679 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.711 ' N ' HD13 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.569 ' H ' HG12 ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.837 HD13 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.705 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.424 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 20.3 m-70 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.523 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.624 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.593 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.594 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.603 ' HE1' HD23 ' A' ' 78' ' ' LEU . 81.4 t60 -123.01 138.48 54.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.7 p -114.05 171.83 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.963 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.72 162.73 71.59 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.438 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 73.4 Cg_endo -75.51 -5.27 16.36 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.581 2.188 . . . . 0.0 112.612 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -65.7 -35.46 80.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.88 8.17 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.221 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.438 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -49.48 -27.58 4.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.787 0.327 . . . . 0.0 111.511 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.01 -23.65 3.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.648 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.0 138.13 6.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.961 0.41 . . . . 0.0 111.484 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -60.44 -21.85 62.77 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.153 179.718 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.49 ' C ' HD13 ' A' ' 112' ' ' LEU . 8.3 m 82.45 110.85 0.06 Allowed 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.81 147.89 34.34 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.436 -178.94 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.05 -6.63 19.31 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.986 2.457 . . . . 0.0 112.489 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.88 -37.49 22.39 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.782 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 25.7 p30 -136.84 54.95 9.64 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.702 0.287 . . . . 0.0 111.32 -179.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.525 ' O ' HG21 ' A' ' 120' ' ' VAL . 97.8 Cg_endo -80.36 -0.46 10.66 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.51 2.14 . . . . 0.0 112.59 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.425 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.2 m120 -130.84 12.54 5.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.102 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.615 ' CG ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.1 -79.89 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.521 -179.664 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.665 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -89.0 -2.97 58.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.839 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.525 HG21 ' O ' ' A' ' 116' ' ' PRO . 77.0 t -52.86 -28.2 13.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.856 0.36 . . . . 0.0 110.736 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -109.41 -20.88 7.55 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.056 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.67 -64.57 0.86 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.913 0.387 . . . . 0.0 111.109 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.23 61.84 1.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.959 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p -84.77 132.82 34.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.861 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.915 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.562 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.954 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.954 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 -96.84 135.15 39.21 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.57 -173.06 0.07 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 98.4 p -106.98 55.13 0.66 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.367 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.763 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.38 -128.9 10.74 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.894 179.51 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 67.69 9.49 7.11 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.534 0.198 . . . . 0.0 111.534 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 129.86 -18.91 5.31 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.379 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.763 HG22 ' HA2' ' A' ' 135' ' ' GLY . 16.6 m -49.55 119.15 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.424 HG12 ' HA ' ' A' ' 83' ' ' MET . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.748 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.75 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.628 ' CG ' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.425 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 120.776 0.322 . . . . 0.0 111.364 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.9 m -55.08 173.18 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.147 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p -118.57 174.69 6.11 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.833 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.061 HD23 HG11 ' A' ' 125' ' ' VAL . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.66 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.734 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.696 ' HG2' HG11 ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.436 HG22 ' SG ' ' A' ' 60' ' ' CYS . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.918 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.667 HG23 ' CG ' ' A' ' 58' ' ' LYS . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.775 ' HB1' HD11 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.658 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.696 ' HZ ' HD23 ' A' ' 31' ' ' LEU . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.97 HD12 ' CE2' ' A' ' 57' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.432 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.647 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.105 HG21 HG11 ' A' ' 59' ' ' VAL . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.589 HG22 ' HD2' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.48 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.621 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.815 ' HG2' HG11 ' A' ' 51' ' ' VAL . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 26' ' ' SER . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.815 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.497 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.97 ' CE2' HD12 ' A' ' 31' ' ' LEU . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.667 ' CG ' HG23 ' A' ' 19' ' ' THR . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.105 HG11 HG21 ' A' ' 36' ' ' THR . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.436 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.5 p-10 -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.899 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.571 ' HA ' HD23 ' A' ' 8' ' ' LEU . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.563 ' HD3' HD23 ' A' ' 8' ' ' LEU . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.467 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.579 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.643 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.513 ' HB2' HG12 ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.899 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.791 ' O ' HG23 ' A' ' 139' ' ' VAL . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.413 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.534 HD21 ' CE1' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.534 ' CE1' HD21 ' A' ' 89' ' ' LEU . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 129' ' ' ILE . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.421 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.605 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.559 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.589 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -118.24 128.81 55.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 16.1 m -98.54 171.91 7.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.882 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -72.85 163.45 68.14 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.972 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 55.2 Cg_endo -69.87 -11.57 30.95 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.577 2.184 . . . . 0.0 112.541 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -67.18 -37.11 83.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.921 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.71 8.05 33.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.315 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -47.81 -28.81 2.75 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 120.797 0.332 . . . . 0.0 111.391 179.977 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.444 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 48.4 mt-30 -126.23 -24.93 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.383 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -46.69 138.77 5.78 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.001 0.429 . . . . 0.0 111.437 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 18.8 mtpt -66.78 -21.79 66.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.07 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.473 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 84.39 109.84 0.06 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.115 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.91 148.39 36.9 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.398 -178.96 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -72.95 -8.38 22.17 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.97 2.447 . . . . 0.0 112.573 179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.88 -29.03 39.81 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.764 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.7 m-20 -146.3 56.15 3.04 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 120.76 0.314 . . . . 0.0 111.236 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.485 ' O ' HG21 ' A' ' 120' ' ' VAL . 84.2 Cg_endo -81.81 6.51 5.62 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.543 2.162 . . . . 0.0 112.643 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -127.8 9.46 6.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.874 179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.557 ' CD1' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.87 -25.28 3.04 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.844 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.557 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -164.67 18.03 0.05 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 111.904 0.335 . . . . 0.0 111.904 -179.88 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 116' ' ' PRO . 24.8 t -68.44 -23.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.962 0.411 . . . . 0.0 110.324 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.91 -0.61 9.8 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.229 179.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.07 -66.16 0.93 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.916 0.388 . . . . 0.0 110.972 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.02 59.14 2.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.705 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p -82.86 148.47 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 1.061 HG11 HD23 ' A' ' 5' ' ' LEU . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.722 HG21 ' HE2' ' A' ' 140' ' ' TYR . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.477 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.94 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.94 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.2 m-85 -96.74 138.13 34.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 -167.79 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.522 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 3.2 m -88.01 22.1 2.5 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.38 -152.57 1.15 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.936 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.8 m 56.74 21.87 6.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 111.29 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 169.61 -46.17 0.21 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.544 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.797 HG22 ' HA2' ' A' ' 135' ' ' GLY . 14.1 m -56.13 125.04 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 82' ' ' VAL . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.722 ' HE2' HG21 ' A' ' 127' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.643 ' CG ' HD11 ' A' ' 78' ' ' LEU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 53.3 p-80 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.873 0.368 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -144.09 175.45 10.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.78 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p -135.08 153.71 51.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.898 HD23 HG11 ' A' ' 125' ' ' VAL . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.695 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.613 HG22 ' CE1' ' A' ' 140' ' ' TYR . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.599 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.722 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.722 HG22 ' SG ' ' A' ' 60' ' ' CYS . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.811 HG23 ' HG3' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD3' ' CD2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.487 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.535 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.535 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.116 HG21 HG11 ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.622 ' CG2' HD23 ' A' ' 99' ' ' LEU . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.609 HD12 ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.655 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.503 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.814 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.814 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.442 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.564 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.482 ' CD2' ' HD3' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.609 ' CD1' HD12 ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.811 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.116 HG11 HG21 ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.722 ' SG ' HG22 ' A' ' 16' ' ' VAL . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.3 p-10 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.708 HD13 HD11 ' A' ' 81' ' ' LEU . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.599 ' HA ' HD23 ' A' ' 8' ' ' LEU . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.531 HG22 ' CD ' ' A' ' 144' ' ' ARG . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.802 HD11 ' HG3' ' A' ' 144' ' ' ARG . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.575 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.437 ' HB2' HG13 ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.708 HD11 HD13 ' A' ' 65' ' ' ILE . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.564 HG13 ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.451 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.524 ' HG2' HD12 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.823 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.738 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.823 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.467 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.696 HG22 ' O ' ' A' ' 129' ' ' ILE . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 41' ' ' ILE . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.611 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.622 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 -107.27 118.4 36.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 119' ' ' LEU . 18.5 p -95.38 171.91 8.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.86 163.36 50.46 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.096 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.424 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 60.8 Cg_endo -72.56 -14.51 27.56 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.668 2.246 . . . . 0.0 112.441 179.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.2 mmmt -57.84 -35.6 71.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.831 0.348 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.27 8.16 31.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.254 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.453 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.03 -28.81 1.8 Allowed 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.775 0.321 . . . . 0.0 111.555 -179.851 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.453 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 17.0 mt-30 -121.52 -31.84 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.996 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -48.69 138.12 11.27 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 111.439 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.456 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 3.8 mptt -68.1 -21.57 64.94 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.956 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.477 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 85.18 109.97 0.05 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.788 -179.08 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.724 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.44 148.44 36.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 121.118 0.485 . . . . 0.0 111.436 -178.792 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.22 -8.69 23.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.904 2.403 . . . . 0.0 112.311 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.76 -39.54 33.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.679 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 38.4 p30 -142.8 56.42 4.98 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 120.699 0.285 . . . . 0.0 111.339 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.485 ' O ' HG21 ' A' ' 120' ' ' VAL . 69.0 Cg_endo -86.52 18.33 1.59 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.717 2.278 . . . . 0.0 112.781 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -128.36 8.61 6.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.908 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.549 ' C ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.9 -23.94 2.22 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.621 -179.771 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.549 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -170.84 21.93 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.55 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 116' ' ' PRO . 15.5 t -66.77 -25.92 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.939 0.399 . . . . 0.0 110.382 179.762 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -123.34 4.64 9.49 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.257 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.82 -42.73 11.1 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.842 0.353 . . . . 0.0 111.076 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -94.65 34.13 1.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.051 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p -59.75 137.56 58.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.044 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.898 HG11 HD23 ' A' ' 5' ' ' LEU . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.535 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.915 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.738 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.8 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.915 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.1 m-85 -96.44 107.39 19.78 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.36 168.3 0.02 OUTLIER Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.927 -0.578 . . . . 0.0 113.51 -178.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.4 25.11 11.82 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.612 0.244 . . . . 0.0 111.286 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.792 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -59.92 167.57 8.9 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.45 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 53.0 p -80.83 -20.78 41.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.677 0.275 . . . . 0.0 111.158 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.95 22.13 2.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.979 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.792 HG13 ' HA3' ' A' ' 135' ' ' GLY . 23.3 m -58.4 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.613 ' CE1' HG22 ' A' ' 7' ' ' VAL . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.447 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.802 ' HG3' HD11 ' A' ' 78' ' ' LEU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 22.0 p-80 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.844 0.354 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -174.22 150.18 1.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p -128.69 168.04 16.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.796 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.796 ' N ' HD13 ' A' ' 5' ' ' LEU . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.47 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.781 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.834 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.678 HG22 ' SG ' ' A' ' 60' ' ' CYS . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.954 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.919 HG22 ' HD2' ' A' ' 21' ' ' ARG . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.416 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.919 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.595 ' HD2' HD12 ' A' ' 55' ' ' ILE . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.416 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.663 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.017 HG21 HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.566 HG22 ' HD2' ' A' ' 100' ' ' PRO . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.499 HD12 ' CD1' ' A' ' 57' ' ' PHE . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.893 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.893 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.595 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.687 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.683 ' HB2' HG13 ' A' ' 82' ' ' VAL . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.717 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.017 HG11 HG21 ' A' ' 36' ' ' THR . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.678 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.835 HG21 ' CD1' ' A' ' 81' ' ' LEU . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.718 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.47 ' HA ' HD23 ' A' ' 8' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 76' ' ' THR . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 69' ' ' LEU . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 79' ' ' SER . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.912 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.745 ' O ' HD23 ' A' ' 77' ' ' LEU . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.835 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.683 HG13 ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.696 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.413 ' HB2' ' HB3' ' A' ' 134' ' ' SER . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.507 HD21 ' CE1' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.507 ' CE1' HD21 ' A' ' 89' ' ' LEU . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.452 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.713 HG12 HG23 ' A' ' 42' ' ' ILE . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.597 ' C ' HD23 ' A' ' 97' ' ' LEU . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.578 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HD2' HG22 ' A' ' 38' ' ' VAL . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -128.71 131.71 47.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 17.3 p -105.18 171.85 7.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.068 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.38 163.39 58.84 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 62.3 Cg_endo -73.26 -14.72 25.58 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.553 2.168 . . . . 0.0 112.441 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -35.6 72.9 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.2 8.17 31.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.29 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.469 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.68 -28.44 2.41 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.568 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.469 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 14.0 mt-30 -123.43 -30.42 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.28 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.05 138.21 6.86 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.973 0.416 . . . . 0.0 111.352 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.451 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -65.55 -21.8 66.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.07 179.711 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.49 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.9 OUTLIER 84.64 110.79 0.05 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.983 -179.17 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.7 147.81 34.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.471 -178.972 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.46 -7.9 21.68 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.913 2.409 . . . . 0.0 112.471 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.0 -40.06 22.1 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.859 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.458 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.2 t0 -138.66 55.93 8.9 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.618 0.247 . . . . 0.0 111.342 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.506 ' O ' HG21 ' A' ' 120' ' ' VAL . 94.7 Cg_endo -84.44 12.32 3.08 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.595 2.197 . . . . 0.0 112.797 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -128.79 8.24 5.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.758 0.313 . . . . 0.0 111.005 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.83 -24.59 2.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.666 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.451 ' C ' ' CD2' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -168.56 20.23 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -179.839 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.506 HG21 ' O ' ' A' ' 116' ' ' PRO . 20.5 t -67.44 -24.29 31.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.88 0.372 . . . . 0.0 110.48 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -126.21 4.16 7.79 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.253 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.6 -44.35 10.14 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.945 0.403 . . . . 0.0 111.284 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -95.12 35.64 1.27 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.084 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m -59.84 158.62 10.24 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.09 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.789 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.565 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.964 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.604 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.964 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.8 m-85 -96.72 116.25 28.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 177.96 0.17 Allowed Glycine 0 C--N 1.33 0.219 0 C-N-CA 121.061 -0.59 . . . . 0.0 113.12 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 87' ' ' HIS . 0.0 OUTLIER -143.39 96.56 2.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.78 0.324 . . . . 0.0 110.705 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.41 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -128.22 -174.11 13.65 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.517 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.7 m -57.78 -27.74 63.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.939 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -169.84 43.9 0.21 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.494 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.781 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m -57.5 92.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.696 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.634 ' CD2' HD11 ' A' ' 5' ' ' LEU . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.912 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 88.7 m-70 . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.768 0.318 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 78.0 p -161.15 177.95 9.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p -134.62 150.71 50.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.922 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.595 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.638 HD11 ' CD2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.603 ' N ' HD13 ' A' ' 5' ' ' LEU . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 77' ' ' LEU . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.694 HG22 ' SG ' ' A' ' 60' ' ' CYS . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.956 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.742 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.501 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.637 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.664 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.081 HG21 HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.545 ' CG2' HD23 ' A' ' 99' ' ' LEU . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.546 HD12 ' CD1' ' A' ' 57' ' ' PHE . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.708 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.783 ' HG2' HG11 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.783 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.494 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.595 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.676 ' HB2' HG13 ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.742 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.081 HG11 HG21 ' A' ' 36' ' ' THR . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.694 ' SG ' HG22 ' A' ' 16' ' ' VAL . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.525 HG21 HD22 ' A' ' 81' ' ' LEU . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.703 ' O ' HD23 ' A' ' 66' ' ' LEU . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' O ' ' HB ' ' A' ' 76' ' ' THR . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.508 HG22 ' CD ' ' A' ' 144' ' ' ARG . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 8' ' ' LEU . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.728 HD21 ' HD2' ' A' ' 144' ' ' ARG . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.513 ' O ' HD23 ' A' ' 77' ' ' LEU . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.525 HD22 HG21 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.676 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.482 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.431 ' HA ' ' O ' ' A' ' 134' ' ' SER . 44.8 p-80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.525 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.708 HG12 HG23 ' A' ' 42' ' ' ILE . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.406 ' HA ' HD23 ' A' ' 128' ' ' LEU . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.77 HD22 ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 38' ' ' VAL . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.545 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.545 ' CD ' HG22 ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.44 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 -106.68 119.33 39.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.456 ' HB3' HG21 ' A' ' 106' ' ' THR . 72.3 m -85.52 171.8 11.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.009 0.433 . . . . 0.0 111.183 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.56 163.52 67.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.924 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 29.1 Cg_endo -62.69 -16.29 51.99 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.679 2.253 . . . . 0.0 112.555 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 28.9 mmtt -59.84 -37.31 78.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.999 0.428 . . . . 0.0 110.892 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.456 HG21 ' HB3' ' A' ' 102' ' ' CYS . 1.7 t -89.29 8.12 32.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.254 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.432 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.59 -30.04 1.38 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.753 0.311 . . . . 0.0 111.495 -179.81 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 2.7 mt-30 -119.44 -31.05 4.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.976 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -50.94 138.23 19.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.028 0.442 . . . . 0.0 111.444 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 15.0 mttt -74.97 -21.6 59.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.031 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.499 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 5.3 t 89.96 109.03 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.886 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.713 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.75 150.68 39.09 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.428 -179.033 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -70.7 -11.68 29.98 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.799 2.333 . . . . 0.0 112.51 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.38 -31.63 71.46 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.661 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.449 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.2 t0 -157.7 60.99 2.1 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.231 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.491 ' O ' HG21 ' A' ' 120' ' ' VAL . 81.8 Cg_endo -86.91 20.04 1.29 Allowed 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.753 2.302 . . . . 0.0 112.738 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -127.16 7.8 6.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.825 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.678 ' C ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.86 -23.28 1.83 Allowed 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.689 -179.676 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.678 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -174.78 24.6 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 179.614 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.491 HG21 ' O ' ' A' ' 116' ' ' PRO . 28.9 t -69.3 -25.01 28.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.761 0.315 . . . . 0.0 110.492 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -114.87 -14.44 8.6 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.28 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.54 -70.17 0.32 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -71.49 63.93 0.41 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -83.54 134.24 34.84 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.105 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.77 ' CG1' HD22 ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.968 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.968 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.1 m-85 -96.75 133.31 41.48 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.92 -165.48 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.776 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.431 ' O ' ' HA ' ' A' ' 87' ' ' HIS . 28.3 t -62.06 -115.65 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 O-C-N 123.01 -0.112 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.494 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . -179.05 -31.05 0.05 OUTLIER Glycine 0 C--N 1.335 0.504 0 C-N-CA 120.226 -0.988 . . . . 0.0 112.864 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.0 p -75.97 57.47 1.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.686 0.279 . . . . 0.0 111.6 -179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 127.43 27.26 0.99 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.97 179.528 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 138' ' ' VAL . 33.4 m -129.53 110.91 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.687 ' HE2' HG21 ' A' ' 127' ' ' VAL . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.595 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.728 ' HD2' HD21 ' A' ' 78' ' ' LEU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.403 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.7 p-80 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.795 0.331 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.95 -174.51 4.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.87 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p -138.58 148.76 44.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.772 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.528 ' HB2' HG11 ' A' ' 125' ' ' VAL . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.611 HD12 ' N ' ' A' ' 8' ' ' LEU . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.477 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.496 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' SG ' ' A' ' 60' ' ' CYS . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.584 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.619 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.799 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.502 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.54 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.491 ' HB2' ' HB1' ' A' ' 18' ' ' ALA . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.033 HG21 HG11 ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.565 HG22 ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.822 HG12 HD12 ' A' ' 97' ' ' LEU . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.564 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.782 ' HG2' HG11 ' A' ' 51' ' ' VAL . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.782 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.493 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.55 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.502 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.438 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.799 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.033 HG11 HG21 ' A' ' 36' ' ' THR . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.448 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.584 ' HD3' HG11 ' A' ' 17' ' ' VAL . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.914 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.697 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.475 ' HA ' HD23 ' A' ' 8' ' ' LEU . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.455 HD22 ' CA ' ' A' ' 76' ' ' THR . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.488 HG22 ' CD ' ' A' ' 144' ' ' ARG . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.533 HD11 ' CG ' ' A' ' 144' ' ' ARG . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.914 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 139' ' ' VAL . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.408 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.635 HD21 ' CE1' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.635 ' CE1' HD21 ' A' ' 89' ' ' LEU . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.683 HG12 HG23 ' A' ' 42' ' ' ILE . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.822 HD12 HG12 ' A' ' 40' ' ' ILE . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.654 ' HG3' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.657 HD12 ' HB ' ' A' ' 125' ' ' VAL . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.565 ' CD ' HG22 ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.763 ' CD2' HG21 ' A' ' 142' ' ' VAL . 23.0 t-80 -120.93 116.08 24.44 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 106' ' ' THR . 37.3 m -94.5 171.93 8.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -72.58 163.52 67.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.853 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.415 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.9 Cg_endo -64.64 -14.74 46.32 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.687 2.258 . . . . 0.0 112.544 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.5 mmmt -64.35 -40.0 95.01 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 110.912 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.435 HG21 ' HB3' ' A' ' 102' ' ' CYS . 1.9 t -89.27 8.31 31.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.362 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.415 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.75 -28.09 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.831 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -147.1 18.66 1.24 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.824 0.305 . . . . 0.0 111.824 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.8 t-20 -79.07 136.87 37.29 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.901 0.382 . . . . 0.0 111.048 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.462 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.5 mttt -59.66 -21.91 61.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.103 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.508 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 85.35 113.12 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.993 -179.242 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.697 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.78 154.18 39.93 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.267 -179.211 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.83 -14.39 35.81 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.62 2.214 . . . . 0.0 112.076 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.5 95.09 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.516 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.407 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 33.3 p-10 -174.93 73.91 0.3 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.698 0.285 . . . . 0.0 111.324 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -84.6 9.81 3.99 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.731 2.287 . . . . 0.0 112.68 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.472 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 5.5 m120 -129.78 15.57 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.113 0.482 . . . . 0.0 110.851 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.575 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.05 -79.73 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.572 -179.681 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.661 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.57 2.83 56.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.914 -179.807 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.472 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 42.7 t -52.38 -28.98 12.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.802 0.334 . . . . 0.0 110.739 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.03 3.88 10.62 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.35 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.523 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -89.61 -46.22 8.8 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.933 0.397 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 101' ' ' HIS . 1.2 m-80 -92.17 25.14 3.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.356 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p -53.69 157.78 2.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.657 ' HB ' HD12 ' A' ' 99' ' ' LEU . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.897 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.897 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.6 m-85 -96.74 134.64 39.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.03 -171.35 0.05 OUTLIER Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.979 -0.555 . . . . 0.0 113.295 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.408 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 2.3 m -95.74 32.34 1.87 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.581 0.229 . . . . 0.0 111.534 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.84 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.44 -143.87 5.76 Favored Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.853 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.43 14.26 9.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.578 0.228 . . . . 0.0 111.562 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 157.6 -40.55 0.53 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.577 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.84 HG22 ' HA2' ' A' ' 135' ' ' GLY . 3.9 m -49.68 123.02 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 82' ' ' VAL . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.763 HG21 ' CD2' ' A' ' 101' ' ' HIS . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.772 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.533 ' CG ' HD11 ' A' ' 78' ' ' LEU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.416 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 12.8 p-80 . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.868 0.366 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.5 m -165.76 139.39 4.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.798 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 87.4 p -104.35 143.12 33.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.019 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.714 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.885 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.674 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.514 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.705 ' OE1' HG22 ' A' ' 65' ' ' ILE . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.67 HG22 ' SG ' ' A' ' 60' ' ' CYS . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.465 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.865 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.827 HG23 ' HG3' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.419 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.546 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.4 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.676 HG21 HG11 ' A' ' 59' ' ' VAL . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.599 HG22 ' HD2' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.596 HD12 ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.559 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.639 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.767 ' HG2' HG11 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.767 HG11 ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.486 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.596 ' CD1' HD12 ' A' ' 40' ' ' ILE . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.827 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.865 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.67 ' SG ' HG22 ' A' ' 16' ' ' VAL . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.465 ' HD3' HG11 ' A' ' 17' ' ' VAL . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 11.1 p-10 -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.78 HD13 HD11 ' A' ' 81' ' ' LEU . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HA ' HD23 ' A' ' 8' ' ' LEU . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.55 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.82 HD11 ' HG3' ' A' ' 144' ' ' ARG . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.477 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.78 HD11 HD13 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 59' ' ' VAL . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.402 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.612 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.551 ' CE1' HD21 ' A' ' 89' ' ' LEU . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.459 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.639 HG12 HG23 ' A' ' 42' ' ' ILE . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.469 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.669 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.669 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' HG22 ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 125' ' ' VAL . 12.6 t60 -91.02 127.77 36.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 37.9 m -85.33 171.82 11.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.995 0.426 . . . . 0.0 111.254 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.06 163.6 54.56 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.973 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 32.7 Cg_endo -63.85 -14.83 45.45 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.662 2.241 . . . . 0.0 112.54 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.3 mttt -61.88 -39.61 92.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.916 0.389 . . . . 0.0 110.958 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.35 8.14 32.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.275 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.429 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.53 -28.67 1.49 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.66 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 33.8 mt-30 -126.13 -26.79 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.537 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -46.98 138.12 6.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.029 0.442 . . . . 0.0 111.405 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.446 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -63.79 -21.83 66.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.033 179.737 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.468 ' C ' HD13 ' A' ' 112' ' ' LEU . 5.2 t 83.89 109.82 0.06 Allowed 'General case' 0 N--CA 1.462 0.14 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.061 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.709 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.18 147.51 34.8 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.553 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.75 -6.39 18.56 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 123.055 2.503 . . . . 0.0 112.597 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.35 -31.17 20.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.768 -179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.447 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.3 m-20 -130.74 53.9 13.14 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.732 0.301 . . . . 0.0 111.306 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.515 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.6 Cg_endo -82.45 9.51 3.98 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.489 2.126 . . . . 0.0 112.716 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -129.88 6.83 5.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.106 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.533 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.13 -23.93 2.45 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.819 -179.792 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.446 ' C ' ' CD2' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -168.05 20.53 0.03 OUTLIER 'General case' 0 C--O 1.233 0.212 0 N-CA-C 111.826 0.306 . . . . 0.0 111.826 179.877 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.515 HG21 ' O ' ' A' ' 116' ' ' PRO . 13.2 t -68.43 -24.35 29.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.985 0.421 . . . . 0.0 110.472 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -118.3 4.63 15.59 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.104 179.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.67 -70.73 0.65 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.89 0.376 . . . . 0.0 111.13 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -77.94 61.41 2.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.812 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -77.04 155.82 32.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.173 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.885 HG11 HD23 ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.768 HG21 ' HE2' ' A' ' 140' ' ' TYR . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 96' ' ' GLU . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.612 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.0 m-85 -96.73 138.55 34.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.92 -168.21 0.02 OUTLIER Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.586 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.416 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 74.5 p -89.73 23.45 2.68 Favored 'General case' 0 C--N 1.333 -0.126 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.755 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.57 -153.85 0.95 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.96 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 58.82 19.97 7.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 111.427 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.77 -46.06 0.24 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.451 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.755 HG22 ' HA2' ' A' ' 135' ' ' GLY . 16.2 m -56.88 119.95 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 10' ' ' GLN . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.768 ' HE2' HG21 ' A' ' 127' ' ' VAL . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.453 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.82 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' HIS . . . . . 0.426 ' CD2' ' HA ' ' A' ' 146' ' ' SER . 13.4 m80 . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.815 0.341 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -107.99 -169.03 1.45 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.839 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -136.54 152.61 50.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.822 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.82 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.82 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.476 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.656 HG22 ' SG ' ' A' ' 60' ' ' CYS . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.935 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.657 HG23 ' HG3' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.58 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.451 HD13 ' CA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.68 ' HD2' HD12 ' A' ' 55' ' ' ILE . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.61 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.854 HG21 HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.57 HG22 ' HD2' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.604 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.675 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.638 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.8 ' HG2' HG11 ' A' ' 51' ' ' VAL . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.8 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.451 ' CA ' HD13 ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.68 HD12 ' HD2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.58 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.657 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.935 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.656 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.8 p-10 -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.794 HD13 HD11 ' A' ' 81' ' ' LEU . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.541 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.476 ' HA ' HD23 ' A' ' 8' ' ' LEU . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.552 HG23 ' CD2' ' A' ' 78' ' ' LEU . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.878 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.726 ' O ' HD23 ' A' ' 77' ' ' LEU . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.406 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.794 HD11 HD13 ' A' ' 65' ' ' ILE . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.651 ' O ' HG12 ' A' ' 139' ' ' VAL . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.606 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.606 ' CE1' HD21 ' A' ' 89' ' ' LEU . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.472 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.675 HG12 HG23 ' A' ' 42' ' ' ILE . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.606 HD21 ' HG ' ' A' ' 99' ' ' LEU . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.606 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -129.86 99.93 5.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 24.9 p -66.62 171.81 4.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.427 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -75.85 163.65 65.59 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.023 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.449 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 36.6 Cg_endo -64.95 -10.98 27.46 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.663 2.242 . . . . 0.0 112.771 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 14.1 mmtt -71.43 -40.5 70.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 110.981 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -97.12 8.31 44.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.295 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.449 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -45.32 -28.64 0.87 Allowed 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.715 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.426 ' NE2' ' CZ2' ' A' ' 107' ' ' TRP . 68.0 mt-30 -125.98 -26.23 3.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.412 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -46.86 138.35 6.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.048 0.451 . . . . 0.0 111.475 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -62.12 -21.94 65.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 179.878 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.489 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 84.9 111.9 0.05 Allowed 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.182 -179.275 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.693 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.69 152.4 39.8 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.269 -179.212 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.77 -13.2 31.94 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.72 2.28 . . . . 0.0 112.333 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.31 -31.0 77.71 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.549 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.446 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.1 m-20 -165.51 62.21 0.81 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.84 0.353 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.525 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.3 Cg_endo -83.92 11.68 3.24 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.6 2.2 . . . . 0.0 112.825 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -128.97 9.04 5.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.92 179.581 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.508 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.84 -25.35 3.05 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.757 -179.821 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.45 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -166.1 17.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.872 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.525 HG21 ' O ' ' A' ' 116' ' ' PRO . 52.3 t -69.09 -23.91 27.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 121.008 0.432 . . . . 0.0 110.175 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -124.16 -1.11 8.76 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.26 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.02 -65.43 1.01 Allowed 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.931 0.396 . . . . 0.0 110.984 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.82 59.8 1.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.679 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m -82.87 150.08 26.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.725 HG11 HD23 ' A' ' 5' ' ' LEU . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 8.6 m-85 -96.75 133.93 40.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -60.94 -151.76 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.782 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -75.69 -24.17 56.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.794 0.33 . . . . 0.0 111.41 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.5 ' H ' HG22 ' A' ' 138' ' ' VAL . . . 82.46 -53.93 4.85 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.803 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 12.4 t -52.67 -24.3 8.26 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -124.29 -9.63 5.45 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.419 -0.896 . . . . 0.0 113.109 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.5 HG22 ' H ' ' A' ' 135' ' ' GLY . 2.4 m -110.99 126.84 68.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.938 0.369 . . . . 0.0 111.018 -179.748 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 82' ' ' VAL . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.461 ' HD2' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.505 HG12 ' N ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.878 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.426 ' HA ' ' CD2' ' A' ' 1' ' ' HIS . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.636 0.255 . . . . 0.0 111.458 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.8 p -113.32 178.33 4.32 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.804 0.335 . . . . 0.0 110.998 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p -136.42 158.11 45.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.821 HD23 ' HB ' ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.645 HD22 ' HD3' ' A' ' 68' ' ' PRO . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.645 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.534 ' HG2' HG21 ' A' ' 139' ' ' VAL . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.612 HG11 HH11 ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.884 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.802 HG23 ' HG3' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.44 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.669 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.583 HD23 ' CE1' ' A' ' 57' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.412 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.88 HG21 HG11 ' A' ' 59' ' ' VAL . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.553 HG22 ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.576 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.587 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.486 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.866 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.866 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.631 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.583 ' CE1' HD23 ' A' ' 31' ' ' LEU . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.802 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.884 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 15' ' ' THR . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.612 HH11 HG11 ' A' ' 17' ' ' VAL . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 10.7 p-10 -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.936 HG21 ' HG ' ' A' ' 81' ' ' LEU . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.645 ' HD3' HD22 ' A' ' 8' ' ' LEU . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.491 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HE2' HD11 ' A' ' 69' ' ' LEU . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.491 ' N ' HD13 ' A' ' 69' ' ' LEU . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.81 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.48 ' N ' HG11 ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.936 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.601 ' O ' HG12 ' A' ' 139' ' ' VAL . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.636 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 27.7 p-80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.407 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.487 HD21 ' CE1' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.498 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 129' ' ' ILE . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.603 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.567 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.553 ' CD ' HG22 ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.456 ' HB2' HG23 ' A' ' 125' ' ' VAL . 50.5 t-80 -112.26 128.74 56.35 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.3 m -99.74 171.83 7.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.011 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.3 163.54 66.6 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.3 Cg_endo -64.58 -13.08 36.78 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.61 2.206 . . . . 0.0 112.677 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.91 -42.25 63.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.842 0.353 . . . . 0.0 110.984 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.486 HG21 HD21 ' A' ' 119' ' ' LEU . 1.8 t -94.76 8.31 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.329 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.439 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.06 -28.22 1.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.869 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.439 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 8.2 mt-30 -147.04 17.76 1.23 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.636 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 3.8 t-20 -76.13 142.49 41.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.933 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.415 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -56.99 -22.0 35.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.195 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.513 ' C ' HD13 ' A' ' 112' ' ' LEU . 8.1 m 82.15 111.82 0.06 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.118 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.71 154.83 39.88 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.265 -179.244 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 -16.04 36.67 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.642 2.228 . . . . 0.0 112.281 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.78 -35.25 85.79 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.333 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.438 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 6.9 t0 -176.12 67.24 0.24 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.943 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.455 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.7 Cg_endo -81.12 5.85 5.97 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.668 2.245 . . . . 0.0 112.879 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.464 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 6.1 m120 -130.53 14.08 5.47 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.909 0.385 . . . . 0.0 111.007 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.08 -79.88 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.563 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.688 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -90.36 -1.88 57.94 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.929 -179.694 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.464 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 70.4 t -51.46 -29.2 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.963 0.411 . . . . 0.0 110.673 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.36 -9.32 10.5 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.34 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -76.44 -68.45 0.59 Allowed 'General case' 0 C--O 1.232 0.172 0 CA-C-O 120.835 0.35 . . . . 0.0 111.241 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -78.9 59.84 2.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.853 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m -80.11 160.6 25.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.105 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.821 ' HB ' HD23 ' A' ' 5' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.955 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.491 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.955 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 9.4 m-85 -96.86 139.1 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.44 -167.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 116.0 -0.546 . . . . 0.0 113.497 -179.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.407 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 87.0 p -87.58 21.38 2.57 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.768 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.28 -154.12 1.18 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.934 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.5 p 58.85 20.14 7.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.626 0.25 . . . . 0.0 111.429 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.72 -43.92 0.24 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.525 -0.845 . . . . 0.0 112.304 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.768 HG22 ' HA2' ' A' ' 135' ' ' GLY . 11.9 m -59.85 121.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 83' ' ' MET . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.765 ' HE2' HG21 ' A' ' 127' ' ' VAL . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 79' ' ' SER . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 143' ' ' VAL . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.81 ' CG ' HD11 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.915 0.388 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.9 131.36 7.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.89 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -105.25 146.74 28.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.929 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.872 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.872 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.771 HD23 ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.608 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.487 ' HG2' HG21 ' A' ' 139' ' ' VAL . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.938 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.846 HG23 ' HG3' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.64 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.623 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.553 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.708 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.041 HG21 HG11 ' A' ' 59' ' ' VAL . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.548 HG22 ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.63 HD12 ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.625 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' HB1' ' HB3' ' A' ' 91' ' ' PHE . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.562 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.668 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.668 HG11 ' HG2' ' A' ' 48' ' ' PRO . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.623 HD12 ' HD2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.64 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.63 ' CD1' HD12 ' A' ' 40' ' ' ILE . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.846 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.041 HG11 HG21 ' A' ' 36' ' ' THR . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 81' ' ' LEU . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.607 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.771 ' HD2' HD23 ' A' ' 8' ' ' LEU . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.877 HG22 ' HD3' ' A' ' 144' ' ' ARG . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.645 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.65 HD21 ' HD2' ' A' ' 144' ' ' ARG . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.645 ' O ' HD23 ' A' ' 77' ' ' LEU . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.75 HD11 HD13 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG22 ' A' ' 59' ' ' VAL . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.419 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.599 ' CD2' ' HA3' ' A' ' 135' ' ' GLY . 0.4 OUTLIER -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.431 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.462 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.653 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.653 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.548 ' CD ' HG22 ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 1.4 t60 -101.29 100.02 10.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 106' ' ' THR . 14.6 p -75.83 171.85 13.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.007 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.32 163.44 58.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.949 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.421 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.2 Cg_endo -66.21 -13.05 38.14 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.653 2.236 . . . . 0.0 112.608 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.0 mmtt -66.98 -42.35 85.23 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.958 0.409 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.573 HG23 ' SG ' ' A' ' 102' ' ' CYS . 1.8 t -89.87 8.47 31.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.335 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.431 ' CG ' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.08 -28.18 1.13 Allowed 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.654 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.431 ' HG3' ' CG ' ' A' ' 107' ' ' TRP . 39.8 mt-30 -150.45 21.61 0.83 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.437 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.8 t-20 -78.1 145.51 35.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.864 0.364 . . . . 0.0 110.999 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.429 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 73.4 mttt -58.64 -21.94 55.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.224 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.502 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.6 OUTLIER 82.24 111.43 0.06 Allowed 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.953 0.406 . . . . 0.0 109.988 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.694 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.82 153.66 39.99 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.263 -179.248 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.92 -14.35 35.48 Favored 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.615 2.21 . . . . 0.0 112.111 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.77 -41.13 95.8 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.543 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.413 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.2 OUTLIER -174.03 74.41 0.35 Allowed Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.89 0.376 . . . . 0.0 111.188 -179.916 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.538 ' O ' HG21 ' A' ' 120' ' ' VAL . 83.0 Cg_endo -82.74 4.27 7.21 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.644 2.23 . . . . 0.0 112.484 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.452 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.8 m120 -131.01 13.86 5.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.811 0.339 . . . . 0.0 111.007 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.577 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.18 -80.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.383 -179.686 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.646 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -88.41 -5.15 58.45 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.731 -179.987 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.538 HG21 ' O ' ' A' ' 116' ' ' PRO . 94.9 t -51.52 -28.23 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.983 0.42 . . . . 0.0 110.756 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.22 -11.66 10.57 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.263 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.2 -58.7 3.13 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.921 0.391 . . . . 0.0 111.219 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.84 49.87 1.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.112 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m -72.85 171.83 11.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.275 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.649 HG11 HD23 ' A' ' 5' ' ' LEU . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.64 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.447 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.948 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.948 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 -96.82 134.62 39.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.73 -173.46 0.06 OUTLIER Glycine 0 C--N 1.332 0.311 0 C-N-CA 121.021 -0.609 . . . . 0.0 113.225 -179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.431 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.5 p -102.54 50.38 0.83 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.349 . . . . 0.0 111.414 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.829 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.47 -128.86 10.91 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.818 -0.706 . . . . 0.0 113.024 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 133.65 -20.48 4.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.829 HG22 ' HA2' ' A' ' 135' ' ' GLY . 10.7 m -50.56 119.75 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.487 HG21 ' HG2' ' A' ' 10' ' ' GLN . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.64 ' HE2' HG21 ' A' ' 127' ' ' VAL . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.877 ' HD3' HG22 ' A' ' 76' ' ' THR . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.775 0.322 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.6 p -115.91 129.5 56.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.924 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p -89.93 154.08 20.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.825 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.733 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 77' ' ' LEU . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.707 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.486 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.439 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.504 HG22 ' SG ' ' A' ' 60' ' ' CYS . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.45 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.872 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.661 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.65 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.602 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.578 ' HD2' HD12 ' A' ' 55' ' ' ILE . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.532 HD23 ' CD2' ' A' ' 57' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.978 HG21 HG11 ' A' ' 59' ' ' VAL . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.574 HG22 ' HD2' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.608 HD12 ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.573 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.629 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.581 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.882 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.882 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.578 HD12 ' HD2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.602 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.687 ' HB2' HG13 ' A' ' 82' ' ' VAL . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.661 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.978 HG11 HG21 ' A' ' 36' ' ' THR . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' CYS . . . . . 0.504 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.45 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.642 HG21 ' CD1' ' A' ' 81' ' ' LEU . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.722 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.829 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 8' ' ' LEU . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.742 HD11 ' HG3' ' A' ' 144' ' ' ARG . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 79' ' ' SER . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.642 ' CD1' HG21 ' A' ' 65' ' ' ILE . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.441 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 134' ' ' SER . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.502 HD21 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.606 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.629 HG12 HG23 ' A' ' 42' ' ' ILE . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.617 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.617 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -132.08 114.66 14.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 12.8 m -87.93 171.87 10.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.289 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -71.33 163.53 65.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.022 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.3 Cg_endo -67.96 -12.63 35.89 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.606 2.204 . . . . 0.0 112.618 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.9 mmtt -66.1 -38.66 88.8 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.809 0.338 . . . . 0.0 110.869 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.27 8.17 31.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.268 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -46.54 -29.66 1.89 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.871 0.367 . . . . 0.0 111.532 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -122.45 -28.91 4.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -47.24 138.17 7.41 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.112 0.482 . . . . 0.0 111.453 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.439 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -68.41 -21.59 64.67 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.048 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.513 ' C ' HD13 ' A' ' 112' ' ' LEU . 10.6 m 84.69 113.24 0.05 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.725 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.6 149.53 36.66 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.461 -178.827 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.28 -11.45 28.7 Favored 'Trans proline' 0 N--CA 1.465 -0.193 0 C-N-CA 122.909 2.406 . . . . 0.0 112.21 179.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -68.96 -36.92 82.62 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.621 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.455 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.7 m-20 -156.37 65.12 3.86 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.711 0.291 . . . . 0.0 111.231 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.49 ' O ' HG21 ' A' ' 120' ' ' VAL . 86.8 Cg_endo -85.48 16.91 1.86 Allowed 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.728 2.285 . . . . 0.0 112.77 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -128.76 10.76 6.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.779 179.618 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.474 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.98 -25.2 3.1 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.612 -179.676 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.472 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.8 19.32 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 116' ' ' PRO . 10.3 t -64.81 -26.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.913 0.387 . . . . 0.0 110.286 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.37 2.56 10.44 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.18 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -86.63 -45.26 11.19 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.902 0.382 . . . . 0.0 111.067 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -95.08 30.81 2.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.041 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p -57.77 157.42 7.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.051 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.587 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.967 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.606 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.967 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.5 m-85 -96.78 118.87 34.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.71 174.49 0.66 Allowed Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.191 -179.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.428 ' HB3' ' N ' ' A' ' 88' ' ' GLY . 7.5 p -140.59 108.11 5.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.792 0.33 . . . . 0.0 110.626 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.12 -172.39 13.56 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.626 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.63 -27.43 66.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 110.987 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.74 48.19 0.17 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.56 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.707 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 30.0 m -61.24 93.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.486 HG21 ' HG2' ' A' ' 10' ' ' GLN . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.505 ' HD2' HD11 ' A' ' 5' ' ' LEU . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.411 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.829 ' HD2' HG22 ' A' ' 76' ' ' THR . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.6 m80 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.785 0.326 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.79 179.45 8.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER -138.24 153.93 49.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.949 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.642 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 1.055 HD23 HG11 ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLU . . . . . 0.714 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.504 HD23 ' CD ' ' A' ' 68' ' ' PRO . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.598 ' NE2' HG11 ' A' ' 139' ' ' VAL . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.839 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.82 HG23 ' HG3' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.466 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.408 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.668 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . 1.103 HG21 HG11 ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.756 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.516 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.79 ' HG2' HG11 ' A' ' 51' ' ' VAL . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.79 HG11 ' HG2' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.478 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' HG13 ' A' ' 82' ' ' VAL . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.82 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 1.103 HG11 HG21 ' A' ' 36' ' ' THR . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ARG . . . . . 0.422 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.9 HG21 ' HG ' ' A' ' 81' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.504 ' CD ' HD23 ' A' ' 8' ' ' LEU . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.512 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.585 HG22 ' CD ' ' A' ' 144' ' ' ARG . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.657 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.674 HD21 ' HD2' ' A' ' 144' ' ' ARG . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' HG12 ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PRO . . . . . 0.44 ' HB2' HG13 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.9 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG12 ' A' ' 139' ' ' VAL . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' MET . . . . . 0.513 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.639 HD21 ' CE1' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CE1' HD21 ' A' ' 89' ' ' LEU . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.423 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 42' ' ' ILE . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLU . . . . . 0.418 ' HB3' ' HB ' ' A' ' 41' ' ' ILE . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.76 ' N ' HD23 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.569 ' CD1' HD22 ' A' ' 97' ' ' LEU . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.552 ' HD2' HG22 ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' HIS . . . . . 0.552 ' ND1' HG21 ' A' ' 142' ' ' VAL . 86.7 t60 -117.33 111.67 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 87.8 m -94.73 171.87 8.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.953 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -66.34 163.49 39.25 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.986 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.7 Cg_endo -66.64 -11.65 32.68 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.551 2.167 . . . . 0.0 112.637 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -67.42 -37.13 82.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 110.922 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -94.05 8.25 42.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.355 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' TRP . . . . . 0.512 ' CZ2' ' NE2' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -46.21 -29.15 1.47 Allowed 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 120.723 0.296 . . . . 0.0 111.447 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLN . . . . . 0.512 ' NE2' ' CZ2' ' A' ' 107' ' ' TRP . 60.0 mt-30 -122.81 -29.72 3.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.219 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -50.15 138.43 16.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.997 0.427 . . . . 0.0 111.366 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.45 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mttp -69.61 -21.63 63.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.064 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.463 ' C ' HD13 ' A' ' 112' ' ' LEU . 14.0 m 87.39 111.9 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.904 -179.173 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.687 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.61 154.12 42.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.27 -179.181 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.32 -15.05 34.93 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.67 2.246 . . . . 0.0 112.44 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.84 -29.17 74.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.407 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ASP . . . . . 0.464 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 21.5 t0 -165.61 63.46 0.9 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.756 0.312 . . . . 0.0 111.039 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.524 ' O ' HG21 ' A' ' 120' ' ' VAL . 95.8 Cg_endo -86.24 12.84 2.9 Favored 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.655 2.237 . . . . 0.0 112.831 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -131.55 13.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.867 0.365 . . . . 0.0 110.784 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.84 -26.55 4.12 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.505 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -160.12 16.54 0.14 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.523 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 120' ' ' VAL . . . . . 0.524 HG21 ' O ' ' A' ' 116' ' ' PRO . 5.5 t -62.95 -26.78 41.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.318 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -111.1 -18.82 7.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.01 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.96 -73.59 0.13 Allowed 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.919 0.39 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -73.07 63.44 0.68 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.895 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m -86.21 133.69 33.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 1.055 HG11 HD23 ' A' ' 5' ' ' LEU . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 127' ' ' VAL . . . . . 0.88 HG11 ' CE1' ' A' ' 140' ' ' TYR . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' LEU . . . . . 0.423 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.95 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.95 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.4 m-85 -96.65 130.61 43.84 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.34 -174.27 0.05 OUTLIER Glycine 0 C--N 1.331 0.262 0 C-N-CA 121.007 -0.616 . . . . 0.0 113.097 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.1 m -100.38 49.97 0.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.368 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.79 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.43 -132.44 15.12 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.819 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 67.26 9.86 7.28 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 138.08 -23.79 3.01 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.846 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' VAL . . . . . 0.79 HG22 ' HA2' ' A' ' 135' ' ' GLY . 14.9 m -49.29 118.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.598 HG11 ' NE2' ' A' ' 10' ' ' GLN . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.88 ' CE1' HG11 ' A' ' 127' ' ' VAL . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.552 HG21 ' ND1' ' A' ' 101' ' ' HIS . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' ARG . . . . . 0.674 ' HD2' HD21 ' A' ' 78' ' ' LEU . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.777 0.323 . . . . 0.0 110.751 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.808 HD13 ' N ' ' A' ' 6' ' ' GLU . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.808 ' N ' HD13 ' A' ' 5' ' ' LEU . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.615 ' NE2' HG11 ' A' ' 139' ' ' VAL . 73.5 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.684 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.565 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.892 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.852 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.463 ' HB2' ' HB2' ' A' ' 33' ' ' SER . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.65 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.581 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.94 HG21 HG11 ' A' ' 59' ' ' VAL . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.54 HG22 ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.543 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.581 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.428 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.588 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.864 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.864 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.482 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.581 HD12 ' HD2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.65 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.713 ' HB2' HG13 ' A' ' 82' ' ' VAL . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.852 ' HG3' HG23 ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.94 HG11 HG21 ' A' ' 36' ' ' THR . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.684 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.565 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.447 HD13 HD21 ' A' ' 81' ' ' LEU . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.688 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 8' ' ' LEU . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.681 HG23 ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.759 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.637 ' O ' HD23 ' A' ' 77' ' ' LEU . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 140' ' ' TYR . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.404 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . 0.531 ' SG ' HG23 ' A' ' 138' ' ' VAL . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.481 HD21 ' CE1' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.5 ' HE1' HD11 ' A' ' 55' ' ' ILE . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.474 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.659 HG12 HG23 ' A' ' 42' ' ' ILE . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.609 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.515 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.54 ' CD ' HG22 ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' HB2' ' A' ' 78' ' ' LEU . 16.5 t-160 . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.865 0.364 . . . . 0.0 110.955 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.542 HG11 HD23 ' A' ' 5' ' ' LEU . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.594 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.474 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.962 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.962 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.5 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.641 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 20.1 m . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.615 HG11 ' NE2' ' A' ' 10' ' ' GLN . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.475 ' O ' HD23 ' A' ' 81' ' ' LEU . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 78' ' ' LEU . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.544 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.648 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.728 0.299 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.867 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.867 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.629 HD13 ' HA3' ' A' ' 141' ' ' GLY . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.704 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.698 HG22 ' SG ' ' A' ' 60' ' ' CYS . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.688 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.964 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.784 HG23 ' HG3' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.721 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.059 HG21 HG11 ' A' ' 59' ' ' VAL . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.614 ' CG2' HD23 ' A' ' 99' ' ' LEU . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.593 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.6 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.625 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.594 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.878 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.878 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.547 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.617 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.684 ' HB2' HG13 ' A' ' 82' ' ' VAL . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.784 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.059 HG11 HG21 ' A' ' 36' ' ' THR . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.698 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.688 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.45 ' OD1' HD11 ' A' ' 65' ' ' ILE . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.83 HG21 HD22 ' A' ' 81' ' ' LEU . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.713 ' O ' HD23 ' A' ' 66' ' ' LEU . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.425 ' HA ' HD23 ' A' ' 8' ' ' LEU . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 76' ' ' THR . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.828 HG22 ' HD2' ' A' ' 144' ' ' ARG . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.923 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.723 ' O ' HD23 ' A' ' 77' ' ' LEU . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.407 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.83 HD22 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.684 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.537 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.54 HD21 ' CE1' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.547 ' HE1' HD11 ' A' ' 55' ' ' ILE . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.625 HG12 HG23 ' A' ' 42' ' ' ILE . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.617 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.432 ' HD2' HD13 ' A' ' 41' ' ' ILE . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.614 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 142' ' ' VAL . 44.4 t-80 . . . . . 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.87 0.367 . . . . 0.0 111.071 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.619 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.61 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.937 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.937 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.9 m-85 . . . . . 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.704 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.3 m . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.537 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.656 ' HD1' HD11 ' A' ' 5' ' ' LEU . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.629 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.431 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.923 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.232 0.174 0 CA-C-O 120.712 0.291 . . . . 0.0 110.779 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.679 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.964 HD23 HG11 ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.688 ' N ' HD13 ' A' ' 5' ' ' LEU . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.526 HD23 ' HA ' ' A' ' 67' ' ' PRO . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.684 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.71 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.679 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.535 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.901 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 21' ' ' ARG . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.816 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.072 HG21 HG11 ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.596 HG22 ' HD2' ' A' ' 100' ' ' PRO . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.58 HD12 ' CD1' ' A' ' 57' ' ' PHE . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.679 HG23 HG12 ' A' ' 95' ' ' VAL . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.589 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.799 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.799 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.623 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.637 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.777 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.072 HG11 HG21 ' A' ' 36' ' ' THR . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.679 ' SG ' HG22 ' A' ' 16' ' ' VAL . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.535 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.85 HG21 ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.71 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.526 ' HA ' HD23 ' A' ' 8' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.488 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.478 HG22 ' NE ' ' A' ' 144' ' ' ARG . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.881 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.737 ' O ' HD23 ' A' ' 77' ' ' LEU . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.85 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.637 HG13 ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.605 HD21 ' CE1' ' A' ' 91' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.605 ' CE1' HD21 ' A' ' 89' ' ' LEU . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.679 HG12 HG23 ' A' ' 42' ' ' ILE . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 41' ' ' ILE . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.637 ' C ' HD23 ' A' ' 97' ' ' LEU . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.635 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HD2' HG22 ' A' ' 38' ' ' VAL . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.5 ' CE1' HG21 ' A' ' 142' ' ' VAL . 13.6 t60 . . . . . 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.912 0.386 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.964 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.592 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.932 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.684 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 8.0 m . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.603 HG12 ' O ' ' A' ' 82' ' ' VAL . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.406 ' OH ' HG12 ' A' ' 129' ' ' ILE . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.488 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.501 HG12 ' N ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.881 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.792 0.329 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.622 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.799 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.599 HD12 ' N ' ' A' ' 8' ' ' LEU . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.833 ' OE1' HG22 ' A' ' 65' ' ' ILE . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.631 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.742 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.818 HG23 ' HG3' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.467 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.497 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.531 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.607 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.648 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.052 HG21 HG11 ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.576 HG22 ' HD2' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.522 HD12 ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.549 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.661 HG23 HG12 ' A' ' 95' ' ' VAL . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.618 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.78 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.78 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.418 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.497 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.607 ' CE1' HD23 ' A' ' 31' ' ' LEU . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.818 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.052 HG11 HG21 ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.631 ' SG ' HG22 ' A' ' 16' ' ' VAL . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.742 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.416 ' ND2' ' N ' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.867 HG21 ' HG ' ' A' ' 81' ' ' LEU . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.415 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.686 HG22 ' HD2' ' A' ' 144' ' ' ARG . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.487 HD13 HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.738 HD11 ' HG3' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.452 ' HB2' HG12 ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.468 ' HB2' HG13 ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.867 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.457 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.481 ' HG2' HD23 ' A' ' 89' ' ' LEU . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.482 ' C ' HD12 ' A' ' 89' ' ' LEU . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.463 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.661 HG12 HG23 ' A' ' 42' ' ' ILE . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.587 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.514 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.44 ' HB2' HG23 ' A' ' 125' ' ' VAL . 52.7 t-80 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.715 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.961 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.961 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.2 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.8 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.457 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.715 ' HE2' HG21 ' A' ' 127' ' ' VAL . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.452 HG12 ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.622 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.738 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.457 -0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.695 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.679 HD23 HG11 ' A' ' 125' ' ' VAL . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.582 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.578 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.619 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.539 ' CG ' HG11 ' A' ' 139' ' ' VAL . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.525 HG22 ' SG ' ' A' ' 60' ' ' CYS . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.851 HG23 ' HG3' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.513 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.562 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.037 HG21 HG11 ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.575 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.609 HG12 HD12 ' A' ' 97' ' ' LEU . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.615 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.674 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.547 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.853 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.853 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.552 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' HD12 ' A' ' 40' ' ' ILE . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.851 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.037 HG11 HG21 ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.525 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.427 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.864 HG21 ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.578 ' HA ' HD23 ' A' ' 8' ' ' LEU . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.433 HD13 ' N ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.43 ' O ' ' HB ' ' A' ' 76' ' ' THR . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.622 HG22 ' HE ' ' A' ' 144' ' ' ARG . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.721 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.836 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.48 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.864 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.518 ' O ' HG12 ' A' ' 139' ' ' VAL . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.4 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.0 p-80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.526 HD21 ' CE1' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.552 ' HE1' HD11 ' A' ' 55' ' ' ILE . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.674 HG12 HG23 ' A' ' 42' ' ' ILE . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.609 HD12 HG12 ' A' ' 40' ' ' ILE . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 14.7 t-160 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.919 0.39 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.679 HG11 HD23 ' A' ' 5' ' ' LEU . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.956 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.956 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 7.5 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.619 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 5.3 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.539 HG11 ' CG ' ' A' ' 10' ' ' GLN . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.617 ' HD1' HD11 ' A' ' 5' ' ' LEU . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.48 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.695 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.836 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.419 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.671 0.272 . . . . 0.0 110.802 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.733 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.895 HD23 HG11 ' A' ' 125' ' ' VAL . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.467 ' N ' HD13 ' A' ' 5' ' ' LEU . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.586 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.575 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.491 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.95 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.809 HG22 ' HD2' ' A' ' 21' ' ' ARG . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.809 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.531 HD23 ' CE1' ' A' ' 57' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.085 HG21 HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.58 HG22 ' HD2' ' A' ' 100' ' ' PRO . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.51 HD12 ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.566 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.795 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.603 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.743 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.743 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.608 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.751 ' HB2' HG13 ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.734 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.085 HG11 HG21 ' A' ' 36' ' ' THR . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.491 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.63 HD13 HD11 ' A' ' 81' ' ' LEU . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.73 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.586 ' HA ' HD23 ' A' ' 8' ' ' LEU . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.472 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.444 ' O ' ' HB ' ' A' ' 76' ' ' THR . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.527 HG22 ' NE ' ' A' ' 144' ' ' ARG . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.902 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.768 ' O ' HD23 ' A' ' 77' ' ' LEU . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.458 ' HB2' HG13 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.63 HD11 HD13 ' A' ' 65' ' ' ILE . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.881 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.875 ' HG2' HD12 ' A' ' 89' ' ' LEU . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.875 HD12 ' HG2' ' A' ' 86' ' ' PRO . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.513 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.795 HG12 HG23 ' A' ' 42' ' ' ILE . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.757 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.757 ' N ' HD23 ' A' ' 97' ' ' LEU . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.559 HD21 HG21 ' A' ' 82' ' ' VAL . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' HG22 ' A' ' 38' ' ' VAL . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.78 ' ND1' HG21 ' A' ' 142' ' ' VAL . 37.1 t60 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.827 0.346 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.895 HG11 HD23 ' A' ' 5' ' ' LEU . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.927 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.593 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.9 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.881 HG12 ' HA ' ' A' ' 83' ' ' MET . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.441 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.78 HG21 ' ND1' ' A' ' 101' ' ' HIS . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.902 ' HG3' HD11 ' A' ' 78' ' ' LEU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.686 0.279 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.668 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.764 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.711 HD23 ' HD2' ' A' ' 68' ' ' PRO . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.774 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.473 HG22 ' SG ' ' A' ' 60' ' ' CYS . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.556 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.82 HG22 ' HD2' ' A' ' 21' ' ' ARG . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.537 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.82 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.538 ' HD2' HD12 ' A' ' 55' ' ' ILE . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.748 HD23 ' CD2' ' A' ' 57' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.464 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.875 HG21 HG11 ' A' ' 59' ' ' VAL . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.572 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.665 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.659 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.859 ' HG2' HG11 ' A' ' 51' ' ' VAL . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.859 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.496 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.538 HD12 ' HD2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.748 ' CD2' HD23 ' A' ' 31' ' ' LEU . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.732 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.941 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.473 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.556 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.402 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.92 HG21 ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.711 ' HD2' HD23 ' A' ' 8' ' ' LEU . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.628 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.539 HD22 HD22 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.84 HD11 ' HG3' ' A' ' 144' ' ' ARG . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.464 ' HB2' HG12 ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.452 ' HB2' HG13 ' A' ' 59' ' ' VAL . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.92 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.581 HG22 HG22 ' A' ' 59' ' ' VAL . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.443 ' CG ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.869 ' HG2' HD12 ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.869 HD12 ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.664 ' N ' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 129' ' ' ILE . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' HA ' HD23 ' A' ' 128' ' ' LEU . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.629 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HD2' HD13 ' A' ' 41' ' ' ILE . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.59 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.559 ' CD ' HG22 ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.451 ' CD2' HG21 ' A' ' 142' ' ' VAL . 29.8 t-80 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.844 0.354 . . . . 0.0 110.96 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.629 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.939 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.597 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.939 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.8 m-85 . . . . . 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.774 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.443 HG12 ' CG ' ' A' ' 83' ' ' MET . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.488 ' HE2' HG11 ' A' ' 127' ' ' VAL . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.464 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.84 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.801 0.334 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.044 HD23 HG11 ' A' ' 125' ' ' VAL . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.686 ' N ' HD13 ' A' ' 5' ' ' LEU . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.406 ' CG ' HG11 ' A' ' 139' ' ' VAL . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.406 HG13 ' HB3' ' A' ' 58' ' ' LYS . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.447 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.779 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.601 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.563 ' HB3' ' HB2' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.475 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.673 ' HD2' HD12 ' A' ' 55' ' ' ILE . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.701 HD23 ' CD2' ' A' ' 57' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.612 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.776 HG21 HG11 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HD2' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.61 HD12 ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.618 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.588 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.643 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.874 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.874 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.673 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.563 ' HB2' ' HB3' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.701 ' CD2' HD23 ' A' ' 31' ' ' LEU . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.779 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 82' ' ' VAL . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.447 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.404 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.8 OUTLIER -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.992 HG21 ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.512 ' HA ' HD23 ' A' ' 8' ' ' LEU . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 8' ' ' LEU . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.453 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.703 HG23 ' CD1' ' A' ' 78' ' ' LEU . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.703 ' CD1' HG23 ' A' ' 76' ' ' THR . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.548 ' HB2' HG12 ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.405 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.992 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 59' ' ' VAL . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.456 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.871 ' CG ' HD12 ' A' ' 89' ' ' LEU . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.871 HD12 ' CG ' ' A' ' 86' ' ' PRO . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.651 ' N ' HD23 ' A' ' 89' ' ' LEU . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 129' ' ' ILE . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.455 ' HA ' HD23 ' A' ' 128' ' ' LEU . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.614 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.581 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.592 ' HD2' HG22 ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 1.044 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.785 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.96 HG21 ' CD1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.6 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.96 ' CD1' HG21 ' A' ' 129' ' ' ILE . 5.9 m-85 . . . . . 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.507 ' O ' HG23 ' A' ' 138' ' ' VAL . 8.8 m . . . . . 0 N--CA 1.455 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 82' ' ' VAL . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.785 ' HE2' HG21 ' A' ' 127' ' ' VAL . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.548 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.478 HG21 HH21 ' A' ' 145' ' ' ARG . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.672 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . 0.478 HH21 HG21 ' A' ' 143' ' ' VAL . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.774 0.321 . . . . 0.0 110.952 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.75 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.915 HD23 HG11 ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.748 HD12 ' HA3' ' A' ' 141' ' ' GLY . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.551 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.66 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.452 HG11 ' NE ' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.803 HG22 ' HD2' ' A' ' 21' ' ' ARG . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.424 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.803 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.556 ' HD2' HD12 ' A' ' 55' ' ' ILE . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.518 HD22 ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.956 HG21 HG11 ' A' ' 59' ' ' VAL . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.594 HG22 ' HD2' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.574 HD12 ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.558 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.771 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.771 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.556 HD12 ' HD2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.705 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.792 ' HG3' HG23 ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.956 HG11 HG21 ' A' ' 36' ' ' THR . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.66 ' SG ' HG22 ' A' ' 16' ' ' VAL . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.452 ' NE ' HG11 ' A' ' 17' ' ' VAL . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.411 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.2 OUTLIER -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.837 HG21 HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.575 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.434 ' O ' ' HB ' ' A' ' 76' ' ' THR . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.647 HG23 ' CD1' ' A' ' 78' ' ' LEU . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.679 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.711 ' N ' HD13 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.569 ' H ' HG12 ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.837 HD13 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.705 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.424 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 16.2 m170 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.523 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.624 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.593 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.594 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p . . . . . 0 C--O 1.23 0.054 0 CA-C-O 120.829 0.347 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.915 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.562 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.954 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.954 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 . . . . . 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.551 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 16.6 m . . . . . 0 CA--C 1.53 0.176 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.424 HG12 ' HA ' ' A' ' 83' ' ' MET . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.748 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.75 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.628 ' CG ' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.425 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.842 0.353 . . . . 0.0 110.833 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.061 HD23 HG11 ' A' ' 125' ' ' VAL . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.66 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.734 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.696 ' HG2' HG11 ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.436 HG22 ' SG ' ' A' ' 60' ' ' CYS . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.918 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.667 HG23 ' CG ' ' A' ' 58' ' ' LYS . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.775 ' HB1' HD11 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.658 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.696 ' HZ ' HD23 ' A' ' 31' ' ' LEU . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.97 HD12 ' CE2' ' A' ' 57' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.432 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.647 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.105 HG21 HG11 ' A' ' 59' ' ' VAL . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.589 HG22 ' HD2' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.48 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.621 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.815 ' HG2' HG11 ' A' ' 51' ' ' VAL . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 26' ' ' SER . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.815 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.497 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.97 ' CE2' HD12 ' A' ' 31' ' ' LEU . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.667 ' CG ' HG23 ' A' ' 19' ' ' THR . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.105 HG11 HG21 ' A' ' 36' ' ' THR . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.436 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.403 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.403 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.8 OUTLIER -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.899 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.571 ' HA ' HD23 ' A' ' 8' ' ' LEU . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.563 ' HD3' HD23 ' A' ' 8' ' ' LEU . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.467 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.579 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.643 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.513 ' HB2' HG12 ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.899 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.791 ' O ' HG23 ' A' ' 139' ' ' VAL . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.433 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.534 HD21 ' CE1' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.534 ' CE1' HD21 ' A' ' 89' ' ' LEU . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 129' ' ' ILE . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.421 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.605 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.559 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.589 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p . . . . . 0 CA--C 1.523 -0.067 0 CA-C-O 120.975 0.417 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 1.061 HG11 HD23 ' A' ' 5' ' ' LEU . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.722 HG21 ' HE2' ' A' ' 140' ' ' TYR . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.477 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.94 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.94 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.2 m-85 . . . . . 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.734 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 14.1 m . . . . . 0 N--CA 1.455 -0.189 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 82' ' ' VAL . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.722 ' HE2' HG21 ' A' ' 127' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.643 ' CG ' HD11 ' A' ' 78' ' ' LEU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.749 0.309 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.898 HD23 HG11 ' A' ' 125' ' ' VAL . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.695 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.613 HG22 ' CE1' ' A' ' 140' ' ' TYR . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.599 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.722 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.722 HG22 ' SG ' ' A' ' 60' ' ' CYS . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.811 HG23 ' HG3' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD3' ' CD2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.487 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.535 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.535 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.116 HG21 HG11 ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.622 ' CG2' HD23 ' A' ' 99' ' ' LEU . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.609 HD12 ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.655 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.503 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.814 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.814 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.442 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.564 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.482 ' CD2' ' HD3' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.609 ' CD1' HD12 ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.811 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.116 HG11 HG21 ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.722 ' SG ' HG22 ' A' ' 16' ' ' VAL . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.708 HD13 HD11 ' A' ' 81' ' ' LEU . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.599 ' HA ' HD23 ' A' ' 8' ' ' LEU . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.531 HG22 ' CD ' ' A' ' 144' ' ' ARG . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.802 HD11 ' HG3' ' A' ' 144' ' ' ARG . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.575 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.437 ' HB2' HG13 ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.708 HD11 HD13 ' A' ' 65' ' ' ILE . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.564 HG13 ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.451 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.524 ' HG2' HD12 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.823 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.738 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.823 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.467 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.696 HG22 ' O ' ' A' ' 129' ' ' ILE . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 41' ' ' ILE . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.611 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.622 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.828 0.346 . . . . 0.0 111.044 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.898 HG11 HD23 ' A' ' 5' ' ' LEU . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.535 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.915 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.738 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.915 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.1 m-85 . . . . . 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.722 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 23.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.613 ' CE1' HG22 ' A' ' 7' ' ' VAL . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.447 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.802 ' HG3' HD11 ' A' ' 78' ' ' LEU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.735 0.302 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.796 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.796 ' N ' HD13 ' A' ' 5' ' ' LEU . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.47 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.781 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.834 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.678 HG22 ' SG ' ' A' ' 60' ' ' CYS . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.954 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.919 HG22 ' HD2' ' A' ' 21' ' ' ARG . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.416 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.919 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.595 ' HD2' HD12 ' A' ' 55' ' ' ILE . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.416 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.663 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.017 HG21 HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.566 HG22 ' HD2' ' A' ' 100' ' ' PRO . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.499 HD12 ' CD1' ' A' ' 57' ' ' PHE . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.893 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.893 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.595 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.687 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.683 ' HB2' HG13 ' A' ' 82' ' ' VAL . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.717 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.017 HG11 HG21 ' A' ' 36' ' ' THR . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.678 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.427 ' HB2' HD21 ' A' ' 63' ' ' ASN . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.427 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.2 OUTLIER -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.835 HG21 ' CD1' ' A' ' 81' ' ' LEU . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.718 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.47 ' HA ' HD23 ' A' ' 8' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 76' ' ' THR . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 69' ' ' LEU . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 79' ' ' SER . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.912 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.745 ' O ' HD23 ' A' ' 77' ' ' LEU . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.835 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.683 HG13 ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.696 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.507 HD21 ' CE1' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.507 ' CE1' HD21 ' A' ' 89' ' ' LEU . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.452 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.713 HG12 HG23 ' A' ' 42' ' ' ILE . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.597 ' C ' HD23 ' A' ' 97' ' ' LEU . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.578 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HD2' HG22 ' A' ' 38' ' ' VAL . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.847 0.356 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.789 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.565 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.964 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.604 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.964 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.8 m-85 . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.781 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.696 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.634 ' CD2' HD11 ' A' ' 5' ' ' LEU . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.912 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.684 0.278 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.595 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.638 HD11 ' CD2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.603 ' N ' HD13 ' A' ' 5' ' ' LEU . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 77' ' ' LEU . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.694 HG22 ' SG ' ' A' ' 60' ' ' CYS . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.956 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.742 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.501 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.637 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.664 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.081 HG21 HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.545 ' CG2' HD23 ' A' ' 99' ' ' LEU . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.546 HD12 ' CD1' ' A' ' 57' ' ' PHE . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.708 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.9 tm0? -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.783 ' HG2' HG11 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.783 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.494 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.595 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.676 ' HB2' HG13 ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.742 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.081 HG11 HG21 ' A' ' 36' ' ' THR . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.694 ' SG ' HG22 ' A' ' 16' ' ' VAL . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.525 HG21 HD22 ' A' ' 81' ' ' LEU . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.703 ' O ' HD23 ' A' ' 66' ' ' LEU . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' O ' ' HB ' ' A' ' 76' ' ' THR . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.508 HG22 ' CD ' ' A' ' 144' ' ' ARG . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 8' ' ' LEU . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.728 HD21 ' HD2' ' A' ' 144' ' ' ARG . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.513 ' O ' HD23 ' A' ' 77' ' ' LEU . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.525 HD22 HG21 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.676 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.482 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 15.3 p80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.525 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.708 HG12 HG23 ' A' ' 42' ' ' ILE . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.406 ' HA ' HD23 ' A' ' 128' ' ' LEU . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.77 HD22 ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 38' ' ' VAL . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.545 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.545 ' CD ' HG22 ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.44 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.884 0.373 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.77 ' CG1' HD22 ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.968 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.968 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.1 m-85 . . . . . 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 138' ' ' VAL . 33.4 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.687 ' HE2' HG21 ' A' ' 127' ' ' VAL . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.595 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.728 ' HD2' HD21 ' A' ' 78' ' ' LEU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.403 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.838 0.351 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.772 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.528 ' HB2' HG11 ' A' ' 125' ' ' VAL . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.611 HD12 ' N ' ' A' ' 8' ' ' LEU . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.477 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.496 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' SG ' ' A' ' 60' ' ' CYS . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.584 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.619 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.799 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.502 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.54 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.491 ' HB2' ' HB1' ' A' ' 18' ' ' ALA . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.033 HG21 HG11 ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.565 HG22 ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.822 HG12 HD12 ' A' ' 97' ' ' LEU . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.564 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.782 ' HG2' HG11 ' A' ' 51' ' ' VAL . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.782 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.493 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.55 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.502 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.438 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.799 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.033 HG11 HG21 ' A' ' 36' ' ' THR . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.448 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.584 ' HD3' HG11 ' A' ' 17' ' ' VAL . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.914 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.697 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.475 ' HA ' HD23 ' A' ' 8' ' ' LEU . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.455 HD22 ' CA ' ' A' ' 76' ' ' THR . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.488 HG22 ' CD ' ' A' ' 144' ' ' ARG . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.533 HD11 ' CG ' ' A' ' 144' ' ' ARG . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.914 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 139' ' ' VAL . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.458 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.635 HD21 ' CE1' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.635 ' CE1' HD21 ' A' ' 89' ' ' LEU . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.683 HG12 HG23 ' A' ' 42' ' ' ILE . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.822 HD12 HG12 ' A' ' 40' ' ' ILE . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.654 ' HG3' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.657 HD12 ' HB ' ' A' ' 125' ' ' VAL . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.565 ' CD ' HG22 ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.763 ' CD2' HG21 ' A' ' 142' ' ' VAL . 23.0 t-80 . . . . . 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.657 ' HB ' HD12 ' A' ' 99' ' ' LEU . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.897 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.897 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.6 m-85 . . . . . 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.477 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 3.9 m . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 82' ' ' VAL . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.763 HG21 ' CD2' ' A' ' 101' ' ' HIS . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.772 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.533 ' CG ' HD11 ' A' ' 78' ' ' LEU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.416 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 87.4 p . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.764 0.316 . . . . 0.0 111.019 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.714 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.885 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.674 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.514 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.705 ' OE1' HG22 ' A' ' 65' ' ' ILE . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.67 HG22 ' SG ' ' A' ' 60' ' ' CYS . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.465 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.865 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.827 HG23 ' HG3' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.419 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.546 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.4 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.676 HG21 HG11 ' A' ' 59' ' ' VAL . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.599 HG22 ' HD2' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.596 HD12 ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.559 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.639 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.767 ' HG2' HG11 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.767 HG11 ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.486 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.596 ' CD1' HD12 ' A' ' 40' ' ' ILE . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.827 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.865 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.67 ' SG ' HG22 ' A' ' 16' ' ' VAL . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.465 ' HD3' HG11 ' A' ' 17' ' ' VAL . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.78 HD13 HD11 ' A' ' 81' ' ' LEU . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HA ' HD23 ' A' ' 8' ' ' LEU . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.55 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.82 HD11 ' HG3' ' A' ' 144' ' ' ARG . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.477 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.78 HD11 HD13 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 59' ' ' VAL . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.402 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.429 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.612 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.551 ' CE1' HD21 ' A' ' 89' ' ' LEU . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.459 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.639 HG12 HG23 ' A' ' 42' ' ' ILE . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.469 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.669 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.669 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' HG22 ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 125' ' ' VAL . 12.6 t60 . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.965 0.412 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.885 HG11 HD23 ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.768 HG21 ' HE2' ' A' ' 140' ' ' TYR . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 96' ' ' GLU . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.612 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.0 m-85 . . . . . 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.518 ' O ' HG23 ' A' ' 138' ' ' VAL . 16.2 m . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 10' ' ' GLN . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.768 ' HE2' HG21 ' A' ' 127' ' ' VAL . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.453 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.82 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.862 0.363 . . . . 0.0 110.822 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.82 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.82 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.476 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.656 HG22 ' SG ' ' A' ' 60' ' ' CYS . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.935 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.657 HG23 ' HG3' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.58 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.451 HD13 ' CA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.68 ' HD2' HD12 ' A' ' 55' ' ' ILE . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.61 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.854 HG21 HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.57 HG22 ' HD2' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.604 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.675 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.638 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.8 ' HG2' HG11 ' A' ' 51' ' ' VAL . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.8 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.451 ' CA ' HD13 ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.68 HD12 ' HD2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.58 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.657 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.935 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.656 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.794 HD13 HD11 ' A' ' 81' ' ' LEU . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.541 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.476 ' HA ' HD23 ' A' ' 8' ' ' LEU . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.552 HG23 ' CD2' ' A' ' 78' ' ' LEU . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.878 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.726 ' O ' HD23 ' A' ' 77' ' ' LEU . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.406 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.794 HD11 HD13 ' A' ' 65' ' ' ILE . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.651 ' O ' HG12 ' A' ' 139' ' ' VAL . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.606 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.606 ' CE1' HD21 ' A' ' 89' ' ' LEU . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.472 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.675 HG12 HG23 ' A' ' 42' ' ' ILE . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.606 HD21 ' HG ' ' A' ' 99' ' ' LEU . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.606 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.937 0.398 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.725 HG11 HD23 ' A' ' 5' ' ' LEU . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.472 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 8.6 m-85 . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 CA--C 1.528 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 82' ' ' VAL . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.461 ' HD2' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.505 HG12 ' N ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.878 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.635 0.255 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.821 HD23 ' HB ' ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.645 HD22 ' HD3' ' A' ' 68' ' ' PRO . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.645 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.534 ' HG2' HG21 ' A' ' 139' ' ' VAL . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.612 HG11 HH11 ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.884 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.802 HG23 ' HG3' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.44 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.669 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.583 HD23 ' CE1' ' A' ' 57' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.412 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.88 HG21 HG11 ' A' ' 59' ' ' VAL . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.553 HG22 ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.576 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.587 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.486 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.866 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.866 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.631 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.583 ' CE1' HD23 ' A' ' 31' ' ' LEU . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.802 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.884 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 15' ' ' THR . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.612 HH11 HG11 ' A' ' 17' ' ' VAL . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.936 HG21 ' HG ' ' A' ' 81' ' ' LEU . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.645 ' HD3' HD22 ' A' ' 8' ' ' LEU . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.491 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HE2' HD11 ' A' ' 69' ' ' LEU . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.491 ' N ' HD13 ' A' ' 69' ' ' LEU . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.81 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.48 ' N ' HG11 ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.936 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.601 ' O ' HG12 ' A' ' 139' ' ' VAL . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.636 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.2 p80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.487 HD21 ' CE1' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.498 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 129' ' ' ILE . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.603 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.567 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.553 ' CD ' HG22 ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.456 ' HB2' HG23 ' A' ' 125' ' ' VAL . 50.5 t-80 . . . . . 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.93 0.395 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.821 ' HB ' HD23 ' A' ' 5' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.955 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.491 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.955 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 9.4 m-85 . . . . . 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.645 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 11.9 m . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 83' ' ' MET . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.765 ' HE2' HG21 ' A' ' 127' ' ' VAL . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 79' ' ' SER . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 143' ' ' VAL . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.81 ' CG ' HD11 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.457 -0.077 0 CA-C-O 120.821 0.343 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.872 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.872 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.771 HD23 ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.608 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.487 ' HG2' HG21 ' A' ' 139' ' ' VAL . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.938 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.846 HG23 ' HG3' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.64 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.623 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.553 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.708 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.041 HG21 HG11 ' A' ' 59' ' ' VAL . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.548 HG22 ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.63 HD12 ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.625 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.471 ' HB1' ' HB3' ' A' ' 91' ' ' PHE . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.562 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.668 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.668 HG11 ' HG2' ' A' ' 48' ' ' PRO . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.623 HD12 ' HD2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.64 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.63 ' CD1' HD12 ' A' ' 40' ' ' ILE . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.846 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.041 HG11 HG21 ' A' ' 36' ' ' THR . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 81' ' ' LEU . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.607 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.771 ' HD2' HD23 ' A' ' 8' ' ' LEU . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.877 HG22 ' HD3' ' A' ' 144' ' ' ARG . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.645 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.65 HD21 ' HD2' ' A' ' 144' ' ' ARG . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.645 ' O ' HD23 ' A' ' 77' ' ' LEU . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.75 HD11 HD13 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG22 ' A' ' 59' ' ' VAL . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.419 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.454 ' N ' ' CD2' ' A' ' 87' ' ' HIS . 2.6 m170 -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.462 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.653 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.653 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.548 ' CD ' HG22 ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.899 0.38 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.649 HG11 HD23 ' A' ' 5' ' ' LEU . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.64 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.447 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.948 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.948 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.608 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 10.7 m . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.487 HG21 ' HG2' ' A' ' 10' ' ' GLN . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.64 ' HE2' HG21 ' A' ' 127' ' ' VAL . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.877 ' HD3' HG22 ' A' ' 76' ' ' THR . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.81 0.338 . . . . 0.0 110.825 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.733 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 77' ' ' LEU . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.707 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.486 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.439 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.504 HG22 ' SG ' ' A' ' 60' ' ' CYS . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.45 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.872 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.661 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.65 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.602 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.578 ' HD2' HD12 ' A' ' 55' ' ' ILE . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.532 HD23 ' CD2' ' A' ' 57' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.978 HG21 HG11 ' A' ' 59' ' ' VAL . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.574 HG22 ' HD2' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.608 HD12 ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.573 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.629 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.581 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.882 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.882 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.578 HD12 ' HD2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.602 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.687 ' HB2' HG13 ' A' ' 82' ' ' VAL . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.661 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.978 HG11 HG21 ' A' ' 36' ' ' THR . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . 0.504 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.45 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . 0.447 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.3 OUTLIER -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.642 HG21 ' CD1' ' A' ' 81' ' ' LEU . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.722 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.829 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 8' ' ' LEU . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.742 HD11 ' HG3' ' A' ' 144' ' ' ARG . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 79' ' ' SER . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.642 ' CD1' HG21 ' A' ' 65' ' ' ILE . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.441 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.502 HD21 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.606 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.629 HG12 HG23 ' A' ' 42' ' ' ILE . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.617 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.617 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.911 0.386 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.587 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.967 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.606 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.967 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.5 m-85 . . . . . 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.707 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 30.0 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.486 HG21 ' HG2' ' A' ' 10' ' ' GLN . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.505 ' HD2' HD11 ' A' ' 5' ' ' LEU . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.411 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.829 ' HD2' HG22 ' A' ' 76' ' ' THR . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.73 0.3 . . . . 0.0 110.887 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.642 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 1.055 HD23 HG11 ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLU . . . . . 0.714 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.504 HD23 ' CD ' ' A' ' 68' ' ' PRO . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.598 ' NE2' HG11 ' A' ' 139' ' ' VAL . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.839 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' THR . . . . . 0.82 HG23 ' HG3' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.466 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.408 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.668 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 1.103 HG21 HG11 ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.552 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.756 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.516 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.79 ' HG2' HG11 ' A' ' 51' ' ' VAL . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.79 HG11 ' HG2' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . 0.478 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' HG13 ' A' ' 82' ' ' VAL . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.82 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 1.103 HG11 HG21 ' A' ' 36' ' ' THR . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ARG . . . . . 0.422 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.9 HG21 ' HG ' ' A' ' 81' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.504 ' CD ' HD23 ' A' ' 8' ' ' LEU . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.512 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.585 HG22 ' CD ' ' A' ' 144' ' ' ARG . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.657 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.674 HD21 ' HD2' ' A' ' 144' ' ' ARG . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' HG12 ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . 0.44 ' HB2' HG13 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.9 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG12 ' A' ' 139' ' ' VAL . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' MET . . . . . 0.513 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.455 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.639 HD21 ' CE1' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CE1' HD21 ' A' ' 89' ' ' LEU . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' PRO . . . . . 0.423 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 42' ' ' ILE . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.418 ' HB3' ' HB ' ' A' ' 41' ' ' ILE . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.76 ' N ' HD23 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.569 ' CD1' HD22 ' A' ' 97' ' ' LEU . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.552 ' HD2' HG22 ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' HIS . . . . . 0.747 ' CD2' HG21 ' A' ' 142' ' ' VAL . 47.1 t-80 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.853 0.359 . . . . 0.0 110.882 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 1.055 HG11 HD23 ' A' ' 5' ' ' LEU . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' VAL . . . . . 0.88 HG11 ' CE1' ' A' ' 140' ' ' TYR . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' LEU . . . . . 0.423 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.95 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.95 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.4 m-85 . . . . . 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' VAL . . . . . 0.536 ' O ' HG23 ' A' ' 138' ' ' VAL . 14.9 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.598 HG11 ' NE2' ' A' ' 10' ' ' GLN . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.88 ' CE1' HG11 ' A' ' 127' ' ' VAL . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.747 HG21 ' CD2' ' A' ' 101' ' ' HIS . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' ARG . . . . . 0.674 ' HD2' HD21 ' A' ' 78' ' ' LEU . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.1 p-80 . . . . . 0 N--CA 1.487 1.418 0 CA-C-O 120.768 0.318 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.6 t -170.89 162.52 7.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.92 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.7 p -119.27 154.41 33.5 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.751 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.88 -175.59 34.94 Favored Glycine 0 N--CA 1.453 -0.188 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.497 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.808 HD13 ' N ' ' A' ' 6' ' ' GLU . 2.8 tm? -98.56 138.6 35.52 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.793 0.33 . . . . 0.0 110.762 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.808 ' N ' HD13 ' A' ' 5' ' ' LEU . 2.4 mm-40 -149.0 151.94 35.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.44 104.42 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.053 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.508 HD11 HD11 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.6 169.19 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.046 179.896 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.641 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 7.7 m-85 -119.76 150.23 40.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.615 ' NE2' HG11 ' A' ' 139' ' ' VAL . 73.5 mt-30 -99.57 125.53 45.38 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.153 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.3 -72.15 0.96 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.075 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.04 -166.64 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.65 2.234 . . . . 0.0 112.082 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.44 102.6 0.63 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.46 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.3 p -64.16 146.81 53.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 110.908 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.4 m -100.61 98.71 9.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.004 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.684 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.7 t -86.41 110.67 20.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 121.134 0.492 . . . . 0.0 110.204 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.565 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.88 -27.88 3.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.811 -179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.892 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.83 142.05 48.77 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.437 179.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.852 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.2 m -139.85 107.78 5.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.998 0.428 . . . . 0.0 111.115 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.463 ' HB2' ' HB2' ' A' ' 33' ' ' SER . . . -96.15 132.88 41.11 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.94 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.65 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.1 OUTLIER -142.48 138.68 31.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.959 0.409 . . . . 0.0 111.93 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.77 123.92 1.19 Allowed Glycine 0 N--CA 1.446 -0.676 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.65 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.458 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.98 122.63 28.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 178.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.581 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.9 m-85 -118.59 138.99 52.18 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.487 0.661 . . . . 0.0 112.099 -178.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.9 p-10 -116.19 167.55 10.9 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 114.77 -1.105 . . . . 0.0 110.449 -179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.5 0.21 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.428 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -54.25 -44.28 71.63 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.037 0.446 . . . . 0.0 109.891 178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.58 -176.87 26.67 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.754 -0.657 . . . . 0.0 113.608 178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.72 -170.79 30.55 Favored Glycine 0 N--CA 1.451 -0.365 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -179.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -134.34 152.02 33.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 117.301 0.551 . . . . 0.0 111.219 179.542 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -116.38 106.6 13.81 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.936 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.2 p -96.65 144.38 26.73 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.257 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.463 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 45.6 t -129.13 92.75 3.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.924 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -33.13 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.344 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -48.0 -27.4 2.21 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.94 HG21 HG11 ' A' ' 59' ' ' VAL . 68.9 p -130.68 -41.71 1.17 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.086 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.47 18.87 5.6 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.916 -0.659 . . . . 0.0 112.316 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.54 HG22 ' CD ' ' A' ' 100' ' ' PRO . 70.5 t -97.81 131.75 44.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.79 0.328 . . . . 0.0 111.162 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.4 OUTLIER -132.47 131.18 41.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.032 -179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.543 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.9 mt -111.94 112.31 39.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.213 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.581 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.29 125.84 47.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.495 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -111.18 118.17 48.31 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.43 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -66.05 139.96 58.1 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.406 2.071 . . . . 0.0 111.816 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -56.64 92.15 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.971 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.52 1.08 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.617 -0.801 . . . . 0.0 112.732 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.428 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.71 -31.47 64.54 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.904 0.383 . . . . 0.0 111.282 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.588 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.0 mt -110.44 139.5 21.59 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.481 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.864 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.8 Cg_endo -67.81 171.84 11.59 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.443 2.095 . . . . 0.0 112.194 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -85.13 155.92 21.27 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.446 -179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.91 38.48 96.09 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.539 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.864 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -147.07 157.68 10.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.986 0.422 . . . . 0.0 111.443 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.482 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mp0 -138.48 108.32 6.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.388 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.3 mm100 -106.6 124.48 49.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.586 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.8 tt0 -84.54 101.77 12.35 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.185 178.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.581 HD12 ' HD2' ' A' ' 24' ' ' PHE . 62.5 mt -101.17 116.78 45.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.091 0.472 . . . . 0.0 110.535 179.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.65 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 6.5 p90 -135.79 125.84 26.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.826 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.713 ' HB2' HG13 ' A' ' 82' ' ' VAL . 30.6 p90 -110.38 123.17 49.36 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.378 179.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.852 ' HG3' HG23 ' A' ' 19' ' ' THR . 3.8 mttt -96.86 121.31 38.59 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.937 -179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.94 HG11 HG21 ' A' ' 36' ' ' THR . 84.7 t -89.26 117.38 32.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.06 179.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.684 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.9 m -106.59 168.72 8.98 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.461 -179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.565 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -82.63 161.3 22.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.567 179.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 31.3 p-10 -89.93 79.2 6.64 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.843 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -147.77 -46.57 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.121 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -104.42 63.36 0.74 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.833 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.447 HD13 HD21 ' A' ' 81' ' ' LEU . 9.3 pt -140.43 169.48 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.209 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.688 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.7 tt -108.66 77.51 0.79 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.954 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.62 110.73 3.15 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.712 2.275 . . . . 0.0 112.269 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 8' ' ' LEU . 59.0 Cg_endo -71.72 -12.17 28.61 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.521 2.147 . . . . 0.0 112.63 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.48 177.1 0.15 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.08 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 18.3 m-20 -121.74 98.26 5.87 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.886 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 22.3 mtpt -66.02 -28.67 69.04 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.886 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.01 -33.64 65.07 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.875 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -88.64 -26.75 21.72 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 133.79 -7.85 4.87 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.458 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.462 ' O ' ' HB ' ' A' ' 76' ' ' THR . 11.5 mt-10 -59.71 160.09 7.85 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.706 0.289 . . . . 0.0 110.779 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.681 HG23 ' CD1' ' A' ' 78' ' ' LEU . 4.9 t -179.11 -168.88 0.14 Allowed 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.11 0.481 . . . . 0.0 111.609 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.759 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -118.05 123.73 46.39 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.337 179.655 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.759 HD13 ' C ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -114.33 6.27 16.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.363 -179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.637 ' O ' HD23 ' A' ' 77' ' ' LEU . 74.1 m -124.83 141.09 37.22 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 120.492 0.187 . . . . 0.0 111.112 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -63.0 127.55 20.62 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.349 2.032 . . . . 0.0 111.987 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 140' ' ' TYR . 1.6 mt -58.59 169.34 0.95 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.776 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.0 t -145.67 143.32 21.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.915 0.388 . . . . 0.0 111.093 -179.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.404 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.08 105.04 10.24 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.831 179.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.531 ' SG ' HG23 ' A' ' 138' ' ' VAL . 27.4 p -54.71 122.5 10.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.834 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -51.12 -82.78 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.566 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.85 135.12 20.93 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.377 2.052 . . . . 0.0 112.372 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -94.73 122.35 37.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.448 179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.403 ' CA ' ' HB2' ' A' ' 134' ' ' SER . . . 87.91 48.54 4.11 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.938 -179.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.481 HD21 ' CE1' ' A' ' 91' ' ' PHE . 29.2 tp -100.67 142.87 31.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.536 0.207 . . . . 0.0 110.451 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.598 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.8 OUTLIER -138.96 107.14 5.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.175 0.512 . . . . 0.0 111.472 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.5 ' HE1' HD11 ' A' ' 55' ' ' ILE . 27.8 m-85 -83.17 161.5 21.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.958 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -79.79 -19.99 47.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.13 0.49 . . . . 0.0 109.81 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.5 mtmt -142.22 150.65 56.11 Favored Pre-proline 0 C--N 1.334 -0.104 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.978 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.474 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.6 Cg_endo -67.67 135.81 37.06 Favored 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.551 2.168 . . . . 0.0 112.65 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.659 HG12 HG23 ' A' ' 42' ' ' ILE . 28.6 m -100.21 135.86 34.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.715 179.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -83.21 114.05 21.09 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.932 0.396 . . . . 0.0 111.381 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.609 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.9 tt -105.82 128.41 53.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.165 179.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -118.29 132.54 56.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.918 0.389 . . . . 0.0 111.446 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.515 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -118.83 147.65 42.79 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.058 179.755 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.54 ' CD ' HG22 ' A' ' 38' ' ' VAL . 67.7 Cg_endo -75.33 87.98 1.31 Allowed 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.842 2.362 . . . . 0.0 112.473 -179.753 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' HB2' ' A' ' 78' ' ' LEU . 16.5 t-160 -109.31 117.71 34.8 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.689 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.464 ' CB ' HD23 ' A' ' 119' ' ' LEU . 13.0 p -95.31 171.81 8.48 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.986 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.78 161.76 42.77 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.821 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.425 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 67.2 Cg_endo -73.97 -8.77 21.59 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.62 2.213 . . . . 0.0 112.768 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 3.0 mmmt -65.68 -38.21 88.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.78 0.324 . . . . 0.0 110.937 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.417 ' HA ' ' HB2' ' A' ' 109' ' ' ASN . 2.0 t -89.3 8.21 31.63 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.424 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.425 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -48.0 -27.56 2.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 116.484 -0.326 . . . . 0.0 111.77 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -144.91 16.52 1.58 Allowed 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 111.758 0.281 . . . . 0.0 111.758 -179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.417 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.3 t-20 -82.2 142.99 31.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.936 0.398 . . . . 0.0 110.903 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.441 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.8 mtpt -57.64 -21.86 42.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.181 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.499 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 82.85 111.3 0.06 Allowed 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.102 -179.441 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.699 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.83 151.19 38.84 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.129 -179.25 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.37 -12.36 31.61 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.727 2.285 . . . . 0.0 112.254 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.32 -39.13 96.73 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.564 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 17.2 p30 -165.72 59.44 0.6 Allowed Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.725 0.298 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.452 ' O ' HG21 ' A' ' 120' ' ' VAL . 95.8 Cg_endo -80.23 -1.11 11.14 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.468 2.112 . . . . 0.0 112.589 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.45 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 13.3 m-80 -131.12 12.81 5.15 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.097 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.604 ' CG ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.3 -79.97 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.615 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -87.25 -4.67 59.09 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.851 -179.752 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.452 HG21 ' O ' ' A' ' 116' ' ' PRO . 79.2 t -51.12 -28.99 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.96 0.409 . . . . 0.0 110.742 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.74 -9.86 9.72 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.283 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.8 -64.39 1.16 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.875 0.369 . . . . 0.0 111.064 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 6.0 m-80 -79.48 58.43 2.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.926 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 19.2 m -81.18 150.45 28.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.955 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.542 HG11 HD23 ' A' ' 5' ' ' LEU . 2.0 t -85.8 119.86 34.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.69 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -104.25 125.49 50.56 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.989 0.423 . . . . 0.0 111.369 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.594 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.0 p -136.16 134.09 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.441 179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.474 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 55.4 mt -97.02 122.95 40.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.471 -179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.962 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.61 112.25 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 CA-C-O 121.237 0.541 . . . . 0.0 112.231 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.493 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.0 p30 -88.34 -38.52 15.06 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.598 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.81 133.74 32.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.019 178.234 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.962 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.5 m-85 -96.71 120.52 37.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.952 0.406 . . . . 0.0 110.694 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.84 172.92 0.37 Allowed Glycine 0 CA--C 1.518 0.263 0 CA-C-N 115.888 -0.596 . . . . 0.0 113.427 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.403 ' HB2' ' CA ' ' A' ' 88' ' ' GLY . 22.5 t -131.58 99.66 4.88 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.607 0.241 . . . . 0.0 110.621 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -137.71 174.67 21.71 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.704 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.2 t -59.09 -25.6 63.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.73 0.3 . . . . 0.0 111.136 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -168.74 46.05 0.22 Allowed Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.573 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.641 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 20.1 m -61.6 87.75 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.724 179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.615 HG11 ' NE2' ' A' ' 10' ' ' GLN . 5.0 m -106.29 164.3 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.559 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.475 ' O ' HD23 ' A' ' 81' ' ' LEU . 12.1 m-85 -100.52 175.29 5.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.17 179.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 168.16 135.63 1.91 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.194 -1.003 . . . . 0.0 112.976 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 78' ' ' LEU . 6.1 p -72.22 130.3 35.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.544 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.1 p -98.55 115.87 39.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-O 120.933 0.397 . . . . 0.0 111.547 -179.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.648 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -95.03 101.7 13.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.132 179.437 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 3.0 mmm180 -73.62 163.06 28.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.159 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 C--O 1.25 1.081 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.891 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.8 m-70 . . . . . 0 N--CA 1.488 1.43 0 CA-C-O 120.846 0.355 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -119.42 179.55 4.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.945 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.4 p -136.14 161.01 36.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.7 -175.19 35.24 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.867 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.9 tm? -92.45 139.65 30.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.766 0.317 . . . . 0.0 110.903 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.867 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.8 OUTLIER -149.07 147.03 28.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.958 179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.78 106.22 17.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.063 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.629 HD13 ' HA3' ' A' ' 141' ' ' GLY . 5.7 mp -98.89 170.29 8.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.704 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.6 m-85 -123.07 161.22 24.76 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.81 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -113.61 112.3 23.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.034 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -88.06 -76.34 1.28 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.459 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.09 -167.62 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.587 2.192 . . . . 0.0 112.253 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.9 112.04 4.47 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.457 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 16.5 p -72.81 143.0 48.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.884 0.373 . . . . 0.0 110.85 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 7.8 m -100.42 98.65 9.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.117 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.698 HG22 ' SG ' ' A' ' 60' ' ' CYS . 59.5 t -83.95 110.57 18.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.215 0.531 . . . . 0.0 110.01 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.688 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.92 -24.83 3.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.832 -179.568 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.964 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.56 143.66 43.76 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.598 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.784 HG23 ' HG3' ' A' ' 58' ' ' LYS . 36.8 m -140.53 108.0 5.57 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.856 0.36 . . . . 0.0 111.109 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.408 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.24 121.95 41.75 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.098 179.279 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.721 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -134.52 136.28 42.97 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 120.974 0.416 . . . . 0.0 112.073 -179.078 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.33 127.69 1.72 Allowed Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.498 179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.501 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.8 127.33 37.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.8 m-85 -123.49 141.64 51.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.358 0.599 . . . . 0.0 111.967 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 -116.22 167.48 10.97 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.689 -178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -42.42 -29.28 0.26 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.374 -179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -52.78 -44.23 66.41 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.102 0.477 . . . . 0.0 109.799 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.86 -177.04 28.88 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.546 -0.752 . . . . 0.0 113.689 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.05 -168.8 31.34 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.35 146.53 28.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.256 0.528 . . . . 0.0 111.314 179.513 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.9 tp -111.53 106.4 15.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.998 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 5.0 p -94.51 146.21 24.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.076 -179.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 7.9 t -127.86 92.74 3.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 0.0 109.979 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.65 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.54 -29.82 48.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.415 -179.711 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -52.66 -24.73 9.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.43 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.059 HG21 HG11 ' A' ' 59' ' ' VAL . 66.5 p -134.11 -40.82 0.83 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.239 -179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.06 20.18 5.32 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.27 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.614 ' CG2' HD23 ' A' ' 99' ' ' LEU . 78.5 t -100.6 129.79 50.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.829 0.347 . . . . 0.0 111.085 -179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.75 131.9 46.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.959 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.593 HD12 ' CD1' ' A' ' 57' ' ' PHE . 45.2 mt -111.01 112.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.216 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.6 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.23 129.02 45.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.439 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.625 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -115.41 118.35 39.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.481 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.23 140.01 57.32 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.465 2.11 . . . . 0.0 111.949 179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.98 91.63 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.964 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.04 -22.78 0.69 Allowed Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.84 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.87 -37.23 71.06 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.869 0.366 . . . . 0.0 111.187 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.594 HG23 ' HD2' ' A' ' 48' ' ' PRO . 14.3 mt -104.64 139.89 20.54 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.492 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.878 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -68.43 170.23 15.36 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.586 2.191 . . . . 0.0 112.278 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -84.37 157.58 21.39 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.589 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.87 37.65 94.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.512 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.878 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -146.95 157.97 10.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.939 0.4 . . . . 0.0 111.504 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.7 OUTLIER -136.49 108.25 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.252 179.497 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.4 mm100 -106.61 124.58 49.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.46 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.6 tt0 -83.47 101.87 11.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.195 179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.547 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.7 mt -101.64 116.95 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 120.928 0.394 . . . . 0.0 110.383 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.617 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 21.7 p90 -136.92 132.68 34.79 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.2 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.684 ' HB2' HG13 ' A' ' 82' ' ' VAL . 11.4 p90 -116.03 123.48 48.07 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.028 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.784 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.5 mttt -97.4 122.51 40.52 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.86 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.059 HG11 HG21 ' A' ' 36' ' ' THR . 95.3 t -89.07 121.69 39.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.117 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.698 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.0 m -113.01 169.35 8.99 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.989 0.423 . . . . 0.0 111.618 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.688 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.0 mmm180 -86.07 148.67 25.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.664 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.45 ' OD1' HD11 ' A' ' 65' ' ' ILE . 64.0 t0 -81.45 60.06 4.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.945 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.19 -4.25 5.58 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.805 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.1 m -145.8 42.13 1.23 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.082 0.468 . . . . 0.0 110.515 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.83 HG21 HD22 ' A' ' 81' ' ' LEU . 5.8 pt -119.59 169.47 10.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.205 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.713 ' O ' HD23 ' A' ' 66' ' ' LEU . 6.9 tt -110.25 78.88 1.47 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.765 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.425 ' HA ' HD23 ' A' ' 8' ' ' LEU . 98.7 Cg_endo -79.09 111.45 2.92 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.69 2.26 . . . . 0.0 112.289 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.46 -16.42 51.87 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.496 2.131 . . . . 0.0 112.494 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.4 HD13 ' N ' ' A' ' 76' ' ' THR . 1.7 pp -58.4 177.46 0.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.072 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -131.28 111.65 12.08 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -68.13 -27.86 66.81 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -33.24 64.72 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.972 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.76 -23.73 24.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.979 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.75 2.63 9.47 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.485 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 36.0 mt-10 -69.73 163.81 24.88 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.64 0.257 . . . . 0.0 110.764 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.828 HG22 ' HD2' ' A' ' 144' ' ' ARG . 11.1 t -178.12 -176.31 0.53 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.103 0.477 . . . . 0.0 111.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.723 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -111.12 102.99 11.39 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.511 -179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.923 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.6 mt -94.05 19.39 9.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.742 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.723 ' O ' HD23 ' A' ' 77' ' ' LEU . 67.2 m -139.68 153.68 70.4 Favored Pre-proline 0 C--N 1.331 -0.204 0 CA-C-O 120.703 0.287 . . . . 0.0 111.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.407 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 73.1 Cg_endo -76.16 125.21 8.39 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.63 2.22 . . . . 0.0 112.187 179.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.83 HD22 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.45 162.8 3.49 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.96 -179.898 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.684 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -143.42 138.22 26.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.986 -179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.537 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -115.89 116.08 27.35 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.738 179.847 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -57.19 123.33 14.91 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.012 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -55.44 -78.83 0.1 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.432 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -70.51 134.32 26.13 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.359 2.04 . . . . 0.0 112.023 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -91.1 129.36 37.11 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.711 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.42 ' CA ' ' HB2' ' A' ' 134' ' ' SER . . . 71.84 55.65 7.15 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.09 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.54 HD21 ' CE1' ' A' ' 91' ' ' PHE . 26.9 tp -104.43 142.97 33.66 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 110.248 -0.279 . . . . 0.0 110.248 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -138.75 104.7 5.16 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.077 0.465 . . . . 0.0 111.294 -179.85 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.547 ' HE1' HD11 ' A' ' 55' ' ' ILE . 45.9 m-85 -79.4 164.16 24.23 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.006 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.6 mt -81.71 -24.08 36.38 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.739 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 7.2 mtmt -138.77 152.12 69.93 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.952 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 53.3 Cg_endo -69.27 130.31 19.7 Favored 'Trans proline' 0 N--CA 1.464 -0.217 0 C-N-CA 122.439 2.093 . . . . 0.0 112.494 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.625 HG12 HG23 ' A' ' 42' ' ' ILE . 28.4 m -94.58 139.21 18.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.648 179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -85.05 127.13 34.09 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.91 0.386 . . . . 0.0 111.006 -179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.617 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.6 tt -121.01 129.58 53.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.196 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.432 ' HD2' HD13 ' A' ' 41' ' ' ILE . 3.8 mtt180 -118.94 130.02 55.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.909 0.385 . . . . 0.0 111.451 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.614 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.4 mt -116.33 146.06 36.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.639 179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.1 Cg_endo -72.55 110.06 2.9 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.654 2.236 . . . . 0.0 112.532 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.429 ' CD2' HG21 ' A' ' 142' ' ' VAL . 44.4 t-80 -134.36 127.5 31.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.541 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' HD23 ' A' ' 119' ' ' LEU . 17.0 p -93.85 171.75 8.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.21 163.53 67.65 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.929 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 40.5 Cg_endo -67.03 -14.0 41.94 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.546 2.164 . . . . 0.0 112.588 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 19.0 mmtt -61.58 -38.02 86.01 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.778 0.323 . . . . 0.0 110.974 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -88.98 8.09 31.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.338 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.19 -29.24 1.49 Allowed 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.776 0.322 . . . . 0.0 111.508 -179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.444 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.8 mt-30 -121.09 -30.46 4.35 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.041 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -49.82 138.9 14.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.07 0.462 . . . . 0.0 111.375 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.463 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mtpp -72.95 -21.57 60.85 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.111 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.463 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 14.0 m 88.15 111.02 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.956 -179.148 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.713 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.96 154.55 45.26 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.33 -179.13 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.87 -11.47 30.76 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.668 2.246 . . . . 0.0 112.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.15 -32.38 82.11 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.528 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.419 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 7.5 t0 -163.78 62.71 1.11 Allowed Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.807 0.337 . . . . 0.0 110.941 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.615 ' O ' HG21 ' A' ' 120' ' ' VAL . 87.9 Cg_endo -83.31 7.77 5.01 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.744 2.296 . . . . 0.0 112.798 -179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.427 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.9 m-80 -132.61 12.46 4.47 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.686 0.279 . . . . 0.0 111.233 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.571 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.1 -79.55 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.228 -179.751 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.687 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.8 -2.17 57.04 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.73 -179.8 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.615 HG21 ' O ' ' A' ' 116' ' ' PRO . 83.5 t -51.84 -28.05 9.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.91 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -113.68 -10.78 13.96 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.354 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -77.42 -71.73 0.39 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.867 0.365 . . . . 0.0 111.24 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -71.4 63.49 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 33.4 m -88.26 144.74 26.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.071 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.619 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -84.8 115.35 26.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.833 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -100.97 129.64 46.85 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.979 0.418 . . . . 0.0 111.423 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.61 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.4 p -138.59 142.77 33.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.225 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 28.8 mt -106.83 123.42 48.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.867 0.365 . . . . 0.0 111.638 -179.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.937 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.29 112.05 36.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.495 0 CA-C-O 121.37 0.605 . . . . 0.0 112.206 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.534 ' O ' ' N ' ' A' ' 91' ' ' PHE . 20.8 t0 -89.32 -37.61 14.78 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 177.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.86 133.61 32.22 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.045 178.333 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.937 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.9 m-85 -96.87 123.3 40.54 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.019 0.438 . . . . 0.0 110.905 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.19 172.55 0.31 Allowed Glycine 0 C--N 1.331 0.258 0 CA-C-N 115.857 -0.61 . . . . 0.0 113.512 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.42 ' HB2' ' CA ' ' A' ' 88' ' ' GLY . 12.2 t -130.06 74.71 1.61 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.838 0.351 . . . . 0.0 110.688 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.767 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -113.76 169.86 13.09 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.6 t -69.6 -20.94 63.62 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.648 0.261 . . . . 0.0 111.128 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -156.23 31.26 0.59 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.384 -0.912 . . . . 0.0 113.003 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.767 HG13 ' HA3' ' A' ' 135' ' ' GLY . 27.3 m -61.08 98.65 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.851 0.357 . . . . 0.0 110.707 179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.537 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.3 m -122.84 165.37 18.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.49 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.656 ' HD1' HD11 ' A' ' 5' ' ' LEU . 49.6 m-85 -100.22 161.87 13.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.55 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.629 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -177.1 138.33 3.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.808 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.431 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 5.3 p -76.54 128.12 37.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.64 0.257 . . . . 0.0 110.698 179.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.61 115.28 38.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 120.821 0.343 . . . . 0.0 111.146 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.923 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.7 108.09 20.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.108 179.409 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -71.28 163.05 28.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.93 -0.577 . . . . 0.0 111.146 -179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.412 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.267 -0.873 . . . . 0.0 110.805 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 . . . . . 0 N--CA 1.486 1.347 0 CA-C-O 120.73 0.3 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.2 -168.56 1.55 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.927 0.394 . . . . 0.0 110.962 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.9 p -141.22 164.09 31.2 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.679 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -165.32 146.32 11.06 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.633 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.964 HD23 HG11 ' A' ' 125' ' ' VAL . 1.0 OUTLIER -70.04 132.98 46.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.889 0.376 . . . . 0.0 110.904 -179.949 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.688 ' N ' HD13 ' A' ' 5' ' ' LEU . 5.7 mm-40 -142.1 151.48 42.37 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.655 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.97 100.3 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.183 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.526 HD23 ' HA ' ' A' ' 67' ' ' PRO . 4.4 mp -91.2 -179.21 5.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.717 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.684 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.6 m-85 -139.89 136.37 33.85 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.936 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.71 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.0 mm100 -84.62 143.16 29.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.986 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -121.72 -76.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.242 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.19 -167.82 0.22 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.492 2.128 . . . . 0.0 112.222 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.18 110.55 2.75 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.54 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 53.4 p -75.25 146.37 41.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.813 0.339 . . . . 0.0 110.878 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.448 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 5.5 m -106.09 98.6 8.26 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.679 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.3 t -85.98 110.52 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.103 0.477 . . . . 0.0 110.14 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.535 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.95 -24.5 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.874 -179.762 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.901 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.23 141.06 43.93 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.571 179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.816 HG22 ' HD2' ' A' ' 21' ' ' ARG . 47.8 m -138.56 108.04 6.17 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.953 0.406 . . . . 0.0 110.88 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -99.12 119.28 37.58 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.113 179.3 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.816 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -133.17 137.08 46.08 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.01 0.433 . . . . 0.0 112.04 -179.121 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.85 127.38 1.69 Allowed Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.697 -0.764 . . . . 0.0 112.436 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.81 126.02 36.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.3 m-85 -122.24 141.87 51.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.438 0.637 . . . . 0.0 111.879 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.5 p-10 -116.27 167.51 10.95 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.906 -1.043 . . . . 0.0 110.697 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 2.3 p -42.44 -28.67 0.22 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.366 -179.391 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 6.3 m-80 -53.46 -44.49 68.96 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.111 0.481 . . . . 0.0 109.833 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.95 -176.55 27.16 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.663 -0.699 . . . . 0.0 113.695 178.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 150.98 -170.41 30.72 Favored Glycine 0 N--CA 1.451 -0.326 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.4 148.3 28.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.132 0.491 . . . . 0.0 111.352 179.621 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.5 tp -113.59 106.56 14.67 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.829 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.4 p -95.35 143.33 26.81 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.9 t -125.37 92.6 3.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.942 179.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.61 -28.25 44.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.404 -179.702 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -54.53 -24.08 19.29 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.418 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.072 HG21 HG11 ' A' ' 59' ' ' VAL . 81.2 p -133.81 -40.34 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.233 -179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.11 19.82 5.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.28 -179.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.596 HG22 ' HD2' ' A' ' 100' ' ' PRO . 75.0 t -101.72 127.31 55.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.887 0.375 . . . . 0.0 111.091 -179.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.27 131.71 50.48 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.58 HD12 ' CD1' ' A' ' 57' ' ' PHE . 40.7 mt -110.11 112.39 40.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.182 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -95.2 126.52 47.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.493 179.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.679 HG23 HG12 ' A' ' 95' ' ' VAL . 3.1 mt -112.77 117.86 45.82 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.464 -179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.96 140.06 58.98 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.518 2.146 . . . . 0.0 112.005 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.01 89.97 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.952 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 155.91 -23.88 0.54 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.789 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.63 -30.03 62.85 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.785 0.326 . . . . 0.0 111.241 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.589 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.1 mt -113.31 139.57 23.32 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.416 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.799 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.0 Cg_endo -71.57 160.38 48.51 Favored 'Trans proline' 0 N--CA 1.462 -0.33 0 C-N-CA 122.633 2.222 . . . . 0.0 111.865 179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -77.61 151.89 34.17 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.5 -179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.05 28.08 63.08 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.849 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.799 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.2 p -147.11 157.44 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.002 0.43 . . . . 0.0 111.681 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -133.69 108.31 8.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.281 179.455 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 27.2 mm100 -103.45 124.98 49.74 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.381 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.9 101.96 11.36 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.311 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.497 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 61.2 mt -102.21 116.87 46.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 120.93 0.395 . . . . 0.0 110.21 179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.623 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 20.6 p90 -137.31 134.5 36.15 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.214 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.637 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.6 p90 -117.12 123.28 46.38 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.95 179.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.777 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.6 mttp -97.43 120.88 38.61 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.826 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.072 HG11 HG21 ' A' ' 36' ' ' THR . 63.8 t -89.03 121.01 38.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.442 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.679 ' SG ' HG22 ' A' ' 16' ' ' VAL . 68.9 m -110.05 168.15 9.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.47 -179.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.535 ' HD3' HG11 ' A' ' 17' ' ' VAL . 9.3 mmm-85 -83.55 152.64 24.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.576 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -85.46 53.91 2.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.135 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -122.99 -6.97 8.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.678 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.5 m -146.97 63.72 1.18 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.975 0.417 . . . . 0.0 110.401 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.85 HG21 ' CD1' ' A' ' 81' ' ' LEU . 9.5 pt -136.65 169.7 19.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.246 -179.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.71 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.1 tt -108.27 78.89 0.88 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.952 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.526 ' HA ' HD23 ' A' ' 8' ' ' LEU . 94.6 Cg_endo -78.94 111.61 2.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.673 2.248 . . . . 0.0 112.564 -179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.27 -20.75 67.11 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.62 2.213 . . . . 0.0 112.602 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.488 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.3 pp -58.42 177.39 0.13 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.79 0.328 . . . . 0.0 111.056 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -117.83 106.21 12.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.04 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -68.22 -29.12 67.88 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.921 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.11 -34.99 66.58 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 11.4 mttt -83.75 -21.98 32.06 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.967 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 122.98 2.45 9.3 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.937 -0.649 . . . . 0.0 112.498 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 15.0 mt-10 -67.53 161.53 25.34 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.68 0.276 . . . . 0.0 110.811 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.478 HG22 ' NE ' ' A' ' 144' ' ' ARG . 12.2 t -177.26 -172.9 0.41 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.012 0.434 . . . . 0.0 111.588 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.737 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -111.77 106.49 15.27 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.933 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.881 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.6 mt -94.79 17.98 12.59 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.465 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.737 ' O ' HD23 ' A' ' 77' ' ' LEU . 42.6 t -135.74 145.42 52.96 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.604 0.24 . . . . 0.0 110.935 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.99 125.15 12.68 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.387 2.058 . . . . 0.0 112.212 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.85 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.5 mt -58.73 164.15 2.93 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.637 HG13 ' HB2' ' A' ' 57' ' ' PHE . 86.9 t -144.87 146.83 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.161 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.1 114.02 18.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.68 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 84.3 m -53.65 122.18 9.33 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.215 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -58.8 -79.43 0.1 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.402 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.81 134.98 29.2 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.422 2.081 . . . . 0.0 112.084 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -95.57 127.18 41.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.923 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.415 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 75.72 52.43 6.48 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.74 -0.743 . . . . 0.0 111.812 -179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.605 HD21 ' CE1' ' A' ' 91' ' ' PHE . 44.7 tp -106.2 140.1 39.68 Favored 'General case' 0 N--CA 1.453 -0.317 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.605 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -137.96 103.61 5.02 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.029 0.442 . . . . 0.0 111.312 -179.655 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.605 ' CE1' HD21 ' A' ' 89' ' ' LEU . 31.2 m-85 -75.93 170.52 16.09 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.999 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.8 mt -88.08 -20.39 25.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.701 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.1 mtpp -143.47 150.26 50.58 Favored Pre-proline 0 N--CA 1.456 -0.137 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.846 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.1 Cg_endo -66.96 133.95 32.85 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.45 2.1 . . . . 0.0 112.66 -179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.679 HG12 HG23 ' A' ' 42' ' ' ILE . 28.2 m -97.79 139.98 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.585 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.406 ' O ' ' N ' ' A' ' 41' ' ' ILE . 3.9 tt0 -86.61 129.92 34.68 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.019 0.438 . . . . 0.0 111.212 -179.61 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.637 ' C ' HD23 ' A' ' 97' ' ' LEU . 5.8 tt -124.26 128.18 48.79 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.018 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 mtt180 -115.78 126.86 54.57 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.339 -179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.635 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.95 145.87 33.96 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.531 179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.596 ' HD2' HG22 ' A' ' 38' ' ' VAL . 52.4 Cg_endo -69.83 114.36 3.69 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.648 2.232 . . . . 0.0 112.644 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.5 ' CE1' HG21 ' A' ' 142' ' ' VAL . 13.6 t60 -140.04 107.77 5.64 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.619 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 9.8 m -75.41 171.88 13.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.122 0.486 . . . . 0.0 111.382 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.472 ' O ' HG22 ' A' ' 106' ' ' THR . 11.7 p-10 -65.9 158.39 75.74 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.094 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 103' ' ' ASP . 54.0 Cg_endo -69.63 -19.43 36.76 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.173 . . . . 0.0 112.418 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.85 -31.6 72.31 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.847 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 103' ' ' ASP . 2.8 t -88.84 7.25 35.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.085 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.407 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.3 OUTLIER -50.18 -27.75 6.36 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.554 179.897 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -128.48 -21.53 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.541 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -46.21 139.07 4.9 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.959 0.409 . . . . 0.0 111.445 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -62.95 -21.95 66.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.123 179.946 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.518 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 82.07 112.38 0.06 Allowed 'General case' 0 N--CA 1.462 0.172 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 -179.015 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.728 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.61 147.0 32.47 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.117 0.484 . . . . 0.0 111.547 -178.799 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -73.88 -6.06 18.0 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 123.03 2.487 . . . . 0.0 112.533 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -84.33 -26.25 40.54 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.56 -0.828 . . . . 0.0 112.754 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.453 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.7 p-10 -148.67 57.64 3.15 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-O 120.764 0.316 . . . . 0.0 111.288 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.489 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.1 Cg_endo -83.49 8.27 4.72 Favored 'Trans proline' 0 N--CA 1.46 -0.453 0 C-N-CA 122.575 2.183 . . . . 0.0 112.753 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -129.57 7.72 5.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.518 -0.31 . . . . 0.0 110.945 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.543 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.86 -24.82 2.67 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.863 -179.82 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.467 HD13 ' CG ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -167.29 18.57 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.032 0.382 . . . . 0.0 112.032 -179.668 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.489 HG21 ' O ' ' A' ' 116' ' ' PRO . 9.0 t -63.98 -25.53 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.936 0.398 . . . . 0.0 110.375 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -129.64 8.6 6.16 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.016 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.413 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -89.7 -50.86 5.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.897 0.38 . . . . 0.0 111.288 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -91.16 42.58 1.11 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.02 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 m -66.68 162.34 21.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.914 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.964 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -97.04 121.23 47.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.772 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -99.13 136.04 39.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.092 0.472 . . . . 0.0 111.755 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.592 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.6 p -145.46 138.14 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.105 179.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.8 mt -104.65 123.56 47.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.913 0.387 . . . . 0.0 111.908 -178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.932 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.62 112.25 37.96 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 CA-C-O 121.358 0.599 . . . . 0.0 112.105 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 t0 -90.07 -36.78 14.69 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.605 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 132.15 30.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.138 178.347 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.932 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 -96.7 136.86 36.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.839 0.352 . . . . 0.0 110.82 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.67 -168.39 0.04 OUTLIER Glycine 0 N--CA 1.453 -0.22 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.456 -179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.415 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.7 m -91.09 22.21 3.86 Favored 'General case' 0 C--N 1.333 -0.147 0 N-CA-C 111.952 0.353 . . . . 0.0 111.952 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.826 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.79 -151.3 2.4 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.924 179.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.89 19.61 8.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.624 0.249 . . . . 0.0 111.355 179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 166.72 -43.23 0.26 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.529 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.826 HG22 ' HA2' ' A' ' 135' ' ' GLY . 8.0 m -57.03 122.02 5.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.892 0.377 . . . . 0.0 111.179 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.603 HG12 ' O ' ' A' ' 82' ' ' VAL . 3.9 m -145.64 150.65 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.339 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.406 ' OH ' HG12 ' A' ' 129' ' ' ILE . 68.9 m-85 -97.77 146.53 25.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.47 179.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.488 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -166.23 138.88 5.45 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.779 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.501 HG12 ' N ' ' A' ' 79' ' ' SER . 4.0 p -80.22 128.28 38.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.659 0.266 . . . . 0.0 110.506 179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.679 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.7 p -98.36 115.68 39.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.976 0.417 . . . . 0.0 111.156 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.881 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -93.21 109.66 21.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.151 179.66 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.8 mmt180 -71.48 163.09 28.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.235 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.308 -0.853 . . . . 0.0 110.863 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 36.1 m-70 . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 120.808 0.337 . . . . 0.0 111.187 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -169.66 144.97 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 94.2 p -103.81 149.45 25.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.826 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.622 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.4 155.97 27.56 Favored Glycine 0 C--N 1.33 0.243 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.712 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.2 tm? -72.8 136.1 45.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.925 0.393 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.799 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.5 mm-40 -145.37 153.2 40.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.764 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -95.43 100.35 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.169 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.599 HD12 ' N ' ' A' ' 8' ' ' LEU . 3.4 mp -89.5 177.15 6.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.723 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.408 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.7 m-85 -129.47 164.86 22.8 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.714 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.833 ' OE1' HG22 ' A' ' 65' ' ' ILE . 15.4 mm100 -113.28 139.67 48.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.173 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.57 -87.23 0.85 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.278 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.14 -156.82 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.559 2.173 . . . . 0.0 112.075 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.64 96.33 0.83 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.422 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.9 p -57.27 136.89 56.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.807 0.337 . . . . 0.0 110.991 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 4.8 m -93.55 98.53 11.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.206 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.631 HG22 ' SG ' ' A' ' 60' ' ' CYS . 53.7 t -90.3 110.73 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.105 0.478 . . . . 0.0 110.01 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.742 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.04 -23.49 4.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.956 -179.617 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.77 142.05 38.8 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.826 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.818 HG23 ' HG3' ' A' ' 58' ' ' LYS . 48.1 m -137.48 107.84 6.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.887 0.375 . . . . 0.0 110.845 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.467 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.29 114.24 25.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.121 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.497 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -128.87 137.52 51.5 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.08 0.467 . . . . 0.0 112.165 -179.095 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.58 128.43 1.84 Allowed Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.687 -0.688 . . . . 0.0 112.455 179.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.531 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.63 122.15 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.549 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.9 m-85 -116.59 141.05 48.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.448 0.642 . . . . 0.0 111.881 -178.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -119.08 167.56 11.67 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.508 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.9 t -42.38 -27.87 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.689 -0.232 . . . . 0.0 111.547 -179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.43 -43.87 68.34 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.0 -177.9 31.7 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.719 178.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.16 -166.86 30.61 Favored Glycine 0 N--CA 1.451 -0.311 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -137.45 145.83 28.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.285 0.543 . . . . 0.0 111.179 179.428 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.607 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -109.85 106.58 16.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.915 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.4 p -96.56 143.44 27.55 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.989 0.423 . . . . 0.0 111.142 -179.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 27.2 t -125.58 92.54 3.63 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.03 -0.532 . . . . 0.0 109.849 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.648 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.55 -29.76 48.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.476 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -53.23 -24.56 11.52 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.376 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.052 HG21 HG11 ' A' ' 59' ' ' VAL . 80.6 p -134.0 -39.9 0.85 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.342 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.8 19.97 5.88 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.348 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.576 HG22 ' HD2' ' A' ' 100' ' ' PRO . 69.5 t -100.37 124.84 54.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.846 0.355 . . . . 0.0 111.013 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.03 131.61 50.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.098 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.522 HD12 ' CD1' ' A' ' 57' ' ' PHE . 32.1 mt -110.51 112.23 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.198 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.549 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -94.17 124.28 46.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.606 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.661 HG23 HG12 ' A' ' 95' ' ' VAL . 3.3 mt -111.91 118.59 46.17 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.48 -179.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.01 139.83 57.84 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.393 2.062 . . . . 0.0 111.809 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.35 93.54 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.07 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.35 -20.74 0.94 Allowed Glycine 0 C--N 1.331 0.256 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.846 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.83 -29.16 59.37 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.901 0.382 . . . . 0.0 111.259 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.618 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.8 mt -113.88 140.42 24.74 Favored Pre-proline 0 N--CA 1.452 -0.339 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.04 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.78 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.6 Cg_endo -70.85 149.8 60.54 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 122.474 2.116 . . . . 0.0 111.847 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -66.67 141.69 57.69 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.497 -179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 89.02 15.52 59.11 Favored Glycine 0 C--N 1.33 0.247 0 C-N-CA 120.905 -0.664 . . . . 0.0 113.037 179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.78 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -147.17 152.0 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.037 0.446 . . . . 0.0 111.496 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.418 ' O ' ' HG3' ' A' ' 52' ' ' GLU . 12.7 pt-20 -139.62 113.47 8.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.033 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -99.05 135.55 40.29 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.437 -179.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.531 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.2 tt0 -79.35 101.52 8.15 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.069 179.051 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.501 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 62.0 mt -100.81 116.86 45.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.497 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 40.0 p90 -137.79 129.56 28.48 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.545 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.607 ' CE1' HD23 ' A' ' 31' ' ' LEU . 26.7 p90 -113.11 123.47 50.32 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.007 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.818 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.9 mttt -97.41 123.9 41.41 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.087 0.47 . . . . 0.0 110.814 -179.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.052 HG11 HG21 ' A' ' 36' ' ' THR . 93.5 t -89.18 120.91 38.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.753 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.631 ' SG ' HG22 ' A' ' 16' ' ' VAL . 20.3 m -109.25 158.66 17.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.03 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.742 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.6 OUTLIER -75.67 157.88 33.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.403 179.459 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.97 80.54 5.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.701 179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.416 ' ND2' ' N ' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -146.33 -89.8 0.09 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.089 -179.894 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 11.7 t -68.08 67.32 0.11 Allowed 'General case' 0 C--O 1.232 0.157 0 CA-C-O 120.979 0.419 . . . . 0.0 110.813 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.867 HG21 ' HG ' ' A' ' 81' ' ' LEU . 11.1 pt -135.67 168.38 23.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.663 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.415 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.4 tt -109.74 76.4 0.92 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.166 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 84.3 Cg_endo -77.73 108.51 2.57 Favored 'Trans proline' 0 N--CA 1.463 -0.282 0 C-N-CA 122.598 2.199 . . . . 0.0 112.329 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 41.1 Cg_endo -67.13 -17.19 50.49 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.403 2.069 . . . . 0.0 112.474 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -58.48 177.47 0.13 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.087 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -119.92 102.03 8.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.901 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 10.3 mtpp -66.09 -30.47 70.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.916 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.16 -35.12 66.83 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.883 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 15.9 mttt -82.56 -26.78 32.08 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.66 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.36 -4.76 5.57 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.934 -0.65 . . . . 0.0 112.695 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 12.3 mt-10 -61.15 163.37 6.26 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.676 0.274 . . . . 0.0 110.706 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.686 HG22 ' HD2' ' A' ' 144' ' ' ARG . 13.5 t -178.05 -169.64 0.21 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.028 0.442 . . . . 0.0 111.592 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.487 HD13 HD21 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -115.91 109.64 17.88 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.826 179.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.738 HD11 ' HG3' ' A' ' 144' ' ' ARG . 16.4 mt -96.04 11.81 32.77 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.601 -179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.452 ' HB2' HG12 ' A' ' 142' ' ' VAL . 67.8 m -134.79 155.44 79.37 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.674 0.273 . . . . 0.0 110.7 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.468 ' HB2' HG13 ' A' ' 59' ' ' VAL . 67.2 Cg_endo -74.17 130.57 14.34 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.51 2.14 . . . . 0.0 112.144 179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.867 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.5 mm? -61.83 156.21 21.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.225 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.458 ' CG1' ' HB2' ' A' ' 57' ' ' PHE . 70.6 t -147.41 146.24 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.941 0.4 . . . . 0.0 111.556 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.457 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -124.85 118.4 26.25 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.718 179.715 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.8 m -57.68 129.97 44.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.869 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.32 -81.0 0.07 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.523 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.481 ' HG2' HD23 ' A' ' 89' ' ' LEU . 67.0 Cg_endo -74.13 138.05 24.75 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.475 2.116 . . . . 0.0 112.276 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 8.9 p80 -93.7 132.36 38.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.82 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 65.49 47.92 73.52 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.408 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.482 ' C ' HD12 ' A' ' 89' ' ' LEU . 1.3 tp -105.94 107.49 18.52 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.819 0.342 . . . . 0.0 110.749 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.595 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.4 mtmm -94.28 145.84 24.45 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 111.714 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.463 ' N ' ' O ' ' A' ' 130' ' ' ASP . 41.4 m-85 -116.22 164.33 14.66 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.934 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.1 mt -80.02 -21.97 42.96 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.756 178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.2 mtmp? -144.74 151.68 50.44 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.205 179.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.468 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 42.8 Cg_endo -68.87 136.69 36.09 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.616 2.21 . . . . 0.0 112.758 -179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.661 HG12 HG23 ' A' ' 42' ' ' ILE . 28.1 m -99.95 136.61 30.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.683 179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -85.36 108.09 17.67 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.907 0.384 . . . . 0.0 111.508 -179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.587 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.3 tt -97.89 130.12 44.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.264 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 55.6 mtp180 -118.63 132.02 56.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.958 0.409 . . . . 0.0 111.741 -179.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.514 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -120.03 147.45 44.55 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.636 179.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 53.7 Cg_endo -70.45 99.05 0.79 Allowed 'Trans proline' 0 N--CA 1.464 -0.207 0 C-N-CA 122.557 2.171 . . . . 0.0 112.452 -179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.44 ' HB2' HG23 ' A' ' 125' ' ' VAL . 52.7 t-80 -123.06 118.69 28.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.719 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.405 ' HB3' ' CD2' ' A' ' 119' ' ' LEU . 14.3 m -97.49 171.8 8.15 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -70.07 163.56 60.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.76 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.2 Cg_endo -68.07 -13.23 37.58 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.458 2.105 . . . . 0.0 112.625 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 12.0 mmmt -66.28 -37.06 84.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.949 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.9 t -89.09 7.95 32.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.38 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.422 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -47.17 -29.86 2.56 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.78 0.324 . . . . 0.0 111.595 -179.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.422 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 23.9 mt-30 -123.48 -27.2 4.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.351 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -46.42 138.81 5.38 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 121.036 0.446 . . . . 0.0 111.469 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.442 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 10.3 mtpt -69.78 -21.81 63.39 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.108 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 11.2 m 85.03 107.94 0.05 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.904 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.728 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -88.31 152.07 49.57 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.463 -178.89 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.45 -12.45 31.6 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.867 2.378 . . . . 0.0 112.557 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.61 -35.55 74.68 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.535 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CE2' ' A' ' 118' ' ' TYR . 30.6 m-20 -155.42 60.91 2.71 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.828 0.347 . . . . 0.0 110.894 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.639 ' O ' HG21 ' A' ' 120' ' ' VAL . 88.4 Cg_endo -82.92 6.84 5.56 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.824 2.35 . . . . 0.0 112.742 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.432 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.4 m-80 -132.36 11.76 4.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.601 0.239 . . . . 0.0 111.291 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.03 -79.77 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.812 0.339 . . . . 0.0 111.304 -179.744 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.659 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.12 -0.71 57.77 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.655 -179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.639 HG21 ' O ' ' A' ' 116' ' ' PRO . 91.9 t -54.69 -27.45 18.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.358 . . . . 0.0 110.819 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.94 -3.04 20.18 Favored Glycine 0 CA--C 1.519 0.299 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.311 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.42 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -88.53 -49.74 6.72 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.881 0.372 . . . . 0.0 111.233 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.2 m-80 -93.97 29.69 2.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.253 -179.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -65.19 158.57 25.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.952 0.406 . . . . 0.0 110.793 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 2.4 t -94.95 143.4 11.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.604 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.92 130.82 45.62 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.898 0.38 . . . . 0.0 111.302 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.715 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.8 p -141.9 126.53 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.545 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 50.6 mt -90.78 121.6 32.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.429 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.961 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -115.09 111.97 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 CA-C-O 121.318 0.58 . . . . 0.0 112.265 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 91' ' ' PHE . 27.8 t70 -88.95 -37.89 14.89 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 177.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.595 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.29 135.35 35.39 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 114.726 -1.124 . . . . 0.0 109.8 177.804 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.961 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.2 m-85 -98.27 120.53 38.84 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.973 0.416 . . . . 0.0 110.823 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.92 170.3 0.04 OUTLIER Glycine 0 C--N 1.332 0.351 0 CA-C-N 115.891 -0.595 . . . . 0.0 113.473 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -131.57 32.71 4.12 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.743 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.437 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -62.34 -172.85 1.61 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.7 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.3 t -78.37 -27.01 46.83 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.745 0.307 . . . . 0.0 111.016 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -161.61 41.8 0.39 Allowed Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.61 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.8 m -57.15 116.69 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.826 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.457 ' CG1' ' HG3' ' A' ' 83' ' ' MET . 1.9 m -130.03 148.02 33.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 121.025 0.44 . . . . 0.0 111.692 -179.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.715 ' HE2' HG21 ' A' ' 127' ' ' VAL . 15.3 m-85 -93.75 148.29 22.25 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.029 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -176.1 143.6 6.6 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 119.952 -1.118 . . . . 0.0 113.181 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.452 HG12 ' HB2' ' A' ' 79' ' ' SER . 3.4 p -73.87 152.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.708 -0.246 . . . . 0.0 110.341 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.622 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.5 p -125.63 116.13 45.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.812 0.339 . . . . 0.0 111.13 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.738 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -91.85 109.68 21.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.437 179.619 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.1 mmm-85 -77.96 161.18 27.72 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.205 -179.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.213 -0.898 . . . . 0.0 110.948 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 3.5 m-70 . . . . . 0 N--CA 1.488 1.443 0 CA-C-O 120.774 0.321 . . . . 0.0 111.197 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.3 p -71.31 -177.02 1.63 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.895 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.5 OUTLIER -129.67 173.12 10.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.931 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.695 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -178.55 159.44 24.68 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.419 -0.896 . . . . 0.0 112.671 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.679 HD23 HG11 ' A' ' 125' ' ' VAL . 1.5 tm? -67.65 129.77 40.95 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.837 0.351 . . . . 0.0 111.022 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.582 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.6 mm-40 -136.03 144.65 45.38 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.21 105.01 15.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.144 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.578 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.5 mp -97.32 -179.2 4.42 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.619 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.0 m-85 -139.94 134.5 31.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.539 ' CG ' HG11 ' A' ' 139' ' ' VAL . 3.0 mm-40 -83.8 131.25 34.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.132 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -111.45 -80.43 1.08 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.121 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.95 -157.01 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.609 2.206 . . . . 0.0 112.08 179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -75.57 99.5 1.23 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.6 p -61.97 145.27 53.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.893 0.377 . . . . 0.0 110.86 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 40.0 m -105.97 98.5 8.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.238 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.525 HG22 ' SG ' ' A' ' 60' ' ' CYS . 61.9 t -85.53 110.39 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.112 0.482 . . . . 0.0 110.1 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.31 -23.95 4.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.626 -0.715 . . . . 0.0 111.007 -179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.45 141.37 41.59 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.737 179.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.851 HG23 ' HG3' ' A' ' 58' ' ' LYS . 53.8 m -137.06 107.72 6.57 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.9 0.381 . . . . 0.0 110.878 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.439 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.31 116.2 28.46 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.23 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.513 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -130.07 137.35 50.16 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -178.983 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.24 128.64 1.88 Allowed Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.471 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.64 125.43 36.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.531 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.3 m-85 -121.29 141.49 50.86 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.446 0.641 . . . . 0.0 111.852 -178.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -118.73 167.44 11.67 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.955 -1.02 . . . . 0.0 110.526 -179.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.413 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 1.9 t -42.4 -28.19 0.19 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.656 -0.247 . . . . 0.0 111.378 -179.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -53.12 -44.17 67.49 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.071 0.462 . . . . 0.0 109.802 178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -179.5 30.1 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.679 178.562 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.47 -168.89 32.18 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -136.69 145.54 30.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 117.204 0.502 . . . . 0.0 111.104 179.622 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.562 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -109.92 106.66 16.3 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.011 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.7 p -96.2 143.46 27.29 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.097 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 54.0 p -125.2 92.83 3.72 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.51 -28.2 44.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.425 -179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -55.26 -23.04 20.8 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.238 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.037 HG21 HG11 ' A' ' 59' ' ' VAL . 77.4 p -134.18 -40.79 0.82 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.229 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.77 19.66 5.99 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.45 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.575 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.2 t -100.9 127.09 54.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-O 120.846 0.355 . . . . 0.0 110.985 -179.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -127.73 130.45 48.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.03 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.609 HG12 HD12 ' A' ' 97' ' ' LEU . 55.6 mt -109.85 113.63 44.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.615 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.9 mp -94.82 127.21 46.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.528 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.674 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -111.74 117.15 49.15 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.453 -179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.55 139.92 60.66 Favored 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.421 2.081 . . . . 0.0 111.983 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.5 tm0? -59.15 92.05 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.926 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.52 -22.8 0.64 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.685 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.36 -43.69 79.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.887 0.375 . . . . 0.0 111.242 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.547 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.1 mt -99.21 138.51 20.57 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.437 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.853 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.1 Cg_endo -67.97 167.96 20.16 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.584 2.189 . . . . 0.0 112.08 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 60.3 mt-10 -82.66 153.97 25.12 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.43 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 66.44 35.35 89.99 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.674 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.853 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -147.08 157.21 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.928 0.394 . . . . 0.0 111.526 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -137.71 108.33 6.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.471 179.625 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.5 mm100 -108.01 126.55 52.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.418 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 25.4 tt0 -82.76 101.75 11.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.059 179.056 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.552 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -100.27 116.88 44.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.971 0.415 . . . . 0.0 109.944 179.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.513 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 27.3 p90 -137.49 128.51 27.49 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.508 -179.139 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' HD12 ' A' ' 40' ' ' ILE . 18.7 p90 -111.37 123.43 50.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.933 179.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.851 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.3 mttt -96.57 125.42 41.03 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.006 -179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.037 HG11 HG21 ' A' ' 36' ' ' THR . 96.6 t -89.15 123.81 41.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.227 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.525 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -109.8 162.91 14.01 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.368 -179.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.427 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 1.2 mmt180 -76.28 155.6 34.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.552 179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -84.85 64.57 8.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.913 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -137.98 -46.54 0.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.073 179.792 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -99.11 66.17 1.51 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.513 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.864 HG21 ' HG ' ' A' ' 81' ' ' LEU . 21.6 pt -141.24 169.72 14.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.118 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 2.5 tt -118.93 79.94 17.7 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.578 ' HA ' HD23 ' A' ' 8' ' ' LEU . 4.2 Cg_exo -77.37 115.56 3.95 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.916 2.411 . . . . 0.0 112.256 -179.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 39.3 Cg_endo -66.63 -15.56 47.94 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.353 2.036 . . . . 0.0 112.115 179.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.433 HD13 ' N ' ' A' ' 76' ' ' THR . 0.6 OUTLIER -58.3 177.37 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.055 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -116.62 98.58 6.61 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.925 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.3 mttt -64.88 -30.04 71.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.984 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -56.23 -34.58 66.46 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.929 179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 19.4 mttt -83.17 -25.99 31.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.845 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.46 -5.48 5.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.476 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.43 ' O ' ' HB ' ' A' ' 76' ' ' THR . 8.4 mt-10 -60.15 161.82 6.52 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.636 0.255 . . . . 0.0 110.818 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.622 HG22 ' HE ' ' A' ' 144' ' ' ARG . 15.2 t -177.67 -171.28 0.3 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.073 0.464 . . . . 0.0 111.666 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.721 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.36 112.69 24.62 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.69 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.836 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.2 mt -101.78 14.02 33.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.623 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.48 ' CB ' ' HB ' ' A' ' 142' ' ' VAL . 48.0 t -135.04 146.03 56.81 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-O 120.579 0.228 . . . . 0.0 110.901 179.783 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -66.09 127.19 17.12 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.268 1.979 . . . . 0.0 112.106 179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.864 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -60.74 160.49 9.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.575 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.518 ' O ' HG12 ' A' ' 139' ' ' VAL . 89.6 t -148.39 149.25 15.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.938 0.399 . . . . 0.0 111.333 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.4 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -130.71 120.49 23.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.717 179.829 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.1 p -57.66 126.94 29.59 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.023 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.04 -75.01 0.29 Allowed Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.443 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -69.97 134.22 27.03 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.445 2.097 . . . . 0.0 112.102 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.0 p-80 -96.49 119.58 35.22 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.7 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.438 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 83.79 53.34 3.39 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.766 -0.731 . . . . 0.0 111.854 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.526 HD21 ' CE1' ' A' ' 91' ' ' PHE . 27.4 tp -106.08 141.91 36.66 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.66 104.92 5.24 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.072 0.463 . . . . 0.0 111.36 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.552 ' HE1' HD11 ' A' ' 55' ' ' ILE . 23.4 m-85 -80.12 162.74 24.59 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.928 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.31 -20.96 43.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 109.974 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.6 mtpt -141.95 151.04 58.3 Favored Pre-proline 0 C--N 1.332 -0.179 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.174 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 40.0 Cg_endo -67.41 135.11 35.45 Favored 'Trans proline' 0 C--N 1.34 0.115 0 C-N-CA 122.52 2.147 . . . . 0.0 112.627 -179.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.674 HG12 HG23 ' A' ' 42' ' ' ILE . 27.5 m -99.18 137.38 26.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.61 179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -79.45 133.04 36.53 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.891 0.377 . . . . 0.0 111.207 -179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.609 HD12 HG12 ' A' ' 40' ' ' ILE . 1.0 OUTLIER -120.74 130.04 53.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.466 179.673 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 3.1 mtp85 -119.08 122.55 42.36 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.226 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 97' ' ' LEU . 1.4 mt -116.1 144.94 33.83 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.812 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 38' ' ' VAL . 65.2 Cg_endo -73.81 106.68 2.25 Favored 'Trans proline' 0 N--CA 1.464 -0.219 0 C-N-CA 122.754 2.303 . . . . 0.0 112.456 -179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.405 ' CD2' ' O ' ' A' ' 102' ' ' CYS . 14.7 t-160 -129.43 112.51 13.88 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.621 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.442 ' HA ' HD23 ' A' ' 119' ' ' LEU . 24.6 p -79.88 171.91 14.49 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -76.24 163.38 66.76 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.893 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 41.4 Cg_endo -67.45 -14.74 43.48 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.564 2.176 . . . . 0.0 112.483 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.1 mmtt -60.63 -36.94 79.86 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.81 0.338 . . . . 0.0 110.818 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.6 t -89.69 8.21 32.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.377 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.419 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.7 OUTLIER -46.5 -29.91 1.98 Allowed 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 120.754 0.311 . . . . 0.0 111.421 -179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 14.4 mt-30 -126.78 -22.9 3.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.516 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.0 t-20 -47.53 138.8 7.51 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.011 0.434 . . . . 0.0 111.456 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.447 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -68.26 -21.58 64.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.066 179.768 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.464 ' C ' HD13 ' A' ' 112' ' ' LEU . 11.9 m 85.82 110.41 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.109 -179.2 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.685 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.92 150.42 40.63 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.28 -179.146 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.31 -10.3 26.87 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.809 2.339 . . . . 0.0 112.516 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -72.06 -40.72 56.1 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.718 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.409 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 18.2 m-20 -150.47 58.42 3.03 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 111.073 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.599 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.0 Cg_endo -82.87 5.13 6.61 Favored 'Trans proline' 0 N--CA 1.463 -0.323 0 C-N-CA 122.702 2.268 . . . . 0.0 112.695 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.429 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 10.6 m-80 -131.25 12.5 5.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.708 0.289 . . . . 0.0 111.154 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -48.96 -79.82 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.281 -179.737 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.677 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -90.36 -3.45 57.72 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.735 -179.878 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 116' ' ' PRO . 89.6 t -51.77 -28.29 9.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.968 0.413 . . . . 0.0 110.887 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -116.19 -10.13 11.14 Favored Glycine 0 CA--C 1.52 0.365 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.302 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.17 -68.46 0.61 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.87 0.367 . . . . 0.0 111.299 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.25 59.42 1.01 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.063 -179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.6 m -82.19 157.43 23.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.114 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.679 HG11 HD23 ' A' ' 5' ' ' LEU . 3.8 t -92.91 126.66 45.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.813 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.52 127.95 49.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.963 0.411 . . . . 0.0 111.615 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.454 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -130.88 154.12 40.22 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.459 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.558 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 48.4 mt -125.64 118.17 25.09 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.446 178.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.956 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.54 112.26 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 112.445 0.535 . . . . 0.0 112.445 -179.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.8 p-10 -88.53 -37.98 15.29 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 177.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.94 133.14 31.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.157 178.389 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.956 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 7.5 m-85 -96.72 135.71 38.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.786 0.327 . . . . 0.0 110.666 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.51 -173.1 0.05 OUTLIER Glycine 0 C--N 1.33 0.227 0 C-N-CA 121.081 -0.58 . . . . 0.0 113.125 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.438 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 0.5 OUTLIER -102.07 45.65 0.96 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.752 0.311 . . . . 0.0 111.336 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.44 -132.73 15.12 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.811 179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m 68.85 9.87 7.61 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.491 0.182 . . . . 0.0 111.491 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 139.22 -26.82 2.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.57 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.794 HG22 ' HA2' ' A' ' 135' ' ' GLY . 5.3 m -46.59 122.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-O 120.911 0.386 . . . . 0.0 111.36 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.539 HG11 ' CG ' ' A' ' 10' ' ' GLN . 3.7 m -149.55 150.45 13.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.499 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.617 ' HD1' HD11 ' A' ' 5' ' ' LEU . 54.1 m-85 -96.66 137.81 35.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.266 179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -165.06 130.63 2.21 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.145 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.48 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 3.1 p -63.12 152.28 7.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 110.356 -0.238 . . . . 0.0 110.356 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.695 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -123.29 121.91 64.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 120.805 0.336 . . . . 0.0 111.019 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.836 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -97.2 112.45 24.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.479 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.32 163.09 28.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.202 -179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.419 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.7 OUTLIER . . . . . 0 C--O 1.249 1.054 0 CA-C-O 118.213 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . 0.412 ' O ' ' CD2' ' A' ' 1' ' ' HIS . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.426 0 CA-C-O 121.009 0.433 . . . . 0.0 111.266 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.0 p -88.86 -178.1 5.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.012 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -137.22 165.7 25.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.733 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -163.24 141.24 7.0 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.499 -0.858 . . . . 0.0 112.857 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.895 HD23 HG11 ' A' ' 125' ' ' VAL . 1.4 tm? -65.38 121.52 15.04 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.877 0.37 . . . . 0.0 110.806 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.467 ' N ' HD13 ' A' ' 5' ' ' LEU . 54.3 mm-40 -133.02 149.12 52.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.854 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 11.3 p -92.88 112.02 25.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.979 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.586 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -97.96 -178.77 4.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.575 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -133.56 147.78 51.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -88.63 -179.3 6.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.968 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.83 -72.39 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.202 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -71.39 -166.9 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.578 2.185 . . . . 0.0 112.215 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 89.09 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.557 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 24.7 p -57.35 142.58 43.06 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.759 0.314 . . . . 0.0 110.91 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 18.4 m -108.07 98.67 8.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.193 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 88.4 t -86.16 110.5 19.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.884 179.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.491 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -103.97 -25.99 3.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.912 -179.47 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.95 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.59 142.04 46.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.571 179.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.809 HG22 ' HD2' ' A' ' 21' ' ' ARG . 48.4 m -139.35 107.92 5.88 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.977 0.418 . . . . 0.0 111.173 179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -99.07 118.46 35.88 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.877 179.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.809 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -131.6 137.96 48.62 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.023 0.44 . . . . 0.0 112.17 -178.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.95 127.54 1.65 Allowed Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.371 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.52 121.71 29.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.5 m-85 -116.4 140.67 49.1 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.482 0.658 . . . . 0.0 111.842 -178.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 35.3 p-10 -117.3 167.36 11.3 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.624 -179.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 5.1 p -42.4 -28.47 0.21 Allowed 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.518 -0.31 . . . . 0.0 111.446 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 -53.75 -44.4 69.93 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.056 0.455 . . . . 0.0 109.898 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.35 -178.12 27.64 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.625 -0.716 . . . . 0.0 113.695 178.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.32 -170.43 30.94 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.353 -0.699 . . . . 0.0 111.353 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -134.96 150.72 30.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.173 0.487 . . . . 0.0 111.366 179.517 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.531 HD23 ' CE1' ' A' ' 57' ' ' PHE . 15.7 tp -115.67 106.65 14.13 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.791 179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 10.4 p -95.87 145.27 25.51 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.104 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.9 t -127.35 92.74 3.57 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.963 179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.56 -30.18 49.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.565 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 17.2 mt-10 -53.77 -24.18 14.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.342 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.085 HG21 HG11 ' A' ' 59' ' ' VAL . 75.5 p -133.25 -40.73 0.9 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.895 0.379 . . . . 0.0 111.395 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.43 20.66 5.77 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.35 -179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.58 HG22 ' HD2' ' A' ' 100' ' ' PRO . 71.5 t -101.21 128.27 53.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 120.803 0.335 . . . . 0.0 111.09 -179.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.62 132.03 48.12 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.067 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.51 HD12 ' CD1' ' A' ' 57' ' ' PHE . 31.2 mt -110.59 112.28 39.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.797 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.566 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -97.16 119.9 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.745 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.795 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -105.18 117.25 58.93 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.293 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -65.16 139.61 61.39 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.328 2.019 . . . . 0.0 112.006 179.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.2 tm0? -57.53 92.72 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.933 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.42 -20.59 1.06 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.8 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -33.06 65.73 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.884 0.373 . . . . 0.0 111.224 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.603 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.1 mt -110.03 139.57 21.49 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.499 179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.743 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.8 Cg_endo -71.08 157.51 57.53 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.533 2.156 . . . . 0.0 111.718 179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -75.97 146.14 39.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.463 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.04 25.91 46.92 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.963 -0.637 . . . . 0.0 112.94 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.743 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.5 p -146.88 154.79 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.983 0.42 . . . . 0.0 111.582 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.446 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -131.95 108.31 9.28 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.344 179.377 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.0 mm100 -103.26 124.04 47.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.479 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -81.53 101.8 10.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.095 179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.493 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.8 mt -101.98 117.08 46.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.916 0.389 . . . . 0.0 110.395 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.608 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 5.5 p90 -137.93 129.67 28.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.047 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.751 ' HB2' HG13 ' A' ' 82' ' ' VAL . 23.8 p90 -114.02 123.3 49.35 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.106 179.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.734 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -98.05 123.23 41.97 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.84 -179.674 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.085 HG11 HG21 ' A' ' 36' ' ' THR . 78.9 t -89.25 114.6 27.58 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.28 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 82.5 m -105.88 161.63 14.27 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.172 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.491 ' HD3' HG11 ' A' ' 17' ' ' VAL . 0.2 OUTLIER -73.9 167.74 20.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.639 179.754 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -94.28 71.97 3.86 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.91 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -140.88 -46.84 0.4 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.916 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.8 69.12 1.18 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.611 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.63 HD13 HD11 ' A' ' 81' ' ' LEU . 7.3 pt -150.64 169.85 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.143 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.73 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -115.64 84.48 12.55 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.818 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.586 ' HA ' HD23 ' A' ' 8' ' ' LEU . 5.7 Cg_exo -78.89 111.38 2.95 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 123.041 2.494 . . . . 0.0 112.428 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -60.38 -20.35 62.77 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.515 2.143 . . . . 0.0 112.237 179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.472 ' HB3' HG23 ' A' ' 143' ' ' VAL . 1.0 OUTLIER -58.46 177.45 0.13 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.129 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -122.45 106.2 10.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.948 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.8 mmtp -68.06 -28.45 67.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.938 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.03 -34.0 65.45 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.878 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -85.73 -25.67 26.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.804 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.88 -0.25 7.19 Favored Glycine 0 CA--C 1.52 0.383 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.577 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.444 ' O ' ' HB ' ' A' ' 76' ' ' THR . 38.1 mt-10 -64.69 161.17 18.34 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 120.728 0.299 . . . . 0.0 110.673 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.527 HG22 ' NE ' ' A' ' 144' ' ' ARG . 13.7 t -178.44 176.07 1.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.069 0.461 . . . . 0.0 111.665 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.768 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -101.66 105.69 16.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.947 179.861 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.902 HD11 ' HG3' ' A' ' 144' ' ' ARG . 1.5 mt -94.32 16.64 14.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.621 -179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.768 ' O ' HD23 ' A' ' 77' ' ' LEU . 38.8 m -133.64 150.7 75.54 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 120.716 0.294 . . . . 0.0 111.072 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.458 ' HB2' HG13 ' A' ' 59' ' ' VAL . 47.6 Cg_endo -68.92 126.63 14.11 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.365 2.044 . . . . 0.0 112.135 179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.63 HD11 HD13 ' A' ' 65' ' ' ILE . 1.8 mt -58.47 167.91 1.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.45 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.751 HG13 ' HB2' ' A' ' 57' ' ' PHE . 93.9 t -150.63 126.51 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.919 0.39 . . . . 0.0 111.444 -179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.881 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -107.82 105.29 15.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.502 179.482 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 50.0 t -50.85 125.69 14.06 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.206 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.13 -78.73 0.11 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.421 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.875 ' HG2' HD12 ' A' ' 89' ' ' LEU . 60.2 Cg_endo -74.38 136.43 21.77 Favored 'Trans proline' 0 N--CA 1.462 -0.366 0 C-N-CA 122.446 2.097 . . . . 0.0 112.34 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.7 m170 -97.57 129.65 44.68 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.58 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.58 46.49 7.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.094 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.875 HD12 ' HG2' ' A' ' 86' ' ' PRO . 0.4 OUTLIER -97.3 140.52 31.65 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 110.445 -0.206 . . . . 0.0 110.445 -179.866 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.599 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.6 mtmt -138.78 105.14 5.27 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.197 0.522 . . . . 0.0 111.439 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.513 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 19.8 m-85 -83.2 160.84 21.71 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.883 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 9.3 mt -77.67 -21.64 51.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.052 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.5 mtpp -141.26 151.54 61.83 Favored Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.151 179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -68.21 133.94 30.03 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.472 2.114 . . . . 0.0 112.567 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.795 HG12 HG23 ' A' ' 42' ' ' ILE . 27.8 m -97.55 138.39 22.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.785 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -78.35 133.46 37.58 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.088 0.47 . . . . 0.0 111.282 -179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.757 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -119.68 129.91 54.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.217 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.757 ' N ' HD23 ' A' ' 97' ' ' LEU . 64.0 mtt-85 -122.4 120.37 33.77 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.953 0.406 . . . . 0.0 111.371 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.559 HD21 HG21 ' A' ' 82' ' ' VAL . 1.1 mt -118.55 144.87 36.19 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.654 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' HG22 ' A' ' 38' ' ' VAL . 58.6 Cg_endo -72.55 108.54 2.56 Favored 'Trans proline' 0 C--N 1.343 0.241 0 C-N-CA 122.677 2.252 . . . . 0.0 112.509 -179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.78 ' ND1' HG21 ' A' ' 142' ' ' VAL . 37.1 t60 -128.54 101.35 6.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.653 179.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 6.7 m -68.62 171.88 7.04 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.042 0.449 . . . . 0.0 111.166 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . 0.432 ' HB3' ' HD2' ' A' ' 105' ' ' LYS . 10.2 m-20 -73.35 157.53 87.92 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.075 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.41 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 46.5 Cg_endo -67.95 -12.48 35.42 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.485 2.124 . . . . 0.0 112.113 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . 0.432 ' HD2' ' HB3' ' A' ' 103' ' ' ASP . 10.4 mttt -61.84 -36.5 81.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.98 0.419 . . . . 0.0 110.932 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.2 t -89.56 7.95 33.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.15 179.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.423 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.18 -30.35 1.15 Allowed 'General case' 0 N--CA 1.462 0.125 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.658 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.423 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 6.6 mt-30 -118.56 -31.16 4.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.935 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.3 t-20 -49.9 138.27 15.42 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.09 0.471 . . . . 0.0 111.225 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.434 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -68.13 -21.62 64.92 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.078 179.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.44 ' C ' HD13 ' A' ' 112' ' ' LEU . 10.8 m 84.69 109.25 0.05 Allowed 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.887 -179.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.727 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -89.84 148.28 39.43 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.418 -178.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -71.82 -9.11 24.29 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.833 2.355 . . . . 0.0 112.449 179.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.8 -39.61 28.32 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.693 -179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.445 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.3 t0 -138.05 57.24 12.46 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 120.817 0.341 . . . . 0.0 111.185 -179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.555 ' O ' HG21 ' A' ' 120' ' ' VAL . 82.4 Cg_endo -85.39 15.7 2.15 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.602 2.201 . . . . 0.0 112.804 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -129.99 8.06 5.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.505 -0.316 . . . . 0.0 111.024 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.534 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.77 -24.93 2.62 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.714 -179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.449 HD13 ' CB ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.37 19.72 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.555 HG21 ' O ' ' A' ' 116' ' ' PRO . 44.9 t -68.47 -24.06 28.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.97 0.414 . . . . 0.0 110.474 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -119.91 -2.59 12.6 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 121.037 -0.601 . . . . 0.0 112.273 179.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.65 -68.44 0.69 Allowed 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.902 0.382 . . . . 0.0 111.024 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.64 61.39 0.97 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.891 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.4 p -81.67 146.11 30.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.086 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.895 HG11 HD23 ' A' ' 5' ' ' LEU . 5.3 t -87.43 118.32 33.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.809 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -97.17 129.09 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.935 0.398 . . . . 0.0 111.406 -179.645 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.466 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.4 t -130.99 154.19 40.36 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.604 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 49.4 mt -125.82 117.99 24.57 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.274 -0.421 . . . . 0.0 109.983 178.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.927 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.6 mt -117.2 111.88 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.468 0 CA-C-O 121.123 0.487 . . . . 0.0 112.244 -179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.497 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.6 p-10 -88.63 -38.42 14.84 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.599 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.54 30.39 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.957 178.41 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 -96.68 115.31 27.22 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.011 0.434 . . . . 0.0 110.68 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -51.37 169.59 0.39 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.792 -0.64 . . . . 0.0 113.426 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.46 106.63 7.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.715 0.293 . . . . 0.0 110.437 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.89 -166.66 11.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.699 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -63.84 -27.96 69.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.765 0.316 . . . . 0.0 111.02 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -177.42 50.47 0.1 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.759 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.593 ' O ' HG23 ' A' ' 138' ' ' VAL . 28.9 m -61.41 101.8 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 110.829 179.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.881 HG12 ' HA ' ' A' ' 83' ' ' MET . 10.5 m -121.43 168.79 13.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.577 -179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.3 m-85 -103.96 165.37 11.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.4 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.441 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . 178.11 135.22 2.23 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.253 -0.975 . . . . 0.0 112.896 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.78 HG21 ' ND1' ' A' ' 101' ' ' HIS . 3.6 p -75.97 128.16 37.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.607 0.242 . . . . 0.0 110.454 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -98.64 115.64 39.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-O 120.88 0.371 . . . . 0.0 111.342 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.902 ' HG3' HD11 ' A' ' 78' ' ' LEU . 7.3 tmm_? -91.35 114.84 27.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.851 179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 7.5 mmm180 -77.84 159.29 29.05 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.303 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.248 1.017 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.899 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 . . . . . 0 N--CA 1.486 1.356 0 CA-C-O 120.732 0.301 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -157.97 -172.48 3.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.894 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 3.1 p -143.93 147.04 33.4 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.843 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.668 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.85 162.29 35.46 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.788 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.764 HD13 ' N ' ' A' ' 6' ' ' GLU . 0.7 OUTLIER -72.09 133.02 44.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.816 0.341 . . . . 0.0 110.904 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.764 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.3 mm-40 -143.55 145.4 32.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.763 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.49 100.26 10.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.007 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.711 HD23 ' HD2' ' A' ' 68' ' ' PRO . 2.1 mp -91.82 -179.82 5.42 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.774 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.8 m-85 -132.13 145.9 51.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.86 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 18.9 mt-30 -90.41 168.68 11.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.148 -179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.09 -85.09 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.303 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -58.84 -157.3 0.02 OUTLIER 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.574 2.183 . . . . 0.0 112.121 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.74 95.93 0.92 Allowed Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.501 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.4 p -57.99 141.41 49.79 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.82 0.343 . . . . 0.0 110.84 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.8 m -104.89 98.59 8.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.131 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.473 HG22 ' SG ' ' A' ' 60' ' ' CYS . 66.3 t -84.17 110.44 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.121 0.486 . . . . 0.0 109.847 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.556 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.63 -25.69 3.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.889 -179.621 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.29 141.79 47.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.391 179.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.82 HG22 ' HD2' ' A' ' 21' ' ' ARG . 88.4 m -140.23 107.75 5.58 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.089 0.471 . . . . 0.0 111.004 179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.537 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.01 132.9 42.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.163 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.82 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.1 OUTLIER -142.42 138.29 31.0 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.26 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.36 122.18 1.06 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.447 178.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.63 123.94 29.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.538 ' HD2' HD12 ' A' ' 55' ' ' ILE . 7.1 m-85 -122.14 139.08 54.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.521 0.677 . . . . 0.0 112.084 -177.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 25.4 p-10 -118.0 167.69 11.21 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.404 -179.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 6.4 t -42.21 -28.43 0.19 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.686 -0.234 . . . . 0.0 111.29 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 m-20 -53.44 -45.14 69.36 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.11 174.89 24.41 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.598 -0.728 . . . . 0.0 113.708 178.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.36 -163.93 34.73 Favored Glycine 0 N--CA 1.45 -0.421 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -147.2 147.16 17.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.19 0.495 . . . . 0.0 111.332 179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.748 HD23 ' CD2' ' A' ' 57' ' ' PHE . 36.3 tp -107.8 106.4 16.67 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.002 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.4 p -97.72 140.61 31.85 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.971 -179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.464 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 25.3 t -127.96 92.84 3.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.284 179.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.584 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.78 -30.37 50.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.359 -179.796 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -53.32 -24.83 12.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.415 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.875 HG21 HG11 ' A' ' 59' ' ' VAL . 58.1 p -130.81 -41.95 1.14 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.239 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.4 17.57 6.1 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.427 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.559 HG22 ' CD ' ' A' ' 100' ' ' PRO . 79.5 t -98.77 134.78 36.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 120.824 0.345 . . . . 0.0 111.089 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -135.41 128.78 32.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.959 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 54.9 mt -109.99 112.13 39.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.204 179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.572 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -95.15 131.39 42.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.575 179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.665 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -114.83 118.1 41.24 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.424 -179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -66.13 140.02 57.91 Favored 'Trans proline' 0 N--CA 1.462 -0.326 0 C-N-CA 122.37 2.047 . . . . 0.0 111.823 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -55.77 91.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.112 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.09 -20.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.845 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 42' ' ' ILE . . . -56.74 -32.59 65.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.896 0.379 . . . . 0.0 111.351 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.659 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.5 mt -110.79 141.13 23.48 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.359 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.859 ' HG2' HG11 ' A' ' 51' ' ' VAL . 40.8 Cg_endo -68.95 166.52 26.28 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.501 2.134 . . . . 0.0 111.937 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -81.92 155.51 25.24 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.553 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 65.83 34.36 88.47 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.798 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.859 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.9 p -147.07 157.97 10.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.988 0.423 . . . . 0.0 111.541 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.496 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.4 OUTLIER -136.62 108.33 7.03 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.381 179.523 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -103.54 123.61 47.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.45 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 8.2 tt0 -82.16 101.61 10.55 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.538 HD12 ' HD2' ' A' ' 24' ' ' PHE . 57.9 mt -100.38 117.11 45.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 121.036 0.446 . . . . 0.0 110.471 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 37.8 p90 -138.5 126.96 23.18 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.741 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.748 ' CD2' HD23 ' A' ' 31' ' ' LEU . 33.7 p90 -113.08 124.53 52.8 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.377 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.732 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.78 123.49 41.75 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.921 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.941 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 86.7 t -89.31 115.7 29.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.269 179.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.473 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -101.81 165.64 11.09 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.315 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.556 ' HD3' HG11 ' A' ' 17' ' ' VAL . 2.4 mmm180 -81.44 152.69 27.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.51 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -82.99 72.04 10.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.935 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.402 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -144.04 -46.68 0.27 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.004 179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.43 67.23 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.637 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.92 HG21 ' HG ' ' A' ' 81' ' ' LEU . 4.5 pt -142.88 168.64 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.166 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.5 76.22 0.51 Allowed Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.956 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.415 ' HA ' ' HD2' ' A' ' 68' ' ' PRO . 59.8 Cg_endo -72.2 109.9 2.82 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.571 2.181 . . . . 0.0 112.306 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.711 ' HD2' HD23 ' A' ' 8' ' ' LEU . 44.0 Cg_endo -67.9 -21.65 43.61 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.448 2.099 . . . . 0.0 112.234 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.7 pp -58.42 167.57 1.36 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.928 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -112.88 110.78 21.1 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.963 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.4 mttp -68.14 -30.63 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.86 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -56.51 -36.66 69.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.927 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.42 -23.69 40.15 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.957 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.43 2.33 8.99 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.602 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.427 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 19.6 mt-10 -69.91 160.75 31.27 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.664 0.268 . . . . 0.0 110.771 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.628 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -177.58 171.99 1.84 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.963 0.411 . . . . 0.0 111.57 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.539 HD22 HD22 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -99.91 108.27 20.47 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.618 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.84 HD11 ' HG3' ' A' ' 144' ' ' ARG . 13.5 mt -95.55 11.96 31.23 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.464 ' HB2' HG12 ' A' ' 142' ' ' VAL . 15.8 m -133.29 157.82 77.23 Favored Pre-proline 0 C--N 1.333 -0.15 0 CA-C-O 120.681 0.277 . . . . 0.0 110.941 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.452 ' HB2' HG13 ' A' ' 59' ' ' VAL . 6.1 Cg_exo -73.55 127.19 11.51 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.736 2.291 . . . . 0.0 111.699 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.92 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -60.83 143.22 55.16 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.318 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.581 HG22 HG22 ' A' ' 59' ' ' VAL . 95.1 t -129.97 143.64 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.436 . . . . 0.0 111.375 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.443 ' CG ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -123.67 111.86 16.69 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.642 179.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 p -53.02 130.14 32.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.044 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.447 ' CA ' ' CE2' ' A' ' 56' ' ' TYR . . . -61.16 -62.38 5.93 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.608 -0.805 . . . . 0.0 112.274 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.869 ' HG2' HD12 ' A' ' 89' ' ' LEU . 5.4 Cg_endo -83.07 128.13 4.9 Favored 'Trans proline' 0 N--CA 1.454 -0.803 0 C-N-CA 122.805 2.337 . . . . 0.0 111.969 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 31.9 m80 -94.9 116.07 28.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.688 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.72 41.68 5.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.591 -0.814 . . . . 0.0 112.359 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.869 HD12 ' HG2' ' A' ' 86' ' ' PRO . 1.4 tt -92.8 143.32 26.4 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.664 ' N ' HD23 ' A' ' 89' ' ' LEU . 0.4 OUTLIER -137.8 102.89 4.85 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.237 0.541 . . . . 0.0 111.45 -179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' A' ' 130' ' ' ASP . 22.5 m-85 -81.55 155.87 25.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.938 179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 14.8 mt -74.97 -20.69 59.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.077 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -140.65 150.71 61.18 Favored Pre-proline 0 C--N 1.331 -0.209 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.299 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.457 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.4 Cg_endo -67.96 135.54 35.39 Favored 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.56 2.173 . . . . 0.0 112.571 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.682 HG22 ' O ' ' A' ' 129' ' ' ILE . 22.0 m -99.75 137.02 28.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.777 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' HA ' HD23 ' A' ' 128' ' ' LEU . 5.7 tt0 -83.3 114.16 21.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.288 -179.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.629 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.7 tt -105.41 129.65 53.68 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.246 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HD2' HD13 ' A' ' 41' ' ' ILE . 51.9 mtt180 -118.45 128.96 55.1 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.373 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.59 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -117.13 146.66 38.59 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.559 ' CD ' HG22 ' A' ' 38' ' ' VAL . 73.1 Cg_endo -76.21 77.02 3.65 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.766 2.311 . . . . 0.0 112.598 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.451 ' CD2' HG21 ' A' ' 142' ' ' VAL . 29.8 t-80 -94.38 136.41 34.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.458 179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.463 ' SG ' HG23 ' A' ' 106' ' ' THR . 26.0 p -101.19 171.86 7.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.095 -179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -78.43 163.63 60.56 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.027 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.444 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 33.1 Cg_endo -63.97 -14.56 44.05 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.672 2.248 . . . . 0.0 112.622 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.6 mmmt -63.35 -42.9 98.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.918 0.39 . . . . 0.0 110.883 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.463 HG23 ' SG ' ' A' ' 102' ' ' CYS . 1.8 t -89.43 8.24 31.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.309 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -44.83 -29.66 0.84 Allowed 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.754 -179.738 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.434 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 26.4 mt-30 -123.15 -28.86 3.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.306 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.4 t-20 -47.22 138.4 7.13 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.947 0.403 . . . . 0.0 111.5 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.465 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.9 mttt -69.74 -21.91 63.42 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.054 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.465 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 4.1 t 86.4 109.36 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.028 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -90.52 149.7 41.31 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.41 -179.043 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.31 -10.8 27.75 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.824 2.349 . . . . 0.0 112.444 179.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -76.86 -27.36 60.73 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.646 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.442 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.7 OUTLIER -153.33 58.23 2.25 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.82 0.343 . . . . 0.0 111.077 -179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.538 ' O ' HG21 ' A' ' 120' ' ' VAL . 93.1 Cg_endo -84.73 14.39 2.48 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.625 2.216 . . . . 0.0 112.853 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -129.12 8.27 5.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.951 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.505 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.91 -24.6 2.6 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.735 -179.801 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.466 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -168.87 20.07 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.538 HG21 ' O ' ' A' ' 116' ' ' PRO . 48.4 t -69.91 -23.47 25.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.96 0.409 . . . . 0.0 110.485 179.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.59 5.05 8.08 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.254 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.63 -64.54 1.13 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 120.922 0.391 . . . . 0.0 111.037 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.13 59.52 3.91 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.722 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 73.9 m -81.23 148.53 29.44 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.96 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 2.0 t -90.26 123.03 42.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -106.93 127.44 53.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.952 0.406 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.629 HG13 ' HB3' ' A' ' 97' ' ' LEU . 3.4 p -137.88 142.73 35.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.283 179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.457 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 14.8 mt -105.21 121.39 43.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.634 -179.39 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.939 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.5 mt -116.78 112.07 37.78 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.414 0 CA-C-O 121.237 0.542 . . . . 0.0 112.165 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.553 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.1 p30 -88.63 -38.08 15.11 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.01 -1.107 . . . . 0.0 108.01 177.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.597 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 132.2 30.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.098 178.364 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.939 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.8 m-85 -96.79 122.49 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.976 0.417 . . . . 0.0 110.747 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -46.3 171.18 0.03 OUTLIER Glycine 0 C--N 1.331 0.276 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.521 -179.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -129.82 90.26 2.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.785 0.326 . . . . 0.0 110.818 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.434 ' O ' HG22 ' A' ' 138' ' ' VAL . . . -158.77 143.84 9.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.542 -0.837 . . . . 0.0 112.534 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 20.7 p -75.62 62.97 1.5 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.933 0.397 . . . . 0.0 110.691 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.448 ' O ' HG22 ' A' ' 139' ' ' VAL . . . 173.18 -33.92 0.12 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.576 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.774 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 27.8 m -48.75 103.03 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 120.951 0.405 . . . . 0.0 111.176 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.448 HG22 ' O ' ' A' ' 137' ' ' GLY . 2.6 m -126.85 149.96 32.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.366 -179.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.488 ' HE2' HG11 ' A' ' 127' ' ' VAL . 2.9 m-85 -90.74 139.03 31.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.472 179.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -170.22 141.55 6.65 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.299 -0.953 . . . . 0.0 113.198 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.464 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.9 p -64.39 152.37 8.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.612 0.244 . . . . 0.0 110.522 179.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.7 p -126.84 115.3 41.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.773 0.321 . . . . 0.0 110.689 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.84 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.48 106.87 18.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.27 179.779 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.01 163.06 28.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.183 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.046 0 CA-C-O 118.326 -0.845 . . . . 0.0 110.903 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.778 0.323 . . . . 0.0 111.256 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.4 m -132.3 160.05 37.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.819 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.31 163.88 16.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.88 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.53 -171.3 32.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.516 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.044 HD23 HG11 ' A' ' 125' ' ' VAL . 2.1 tm? -98.41 131.1 44.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.705 0.288 . . . . 0.0 110.969 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.686 ' N ' HD13 ' A' ' 5' ' ' LEU . 9.9 mm-40 -140.57 135.15 31.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.915 179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 28.2 t -86.47 100.35 9.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.975 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.512 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.9 mp -90.47 173.6 8.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.811 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.437 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.9 m-85 -127.01 147.23 50.14 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.752 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.406 ' CG ' HG11 ' A' ' 139' ' ' VAL . 8.2 mm-40 -88.89 157.11 18.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.011 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -142.68 -84.89 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.191 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -58.8 -156.67 0.01 OUTLIER 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.645 2.23 . . . . 0.0 112.087 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.57 91.52 1.28 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.452 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.6 p -58.03 137.85 56.49 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.81 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 89.5 m -96.41 98.6 10.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.146 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.406 HG13 ' HB3' ' A' ' 58' ' ' LYS . 70.8 t -81.14 110.18 16.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 121.058 0.456 . . . . 0.0 109.916 179.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.447 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -104.51 -24.32 4.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.784 -179.659 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.24 142.48 47.37 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.489 179.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.779 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.1 m -139.41 107.28 5.67 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.877 0.37 . . . . 0.0 111.144 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.601 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -97.64 123.88 41.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.819 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.563 ' HB3' ' HB2' ' A' ' 56' ' ' TYR . 2.1 ptt180 -142.8 140.15 31.25 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -178.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.09 128.83 1.85 Allowed Glycine 0 N--CA 1.447 -0.603 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.353 179.105 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.475 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -73.28 127.31 35.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.673 ' HD2' HD12 ' A' ' 55' ' ' ILE . 10.5 m-85 -123.78 142.76 50.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.513 0.673 . . . . 0.0 111.94 -178.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 42.7 p-10 -118.72 167.74 11.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.442 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 47' ' ' ILE . 2.9 p -42.32 -27.96 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.36 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -53.92 -44.63 70.74 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 178.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.12 179.85 24.07 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.575 -0.739 . . . . 0.0 113.72 178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 157.6 -164.04 32.88 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -147.04 138.9 18.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 117.261 0.53 . . . . 0.0 111.338 179.528 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.701 HD23 ' CD2' ' A' ' 57' ' ' PHE . 34.4 tp -100.15 106.24 17.93 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.727 179.061 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 2.3 t -98.21 142.32 30.03 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.143 -179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.443 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 15.7 t -125.17 92.58 3.66 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.901 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.612 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.72 -30.1 49.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.505 -179.445 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -54.18 -23.79 15.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.37 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.776 HG21 HG11 ' A' ' 59' ' ' VAL . 28.2 p -131.61 -42.05 1.05 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.295 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.34 13.72 7.4 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.542 -179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.592 HG22 ' HD2' ' A' ' 100' ' ' PRO . 85.7 t -96.0 129.86 45.49 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 CA-C-O 120.813 0.339 . . . . 0.0 111.128 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.1 OUTLIER -133.37 130.2 38.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.005 179.949 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.61 HD12 ' CD2' ' A' ' 57' ' ' PHE . 59.5 mt -107.6 112.11 38.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.124 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.618 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -93.04 129.12 44.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.391 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.588 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -113.65 117.28 44.86 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.664 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.29 140.39 64.12 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.323 2.015 . . . . 0.0 111.812 179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.11 93.49 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.966 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.07 -20.43 1.1 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.876 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.94 -32.33 65.89 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.898 0.38 . . . . 0.0 111.214 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.643 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.3 mt -110.67 140.92 23.07 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.422 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.874 ' HG2' HG11 ' A' ' 51' ' ' VAL . 38.8 Cg_endo -68.79 167.76 22.14 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.679 2.253 . . . . 0.0 112.093 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 86.5 mt-10 -82.63 156.03 24.09 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.629 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.51 34.72 90.65 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.741 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.874 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.97 158.08 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.969 0.414 . . . . 0.0 111.62 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.502 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.2 mt-10 -137.72 108.24 6.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.306 179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.5 mm100 -104.28 121.9 44.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.394 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.7 tt0 -77.19 101.72 6.3 Favored 'General case' 0 CA--C 1.518 -0.265 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 179.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.673 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.7 mt -97.39 116.59 40.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-O 121.047 0.451 . . . . 0.0 109.893 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.563 ' HB2' ' HB3' ' A' ' 21' ' ' ARG . 24.5 p90 -139.65 125.64 19.77 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.049 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.701 ' CD2' HD23 ' A' ' 31' ' ' LEU . 37.5 p90 -116.25 126.38 53.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.903 179.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.779 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.1 OUTLIER -101.75 129.64 47.97 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.15 0.5 . . . . 0.0 111.329 -179.111 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 82' ' ' VAL . 99.2 t -89.28 127.3 42.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.165 179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 1.1 m -110.93 161.1 16.18 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.387 -179.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.447 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.5 mmm180 -74.31 157.77 35.18 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.594 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -88.03 70.03 9.36 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.91 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.404 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.8 OUTLIER -148.97 -46.03 0.14 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.146 -179.909 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 m -97.12 43.1 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.859 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.992 HG21 ' HG ' ' A' ' 81' ' ' LEU . 9.6 pt -122.54 169.45 13.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.051 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.38 76.07 0.49 Allowed Pre-proline 0 C--N 1.331 -0.231 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.161 -179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.512 ' HA ' HD23 ' A' ' 8' ' ' LEU . 62.7 Cg_endo -73.3 109.68 2.89 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.584 2.189 . . . . 0.0 112.26 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 8' ' ' LEU . 43.5 Cg_endo -67.79 -19.14 47.38 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.399 2.066 . . . . 0.0 112.328 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 75' ' ' GLU . 2.9 pp -58.48 177.43 0.14 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.081 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -124.99 104.2 8.43 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.06 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -68.14 -26.94 66.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.006 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.92 -32.27 63.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.931 0.396 . . . . 0.0 110.794 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -89.34 -27.07 20.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.905 179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 134.03 -6.98 4.77 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.622 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.453 ' HB3' ' HB2' ' A' ' 69' ' ' LEU . 13.0 mt-10 -63.77 160.56 16.98 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-O 120.663 0.268 . . . . 0.0 110.643 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.703 HG23 ' CD1' ' A' ' 78' ' ' LEU . 7.2 t -177.74 -170.85 0.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.144 0.497 . . . . 0.0 111.81 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -115.55 120.76 40.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.39 179.812 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.703 ' CD1' HG23 ' A' ' 76' ' ' THR . 0.0 OUTLIER -108.53 1.54 21.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.41 -179.827 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.548 ' HB2' HG12 ' A' ' 142' ' ' VAL . 23.6 m -119.55 158.05 50.2 Favored Pre-proline 0 C--N 1.331 -0.222 0 CA-C-O 120.645 0.26 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.405 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 72.3 Cg_endo -76.42 127.58 9.83 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.611 2.208 . . . . 0.0 112.413 179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.992 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.5 mm? -66.66 144.55 56.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.205 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.972 HG22 HG22 ' A' ' 59' ' ' VAL . 63.0 t -138.72 149.74 23.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 120.97 0.414 . . . . 0.0 111.783 -179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.456 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -129.09 121.04 26.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.801 179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.9 p -58.3 143.56 44.33 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.876 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 56' ' ' TYR . . . -77.43 -71.11 1.23 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.477 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.871 ' CG ' HD12 ' A' ' 89' ' ' LEU . 24.4 Cg_endo -61.68 131.12 34.05 Favored 'Trans proline' 0 C--N 1.343 0.268 0 C-N-CA 122.477 2.118 . . . . 0.0 112.139 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -92.19 136.19 33.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.752 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 59.0 53.52 45.71 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.705 -0.76 . . . . 0.0 111.936 -179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.871 HD12 ' CG ' ' A' ' 86' ' ' PRO . 1.5 tt -97.04 140.75 31.09 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.651 ' N ' HD23 ' A' ' 89' ' ' LEU . 3.4 mtmt -138.1 99.26 3.83 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.121 0.486 . . . . 0.0 111.211 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.537 ' N ' ' O ' ' A' ' 130' ' ' ASP . 29.1 m-85 -75.84 158.68 31.83 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.05 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.5 mt -78.72 -17.12 56.36 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.023 178.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -144.77 150.54 46.96 Favored Pre-proline 0 C--N 1.333 -0.133 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.071 179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.475 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -68.36 138.24 42.1 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.493 2.129 . . . . 0.0 112.856 -179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 129' ' ' ILE . 16.1 m -101.96 133.23 46.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.76 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.455 ' HA ' HD23 ' A' ' 128' ' ' LEU . 3.2 tt0 -81.61 108.16 14.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.569 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.614 ' HB3' HG13 ' A' ' 127' ' ' VAL . 6.3 tt -97.3 129.94 44.53 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.119 179.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 44.2 mtp85 -117.3 130.55 56.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.908 0.385 . . . . 0.0 111.553 -179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.581 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.59 145.45 39.11 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.743 179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.592 ' HD2' HG22 ' A' ' 38' ' ' VAL . 61.0 Cg_endo -73.01 105.71 2.01 Favored 'Trans proline' 0 N--CA 1.464 -0.258 0 C-N-CA 122.731 2.287 . . . . 0.0 112.333 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 12.3 t-80 -128.39 107.79 10.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.748 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 19.5 m -85.93 171.9 11.11 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.039 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.97 163.48 56.16 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.137 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.422 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 57.1 Cg_endo -70.35 -9.09 25.14 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.661 2.241 . . . . 0.0 112.669 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -68.23 -39.84 82.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.882 0.372 . . . . 0.0 110.983 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 2.0 t -89.33 8.05 32.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.374 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.422 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -47.21 -28.98 2.1 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.811 0.339 . . . . 0.0 111.443 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -123.49 -29.58 3.76 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.238 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -47.31 138.34 7.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 121.008 0.432 . . . . 0.0 111.389 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.468 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -65.98 -21.88 66.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.144 179.831 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.492 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 86.04 112.19 0.05 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.125 -179.263 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.706 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.06 149.45 36.9 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.446 -179.182 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -71.63 -10.41 26.59 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.899 2.399 . . . . 0.0 112.475 179.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -71.94 -36.71 60.94 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.68 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.443 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.1 m-20 -146.33 60.66 6.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 120.868 0.366 . . . . 0.0 111.151 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.545 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.0 Cg_endo -84.05 11.46 3.32 Favored 'Trans proline' 0 N--CA 1.462 -0.35 0 C-N-CA 122.554 2.169 . . . . 0.0 112.818 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -131.04 7.89 4.71 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.013 179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.522 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.03 -25.21 3.17 Favored 'General case' 0 CA--C 1.53 0.183 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.702 -179.768 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.493 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.92 18.68 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.84 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.545 HG21 ' O ' ' A' ' 116' ' ' PRO . 25.6 t -68.03 -24.17 29.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.981 0.419 . . . . 0.0 110.4 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -125.05 5.37 8.32 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.948 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.76 -54.7 3.94 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.99 0.424 . . . . 0.0 111.172 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.4 m-80 -91.35 41.61 1.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.217 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -73.44 157.41 36.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.883 0.373 . . . . 0.0 110.805 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 1.044 HG11 HD23 ' A' ' 5' ' ' LEU . 2.8 t -93.76 147.25 5.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.34 179.748 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.07 131.44 40.6 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.164 0.507 . . . . 0.0 111.525 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.785 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.2 p -142.29 137.13 29.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.222 179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.475 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.7 mt -101.41 122.03 43.0 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.901 0.381 . . . . 0.0 111.613 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.96 HG21 ' CD1' ' A' ' 132' ' ' PHE . 2.2 mt -115.43 112.35 39.47 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.463 0 CA-C-O 121.342 0.591 . . . . 0.0 112.079 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' A' ' 91' ' ' PHE . 2.8 p-10 -89.47 -37.12 15.01 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.6 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.38 131.61 30.19 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.216 178.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.96 ' CD1' HG21 ' A' ' 129' ' ' ILE . 5.9 m-85 -96.62 138.24 34.48 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.8 0.333 . . . . 0.0 110.536 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.04 -164.66 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.436 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.7 t -71.95 -7.24 47.46 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 61.77 15.83 49.47 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.713 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.2 t -98.78 32.2 2.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 121.029 0.442 . . . . 0.0 110.319 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 151.44 -30.35 0.95 Allowed Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.766 -179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 135' ' ' GLY . 8.8 m -55.76 121.76 4.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.75 0.309 . . . . 0.0 110.927 179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.483 HG12 ' O ' ' A' ' 82' ' ' VAL . 7.3 m -147.36 144.43 19.62 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.95 0.405 . . . . 0.0 111.623 -179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.785 ' HE2' HG21 ' A' ' 127' ' ' VAL . 50.3 m-85 -91.46 148.15 22.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.368 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -173.44 132.77 2.4 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.978 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.548 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.6 p -62.07 152.27 6.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.478 HG21 HH21 ' A' ' 145' ' ' ARG . 12.8 p -125.54 121.66 60.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 120.835 0.35 . . . . 0.0 111.642 -179.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.672 ' HB2' HD21 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -93.81 114.83 27.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.048 -0.524 . . . . 0.0 109.842 179.094 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . 0.478 HH21 HG21 ' A' ' 143' ' ' VAL . 0.4 OUTLIER -80.11 163.15 24.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.344 -179.172 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 95.9 p . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.199 -0.905 . . . . 0.0 110.986 -179.927 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 2.0 p-80 . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.813 0.34 . . . . 0.0 111.249 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.2 t -115.84 179.38 4.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.95 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.9 p -103.82 148.35 26.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.952 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.75 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -164.58 136.67 4.33 Favored Glycine 0 C--N 1.331 0.274 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.759 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.915 HD23 HG11 ' A' ' 125' ' ' VAL . 0.3 OUTLIER -62.14 121.17 12.42 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.823 0.344 . . . . 0.0 111.047 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 -127.36 144.83 50.98 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.711 179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -76.75 100.33 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.978 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.748 HD12 ' HA3' ' A' ' 141' ' ' GLY . 59.7 mt -93.07 177.91 5.91 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.808 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.551 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 5.4 m-85 -139.12 148.79 43.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.011 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 14.8 mt-30 -92.61 163.99 13.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.006 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -148.59 -74.91 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.352 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -70.13 -167.78 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.535 2.157 . . . . 0.0 112.282 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.59 96.75 0.13 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.577 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.4 p -61.31 143.69 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.91 0.386 . . . . 0.0 110.88 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.6 m -105.72 98.6 8.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.021 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.66 HG22 ' SG ' ' A' ' 60' ' ' CYS . 60.6 t -84.94 110.46 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.082 179.106 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.452 HG11 ' NE ' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.84 -23.67 4.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.838 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.941 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.06 140.65 42.17 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.462 179.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.803 HG22 ' HD2' ' A' ' 21' ' ' ARG . 36.7 m -139.0 107.85 5.96 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.985 0.421 . . . . 0.0 111.138 179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.424 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -99.57 120.08 39.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.119 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.803 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.17 137.28 42.56 Favored 'General case' 0 C--N 1.332 -0.156 0 N-CA-C 112.171 0.434 . . . . 0.0 112.171 -179.121 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.46 127.93 1.73 Allowed Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.449 179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.91 124.93 34.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.556 ' HD2' HD12 ' A' ' 55' ' ' ILE . 6.7 m-85 -121.27 141.65 50.7 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.413 0.625 . . . . 0.0 111.81 -178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 31.6 p-10 -116.43 167.3 11.17 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.661 -178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 16.4 p -42.49 -29.21 0.26 Allowed 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.471 -0.332 . . . . 0.0 111.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -51.87 -45.16 64.0 Favored 'General case' 0 C--N 1.332 -0.172 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.18 -178.27 27.93 Favored Glycine 0 N--CA 1.448 -0.521 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.854 178.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.23 -169.72 31.49 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 111.192 -0.763 . . . . 0.0 111.192 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.432 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.67 149.02 27.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.197 0.498 . . . . 0.0 111.254 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.518 HD22 ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -114.22 106.53 14.46 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.914 179.255 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 7.8 p -95.62 143.95 26.47 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.196 -179.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 13.8 t -126.44 92.65 3.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.008 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.57 -30.2 49.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.558 -179.583 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -54.08 -23.44 13.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.452 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.956 HG21 HG11 ' A' ' 59' ' ' VAL . 60.6 p -132.8 -41.06 0.94 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.305 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.14 19.32 5.95 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.406 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.594 HG22 ' HD2' ' A' ' 100' ' ' PRO . 81.0 t -101.86 130.76 51.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.827 0.346 . . . . 0.0 111.174 -179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -130.2 132.04 45.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.841 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.574 HD12 ' CD1' ' A' ' 57' ' ' PHE . 42.8 mt -110.96 112.23 39.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.558 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.63 124.32 48.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.5 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.8 mp -110.28 118.31 49.57 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.378 -179.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.43 139.83 55.51 Favored 'Trans proline' 0 C--N 1.343 0.284 0 C-N-CA 122.492 2.128 . . . . 0.0 111.921 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -58.07 92.37 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.942 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.15 -21.79 0.87 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.858 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.54 -27.66 58.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.866 0.365 . . . . 0.0 111.358 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.606 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.7 mt -116.13 139.83 25.62 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.439 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.771 ' HG2' HG11 ' A' ' 51' ' ' VAL . 51.9 Cg_endo -71.04 159.09 53.47 Favored 'Trans proline' 0 N--CA 1.461 -0.395 0 C-N-CA 122.665 2.243 . . . . 0.0 111.772 179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -77.39 141.55 39.74 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.557 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 86.24 28.04 29.01 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.967 -0.635 . . . . 0.0 112.884 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.771 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.14 157.64 10.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.056 0.455 . . . . 0.0 111.485 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.1 OUTLIER -135.1 108.39 7.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.434 179.501 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 26.1 mm100 -104.46 123.61 47.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.363 -0.38 . . . . 0.0 111.276 -179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.5 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.3 tt0 -79.81 101.89 8.77 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.261 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.556 HD12 ' HD2' ' A' ' 24' ' ' PHE . 34.2 mt -100.25 116.98 44.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 120.914 0.387 . . . . 0.0 110.406 179.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 34.7 p90 -139.48 134.84 32.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.259 -179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.705 ' HB2' HG13 ' A' ' 82' ' ' VAL . 6.1 p90 -118.49 123.31 44.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.109 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.792 ' HG3' HG23 ' A' ' 19' ' ' THR . 9.6 mttt -97.14 120.24 37.12 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.455 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.956 HG11 HG21 ' A' ' 36' ' ' THR . 57.8 t -89.0 114.54 27.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.509 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.66 ' SG ' HG22 ' A' ' 16' ' ' VAL . 51.1 m -103.92 170.21 8.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.59 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.452 ' NE ' HG11 ' A' ' 17' ' ' VAL . 13.5 mmt180 -83.02 159.51 22.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.579 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -93.35 44.51 1.14 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.172 -179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.411 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.2 OUTLIER -118.43 -6.65 10.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.562 179.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.17 54.85 1.55 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.111 0.482 . . . . 0.0 110.36 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.837 HG21 HD13 ' A' ' 81' ' ' LEU . 4.7 pt -131.4 169.86 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.322 -179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.575 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.82 75.98 0.67 Allowed Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.087 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.403 ' HB2' ' HG ' ' A' ' 69' ' ' LEU . 90.4 Cg_endo -78.86 111.25 2.93 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.774 2.316 . . . . 0.0 112.422 -179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -65.57 -16.88 55.63 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.555 2.17 . . . . 0.0 112.476 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.403 ' HG ' ' HB2' ' A' ' 67' ' ' PRO . 1.6 pp -58.25 177.37 0.13 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.076 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -122.32 104.66 9.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.045 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 2.0 mttt -68.1 -28.25 67.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.93 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.02 -34.84 66.22 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.8 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.7 mttt -83.79 -25.06 30.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.661 179.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.38 -3.32 6.68 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.364 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.434 ' O ' ' HB ' ' A' ' 76' ' ' THR . 25.8 mt-10 -64.5 161.05 18.04 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.76 0.314 . . . . 0.0 110.902 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.647 HG23 ' CD1' ' A' ' 78' ' ' LEU . 6.2 t -177.94 -170.71 0.26 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.007 0.432 . . . . 0.0 111.435 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.679 ' C ' HD13 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -118.61 121.69 40.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.578 179.703 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.711 ' N ' HD13 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -107.75 0.33 22.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.47 -179.843 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.569 ' H ' HG12 ' A' ' 142' ' ' VAL . 3.6 m -113.0 147.39 37.12 Favored Pre-proline 0 C--O 1.232 0.179 0 CA-C-O 120.54 0.209 . . . . 0.0 111.16 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -68.39 119.01 6.03 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.569 2.18 . . . . 0.0 111.679 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.837 HD13 HG21 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -58.44 124.59 20.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.958 -179.819 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.705 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.5 t -105.53 146.82 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.462 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.424 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -122.87 111.64 16.91 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.451 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.5 m -52.92 126.8 21.55 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.148 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.424 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -66.87 -77.94 0.28 Allowed Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.41 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.04 132.58 28.44 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.296 1.998 . . . . 0.0 112.128 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.403 ' CD2' ' HA3' ' A' ' 135' ' ' GLY . 16.2 m170 -97.27 122.16 39.98 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.767 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.29 49.38 5.55 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.659 -0.781 . . . . 0.0 111.704 -179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.523 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.6 tp -104.46 139.45 39.37 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 7.2 mtmt -136.75 104.22 5.44 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.129 0.49 . . . . 0.0 111.307 -179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.527 ' N ' ' O ' ' A' ' 130' ' ' ASP . 27.8 m-85 -79.04 157.88 27.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.071 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.3 mt -76.93 -19.75 57.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.949 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.2 mtpm? -142.97 149.68 50.21 Favored Pre-proline 0 N--CA 1.455 -0.176 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.21 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.3 Cg_endo -66.85 136.95 43.49 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.627 2.218 . . . . 0.0 112.877 -179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 29.1 m -99.12 139.05 21.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.75 179.455 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -86.68 110.78 20.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.829 0.347 . . . . 0.0 111.518 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.624 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -103.88 129.77 51.41 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.181 179.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 11.2 mtp180 -118.06 129.55 55.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.94 0.4 . . . . 0.0 111.566 -179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.593 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mt -116.96 145.75 36.32 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.638 179.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.594 ' HD2' HG22 ' A' ' 38' ' ' VAL . 59.8 Cg_endo -73.15 99.22 1.08 Allowed 'Trans proline' 0 N--CA 1.464 -0.218 0 C-N-CA 122.662 2.242 . . . . 0.0 112.456 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -123.01 138.48 54.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.628 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.7 p -114.05 171.83 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.963 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.72 162.73 71.59 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.929 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.438 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 73.4 Cg_endo -75.51 -5.27 16.36 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.581 2.188 . . . . 0.0 112.612 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 16.4 mttt -65.7 -35.46 80.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.88 8.17 33.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.221 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.438 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -49.48 -27.58 4.42 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.787 0.327 . . . . 0.0 111.511 -179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -129.01 -23.65 3.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.44 -0.345 . . . . 0.0 111.648 -179.579 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.0 138.13 6.81 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.961 0.41 . . . . 0.0 111.484 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.412 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.1 OUTLIER -60.44 -21.85 62.77 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.153 179.718 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.49 ' C ' HD13 ' A' ' 112' ' ' LEU . 8.3 m 82.45 110.85 0.06 Allowed 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 -179.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.702 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.81 147.89 34.34 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.436 -178.94 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 65.7 Cg_endo -73.05 -6.63 19.31 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.986 2.457 . . . . 0.0 112.489 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -79.88 -37.49 22.39 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.782 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 25.7 p30 -136.84 54.95 9.64 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 120.702 0.287 . . . . 0.0 111.32 -179.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.525 ' O ' HG21 ' A' ' 120' ' ' VAL . 97.8 Cg_endo -80.36 -0.46 10.66 Favored 'Trans proline' 0 N--CA 1.463 -0.276 0 C-N-CA 122.51 2.14 . . . . 0.0 112.59 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.425 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 9.7 m-80 -130.84 12.54 5.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.711 0.291 . . . . 0.0 111.102 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.615 ' CG ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.1 -79.89 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.521 -179.664 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.665 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -89.0 -2.97 58.84 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.839 -179.79 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.525 HG21 ' O ' ' A' ' 116' ' ' PRO . 77.0 t -52.86 -28.2 13.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.856 0.36 . . . . 0.0 110.736 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -109.41 -20.88 7.55 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.056 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.67 -64.57 0.86 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.913 0.387 . . . . 0.0 111.109 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -75.23 61.84 1.2 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.959 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.9 p -84.77 132.82 34.39 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.861 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.915 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -85.18 114.16 24.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.764 179.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -106.6 131.05 54.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.961 0.41 . . . . 0.0 111.62 -179.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.562 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -138.28 132.9 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.042 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 22.8 mt -97.63 121.89 40.06 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.007 0.432 . . . . 0.0 111.934 -178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.954 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -115.53 112.1 38.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.494 0 CA-C-N 115.857 -0.611 . . . . 0.0 112.007 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.527 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.9 t70 -89.6 -36.82 15.08 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 177.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.67 131.19 28.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.207 178.5 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.954 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.5 m-85 -96.84 135.15 39.21 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.013 0.435 . . . . 0.0 110.868 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.57 -173.06 0.07 OUTLIER Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.921 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 98.4 p -106.98 55.13 0.66 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.756 0.313 . . . . 0.0 111.367 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.763 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.38 -128.9 10.74 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.894 179.51 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 67.69 9.49 7.11 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 111.534 0.198 . . . . 0.0 111.534 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 129.86 -18.91 5.31 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.379 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.763 HG22 ' HA2' ' A' ' 135' ' ' GLY . 16.6 m -49.55 119.15 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.866 0.365 . . . . 0.0 111.316 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.424 HG12 ' HA ' ' A' ' 83' ' ' MET . 6.0 m -148.28 154.43 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.402 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -98.66 137.28 37.52 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.569 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.748 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . -157.61 123.46 1.28 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.916 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.569 HG12 ' H ' ' A' ' 79' ' ' SER . 2.1 p -64.77 127.83 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.75 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.1 p -98.71 115.82 40.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.896 0.379 . . . . 0.0 111.423 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.628 ' CG ' HD21 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -92.23 105.02 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.212 179.465 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.6 mmt180 -75.56 163.04 27.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.385 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.425 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.4 t . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.977 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.486 1.374 0 CA-C-O 120.776 0.322 . . . . 0.0 111.364 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.9 m -55.08 173.18 0.1 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.147 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.8 p -118.57 174.69 6.11 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.833 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -173.25 -172.6 38.91 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.245 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.061 HD23 HG11 ' A' ' 125' ' ' VAL . 2.7 tm? -98.41 130.77 45.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.66 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.0 mm-40 -136.43 148.01 47.54 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.833 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.06 100.25 10.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.97 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.2 mp -91.54 176.2 6.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.93 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.734 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 2.4 m-85 -136.99 133.25 35.37 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.696 ' HG2' HG11 ' A' ' 139' ' ' VAL . 3.6 mm-40 -85.12 177.92 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.02 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.53 -66.81 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.248 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.9 -166.86 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.251 0 C-N-CA 122.531 2.154 . . . . 0.0 112.216 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.2 88.61 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.601 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 29.0 p -59.65 146.38 41.29 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.838 0.352 . . . . 0.0 110.822 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.411 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 30.7 m -98.08 98.47 9.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.139 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.436 HG22 ' SG ' ' A' ' 60' ' ' CYS . 51.5 t -84.81 110.42 19.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 121.107 0.479 . . . . 0.0 109.9 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.11 -21.37 5.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.031 -179.524 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.918 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.28 138.83 40.46 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.698 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.667 HG23 ' CG ' ' A' ' 58' ' ' LYS . 51.9 m -136.06 107.9 7.08 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.942 0.401 . . . . 0.0 110.829 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.775 ' HB1' HD11 ' A' ' 31' ' ' LEU . . . -102.25 128.49 48.75 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.502 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.658 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.31 137.64 30.73 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 112.597 0.591 . . . . 0.0 112.597 -178.834 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -159.13 127.87 1.92 Allowed Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.733 -0.667 . . . . 0.0 112.19 178.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.78 125.72 36.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.696 ' HZ ' HD23 ' A' ' 31' ' ' LEU . 6.2 m-85 -121.7 142.5 50.1 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.472 0.653 . . . . 0.0 111.951 -178.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -117.66 167.47 11.31 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.641 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 1.0 OUTLIER -42.42 -27.1 0.14 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.469 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -56.39 -46.72 80.0 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 113.55 -172.54 14.47 Favored Glycine 0 N--CA 1.45 -0.367 0 CA-C-N 115.619 -0.719 . . . . 0.0 113.753 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.48 -170.64 29.69 Favored Glycine 0 N--CA 1.45 -0.372 0 N-CA-C 111.496 -0.642 . . . . 0.0 111.496 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.9 OUTLIER -142.71 141.5 27.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 121.001 0.429 . . . . 0.0 111.061 179.545 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.97 HD12 ' CE2' ' A' ' 57' ' ' PHE . 1.9 tm? -102.41 106.45 17.21 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.802 179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 15.0 p -97.07 144.77 26.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.2 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.432 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 18.4 t -127.53 92.53 3.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.905 179.38 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.647 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -31.05 52.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.495 -179.555 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -53.43 -24.46 12.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.501 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.105 HG21 HG11 ' A' ' 59' ' ' VAL . 71.4 p -132.42 -41.22 0.98 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.836 0.351 . . . . 0.0 111.41 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.65 17.2 6.1 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.897 -0.668 . . . . 0.0 112.402 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.589 HG22 ' HD2' ' A' ' 100' ' ' PRO . 78.9 t -98.37 130.5 47.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 120.778 0.323 . . . . 0.0 110.993 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -134.74 130.36 36.09 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.297 -179.945 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.557 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.0 mt -108.32 112.16 39.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.866 0.365 . . . . 0.0 110.94 179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -92.25 127.3 44.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.742 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.48 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -110.54 117.4 51.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.4 -179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -65.97 140.09 59.07 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.421 2.081 . . . . 0.0 111.884 179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -57.43 93.0 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.76 -20.78 1.01 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.818 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.99 -47.06 78.4 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.91 0.386 . . . . 0.0 111.262 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.621 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.2 mt -94.71 140.28 22.53 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.582 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.815 ' HG2' HG11 ' A' ' 51' ' ' VAL . 44.6 Cg_endo -69.96 163.71 37.44 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.521 2.147 . . . . 0.0 111.868 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.414 ' HA ' ' HB3' ' A' ' 26' ' ' SER . 48.3 mt-10 -79.83 153.02 29.38 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.642 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.64 31.12 67.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.921 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.815 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.8 p -147.11 157.51 10.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.969 0.414 . . . . 0.0 111.631 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.497 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -134.83 108.25 7.84 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.341 179.419 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.2 mm100 -106.28 121.49 44.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.519 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.485 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.1 tt0 -78.62 101.97 7.74 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.127 179.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.508 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 34.0 mt -99.64 116.84 43.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.017 0.437 . . . . 0.0 110.187 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 23.3 p90 -140.62 142.56 35.02 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.938 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.97 ' CE2' HD12 ' A' ' 31' ' ' LEU . 16.4 p90 -130.22 129.42 43.34 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.364 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.667 ' CG ' HG23 ' A' ' 19' ' ' THR . 3.2 mttt -99.54 127.58 45.62 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.014 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.105 HG11 HG21 ' A' ' 36' ' ' THR . 63.9 t -89.0 121.47 39.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.217 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.436 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -105.73 165.12 11.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.243 -179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.403 ' HB2' ' ND2' ' A' ' 63' ' ' ASN . 0.0 OUTLIER -80.1 156.45 27.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.5 179.566 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -84.21 67.44 9.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.837 0.351 . . . . 0.0 110.775 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.403 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.8 OUTLIER -141.69 -46.12 0.36 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.133 -179.947 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.6 m -101.4 65.76 1.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.8 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.899 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.8 pt -141.69 166.32 17.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.087 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.4 tt -106.94 76.04 0.43 Allowed Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.885 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.571 ' HA ' HD23 ' A' ' 8' ' ' LEU . 59.4 Cg_endo -71.85 109.78 2.75 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.675 2.25 . . . . 0.0 112.403 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.563 ' HD3' HD23 ' A' ' 8' ' ' LEU . 16.3 Cg_exo -67.85 -19.21 46.93 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.612 2.208 . . . . 0.0 112.195 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.467 HD13 ' N ' ' A' ' 76' ' ' THR . 0.5 OUTLIER -58.28 177.49 0.13 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.076 -179.841 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -120.97 106.23 11.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 11.0 mttt -68.1 -29.1 67.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.05 -35.07 66.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.944 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -84.04 -25.69 29.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.828 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 128.64 -1.57 6.43 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.825 -0.703 . . . . 0.0 112.643 -179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.447 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 12.8 mt-10 -64.62 161.7 17.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.67 0.272 . . . . 0.0 110.834 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.467 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.4 t -177.85 179.18 0.9 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 121.033 0.444 . . . . 0.0 111.662 179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.579 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -106.33 108.94 20.7 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.45 179.761 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.643 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.6 mt -98.4 15.9 23.3 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.513 ' HB2' HG12 ' A' ' 142' ' ' VAL . 26.3 m -133.93 156.91 78.85 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 120.757 0.313 . . . . 0.0 111.001 179.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.05 125.49 8.66 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.497 2.131 . . . . 0.0 111.983 179.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.899 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.6 mm? -59.62 166.24 2.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.49 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.791 ' O ' HG23 ' A' ' 139' ' ' VAL . 97.5 t -155.34 136.94 5.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.021 0.439 . . . . 0.0 111.443 -179.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.35 114.75 25.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.723 179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 26.2 p -50.48 141.92 11.43 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.231 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -72.3 -80.62 0.38 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.472 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -70.2 132.65 23.05 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.42 2.08 . . . . 0.0 112.261 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.433 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -91.63 132.55 36.25 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.009 -179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.413 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 70.28 55.23 9.22 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.693 -0.765 . . . . 0.0 111.809 -179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.534 HD21 ' CE1' ' A' ' 91' ' ' PHE . 35.7 tp -106.05 141.55 37.24 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.603 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.0 OUTLIER -138.38 102.72 4.71 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.048 0.451 . . . . 0.0 111.304 -179.815 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.534 ' CE1' HD21 ' A' ' 89' ' ' LEU . 30.7 m-85 -77.06 163.11 26.95 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.003 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.0 mt -81.39 -23.11 37.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.624 178.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.95 150.5 65.49 Favored Pre-proline 0 N--CA 1.455 -0.189 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.095 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.477 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.2 Cg_endo -67.33 138.0 45.19 Favored 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.502 2.135 . . . . 0.0 112.767 -179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.634 HG22 ' O ' ' A' ' 129' ' ' ILE . 27.4 m -102.55 133.39 46.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.721 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.421 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.6 tt0 -81.94 115.81 21.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.504 -179.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.605 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.4 tt -107.59 129.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.012 179.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 71.0 mtt180 -119.84 126.97 52.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.858 0.361 . . . . 0.0 111.682 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.559 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -111.1 146.73 35.11 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.549 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.589 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.2 Cg_endo -71.42 92.89 0.67 Allowed 'Trans proline' 0 N--CA 1.464 -0.223 0 C-N-CA 122.605 2.203 . . . . 0.0 112.487 -179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -118.24 128.81 55.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.558 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 16.1 m -98.54 171.91 7.84 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.882 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -72.85 163.45 68.14 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.972 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.419 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 55.2 Cg_endo -69.87 -11.57 30.95 Favored 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.577 2.184 . . . . 0.0 112.541 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -67.18 -37.11 83.17 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.921 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -89.71 8.05 33.63 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.315 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.444 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -47.81 -28.81 2.75 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-O 120.797 0.332 . . . . 0.0 111.391 179.977 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.444 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 23.1 mt-30 -126.23 -24.93 3.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.383 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -46.69 138.77 5.78 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.001 0.429 . . . . 0.0 111.437 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 18.8 mtpt -66.78 -21.79 66.04 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.07 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.473 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 84.39 109.84 0.06 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.115 -179.223 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -91.91 148.39 36.9 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.398 -178.96 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -72.95 -8.38 22.17 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.97 2.447 . . . . 0.0 112.573 179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -81.88 -29.03 39.81 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.764 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.7 m-20 -146.3 56.15 3.04 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 120.76 0.314 . . . . 0.0 111.236 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.485 ' O ' HG21 ' A' ' 120' ' ' VAL . 84.2 Cg_endo -81.81 6.51 5.62 Favored 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.543 2.162 . . . . 0.0 112.643 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -127.8 9.46 6.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.874 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.557 ' CD1' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.87 -25.28 3.04 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.844 -179.709 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.557 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -164.67 18.03 0.05 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 111.904 0.335 . . . . 0.0 111.904 -179.88 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 116' ' ' PRO . 24.8 t -68.44 -23.91 28.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.962 0.411 . . . . 0.0 110.324 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.91 -0.61 9.8 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 121.04 -0.6 . . . . 0.0 112.229 179.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.07 -66.16 0.93 Allowed 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.916 0.388 . . . . 0.0 110.972 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.02 59.14 2.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.705 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 20.1 p -82.86 148.47 27.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.85 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 1.061 HG11 HD23 ' A' ' 5' ' ' LEU . 4.2 t -84.33 111.55 20.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.741 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.3 p -98.9 133.93 42.49 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.498 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.722 HG21 ' HE2' ' A' ' 140' ' ' TYR . 5.7 p -147.48 125.58 3.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.264 179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.477 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.4 mt -91.21 122.67 34.05 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.728 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.94 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.34 112.08 37.99 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 121.261 0.553 . . . . 0.0 112.027 179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 91' ' ' PHE . 10.0 p-10 -89.18 -37.58 14.92 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 177.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.603 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.69 132.39 30.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.727 -1.124 . . . . 0.0 110.195 178.51 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.94 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.2 m-85 -96.74 138.13 34.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.809 0.338 . . . . 0.0 110.535 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 -167.79 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 121.17 -0.538 . . . . 0.0 113.522 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 3.2 m -88.01 22.1 2.5 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.797 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.38 -152.57 1.15 Allowed Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.936 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.8 m 56.74 21.87 6.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.694 0.283 . . . . 0.0 111.29 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 169.61 -46.17 0.21 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.544 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.797 HG22 ' HA2' ' A' ' 135' ' ' GLY . 14.1 m -56.13 125.04 10.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.94 0.4 . . . . 0.0 111.176 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.791 HG23 ' O ' ' A' ' 82' ' ' VAL . 1.5 p -150.07 142.91 17.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.109 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.722 ' HE2' HG21 ' A' ' 127' ' ' VAL . 30.0 m-85 -91.5 146.8 23.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.367 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -166.79 132.07 2.52 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.645 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' HB2' ' A' ' 79' ' ' SER . 2.7 p -67.66 124.34 22.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 120.723 0.297 . . . . 0.0 110.451 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.71 115.46 39.18 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.945 0.402 . . . . 0.0 111.383 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.643 ' CG ' HD11 ' A' ' 78' ' ' LEU . 25.7 ttt-85 -91.16 109.06 20.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.098 179.476 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.5 mmm180 -71.22 163.08 28.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.292 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.408 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.6 OUTLIER . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.194 -0.908 . . . . 0.0 110.807 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 53.3 p-80 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 120.873 0.368 . . . . 0.0 111.133 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -144.09 175.45 10.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.78 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 78.9 p -135.08 153.71 51.93 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.889 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.25 -173.41 32.87 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.898 HD23 HG11 ' A' ' 125' ' ' VAL . 2.5 tm? -98.33 133.22 43.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 110.998 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.695 ' N ' HD13 ' A' ' 5' ' ' LEU . 6.8 mm-40 -140.96 151.94 44.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.832 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.613 HG22 ' CE1' ' A' ' 140' ' ' TYR . 17.1 t -103.16 105.79 18.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.164 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.599 HD23 ' HA ' ' A' ' 67' ' ' PRO . 3.0 mp -95.84 165.41 12.3 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.856 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.722 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.6 m-85 -121.86 127.11 50.14 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 11.4 mt-30 -81.67 144.83 30.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -117.43 -75.88 0.55 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.405 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -71.26 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.587 2.192 . . . . 0.0 112.3 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.23 110.39 2.88 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.51 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.4 p -74.92 150.59 39.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.841 0.353 . . . . 0.0 110.908 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 21.7 m -101.52 98.6 8.9 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.971 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.722 HG22 ' SG ' ' A' ' 60' ' ' CYS . 57.2 t -87.87 110.46 20.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.167 0.508 . . . . 0.0 110.133 179.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.18 -24.22 4.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.004 -179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.883 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -137.32 141.77 41.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.651 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.811 HG23 ' HG3' ' A' ' 58' ' ' LYS . 43.4 m -138.71 107.81 6.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.988 0.423 . . . . 0.0 111.094 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.88 118.23 34.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.19 179.224 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.482 ' HD3' ' CD2' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -130.5 138.34 50.19 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -179.032 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.95 128.05 1.76 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.482 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.487 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -76.86 122.92 32.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.535 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 4.6 m-85 -119.48 140.84 49.82 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.44 0.638 . . . . 0.0 111.783 -178.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 37.3 p-10 -117.98 167.83 11.08 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.807 -1.088 . . . . 0.0 110.593 -178.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -42.29 -28.18 0.18 Allowed 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.405 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -53.57 -44.83 69.65 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.07 -178.46 28.18 Favored Glycine 0 N--CA 1.452 -0.281 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.709 178.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.73 -169.92 31.19 Favored Glycine 0 N--CA 1.452 -0.294 0 N-CA-C 111.354 -0.698 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -135.56 148.86 28.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.227 179.621 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.535 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 16.1 tp -113.72 106.59 14.68 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.008 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -94.86 145.49 24.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.133 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 4.4 t -127.16 92.93 3.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.933 179.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.67 -29.99 48.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.534 -179.706 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -52.02 -25.93 9.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.357 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.116 HG21 HG11 ' A' ' 59' ' ' VAL . 74.3 p -132.75 -41.7 0.93 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.71 19.63 5.25 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.29 -179.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.622 ' CG2' HD23 ' A' ' 99' ' ' LEU . 75.8 t -99.78 129.01 51.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.792 0.329 . . . . 0.0 111.002 -179.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -128.76 132.05 47.89 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.036 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.609 HD12 ' CD1' ' A' ' 57' ' ' PHE . 48.8 mt -110.57 112.35 40.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.138 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.4 mp -95.08 126.12 47.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.767 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.655 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -111.38 119.58 44.92 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.208 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.16 139.2 49.72 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.394 2.063 . . . . 0.0 112.038 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -59.04 90.42 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.009 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.43 -23.19 0.65 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.672 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.01 -50.12 67.35 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.87 0.366 . . . . 0.0 111.212 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.503 HG23 ' HD2' ' A' ' 48' ' ' PRO . 9.1 mt -91.32 137.98 25.85 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.385 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.814 ' HG2' HG11 ' A' ' 51' ' ' VAL . 37.5 Cg_endo -67.8 171.68 11.82 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.458 2.105 . . . . 0.0 112.182 -179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.16 154.64 22.99 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.424 -179.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 64.55 36.76 93.55 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.558 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.814 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.1 p -146.85 155.4 11.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.913 0.387 . . . . 0.0 111.458 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.442 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -138.1 108.41 6.47 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.466 179.645 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.6 mm100 -109.54 124.26 50.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.39 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 7.4 tt0 -80.69 101.74 9.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.564 HD11 ' HE1' ' A' ' 91' ' ' PHE . 56.6 mt -98.68 116.9 42.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 120.946 0.403 . . . . 0.0 110.207 179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.482 ' CD2' ' HD3' ' A' ' 21' ' ' ARG . 32.5 p90 -137.95 128.32 26.27 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.24 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.609 ' CD1' HD12 ' A' ' 40' ' ' ILE . 21.4 p90 -112.31 123.41 50.22 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.166 179.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.811 ' HG3' HG23 ' A' ' 19' ' ' THR . 4.6 mttt -97.36 123.46 41.2 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.065 -179.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.116 HG11 HG21 ' A' ' 36' ' ' THR . 89.4 t -89.16 118.06 33.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.138 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.722 ' SG ' HG22 ' A' ' 16' ' ' VAL . 88.8 m -108.75 169.12 8.86 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.015 0.436 . . . . 0.0 111.427 -179.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 17.0 mmm-85 -81.2 171.56 14.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.607 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -101.31 75.08 1.6 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.898 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -139.92 -46.54 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.019 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -106.64 71.17 0.84 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.936 0.398 . . . . 0.0 110.755 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.708 HD13 HD11 ' A' ' 81' ' ' LEU . 16.3 pt -143.0 166.17 15.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.109 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -108.75 77.48 0.8 Allowed Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.905 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.599 ' HA ' HD23 ' A' ' 8' ' ' LEU . 73.9 Cg_endo -75.18 109.99 3.03 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.563 2.175 . . . . 0.0 112.426 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.9 -16.82 37.13 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.458 2.105 . . . . 0.0 112.412 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.38 170.29 0.75 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.866 0.365 . . . . 0.0 110.975 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -112.15 107.27 16.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 5.9 mttt -68.07 -31.35 70.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.916 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -56.96 -36.02 69.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.915 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.17 -25.46 36.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.87 179.77 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 123.95 2.11 8.67 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.915 -0.66 . . . . 0.0 112.741 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.441 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 14.6 mt-10 -69.79 159.89 32.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.592 0.234 . . . . 0.0 110.683 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.531 HG22 ' CD ' ' A' ' 144' ' ' ARG . 15.4 t -177.42 -173.58 0.44 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.984 0.421 . . . . 0.0 111.896 -179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 79' ' ' SER . 0.1 OUTLIER -112.96 106.91 15.28 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.534 179.951 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.802 HD11 ' HG3' ' A' ' 144' ' ' ARG . 6.1 mt -98.49 19.8 13.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.884 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.575 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.7 m -138.48 155.37 73.79 Favored Pre-proline 0 C--N 1.33 -0.242 0 CA-C-O 120.649 0.261 . . . . 0.0 111.13 179.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.437 ' HB2' HG13 ' A' ' 59' ' ' VAL . 64.5 Cg_endo -73.61 127.21 11.48 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.506 2.137 . . . . 0.0 112.318 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.708 HD11 HD13 ' A' ' 65' ' ' ILE . 1.5 mt -59.13 164.78 2.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.927 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.564 HG13 ' HB2' ' A' ' 57' ' ' PHE . 75.7 t -146.93 143.22 20.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.991 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.12 116.15 22.98 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.935 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 27.7 p -58.75 127.31 31.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.794 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.451 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -56.09 -83.07 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.411 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.524 ' HG2' HD12 ' A' ' 89' ' ' LEU . 57.8 Cg_endo -70.6 136.52 30.96 Favored 'Trans proline' 0 C--N 1.343 0.249 0 C-N-CA 122.354 2.036 . . . . 0.0 111.983 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 2.5 p80 -93.81 135.53 35.03 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.707 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 76.41 38.22 33.97 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.088 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.823 HD13 ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -86.24 139.99 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.88 0.372 . . . . 0.0 110.628 -179.986 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.738 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -142.99 104.76 4.35 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.059 0.456 . . . . 0.0 111.161 -179.926 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.823 ' CZ ' HD13 ' A' ' 89' ' ' LEU . 9.7 m-85 -83.97 168.57 15.86 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.935 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.7 mt -83.13 -24.3 32.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.481 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 5.3 mtmt -136.81 149.88 68.2 Favored Pre-proline 0 N--CA 1.455 -0.191 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.893 179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.467 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 47.4 Cg_endo -68.94 134.51 29.93 Favored 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.435 2.09 . . . . 0.0 112.524 -179.63 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.696 HG22 ' O ' ' A' ' 129' ' ' ILE . 33.4 m -96.58 139.06 20.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.812 179.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.407 ' O ' ' N ' ' A' ' 41' ' ' ILE . 19.4 tt0 -84.93 130.55 34.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.265 -179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.611 ' C ' HD23 ' A' ' 97' ' ' LEU . 6.5 tt -124.41 129.01 49.91 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.034 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.5 mtp180 -118.18 128.52 54.79 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.335 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.622 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.2 mt -114.39 145.15 33.14 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.737 179.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' HG22 ' A' ' 38' ' ' VAL . 63.1 Cg_endo -74.24 84.85 1.47 Allowed 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.773 2.315 . . . . 0.0 112.446 -179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 8.7 t60 -107.27 118.4 36.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.575 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.4 ' HB2' ' CD2' ' A' ' 119' ' ' LEU . 18.5 p -95.38 171.91 8.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.165 -179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.86 163.36 50.46 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.096 -179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.424 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 60.8 Cg_endo -72.56 -14.51 27.56 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.668 2.246 . . . . 0.0 112.441 179.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 25.2 mmmt -57.84 -35.6 71.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.831 0.348 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.27 8.16 31.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.254 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.453 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.03 -28.81 1.8 Allowed 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.775 0.321 . . . . 0.0 111.555 -179.851 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.453 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 17.0 mt-30 -121.52 -31.84 3.95 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.996 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.1 t-20 -48.69 138.12 11.27 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.997 0.427 . . . . 0.0 111.439 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.456 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 3.8 mptt -68.1 -21.57 64.94 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.956 179.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.477 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 85.18 109.97 0.05 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 109.788 -179.08 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.724 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.44 148.44 36.4 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-O 121.118 0.485 . . . . 0.0 111.436 -178.792 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.22 -8.69 23.22 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.904 2.403 . . . . 0.0 112.311 179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -75.76 -39.54 33.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.679 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.451 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 38.4 p30 -142.8 56.42 4.98 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 120.699 0.285 . . . . 0.0 111.339 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.485 ' O ' HG21 ' A' ' 120' ' ' VAL . 69.0 Cg_endo -86.52 18.33 1.59 Allowed 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.717 2.278 . . . . 0.0 112.781 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.36 8.61 6.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.908 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.549 ' C ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.9 -23.94 2.22 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.621 -179.771 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.549 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -170.84 21.93 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.55 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 116' ' ' PRO . 15.5 t -66.77 -25.92 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.939 0.399 . . . . 0.0 110.382 179.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -123.34 4.64 9.49 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.257 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.82 -42.73 11.1 Favored 'General case' 0 C--O 1.232 0.158 0 CA-C-O 120.842 0.353 . . . . 0.0 111.076 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -94.65 34.13 1.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.051 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 7.4 p -59.75 137.56 58.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.044 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.898 HG11 HD23 ' A' ' 5' ' ' LEU . 4.4 t -86.2 118.0 31.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 1.7 p -101.36 131.76 47.27 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.998 0.428 . . . . 0.0 111.327 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.535 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.1 p -143.71 129.5 15.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.542 179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 15.4 mt -93.72 121.53 35.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.34 -179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.915 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.7 mt -116.65 111.9 37.15 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.395 0 CA-C-O 121.329 0.585 . . . . 0.0 111.944 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 91' ' ' PHE . 29.7 p-10 -97.1 -31.22 12.59 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.145 -0.934 . . . . 0.0 108.52 177.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.738 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.4 OUTLIER -138.26 120.03 15.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.471 178.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.915 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 1.1 m-85 -96.44 107.39 19.78 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.573 -0.529 . . . . 0.0 109.573 179.062 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -44.36 168.3 0.02 OUTLIER Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.927 -0.578 . . . . 0.0 113.51 -178.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -112.4 25.11 11.82 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.612 0.244 . . . . 0.0 111.286 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.792 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -59.92 167.57 8.9 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.45 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 53.0 p -80.83 -20.78 41.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.677 0.275 . . . . 0.0 111.158 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -143.95 22.13 2.13 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.979 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.792 HG13 ' HA3' ' A' ' 135' ' ' GLY . 23.3 m -58.4 88.45 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 9.4 m -114.81 165.06 10.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.514 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.613 ' CE1' HG22 ' A' ' 7' ' ' VAL . 6.6 m-85 -102.13 163.2 12.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.383 179.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . 179.14 133.46 1.95 Allowed Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.402 -0.904 . . . . 0.0 112.803 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.447 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -67.73 128.31 30.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.663 0.268 . . . . 0.0 110.43 179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.5 p -98.47 115.5 38.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.935 0.398 . . . . 0.0 111.506 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.802 ' HG3' HD11 ' A' ' 78' ' ' LEU . 5.5 ttt180 -94.87 110.3 22.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.005 179.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.74 163.18 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.239 -179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.272 -0.87 . . . . 0.0 110.871 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.1 p80 . . . . . 0 N--CA 1.486 1.359 0 CA-C-O 120.844 0.354 . . . . 0.0 111.225 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 m -174.22 150.18 1.49 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 91.7 p -128.69 168.04 16.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.878 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -167.1 179.49 40.76 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.561 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.796 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.5 tm? -91.13 136.26 33.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.781 0.324 . . . . 0.0 110.854 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.796 ' N ' HD13 ' A' ' 5' ' ' LEU . 42.8 mm-40 -149.77 156.37 41.72 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.55 106.88 19.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.143 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.47 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.1 mp -93.09 170.34 9.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.875 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.781 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 8.2 m-85 -126.47 144.49 50.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.86 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.834 ' OE1' HG22 ' A' ' 65' ' ' ILE . 4.5 mm100 -94.25 176.72 6.21 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.964 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -160.9 -74.58 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.338 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.31 -167.36 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.546 2.164 . . . . 0.0 112.249 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.52 95.86 0.13 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.553 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 p -64.92 144.11 57.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.845 0.355 . . . . 0.0 110.909 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.3 m -102.02 98.62 8.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.214 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.678 HG22 ' SG ' ' A' ' 60' ' ' CYS . 76.4 t -85.69 110.38 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 CA-C-O 121.066 0.46 . . . . 0.0 110.005 179.13 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -103.53 -26.75 3.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.792 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.954 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -132.8 142.68 49.1 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.495 179.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.919 HG22 ' HD2' ' A' ' 21' ' ' ARG . 95.9 m -142.08 107.67 5.08 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.983 0.42 . . . . 0.0 111.023 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.416 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -97.8 132.42 43.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.289 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.919 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -142.19 139.31 32.01 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.005 0.431 . . . . 0.0 112.063 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.65 123.79 1.18 Allowed Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.517 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -74.46 121.91 26.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.084 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.595 ' HD2' HD12 ' A' ' 55' ' ' ILE . 5.1 m-85 -119.25 139.45 51.87 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.569 0.699 . . . . 0.0 111.949 -178.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 32.1 p30 -116.86 167.7 10.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.373 -179.144 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 2.0 t -42.23 -27.88 0.16 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.569 -0.287 . . . . 0.0 111.447 -179.275 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.7 m120 -54.29 -44.97 72.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.059 0.456 . . . . 0.0 109.807 178.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 103.1 -179.21 25.95 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.633 -0.712 . . . . 0.0 113.708 178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.79 -173.19 31.8 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 111.466 -0.654 . . . . 0.0 111.466 -179.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.416 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -132.89 152.19 35.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.136 0.493 . . . . 0.0 111.235 179.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.527 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 12.5 tp -117.74 106.57 13.18 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.835 179.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 4.9 p -95.94 146.94 24.19 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.255 -179.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 84.2 p -129.31 92.87 3.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.968 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.663 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.6 -29.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.324 -179.584 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -54.31 -23.56 15.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.294 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.017 HG21 HG11 ' A' ' 59' ' ' VAL . 67.5 p -134.23 -41.18 0.81 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.316 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.88 21.68 5.26 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.862 -0.685 . . . . 0.0 112.215 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.566 HG22 ' HD2' ' A' ' 100' ' ' PRO . 73.9 t -102.19 126.94 56.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 120.848 0.356 . . . . 0.0 111.156 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.16 130.41 49.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.942 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.499 HD12 ' CD1' ' A' ' 57' ' ' PHE . 57.5 mt -111.21 112.28 39.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.185 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.613 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -95.12 128.97 45.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.511 179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.713 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.41 117.21 45.48 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.54 -179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.66 140.07 60.69 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.398 2.065 . . . . 0.0 111.861 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -57.17 93.33 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.986 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.4 -21.65 1.07 Allowed Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.819 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.69 -29.63 64.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.831 0.348 . . . . 0.0 111.35 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.641 HG23 ' HD2' ' A' ' 48' ' ' PRO . 17.0 mt -112.63 140.69 24.18 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.468 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.893 ' HG2' HG11 ' A' ' 51' ' ' VAL . 39.5 Cg_endo -68.81 167.95 21.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.604 2.203 . . . . 0.0 112.014 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -83.57 158.48 21.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.476 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.81 35.69 91.66 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 121.014 -0.613 . . . . 0.0 112.584 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.893 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.7 p -147.06 157.66 10.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.068 0.461 . . . . 0.0 111.557 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' N ' HG22 ' A' ' 51' ' ' VAL . 1.4 mt-10 -134.89 108.25 7.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.214 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -104.4 119.05 38.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.489 -179.539 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.5 tt0 -79.97 101.74 8.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.117 179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.595 HD12 ' HD2' ' A' ' 24' ' ' PHE . 54.9 mt -101.21 116.74 45.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.017 0.437 . . . . 0.0 110.449 179.78 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.687 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.2 p90 -136.99 129.17 29.59 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.75 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.683 ' HB2' HG13 ' A' ' 82' ' ' VAL . 20.0 p90 -114.08 123.43 49.65 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.307 179.535 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.717 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.0 mttt -97.84 123.27 41.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.03 -179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.017 HG11 HG21 ' A' ' 36' ' ' THR . 80.7 t -89.25 121.41 39.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.997 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.678 ' SG ' HG22 ' A' ' 16' ' ' VAL . 87.8 m -109.84 169.88 8.43 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.01 0.433 . . . . 0.0 111.525 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.427 ' HB2' HD21 ' A' ' 63' ' ' ASN . 10.8 mmm-85 -75.35 166.21 23.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.745 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -100.27 31.05 3.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.26 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.427 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.2 OUTLIER -112.29 -11.5 13.7 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.409 179.818 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.5 p -131.31 65.4 1.56 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.963 0.411 . . . . 0.0 110.516 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.835 HG21 ' CD1' ' A' ' 81' ' ' LEU . 12.0 pt -144.82 169.37 8.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.145 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.718 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.6 tt -111.07 79.25 1.91 Allowed Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.84 179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.47 ' HA ' HD23 ' A' ' 8' ' ' LEU . 86.6 Cg_endo -80.7 111.57 2.55 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.656 2.237 . . . . 0.0 112.565 -179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -62.96 -16.08 51.85 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.594 2.196 . . . . 0.0 112.615 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 76' ' ' THR . 0.9 OUTLIER -58.51 177.4 0.14 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.834 0.35 . . . . 0.0 111.061 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -119.33 103.87 9.87 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.057 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 43.5 mttt -68.16 -28.33 67.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -56.14 -34.77 66.42 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.86 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -84.04 -24.51 30.42 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.841 179.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.87 -1.66 7.35 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.444 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.433 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.0 mt-10 -61.92 162.23 9.37 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.779 0.323 . . . . 0.0 110.67 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 69' ' ' LEU . 11.2 t -178.74 -173.85 0.33 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.969 0.414 . . . . 0.0 111.402 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.745 HD23 ' O ' ' A' ' 79' ' ' SER . 0.3 OUTLIER -113.42 105.63 13.6 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.77 179.905 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.912 HD11 ' HG3' ' A' ' 144' ' ' ARG . 2.1 mt -92.46 18.35 8.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.61 -179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.745 ' O ' HD23 ' A' ' 77' ' ' LEU . 72.6 m -138.06 153.02 73.05 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.3 . . . . 0.0 111.098 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.29 125.58 10.35 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.52 2.146 . . . . 0.0 112.248 179.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.835 ' CD1' HG21 ' A' ' 65' ' ' ILE . 1.6 mt -58.56 163.61 3.1 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.661 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.683 HG13 ' HB2' ' A' ' 57' ' ' PHE . 71.0 t -146.25 134.01 15.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.095 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.696 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -113.22 104.91 12.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.587 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 32.1 p -49.79 122.44 6.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.125 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -54.35 -78.31 0.12 Allowed Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.453 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.97 134.55 25.67 Favored 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.41 2.073 . . . . 0.0 112.167 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.413 ' HB2' ' HB3' ' A' ' 134' ' ' SER . 38.2 p-80 -92.88 138.23 31.67 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.675 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 63.15 55.6 25.31 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.588 -0.815 . . . . 0.0 112.083 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.507 HD21 ' CE1' ' A' ' 91' ' ' PHE . 41.6 tp -103.46 142.71 33.78 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 2.3 mtmm -138.52 107.79 6.11 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.216 0.531 . . . . 0.0 111.594 -179.747 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.507 ' CE1' HD21 ' A' ' 89' ' ' LEU . 33.1 m-85 -82.61 159.22 22.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.83 179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 12.8 mt -76.95 -18.47 58.24 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.922 178.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 19.4 mtpt -145.89 152.12 47.27 Favored Pre-proline 0 C--N 1.333 -0.142 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.053 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.452 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.7 Cg_endo -66.58 135.8 40.31 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.53 2.153 . . . . 0.0 112.545 -179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.713 HG12 HG23 ' A' ' 42' ' ' ILE . 29.0 m -100.88 139.64 21.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.847 179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.421 ' O ' ' N ' ' A' ' 41' ' ' ILE . 29.6 tt0 -82.56 129.83 35.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.121 -179.588 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.597 ' C ' HD23 ' A' ' 97' ' ' LEU . 7.2 tt -124.3 128.01 48.5 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.237 179.423 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -119.2 127.43 53.28 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.995 0.426 . . . . 0.0 111.426 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.578 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.81 147.08 38.28 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.706 179.619 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.566 ' HD2' HG22 ' A' ' 38' ' ' VAL . 54.0 Cg_endo -70.71 105.19 1.59 Allowed 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.616 2.211 . . . . 0.0 112.443 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -128.71 131.71 47.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.61 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 17.3 p -105.18 171.85 7.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.068 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.38 163.39 58.84 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 62.3 Cg_endo -73.26 -14.72 25.58 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.553 2.168 . . . . 0.0 112.441 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -58.7 -35.6 72.9 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.943 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -89.2 8.17 31.57 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.29 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.469 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.3 OUTLIER -47.68 -28.44 2.41 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.568 -179.792 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.469 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 14.0 mt-30 -123.43 -30.42 3.66 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.28 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -47.05 138.21 6.86 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.973 0.416 . . . . 0.0 111.352 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.451 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.0 OUTLIER -65.55 -21.8 66.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.07 179.711 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.49 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.9 OUTLIER 84.64 110.79 0.05 Allowed 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.983 -179.17 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.707 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.7 147.81 34.89 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.471 -178.972 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -72.46 -7.9 21.68 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.913 2.409 . . . . 0.0 112.471 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -78.0 -40.06 22.1 Favored Glycine 0 N--CA 1.45 -0.423 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.859 -179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.458 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 3.2 t0 -138.66 55.93 8.9 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.618 0.247 . . . . 0.0 111.342 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.506 ' O ' HG21 ' A' ' 120' ' ' VAL . 94.7 Cg_endo -84.44 12.32 3.08 Favored 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.595 2.197 . . . . 0.0 112.797 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -128.79 8.24 5.74 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.758 0.313 . . . . 0.0 111.005 179.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.83 -24.59 2.5 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.666 -179.716 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.451 ' C ' ' CD2' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -168.56 20.23 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 -179.839 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.506 HG21 ' O ' ' A' ' 116' ' ' PRO . 20.5 t -67.44 -24.29 31.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.88 0.372 . . . . 0.0 110.48 179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -126.21 4.16 7.79 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.253 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.6 -44.35 10.14 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.945 0.403 . . . . 0.0 111.284 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -95.12 35.64 1.27 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.084 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.0 m -59.84 158.62 10.24 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.09 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.789 HG11 HD23 ' A' ' 5' ' ' LEU . 2.2 t -96.71 119.45 44.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.87 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.14 129.28 51.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.928 0.394 . . . . 0.0 111.327 -179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.565 HG13 ' HB3' ' A' ' 97' ' ' LEU . 4.9 p -140.62 141.75 31.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.463 179.462 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.0 mt -105.48 123.37 47.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.472 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.964 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.64 112.29 38.14 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.404 0 CA-C-O 121.281 0.562 . . . . 0.0 112.169 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.487 ' O ' ' N ' ' A' ' 91' ' ' PHE . 6.9 t0 -88.04 -38.42 15.48 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.604 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.72 133.1 31.81 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.187 178.408 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.964 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.8 m-85 -96.72 116.25 28.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.871 0.367 . . . . 0.0 110.768 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.48 177.96 0.17 Allowed Glycine 0 C--N 1.33 0.219 0 C-N-CA 121.061 -0.59 . . . . 0.0 113.12 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.413 ' HB3' ' HB2' ' A' ' 87' ' ' HIS . 0.0 OUTLIER -143.39 96.56 2.93 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.78 0.324 . . . . 0.0 110.705 -179.872 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.41 ' HA3' HG13 ' A' ' 138' ' ' VAL . . . -128.22 -174.11 13.65 Favored Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.517 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.7 m -57.78 -27.74 63.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.783 0.325 . . . . 0.0 110.939 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -169.84 43.9 0.21 Allowed Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.494 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.781 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 19.2 m -57.5 92.42 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.874 0.369 . . . . 0.0 111.016 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.696 HG12 ' HA ' ' A' ' 83' ' ' MET . 4.2 m -113.73 162.76 11.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.389 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.634 ' CD2' HD11 ' A' ' 5' ' ' LEU . 6.7 m-85 -101.04 156.13 17.59 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.371 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -177.05 158.94 25.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.433 -0.889 . . . . 0.0 112.855 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.474 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -93.84 128.36 45.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.713 0.292 . . . . 0.0 110.527 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 12.6 p -98.64 115.45 39.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.74 0.305 . . . . 0.0 111.153 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.912 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -94.39 109.89 21.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.333 179.481 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 9.0 mmt180 -73.3 163.05 28.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.3 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.949 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 38.6 m80 . . . . . 0 N--CA 1.487 1.39 0 CA-C-O 120.768 0.318 . . . . 0.0 111.159 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 78.0 p -161.15 177.95 9.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.849 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 77.6 p -134.62 150.71 50.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.922 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.595 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.64 149.86 19.39 Favored Glycine 0 C--O 1.228 -0.227 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.658 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.638 HD11 ' CD2' ' A' ' 140' ' ' TYR . 2.3 tm? -68.16 127.4 32.77 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.903 0.383 . . . . 0.0 110.861 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.603 ' N ' HD13 ' A' ' 5' ' ' LEU . 15.6 mm-40 -138.16 149.58 45.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.4 t -92.96 100.37 11.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.057 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 77' ' ' LEU . 7.0 mt -80.38 176.92 9.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.956 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -128.96 124.33 34.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.957 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 3.0 tm0? -81.04 139.11 35.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.02 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -122.35 -78.66 0.46 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.274 179.697 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.28 -166.36 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.633 2.222 . . . . 0.0 112.05 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.24 103.21 0.9 Allowed Glycine 0 C--N 1.331 0.271 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.389 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -70.62 133.25 46.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.456 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 52.1 m -81.57 98.65 8.42 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.286 -179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.694 HG22 ' SG ' ' A' ' 60' ' ' CYS . 74.1 t -82.07 110.53 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-O 121.102 0.477 . . . . 0.0 110.102 179.09 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.73 -24.0 4.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.887 -179.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.956 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -136.68 143.88 43.64 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.702 179.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.742 HG23 ' HG3' ' A' ' 58' ' ' LYS . 31.7 m -139.14 108.09 6.0 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.919 0.39 . . . . 0.0 110.998 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.501 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -100.09 123.83 44.78 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.153 179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.637 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -135.9 137.45 41.42 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.044 0.449 . . . . 0.0 112.105 -179.148 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -162.23 126.38 1.55 Allowed Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.433 179.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.476 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -76.99 122.5 31.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.277 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 3.8 m-85 -120.32 140.59 51.05 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.368 0.604 . . . . 0.0 111.809 -178.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 34.4 p-10 -115.24 167.28 10.98 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.054 -0.975 . . . . 0.0 110.773 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 4.8 p -42.41 -27.56 0.16 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.446 -179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.411 ' ND2' ' O ' ' A' ' 28' ' ' GLY . 0.1 OUTLIER -55.89 -47.03 78.14 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 178.632 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.411 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 110.4 -173.84 16.77 Favored Glycine 0 N--CA 1.45 -0.421 0 CA-C-N 115.668 -0.697 . . . . 0.0 113.893 178.363 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.46 -178.02 25.35 Favored Glycine 0 N--CA 1.451 -0.347 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -128.27 158.52 40.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.218 0.533 . . . . 0.0 111.031 179.718 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 14.1 tp -124.47 106.57 10.29 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.829 179.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 3.0 p -97.23 145.34 26.16 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.136 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.421 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 99.5 p -128.06 92.88 3.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.835 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.664 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -63.73 -29.02 46.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.414 -179.464 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -54.42 -23.86 17.61 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.261 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.081 HG21 HG11 ' A' ' 59' ' ' VAL . 77.9 p -133.22 -41.68 0.89 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.223 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.02 20.53 5.61 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.545 ' CG2' HD23 ' A' ' 99' ' ' LEU . 72.5 t -100.9 129.08 52.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.798 0.333 . . . . 0.0 110.981 -179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.94 131.43 47.52 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.984 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.546 HD12 ' CD1' ' A' ' 57' ' ' PHE . 61.6 mt -113.58 112.16 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.254 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.622 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.1 mp -94.4 129.31 44.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.445 179.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.708 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -112.94 117.5 46.06 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.471 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -66.24 140.09 57.56 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.387 2.058 . . . . 0.0 111.977 179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.9 tm0? -57.0 91.57 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.12 -23.33 0.78 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.78 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -54.89 -34.71 63.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.943 0.402 . . . . 0.0 111.206 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 48' ' ' PRO . 24.6 mt -108.4 140.78 22.08 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.227 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.783 ' HG2' HG11 ' A' ' 51' ' ' VAL . 45.3 Cg_endo -70.8 155.72 61.98 Favored 'Trans proline' 0 N--CA 1.461 -0.396 0 C-N-CA 122.423 2.082 . . . . 0.0 111.732 179.669 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -75.08 144.31 43.0 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.564 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.67 26.26 43.04 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.935 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.783 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.4 p -147.13 157.31 10.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.012 0.434 . . . . 0.0 111.63 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.494 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.6 OUTLIER -132.49 108.27 9.01 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.152 179.358 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -104.39 119.13 38.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.356 -179.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.476 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 4.7 tt0 -77.04 101.75 6.18 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.124 179.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.506 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 54.0 mt -100.57 117.04 45.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.058 0.456 . . . . 0.0 110.421 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.595 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 32.3 p90 -137.57 136.24 37.41 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.147 -179.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.676 ' HB2' HG13 ' A' ' 82' ' ' VAL . 15.0 p90 -119.27 123.35 44.03 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.214 179.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.742 ' HG3' HG23 ' A' ' 19' ' ' THR . 5.5 mttt -96.22 121.89 38.49 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.568 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.081 HG11 HG21 ' A' ' 36' ' ' THR . 99.6 t -89.03 121.94 39.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.196 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.694 ' SG ' HG22 ' A' ' 16' ' ' VAL . 78.4 m -113.36 168.21 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.091 0.472 . . . . 0.0 111.528 -178.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 2.2 mmp_? -84.09 156.1 22.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.705 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 11.7 p-10 -89.12 95.73 10.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.916 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -162.23 -46.0 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.974 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.11 39.38 1.41 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.802 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.525 HG21 HD22 ' A' ' 81' ' ' LEU . 4.7 pt -121.92 170.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.155 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.703 ' O ' HD23 ' A' ' 66' ' ' LEU . 8.2 tt -113.73 88.56 14.09 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.96 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 4.3 Cg_exo -80.11 111.47 2.68 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 123.006 2.471 . . . . 0.0 112.301 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -60.54 -20.49 64.55 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 122.454 2.103 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.48 177.5 0.13 Allowed 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -119.97 106.42 12.01 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.999 -179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mmtp -68.19 -28.29 67.13 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.992 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.05 -34.08 65.57 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.928 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.8 mttt -85.43 -24.1 27.61 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.769 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 124.17 0.87 8.8 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.434 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' O ' ' HB ' ' A' ' 76' ' ' THR . 24.9 mt-10 -64.97 161.85 17.77 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-O 120.744 0.307 . . . . 0.0 110.857 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.508 HG22 ' CD ' ' A' ' 144' ' ' ARG . 9.4 t -178.14 -174.27 0.41 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.982 0.42 . . . . 0.0 111.526 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.959 HD11 HD11 ' A' ' 8' ' ' LEU . 0.2 OUTLIER -109.59 105.27 14.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.786 179.951 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.728 HD21 ' HD2' ' A' ' 144' ' ' ARG . 6.9 mt -93.92 19.73 8.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.677 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.513 ' O ' HD23 ' A' ' 77' ' ' LEU . 58.6 m -138.39 152.51 71.45 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-O 120.66 0.267 . . . . 0.0 110.983 179.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -72.57 123.84 9.36 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.533 2.155 . . . . 0.0 112.178 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.525 HD22 HG21 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -58.5 161.6 4.41 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.882 179.986 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.676 HG13 ' HB2' ' A' ' 57' ' ' PHE . 54.3 t -142.43 139.95 28.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.299 -179.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.482 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.1 OUTLIER -114.68 110.88 20.43 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.588 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 33.4 m -54.41 122.5 10.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.153 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -57.23 -83.99 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.285 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -66.05 132.83 31.2 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.256 1.971 . . . . 0.0 111.748 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.431 ' HA ' ' O ' ' A' ' 134' ' ' SER . 15.3 p80 -89.2 142.11 27.93 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.018 -179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 56.3 58.56 13.64 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.661 -0.78 . . . . 0.0 111.962 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.525 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.9 tp -105.16 141.81 36.04 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.2 mtmt -137.87 106.56 5.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.191 0.519 . . . . 0.0 111.39 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.532 ' N ' ' O ' ' A' ' 130' ' ' ASP . 34.5 m-85 -81.15 161.65 23.97 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.035 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 10.9 mt -81.13 -19.53 43.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.839 178.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 8.5 mtmt -141.33 150.5 58.38 Favored Pre-proline 0 C--N 1.331 -0.221 0 CA-C-N 115.727 -0.67 . . . . 0.0 109.996 179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 56.4 Cg_endo -70.22 128.38 15.53 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.412 2.075 . . . . 0.0 112.372 -179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.708 HG12 HG23 ' A' ' 42' ' ' ILE . 27.2 m -91.72 139.73 17.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.748 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.406 ' HA ' HD23 ' A' ' 128' ' ' LEU . 9.2 tt0 -84.16 118.96 24.46 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.906 0.384 . . . . 0.0 110.877 -179.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.77 HD22 ' CG1' ' A' ' 127' ' ' VAL . 6.8 tt -113.38 129.34 56.56 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.213 179.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.425 ' O ' HG13 ' A' ' 38' ' ' VAL . 6.6 mtp180 -119.61 136.79 54.23 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.991 0.424 . . . . 0.0 111.358 -179.416 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.545 HD23 ' CG2' ' A' ' 38' ' ' VAL . 1.1 mt -122.58 146.64 48.21 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.717 179.635 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.545 ' CD ' HG22 ' A' ' 38' ' ' VAL . 84.5 Cg_endo -78.41 90.07 1.3 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.833 2.356 . . . . 0.0 112.653 -179.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.44 ' CE1' ' HB2' ' A' ' 78' ' ' LEU . 1.6 t60 -106.68 119.33 39.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.622 179.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.456 ' HB3' HG21 ' A' ' 106' ' ' THR . 72.3 m -85.52 171.8 11.46 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.009 0.433 . . . . 0.0 111.183 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -73.56 163.52 67.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.924 -179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.413 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 29.1 Cg_endo -62.69 -16.29 51.99 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.679 2.253 . . . . 0.0 112.555 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 28.9 mmtt -59.84 -37.31 78.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.999 0.428 . . . . 0.0 110.892 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.456 HG21 ' HB3' ' A' ' 102' ' ' CYS . 1.7 t -89.29 8.12 32.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.254 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.432 ' CE2' ' HG3' ' A' ' 108' ' ' GLN . 0.6 OUTLIER -45.59 -30.04 1.38 Allowed 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.753 0.311 . . . . 0.0 111.495 -179.81 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.432 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 2.7 mt-30 -119.44 -31.05 4.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.976 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -50.94 138.23 19.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.028 0.442 . . . . 0.0 111.444 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.499 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 15.0 mttt -74.97 -21.6 59.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.031 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.499 ' CB ' ' O ' ' A' ' 110' ' ' LYS . 5.3 t 89.96 109.03 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.886 -179.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.713 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -93.75 150.68 39.09 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.428 -179.033 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -70.7 -11.68 29.98 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.799 2.333 . . . . 0.0 112.51 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -69.38 -31.63 71.46 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.661 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.449 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 9.2 t0 -157.7 60.99 2.1 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.231 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.491 ' O ' HG21 ' A' ' 120' ' ' VAL . 81.8 Cg_endo -86.91 20.04 1.29 Allowed 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 122.753 2.302 . . . . 0.0 112.738 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -127.16 7.8 6.58 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.825 179.428 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.678 ' C ' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.86 -23.28 1.83 Allowed 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.689 -179.676 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.678 HD13 ' C ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -174.78 24.6 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 179.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.491 HG21 ' O ' ' A' ' 116' ' ' PRO . 28.9 t -69.3 -25.01 28.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 120.761 0.315 . . . . 0.0 110.492 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -114.87 -14.44 8.6 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.28 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.54 -70.17 0.32 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.899 0.381 . . . . 0.0 111.182 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -71.49 63.93 0.41 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.848 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.4 m -83.54 134.24 34.84 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.105 -179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 3.8 t -87.7 111.89 22.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.747 179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.03 138.07 32.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.143 0.496 . . . . 0.0 111.603 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.77 ' CG1' HD22 ' A' ' 97' ' ' LEU . 6.1 p -148.56 133.38 10.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.059 179.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 53.1 mt -99.33 124.71 44.65 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.06 0.457 . . . . 0.0 112.009 -178.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.968 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -119.21 112.16 36.37 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.111 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.532 ' O ' ' N ' ' A' ' 91' ' ' PHE . 1.7 p30 -88.75 -37.37 15.52 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.66 132.12 30.4 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.06 178.454 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.968 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.1 m-85 -96.75 133.31 41.48 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.965 0.412 . . . . 0.0 110.906 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -56.92 -165.48 0.06 OUTLIER Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.776 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.431 ' O ' ' HA ' ' A' ' 87' ' ' HIS . 28.3 t -62.06 -115.65 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 O-C-N 123.01 -0.112 . . . . 0.0 110.864 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.494 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . -179.05 -31.05 0.05 OUTLIER Glycine 0 C--N 1.335 0.504 0 C-N-CA 120.226 -0.988 . . . . 0.0 112.864 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.0 p -75.97 57.47 1.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.686 0.279 . . . . 0.0 111.6 -179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 127.43 27.26 0.99 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.97 179.528 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.6 ' O ' HG23 ' A' ' 138' ' ' VAL . 33.4 m -129.53 110.91 20.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.756 0.312 . . . . 0.0 110.823 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 83' ' ' MET . 5.9 m -135.22 163.38 36.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 121.046 0.45 . . . . 0.0 111.55 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.687 ' HE2' HG21 ' A' ' 127' ' ' VAL . 7.9 m-85 -99.26 158.43 15.71 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.27 179.36 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -179.09 149.42 8.8 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.971 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.491 HG12 ' N ' ' A' ' 79' ' ' SER . 3.9 p -85.75 129.27 38.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.737 0.303 . . . . 0.0 110.603 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.595 HG12 ' O ' ' A' ' 4' ' ' GLY . 13.9 p -98.54 115.5 39.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.892 0.377 . . . . 0.0 111.022 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.728 ' HD2' HD21 ' A' ' 78' ' ' LEU . 23.4 ttt-85 -94.29 107.68 19.61 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.183 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -74.68 162.97 28.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.207 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.403 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 1.8 t . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.254 -0.879 . . . . 0.0 110.895 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.1 p80 . . . . . 0 N--CA 1.486 1.373 0 CA-C-O 120.795 0.331 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.95 -174.51 4.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.87 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 79.1 p -138.58 148.76 44.54 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.902 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.772 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -159.44 134.83 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.655 -0.784 . . . . 0.0 112.455 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.528 ' HB2' HG11 ' A' ' 125' ' ' VAL . 0.4 OUTLIER -62.87 120.27 10.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.896 0.379 . . . . 0.0 110.953 -179.925 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -123.83 168.43 12.75 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.845 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.5 t -99.87 100.51 10.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.07 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.611 HD12 ' N ' ' A' ' 8' ' ' LEU . 1.5 mp -99.8 173.71 6.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.751 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.477 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -132.6 145.97 51.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.751 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.496 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.2 mt-30 -94.84 146.5 24.16 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.123 -179.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -124.37 -74.69 0.26 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.179 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.39 -156.22 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.64 2.227 . . . . 0.0 112.054 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.66 98.39 2.01 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.537 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.0 p -58.62 143.78 45.21 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.836 0.35 . . . . 0.0 110.877 179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 16.8 m -104.85 98.53 8.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.133 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' SG ' ' A' ' 60' ' ' CYS . 44.6 t -82.64 110.5 17.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.167 0.508 . . . . 0.0 110.005 179.073 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.584 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.0 -24.16 4.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.998 -179.365 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.619 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.06 137.88 38.23 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.677 179.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.799 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.6 m -134.1 107.67 7.88 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.998 0.428 . . . . 0.0 111.1 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -95.8 118.19 31.97 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.491 179.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.502 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -131.39 137.2 48.59 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.995 0.426 . . . . 0.0 112.009 -179.166 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -163.43 127.98 1.77 Allowed Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.399 179.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -75.39 128.83 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 7.2 m-85 -126.08 143.04 51.27 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.511 0.672 . . . . 0.0 111.863 -178.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 23.4 p-10 -119.2 167.56 11.72 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 114.781 -1.1 . . . . 0.0 110.501 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 11.7 t -42.35 -28.73 0.22 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.463 -179.301 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -51.9 -44.24 63.7 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.71 -179.79 31.74 Favored Glycine 0 N--CA 1.449 -0.479 0 CA-C-N 115.502 -0.772 . . . . 0.0 113.714 178.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.95 -164.59 31.36 Favored Glycine 0 N--CA 1.45 -0.375 0 N-CA-C 111.173 -0.771 . . . . 0.0 111.173 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.481 HG11 HG13 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -141.06 142.74 29.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 117.301 0.55 . . . . 0.0 111.414 179.445 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.54 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 13.2 tp -106.48 106.54 17.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.019 179.339 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -94.83 141.6 28.45 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.988 -179.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 51.5 p -125.13 92.77 3.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.062 0.458 . . . . 0.0 110.078 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.47 -27.54 42.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.418 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.491 ' HB2' ' HB1' ' A' ' 18' ' ' ALA . 1.5 mm-40 -53.17 -24.44 10.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.214 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.033 HG21 HG11 ' A' ' 59' ' ' VAL . 72.4 p -134.85 -37.91 0.81 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.346 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.35 19.09 6.37 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.33 -179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.565 HG22 ' CD ' ' A' ' 100' ' ' PRO . 77.2 t -102.02 129.74 52.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 120.847 0.356 . . . . 0.0 111.212 -179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -131.5 130.96 43.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.802 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.822 HG12 HD12 ' A' ' 97' ' ' LEU . 17.8 mt -106.9 115.45 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.082 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 41' ' ' ILE . 1.5 mp -96.21 120.64 45.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.561 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.683 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -107.51 118.35 53.59 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.583 -179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -66.29 139.99 56.89 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.412 2.075 . . . . 0.0 111.887 179.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -59.29 94.2 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.914 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.84 -21.65 0.9 Allowed Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.822 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.68 -40.9 76.38 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 111.307 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.564 HG23 ' HD2' ' A' ' 48' ' ' PRO . 11.7 mt -101.33 138.59 19.97 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.424 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.782 ' HG2' HG11 ' A' ' 51' ' ' VAL . 46.2 Cg_endo -69.57 161.27 46.56 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.51 2.14 . . . . 0.0 111.904 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -78.02 146.98 35.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.51 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 78.96 29.68 50.38 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.968 -0.634 . . . . 0.0 112.915 179.661 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.782 HG11 ' HG2' ' A' ' 48' ' ' PRO . 6.8 p -147.07 157.44 10.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 121.059 0.457 . . . . 0.0 111.562 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.493 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.8 OUTLIER -136.75 108.26 6.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.358 179.405 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 24.1 mm100 -106.62 123.87 48.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.375 -179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.0 tt0 -79.66 101.7 8.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.039 179.09 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.55 HD11 ' HE1' ' A' ' 91' ' ' PHE . 59.4 mt -99.32 117.04 43.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.96 0.409 . . . . 0.0 110.148 179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.502 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 39.6 p90 -137.21 129.75 29.98 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.401 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.438 ' HB2' ' CG1' ' A' ' 82' ' ' VAL . 15.5 p90 -114.14 123.36 49.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.157 179.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.799 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.0 mttt -97.4 124.5 41.6 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.788 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.033 HG11 HG21 ' A' ' 36' ' ' THR . 94.2 t -89.18 119.12 35.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.405 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.448 ' SG ' HG22 ' A' ' 16' ' ' VAL . 1.3 m -103.27 161.92 13.42 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.256 -179.348 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.584 ' HD3' HG11 ' A' ' 17' ' ' VAL . 16.6 mmm180 -77.03 153.02 34.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.579 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -84.15 75.93 10.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.925 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.405 ' ND2' ' HB2' ' A' ' 61' ' ' ARG . 0.9 OUTLIER -150.18 -46.36 0.13 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.049 -179.988 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.15 61.4 0.94 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.775 179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.914 HG21 ' HG ' ' A' ' 81' ' ' LEU . 5.6 pt -139.29 168.0 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.145 -179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.697 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.3 tt -108.6 79.08 0.97 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.929 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.475 ' HA ' HD23 ' A' ' 8' ' ' LEU . 74.2 Cg_endo -75.07 110.52 3.13 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.631 2.221 . . . . 0.0 112.427 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -64.3 -19.48 65.69 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.562 2.174 . . . . 0.0 112.369 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.455 HD22 ' CA ' ' A' ' 76' ' ' THR . 2.4 pp -58.33 165.16 2.15 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.105 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.45 110.74 21.33 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.117 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.2 mmtt -68.21 -27.66 66.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.918 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -55.9 -33.77 64.93 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.023 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -86.64 -23.15 25.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.873 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 120.71 3.81 10.93 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.479 -179.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 41.5 mt-10 -70.3 160.96 31.26 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 120.615 0.245 . . . . 0.0 110.786 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.488 HG22 ' CD ' ' A' ' 144' ' ' ARG . 12.7 t -177.52 -177.98 0.72 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.993 0.425 . . . . 0.0 111.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -103.66 110.22 22.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.609 179.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.533 HD11 ' CG ' ' A' ' 144' ' ' ARG . 19.0 mt -99.96 17.45 20.91 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.781 -179.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.488 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.2 m -137.26 153.4 74.81 Favored Pre-proline 0 C--N 1.331 -0.21 0 CA-C-O 120.489 0.185 . . . . 0.0 111.078 179.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -70.66 125.85 12.11 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.599 2.199 . . . . 0.0 111.983 179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.914 ' HG ' HG21 ' A' ' 65' ' ' ILE . 4.0 mm? -61.64 153.09 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.258 179.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.515 ' O ' HG12 ' A' ' 139' ' ' VAL . 87.4 t -138.17 148.25 25.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.987 0.422 . . . . 0.0 111.451 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -125.45 115.3 20.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.601 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.6 p -54.59 130.05 38.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.059 -179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -62.08 -80.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.386 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -70.31 133.07 23.73 Favored 'Trans proline' 0 C--N 1.343 0.24 0 C-N-CA 122.319 2.013 . . . . 0.0 112.226 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.458 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.6 OUTLIER -93.64 131.07 39.29 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.936 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.408 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 74.46 51.2 8.6 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.81 -179.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.635 HD21 ' CE1' ' A' ' 91' ' ' PHE . 42.2 tp -105.99 139.66 40.19 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.608 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -136.88 104.94 5.64 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.994 0.426 . . . . 0.0 111.445 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.635 ' CE1' HD21 ' A' ' 89' ' ' LEU . 37.2 m-85 -77.88 165.99 23.44 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.845 179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 7.1 mt -83.27 -23.23 32.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.73 178.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.3 mtmm -140.42 150.98 62.82 Favored Pre-proline 0 C--O 1.232 0.167 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.046 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.17 134.83 35.14 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.563 2.175 . . . . 0.0 112.602 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.683 HG12 HG23 ' A' ' 42' ' ' ILE . 19.7 m -97.88 135.59 31.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.794 179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -76.13 137.98 40.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.93 0.395 . . . . 0.0 111.197 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.822 HD12 HG12 ' A' ' 40' ' ' ILE . 1.8 tp -121.05 122.72 40.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.597 179.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.654 ' HG3' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -112.25 113.98 26.51 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.808 0.337 . . . . 0.0 111.092 -179.998 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.657 HD12 ' HB ' ' A' ' 125' ' ' VAL . 0.7 OUTLIER -109.47 145.68 32.4 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.951 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.565 ' CD ' HG22 ' A' ' 38' ' ' VAL . 75.2 Cg_endo -76.94 100.91 1.45 Allowed 'Trans proline' 0 N--CA 1.463 -0.317 0 C-N-CA 122.944 2.429 . . . . 0.0 112.644 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.763 ' CD2' HG21 ' A' ' 142' ' ' VAL . 23.0 t-80 -120.93 116.08 24.44 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.903 0.382 . . . . 0.0 110.705 179.741 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.435 ' HB3' HG21 ' A' ' 106' ' ' THR . 37.3 m -94.5 171.93 8.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.156 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -72.58 163.52 67.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.853 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.415 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.9 Cg_endo -64.64 -14.74 46.32 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.687 2.258 . . . . 0.0 112.544 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 7.5 mmmt -64.35 -40.0 95.01 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.786 0.327 . . . . 0.0 110.912 -179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.435 HG21 ' HB3' ' A' ' 102' ' ' CYS . 1.9 t -89.27 8.31 31.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.362 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.415 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.75 -28.09 1.41 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.831 -179.677 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -147.1 18.66 1.24 Allowed 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 111.824 0.305 . . . . 0.0 111.824 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.426 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.8 t-20 -79.07 136.87 37.29 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.901 0.382 . . . . 0.0 111.048 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.462 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 1.5 mttt -59.66 -21.91 61.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.103 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.508 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 85.35 113.12 0.05 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.993 -179.242 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.697 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.78 154.18 39.93 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.267 -179.211 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.83 -14.39 35.81 Favored 'Trans proline' 0 N--CA 1.464 -0.221 0 C-N-CA 122.62 2.214 . . . . 0.0 112.076 179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.5 95.09 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.516 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.407 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 33.3 p-10 -174.93 73.91 0.3 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.698 0.285 . . . . 0.0 111.324 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -84.6 9.81 3.99 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.731 2.287 . . . . 0.0 112.68 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.472 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 6.0 m-80 -129.78 15.57 5.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.113 0.482 . . . . 0.0 110.851 179.529 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.575 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.05 -79.73 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.872 -0.603 . . . . 0.0 111.572 -179.681 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.661 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -91.57 2.83 56.18 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.914 -179.807 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.472 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 42.7 t -52.38 -28.98 12.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-O 120.802 0.334 . . . . 0.0 110.739 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.03 3.88 10.62 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 121.043 -0.599 . . . . 0.0 112.35 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.523 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -89.61 -46.22 8.8 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.933 0.397 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 101' ' ' HIS . 1.2 m-80 -92.17 25.14 3.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.356 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 5.4 p -53.69 157.78 2.14 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.913 0.387 . . . . 0.0 111.4 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.657 ' HB ' HD12 ' A' ' 99' ' ' LEU . 2.7 t -103.34 144.81 13.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.354 179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -116.78 127.39 54.3 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.095 0.474 . . . . 0.0 111.958 -179.335 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 97' ' ' LEU . 1.7 t -129.5 154.13 39.76 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.244 178.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . . . . . . . . . 34.8 mt -126.7 118.07 23.99 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.198 178.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.897 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.78 112.12 38.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.476 0 CA-C-O 121.261 0.553 . . . . 0.0 112.009 -179.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.505 ' O ' ' N ' ' A' ' 91' ' ' PHE . 12.0 p-10 -89.4 -37.55 14.75 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.608 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.0 132.01 29.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.276 178.502 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.897 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.6 m-85 -96.74 134.64 39.76 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.837 0.351 . . . . 0.0 110.813 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.03 -171.35 0.05 OUTLIER Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.979 -0.555 . . . . 0.0 113.295 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.408 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 2.3 m -95.74 32.34 1.87 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 120.581 0.229 . . . . 0.0 111.534 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.84 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.44 -143.87 5.76 Favored Glycine 0 CA--C 1.518 0.239 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.853 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 65.43 14.26 9.35 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.578 0.228 . . . . 0.0 111.562 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 157.6 -40.55 0.53 Allowed Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.577 179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.84 HG22 ' HA2' ' A' ' 135' ' ' GLY . 3.9 m -49.68 123.02 1.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.958 0.409 . . . . 0.0 111.218 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 82' ' ' VAL . 11.7 m -152.6 143.52 15.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.489 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 10.6 m-85 -87.87 137.37 32.4 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.449 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.462 ' HA3' HD13 ' A' ' 8' ' ' LEU . . . -157.14 130.5 2.66 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.735 -179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.763 HG21 ' CD2' ' A' ' 101' ' ' HIS . 2.5 p -69.98 126.3 29.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.637 0.256 . . . . 0.0 110.593 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.772 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -98.7 115.62 39.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.062 0.458 . . . . 0.0 111.336 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.533 ' CG ' HD11 ' A' ' 78' ' ' LEU . 15.7 ttt180 -91.07 112.47 24.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.19 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.5 mmt180 -73.88 163.07 28.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.245 -179.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.416 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.113 0 CA-C-O 118.206 -0.902 . . . . 0.0 110.92 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 3.4 p80 . . . . . 0 N--CA 1.486 1.364 0 CA-C-O 120.868 0.366 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.5 m -165.76 139.39 4.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.798 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 87.4 p -104.35 143.12 33.42 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.019 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.714 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -160.96 156.37 27.72 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.675 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.885 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -69.44 129.61 40.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.879 0.371 . . . . 0.0 110.897 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.674 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -139.53 139.05 36.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.735 179.812 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.1 t -90.28 100.21 10.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.048 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 67' ' ' PRO . 2.4 mp -89.52 175.01 7.46 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.873 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.514 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 6.8 m-85 -128.2 147.77 50.59 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.971 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.705 ' OE1' HG22 ' A' ' 65' ' ' ILE . 6.0 mt-30 -106.58 168.1 9.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.986 -179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.12 -73.24 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.34 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -72.24 -167.55 0.33 Allowed 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.569 2.179 . . . . 0.0 112.205 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.2 94.28 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.55 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 84.5 p -61.01 145.27 51.32 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.802 0.334 . . . . 0.0 110.832 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.417 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 39.7 m -88.44 98.65 11.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.098 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.67 HG22 ' SG ' ' A' ' 60' ' ' CYS . 91.1 t -84.76 110.65 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.105 179.287 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.465 HG11 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.13 -26.43 3.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.773 -179.752 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.865 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.9 139.25 46.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.527 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.827 HG23 ' HG3' ' A' ' 58' ' ' LYS . 44.7 m -138.26 107.94 6.25 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.045 0.45 . . . . 0.0 111.067 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -97.8 125.1 42.47 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.828 -0.624 . . . . 0.0 109.809 178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -139.0 137.63 36.51 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.86 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.39 128.35 1.72 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.558 179.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -75.07 124.65 33.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.161 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 6.1 m-85 -120.73 141.55 50.35 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.442 0.639 . . . . 0.0 111.735 -178.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.0 p-10 -118.69 167.44 11.66 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.463 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.419 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 28.8 t -42.55 -28.15 0.2 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.373 -179.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -51.97 -45.1 64.3 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.285 0.564 . . . . 0.0 109.538 178.57 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.83 179.59 30.48 Favored Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.395 -0.821 . . . . 0.0 113.884 178.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.98 -171.29 32.01 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.7 OUTLIER -133.7 148.27 30.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 117.284 0.542 . . . . 0.0 111.233 179.477 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.546 HD23 ' CE1' ' A' ' 57' ' ' PHE . 16.6 tp -113.79 106.46 14.51 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.975 179.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.6 p -95.84 142.25 28.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.067 -179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.4 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 60.6 p -124.25 92.85 3.75 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.289 -0.414 . . . . 0.0 109.975 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.43 -29.2 46.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.495 -179.575 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -54.12 -24.48 17.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.236 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.676 HG21 HG11 ' A' ' 59' ' ' VAL . 48.5 p -131.52 -42.27 1.05 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.076 -179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 116.07 17.76 6.18 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.479 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.599 HG22 ' HD2' ' A' ' 100' ' ' PRO . 92.3 t -100.96 129.28 52.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 120.765 0.317 . . . . 0.0 111.112 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.5 132.17 50.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.596 HD12 ' CD1' ' A' ' 57' ' ' PHE . 37.7 mt -110.88 112.41 40.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.854 0.359 . . . . 0.0 111.342 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.559 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.5 mp -94.51 124.02 46.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.518 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.639 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -108.42 117.62 54.1 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.545 -179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -66.14 139.91 57.41 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.44 2.093 . . . . 0.0 112.022 179.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -59.33 93.83 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.07 -21.94 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.694 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.29 -39.14 69.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 111.179 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 48' ' ' PRO . 28.7 mt -105.36 140.16 20.87 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.767 ' HG2' HG11 ' A' ' 51' ' ' VAL . 43.5 Cg_endo -71.3 155.7 60.08 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.576 2.184 . . . . 0.0 111.838 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.7 mt-10 -70.72 147.0 49.51 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.542 -179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 82.98 17.21 67.95 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.914 -0.66 . . . . 0.0 113.038 179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.767 HG11 ' HG2' ' A' ' 48' ' ' PRO . 11.4 p -147.21 158.26 9.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.053 0.454 . . . . 0.0 111.704 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 17.0 pt-20 -147.49 111.74 5.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.94 179.336 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 30.1 mm100 -97.74 134.33 41.06 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.547 -179.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.3 tt0 -76.19 101.79 5.53 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.099 179.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.486 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 36.6 mt -101.35 117.06 46.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.076 0.465 . . . . 0.0 110.398 179.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.639 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 16.2 p90 -138.02 130.38 29.15 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.922 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.596 ' CD1' HD12 ' A' ' 40' ' ' ILE . 11.5 p90 -113.15 123.26 49.82 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.13 179.291 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.827 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -98.63 118.45 35.37 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.731 -179.643 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.865 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 69.4 t -89.35 121.21 39.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.294 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.67 ' SG ' HG22 ' A' ' 16' ' ' VAL . 79.4 m -110.58 168.21 9.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.338 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.465 ' HD3' HG11 ' A' ' 17' ' ' VAL . 1.1 mmm180 -79.67 171.89 14.53 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.42 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 55.4 p-10 -99.91 74.99 1.85 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.911 0.386 . . . . 0.0 110.903 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -143.5 -46.45 0.29 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.68 53.0 0.79 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.001 0.429 . . . . 0.0 110.774 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.78 HD13 HD11 ' A' ' 81' ' ' LEU . 9.6 pt -132.51 169.87 21.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.98 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.699 ' O ' HD23 ' A' ' 66' ' ' LEU . 7.1 tt -114.74 87.55 14.85 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.808 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HA ' HD23 ' A' ' 8' ' ' LEU . 1.7 Cg_endo -82.54 115.15 2.48 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.057 2.505 . . . . 0.0 112.248 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 67' ' ' PRO . 37.3 Cg_endo -65.62 -20.85 59.81 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.447 2.098 . . . . 0.0 112.246 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.2 pp -58.66 177.41 0.14 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -122.44 104.24 9.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.6 mtpp -63.53 -30.48 71.59 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.77 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -56.1 -34.77 66.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.865 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -82.16 -25.66 34.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.796 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.56 0.29 7.9 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.867 -0.682 . . . . 0.0 112.601 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.9 mt-10 -67.0 160.27 26.85 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.669 0.271 . . . . 0.0 110.74 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.55 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.4 t -178.31 169.97 1.78 Allowed 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.041 0.448 . . . . 0.0 111.761 -179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.477 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -97.75 106.19 18.45 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.641 179.665 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.82 HD11 ' HG3' ' A' ' 144' ' ' ARG . 11.6 mt -96.73 19.81 11.88 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.838 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.477 ' O ' HD23 ' A' ' 77' ' ' LEU . 65.1 m -141.54 141.89 24.33 Favored Pre-proline 0 C--N 1.331 -0.214 0 CA-C-O 120.598 0.237 . . . . 0.0 111.111 179.584 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_exo -59.86 125.46 17.78 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.519 2.146 . . . . 0.0 112.263 179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.78 HD11 HD13 ' A' ' 65' ' ' ILE . 0.5 OUTLIER -59.79 170.29 1.18 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.804 179.834 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 59' ' ' VAL . 72.0 t -154.19 139.68 10.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.138 -179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.402 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -120.87 122.49 40.36 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.721 179.799 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.7 p -58.2 128.76 38.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.401 ' CA ' ' O ' ' A' ' 56' ' ' TYR . . . -58.53 -82.35 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.431 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -68.12 131.13 22.91 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.325 2.017 . . . . 0.0 112.157 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.429 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -88.17 129.71 35.25 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.97 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.416 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 74.34 55.29 5.7 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.72 -0.752 . . . . 0.0 111.838 -179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.551 HD21 ' CE1' ' A' ' 91' ' ' PHE . 23.5 tp -106.04 141.15 37.91 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 110.296 -0.261 . . . . 0.0 110.296 -179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.612 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.4 OUTLIER -138.84 102.63 4.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.11 0.481 . . . . 0.0 111.181 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.551 ' CE1' HD21 ' A' ' 89' ' ' LEU . 40.0 m-85 -77.22 164.66 25.4 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.093 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 3.3 mt -83.7 -21.98 32.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.692 178.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 1.1 mtpt -140.29 149.98 59.74 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.97 179.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.459 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 39.8 Cg_endo -67.79 135.98 37.26 Favored 'Trans proline' 0 C--O 1.231 0.153 0 C-N-CA 122.509 2.139 . . . . 0.0 112.835 -179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.639 HG12 HG23 ' A' ' 42' ' ' ILE . 35.1 m -100.2 134.49 39.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.453 179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.469 ' HA ' HD23 ' A' ' 128' ' ' LEU . 2.7 tt0 -83.05 130.81 35.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.928 0.394 . . . . 0.0 111.351 -179.488 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.669 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.0 tt -124.32 129.59 50.99 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.09 179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 21.4 mtt180 -117.05 123.4 46.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.289 -179.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.669 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -107.44 145.17 30.7 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.76 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' HG22 ' A' ' 38' ' ' VAL . 70.2 Cg_endo -74.69 75.0 3.68 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.853 2.369 . . . . 0.0 112.687 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.404 ' HB2' HG23 ' A' ' 125' ' ' VAL . 12.6 t60 -91.02 127.77 36.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.444 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 37.9 m -85.33 171.82 11.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.995 0.426 . . . . 0.0 111.254 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -81.06 163.6 54.56 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.973 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.429 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 32.7 Cg_endo -63.85 -14.83 45.45 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.662 2.241 . . . . 0.0 112.54 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 4.3 mttt -61.88 -39.61 92.52 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.916 0.389 . . . . 0.0 110.958 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.35 8.14 32.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.275 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.429 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.5 OUTLIER -46.53 -28.67 1.49 Allowed 'General case' 0 N--CA 1.462 0.153 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.66 -179.786 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.421 ' HG3' ' CE2' ' A' ' 107' ' ' TRP . 11.6 mt-30 -126.13 -26.79 3.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.537 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -46.98 138.12 6.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 121.029 0.442 . . . . 0.0 111.405 -179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.446 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -63.79 -21.83 66.62 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.033 179.737 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.468 ' C ' HD13 ' A' ' 112' ' ' LEU . 5.2 t 83.89 109.82 0.06 Allowed 'General case' 0 N--CA 1.462 0.14 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.061 -179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.709 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.18 147.51 34.8 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.553 -179.008 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -73.75 -6.39 18.56 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 123.055 2.503 . . . . 0.0 112.597 179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -86.35 -31.17 20.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.768 -179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.447 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.3 m-20 -130.74 53.9 13.14 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 120.732 0.301 . . . . 0.0 111.306 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.515 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.6 Cg_endo -82.45 9.51 3.98 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.489 2.126 . . . . 0.0 112.716 179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -129.88 6.83 5.1 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.586 -0.279 . . . . 0.0 111.106 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.533 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -50.13 -23.93 2.45 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.819 -179.792 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.446 ' C ' ' CD2' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -168.05 20.53 0.03 OUTLIER 'General case' 0 C--O 1.233 0.212 0 N-CA-C 111.826 0.306 . . . . 0.0 111.826 179.877 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.515 HG21 ' O ' ' A' ' 116' ' ' PRO . 13.2 t -68.43 -24.35 29.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.985 0.421 . . . . 0.0 110.472 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -118.3 4.63 15.59 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.938 -0.649 . . . . 0.0 112.104 179.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -89.67 -70.73 0.65 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.89 0.376 . . . . 0.0 111.13 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -77.94 61.41 2.54 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.812 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 1.3 m -77.04 155.82 32.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.173 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.885 HG11 HD23 ' A' ' 5' ' ' LEU . 18.8 t -101.97 111.3 31.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.816 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -92.98 131.4 38.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.039 0.447 . . . . 0.0 111.643 -179.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.768 HG21 ' HE2' ' A' ' 140' ' ' TYR . 3.5 p -143.59 139.01 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.086 179.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.469 HD23 ' HA ' ' A' ' 96' ' ' GLU . 14.3 mt -106.55 123.67 48.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.996 0.427 . . . . 0.0 111.951 -178.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -117.55 112.13 37.54 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 CA-C-O 121.304 0.573 . . . . 0.0 112.149 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.544 ' O ' ' N ' ' A' ' 91' ' ' PHE . 23.0 t0 -89.5 -37.01 15.06 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.558 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.612 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.68 132.01 30.18 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.149 178.423 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 3.0 m-85 -96.73 138.55 34.12 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.738 0.304 . . . . 0.0 110.553 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -52.92 -168.21 0.02 OUTLIER Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.157 -0.544 . . . . 0.0 113.586 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.416 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 74.5 p -89.73 23.45 2.68 Favored 'General case' 0 C--N 1.333 -0.126 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.755 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.57 -153.85 0.95 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.96 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 58.82 19.97 7.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.579 0.228 . . . . 0.0 111.427 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.77 -46.06 0.24 Allowed Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.451 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.755 HG22 ' HA2' ' A' ' 135' ' ' GLY . 16.2 m -56.88 119.95 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.805 0.335 . . . . 0.0 111.117 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.506 HG21 ' HG2' ' A' ' 10' ' ' GLN . 1.3 m -140.95 149.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.993 0.425 . . . . 0.0 111.478 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.768 ' HE2' HG21 ' A' ' 127' ' ' VAL . 22.1 m-85 -95.01 146.18 24.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.232 179.288 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -175.21 135.74 3.16 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.198 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.453 ' HB ' ' CB ' ' A' ' 79' ' ' SER . 4.2 p -63.17 152.35 7.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.8 p -125.59 115.43 43.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.927 0.394 . . . . 0.0 111.286 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.82 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.1 OUTLIER -92.03 111.42 22.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.141 179.348 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 1.5 mmt180 -75.25 163.0 27.96 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.244 -179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.292 -0.861 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 13.9 m-70 . . . . . 0 N--CA 1.485 1.304 0 CA-C-O 120.815 0.341 . . . . 0.0 111.132 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -107.99 -169.03 1.45 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.839 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -136.54 152.61 50.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.822 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.27 -174.41 30.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.423 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.82 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.6 tm? -92.34 140.46 29.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.762 0.315 . . . . 0.0 110.859 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.82 ' N ' HD13 ' A' ' 5' ' ' LEU . 4.9 mm-40 -149.66 138.82 21.27 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.6 t -90.49 100.33 10.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.035 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.476 HD23 ' HA ' ' A' ' 67' ' ' PRO . 5.2 mp -86.47 171.02 11.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -121.31 149.78 42.4 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.767 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 33.4 mm-40 -97.37 160.55 14.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.033 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -159.33 -68.67 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.824 -0.703 . . . . 0.0 112.349 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.95 -167.35 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.491 2.128 . . . . 0.0 112.215 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.0 98.29 0.55 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.536 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 97.2 p -69.15 138.01 53.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.892 0.377 . . . . 0.0 110.757 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.43 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 62.6 m -101.78 98.55 8.8 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.141 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.656 HG22 ' SG ' ' A' ' 60' ' ' CYS . 89.2 t -82.45 110.46 17.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.144 0.497 . . . . 0.0 109.944 179.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.02 -26.54 3.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.857 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.935 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -131.65 141.83 49.7 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.441 179.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.657 HG23 ' HG3' ' A' ' 58' ' ' LYS . 63.6 m -138.83 107.41 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.97 0.414 . . . . 0.0 111.231 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.677 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -100.85 123.05 44.47 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.514 178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.58 ' HB3' ' CB ' ' A' ' 56' ' ' TYR . 0.0 OUTLIER -142.93 139.14 30.6 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 112.727 0.639 . . . . 0.0 112.727 -178.452 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.45 129.93 2.06 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.305 179.041 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.451 HD13 ' CA ' ' A' ' 54' ' ' GLU . 1.1 mm -73.77 132.4 33.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.68 ' HD2' HD12 ' A' ' 55' ' ' ILE . 12.2 m-85 -126.63 143.51 51.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.412 0.625 . . . . 0.0 111.902 -178.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 41.3 p-10 -119.36 167.34 12.0 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.623 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.427 ' HB2' ' C ' ' A' ' 48' ' ' PRO . 9.9 t -42.56 -28.68 0.24 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.221 -179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -52.4 -44.94 65.65 Favored 'General case' 0 C--N 1.332 -0.16 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 102.42 178.67 27.29 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.562 -0.745 . . . . 0.0 113.822 178.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.57 -163.75 32.25 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.236 -0.746 . . . . 0.0 111.236 -179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.58 146.15 20.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 117.25 0.525 . . . . 0.0 111.373 179.448 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 15.7 tp -108.45 106.53 16.69 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.863 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 14.5 p -96.87 144.28 26.97 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.333 -179.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.61 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 30.1 t -128.06 92.47 3.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.038 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.74 -31.87 55.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.593 -179.61 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -53.43 -24.13 11.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.451 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.854 HG21 HG11 ' A' ' 59' ' ' VAL . 44.2 p -131.21 -42.47 1.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.483 -0.326 . . . . 0.0 111.418 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 117.31 16.44 6.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.39 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.57 HG22 ' HD2' ' A' ' 100' ' ' PRO . 76.2 t -97.25 130.84 45.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 120.768 0.318 . . . . 0.0 111.188 -179.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -133.14 130.53 39.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.876 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.604 HD12 ' CD2' ' A' ' 57' ' ' PHE . 52.6 mt -111.03 112.2 39.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.26 -179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.58 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.58 131.89 40.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.508 179.361 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.675 HG23 HG12 ' A' ' 95' ' ' VAL . 3.4 mt -117.41 119.15 34.81 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.329 -179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -66.57 140.04 55.56 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.441 2.094 . . . . 0.0 111.947 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.8 tm0? -57.78 92.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.028 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.0 -21.17 1.12 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.612 -0.804 . . . . 0.0 112.76 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.97 -29.49 63.27 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.855 0.36 . . . . 0.0 111.305 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.638 HG23 ' HD2' ' A' ' 48' ' ' PRO . 18.6 mt -113.81 140.82 25.19 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.47 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.8 ' HG2' HG11 ' A' ' 51' ' ' VAL . 53.7 Cg_endo -70.72 163.98 37.13 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.631 2.221 . . . . 0.0 111.825 179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -81.14 150.11 28.85 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.486 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.95 31.63 57.71 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.738 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.8 HG11 ' HG2' ' A' ' 48' ' ' PRO . 7.6 p -146.92 157.3 10.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.971 0.415 . . . . 0.0 111.52 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.488 ' N ' HG22 ' A' ' 51' ' ' VAL . 2.1 mt-10 -134.76 108.34 7.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.313 179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -100.9 120.04 39.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.506 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.451 ' CA ' HD13 ' A' ' 23' ' ' ILE . 3.3 tt0 -78.45 101.39 7.28 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 178.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.68 HD12 ' HD2' ' A' ' 24' ' ' PHE . 42.1 mt -101.53 116.58 45.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.132 0.491 . . . . 0.0 110.171 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.58 ' CB ' ' HB3' ' A' ' 21' ' ' ARG . 2.8 p90 -138.15 126.49 23.17 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.038 -178.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.677 ' CE1' ' HB3' ' A' ' 20' ' ' ALA . 36.5 p90 -116.6 123.31 47.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.048 179.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.657 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.6 OUTLIER -100.12 126.77 46.4 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.871 -179.459 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.935 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 79.6 t -89.13 120.44 37.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.333 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.656 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.7 m -107.76 161.41 14.92 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.29 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 45.9 mmm-85 -72.21 157.07 38.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.646 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -90.77 71.59 6.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.841 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.42 0.41 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.037 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.83 67.82 0.99 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.798 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.794 HD13 HD11 ' A' ' 81' ' ' LEU . 7.4 pt -143.22 168.93 12.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.161 -179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.541 ' O ' HD23 ' A' ' 66' ' ' LEU . 1.2 tt -108.44 75.61 0.6 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.877 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.476 ' HA ' HD23 ' A' ' 8' ' ' LEU . 58.8 Cg_endo -71.56 113.26 3.58 Favored 'Trans proline' 0 C--N 1.343 0.257 0 C-N-CA 122.622 2.215 . . . . 0.0 112.397 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.4 -20.07 42.58 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.48 2.12 . . . . 0.0 112.485 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.6 pp -58.43 177.43 0.13 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.968 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -119.76 102.21 8.43 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.954 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 4.8 mmtt -68.03 -27.33 66.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.776 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -55.97 -33.81 65.13 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.813 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -86.21 -25.16 25.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.715 179.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 130.21 -4.65 5.98 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.517 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.429 ' O ' ' HB ' ' A' ' 76' ' ' THR . 15.2 mt-10 -60.26 163.29 5.14 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-O 120.686 0.279 . . . . 0.0 110.856 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.552 HG23 ' CD2' ' A' ' 78' ' ' LEU . 13.6 t -178.03 -175.8 0.51 Allowed 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.106 0.479 . . . . 0.0 111.52 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.726 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -113.44 104.43 12.28 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.646 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.878 HD11 ' HG3' ' A' ' 144' ' ' ARG . 3.1 mt -93.77 18.64 9.93 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.387 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.726 ' O ' HD23 ' A' ' 77' ' ' LEU . 43.4 t -135.39 145.56 54.2 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.477 0.179 . . . . 0.0 111.162 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.406 ' HB2' ' CG1' ' A' ' 59' ' ' VAL . 43.4 Cg_endo -68.28 124.74 12.04 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.437 2.091 . . . . 0.0 112.231 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.794 HD11 HD13 ' A' ' 65' ' ' ILE . 1.2 mt -58.56 164.62 2.55 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.752 179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.651 ' O ' HG12 ' A' ' 139' ' ' VAL . 63.2 t -142.31 144.82 24.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 121.05 0.452 . . . . 0.0 111.224 -179.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -121.98 107.82 12.68 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.583 179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 34.1 m -53.56 123.59 12.57 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.14 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.438 ' HA3' ' CD1' ' A' ' 56' ' ' TYR . . . -63.16 -79.24 0.15 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.183 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -65.19 130.76 26.42 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.348 2.032 . . . . 0.0 111.95 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 56.7 p-80 -91.41 144.48 25.53 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 55.24 52.77 45.08 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.044 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.606 HD21 ' CE1' ' A' ' 91' ' ' PHE . 31.8 tp -101.6 138.0 39.17 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -179.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.61 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.2 mtmt -136.73 108.91 7.23 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.056 0.455 . . . . 0.0 111.575 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.606 ' CE1' HD21 ' A' ' 89' ' ' LEU . 24.4 m-85 -83.15 165.36 19.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.874 179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.8 mt -82.7 -23.55 34.06 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.748 178.254 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 2.8 mtmt -138.07 149.82 65.11 Favored Pre-proline 0 C--N 1.332 -0.18 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.92 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.472 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.5 Cg_endo -67.98 135.19 34.24 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.322 2.015 . . . . 0.0 112.499 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.675 HG12 HG23 ' A' ' 42' ' ' ILE . 30.8 m -98.63 139.48 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.875 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.8 tt0 -84.24 123.57 30.27 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.16 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.606 HD21 ' HG ' ' A' ' 99' ' ' LEU . 7.0 tt -115.94 129.45 56.39 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.203 179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -119.04 127.35 53.34 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.918 0.389 . . . . 0.0 111.457 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.606 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -115.59 147.35 38.66 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.718 179.492 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.57 ' HD2' HG22 ' A' ' 38' ' ' VAL . 57.9 Cg_endo -72.04 107.34 2.21 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.764 2.309 . . . . 0.0 112.735 -179.632 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 11.1 t-160 -129.86 99.93 5.29 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.298 179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 24.9 p -66.62 171.81 4.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.427 -179.62 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -75.85 163.65 65.59 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.023 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.449 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 36.6 Cg_endo -64.95 -10.98 27.46 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.663 2.242 . . . . 0.0 112.771 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 14.1 mmtt -71.43 -40.5 70.38 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 110.981 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.5 t -97.12 8.31 44.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.295 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.449 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.4 OUTLIER -45.32 -28.64 0.87 Allowed 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 111.841 0.312 . . . . 0.0 111.841 -179.715 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 -125.98 -26.23 3.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.412 -179.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 10.8 t-20 -46.86 138.35 6.4 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.048 0.451 . . . . 0.0 111.475 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.448 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -62.12 -21.94 65.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.064 179.878 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.489 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.5 OUTLIER 84.9 111.9 0.05 Allowed 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.182 -179.275 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.693 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.69 152.4 39.8 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.269 -179.212 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.77 -13.2 31.94 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.72 2.28 . . . . 0.0 112.333 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -66.31 -31.0 77.71 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.549 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.446 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 1.1 m-20 -165.51 62.21 0.81 Allowed Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 120.84 0.353 . . . . 0.0 111.138 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.525 ' O ' HG21 ' A' ' 120' ' ' VAL . 92.3 Cg_endo -83.92 11.68 3.24 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.6 2.2 . . . . 0.0 112.825 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -128.97 9.04 5.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.92 179.581 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.508 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.84 -25.35 3.05 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.757 -179.821 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.45 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -166.1 17.72 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.872 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.525 HG21 ' O ' ' A' ' 116' ' ' PRO . 52.3 t -69.09 -23.91 27.58 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 121.008 0.432 . . . . 0.0 110.175 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -124.16 -1.11 8.76 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.26 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.02 -65.43 1.01 Allowed 'General case' 0 N--CA 1.456 -0.145 0 CA-C-O 120.931 0.396 . . . . 0.0 110.984 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -76.82 59.8 1.65 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.679 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 18.4 m -82.87 150.08 26.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.725 HG11 HD23 ' A' ' 5' ' ' LEU . 2.1 t -84.4 122.33 37.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.672 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.36 132.22 47.03 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.051 0.453 . . . . 0.0 111.765 -179.219 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.549 HG13 ' HB3' ' A' ' 97' ' ' LEU . 6.4 p -144.79 133.01 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.148 179.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.472 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 24.7 mt -96.68 123.39 40.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.0 0.429 . . . . 0.0 111.851 -179.005 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.945 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -116.52 112.06 37.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 115.914 -0.585 . . . . 0.0 112.142 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.494 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.0 p-10 -89.08 -36.93 15.48 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.61 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.6 130.36 27.86 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.378 178.586 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.945 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 8.6 m-85 -96.75 133.93 40.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.895 0.379 . . . . 0.0 110.698 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -60.94 -151.76 0.02 OUTLIER Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.782 -179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 93.2 p -75.69 -24.17 56.26 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.794 0.33 . . . . 0.0 111.41 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.5 ' H ' HG22 ' A' ' 138' ' ' VAL . . . 82.46 -53.93 4.85 Favored Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.803 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 12.4 t -52.67 -24.3 8.26 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -124.29 -9.63 5.45 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.419 -0.896 . . . . 0.0 113.109 -179.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.5 HG22 ' H ' ' A' ' 135' ' ' GLY . 2.4 m -110.99 126.84 68.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.938 0.369 . . . . 0.0 111.018 -179.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 82' ' ' VAL . 2.9 m -134.62 158.28 41.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.066 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.461 ' HD2' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -104.69 150.77 24.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.975 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.01 159.54 31.63 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.59 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.505 HG12 ' N ' ' A' ' 79' ' ' SER . 5.0 p -93.4 130.18 42.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.797 0.332 . . . . 0.0 110.67 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.66 115.36 38.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.853 0.358 . . . . 0.0 111.176 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.878 ' HG3' HD11 ' A' ' 78' ' ' LEU . 0.0 OUTLIER -95.86 107.7 19.98 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.101 179.589 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -72.44 163.06 28.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.317 -179.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.246 -0.883 . . . . 0.0 110.839 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.636 0.255 . . . . 0.0 111.458 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.8 p -113.32 178.33 4.32 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.804 0.335 . . . . 0.0 110.998 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.2 p -136.42 158.11 45.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -166.74 -178.17 39.08 Favored Glycine 0 C--O 1.227 -0.324 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.534 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.821 HD23 ' HB ' ' A' ' 127' ' ' VAL . 11.0 tp -98.59 135.18 40.48 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.961 0.41 . . . . 0.0 111.064 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -138.72 145.16 39.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.683 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -78.22 100.29 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.933 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.645 HD22 ' HD3' ' A' ' 68' ' ' PRO . 77.2 mt -93.18 170.31 9.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.842 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.645 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 3.9 m-85 -131.54 141.6 49.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.856 179.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.534 ' HG2' HG21 ' A' ' 139' ' ' VAL . 19.2 mm-40 -84.21 153.35 23.68 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.113 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -139.04 -83.56 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.802 -0.714 . . . . 0.0 112.325 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -59.13 -156.69 0.02 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.68 2.253 . . . . 0.0 112.054 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.6 97.4 0.98 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.575 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -61.65 142.58 57.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.735 0.302 . . . . 0.0 110.83 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.4 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 86.4 m -108.42 98.52 8.04 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.079 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 57.2 t -83.95 110.32 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.004 0.431 . . . . 0.0 110.024 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.612 HG11 HH11 ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.21 -24.51 4.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.87 -179.726 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.884 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -134.7 141.19 46.46 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.462 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.802 HG23 ' HG3' ' A' ' 58' ' ' LYS . 55.9 m -139.77 107.88 5.75 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.028 0.442 . . . . 0.0 110.997 179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.44 ' HB3' ' CE2' ' A' ' 57' ' ' PHE . . . -96.48 128.19 43.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.95 179.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.669 ' HD2' HG22 ' A' ' 19' ' ' THR . 0.0 OUTLIER -140.06 137.17 34.36 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.982 0.42 . . . . 0.0 112.012 -179.054 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.59 127.25 1.59 Allowed Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.591 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.3 mm -75.65 123.92 32.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.045 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.54 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.1 m-85 -119.25 139.93 51.08 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.425 0.631 . . . . 0.0 111.999 -178.368 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 29.2 p-10 -117.63 167.56 11.22 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.865 -1.061 . . . . 0.0 110.588 -179.149 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -42.37 -28.55 0.21 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.569 -179.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -53.55 -43.93 68.82 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.077 0.465 . . . . 0.0 109.764 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.9 -177.08 28.86 Favored Glycine 0 N--CA 1.449 -0.458 0 CA-C-N 115.681 -0.691 . . . . 0.0 113.639 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.19 -170.26 30.86 Favored Glycine 0 N--CA 1.45 -0.379 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -135.24 147.2 29.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 117.235 0.518 . . . . 0.0 111.17 179.497 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.583 HD23 ' CE1' ' A' ' 57' ' ' PHE . 17.7 tp -111.78 106.64 15.45 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.91 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 9.1 p -95.98 142.97 27.56 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.119 -179.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.412 ' HB3' ' HB2' ' A' ' 20' ' ' ALA . 81.5 p -126.94 92.9 3.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.967 -0.561 . . . . 0.0 109.86 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -64.52 -34.36 69.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.41 -179.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -48.02 -27.7 2.39 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.298 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.88 HG21 HG11 ' A' ' 59' ' ' VAL . 44.4 p -128.99 -42.16 1.4 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.097 -179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 33' ' ' SER . . . 116.85 16.71 6.2 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 121.024 -0.608 . . . . 0.0 112.478 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.553 HG22 ' CD ' ' A' ' 100' ' ' PRO . 76.3 t -97.17 130.4 45.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.809 0.337 . . . . 0.0 111.165 -179.273 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -131.33 129.52 41.54 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 33.8 mt -109.75 112.6 41.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.467 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.576 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.3 mp -94.9 122.48 46.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.524 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.587 HG23 HG12 ' A' ' 95' ' ' VAL . 3.0 mt -107.92 118.34 53.07 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.318 -179.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -66.04 139.65 56.97 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.486 2.124 . . . . 0.0 111.93 179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -57.65 91.69 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.025 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 151.63 -21.24 0.92 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.869 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -55.72 -36.39 67.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.891 0.377 . . . . 0.0 111.255 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.486 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.3 mt -106.77 138.26 19.73 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.373 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.866 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.1 Cg_endo -66.51 172.88 8.53 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.497 2.131 . . . . 0.0 112.088 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -84.95 157.37 20.84 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.358 -179.444 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 60.32 37.44 93.09 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.47 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.866 HG11 ' HG2' ' A' ' 48' ' ' PRO . 8.0 p -146.96 148.79 16.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.914 0.388 . . . . 0.0 111.457 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -132.41 108.25 9.04 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.331 179.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.9 mm100 -107.74 126.65 52.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.378 -179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.4 tt0 -82.76 101.86 11.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.198 179.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.512 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 63.6 mt -100.52 117.03 45.13 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-O 121.018 0.437 . . . . 0.0 110.264 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.631 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 4.2 p90 -136.54 128.83 29.97 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.075 -179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.583 ' CE1' HD23 ' A' ' 31' ' ' LEU . 23.1 p90 -112.33 123.49 50.4 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.258 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.802 ' HG3' HG23 ' A' ' 19' ' ' THR . 7.9 mttt -97.81 123.83 41.93 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.819 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.884 ' HB ' ' HB3' ' A' ' 18' ' ' ALA . 91.8 t -89.13 118.92 35.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.637 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.4 ' HA ' ' O ' ' A' ' 15' ' ' THR . 0.8 OUTLIER -102.02 163.07 12.45 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.275 -179.449 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.612 HH11 HG11 ' A' ' 17' ' ' VAL . 27.8 mmm-85 -78.56 159.99 27.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.581 179.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -87.88 66.8 8.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.85 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -139.86 -46.64 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.091 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 27.9 t -104.36 65.74 0.79 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.818 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.936 HG21 ' HG ' ' A' ' 81' ' ' LEU . 13.4 pt -140.25 169.39 16.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.963 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.58 76.33 1.52 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.891 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -79.36 110.83 2.76 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.659 2.24 . . . . 0.0 112.402 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.645 ' HD3' HD22 ' A' ' 8' ' ' LEU . 22.2 Cg_exo -65.17 -12.93 37.07 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.629 2.22 . . . . 0.0 112.629 -179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.491 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.44 177.51 0.13 Allowed 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.935 0.398 . . . . 0.0 111.166 -179.788 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -124.57 103.77 8.33 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.937 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.425 ' HE2' HD11 ' A' ' 69' ' ' LEU . 7.4 mttt -68.28 -27.9 66.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.026 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -55.95 -34.15 65.41 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.873 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -86.71 -23.41 25.56 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.792 179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 127.82 -4.37 6.98 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.394 -179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.7 mt-10 -61.01 162.99 6.34 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.667 0.27 . . . . 0.0 110.627 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.491 ' N ' HD13 ' A' ' 69' ' ' LEU . 13.3 t -176.57 -168.73 0.25 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.006 0.432 . . . . 0.0 111.69 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -116.28 108.39 16.04 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.779 -179.84 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.81 HD11 ' CG ' ' A' ' 144' ' ' ARG . 4.8 mt -96.75 18.21 14.89 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.497 -0.32 . . . . 0.0 111.714 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.48 ' N ' HG11 ' A' ' 142' ' ' VAL . 5.6 p -143.04 152.43 58.37 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-O 120.714 0.292 . . . . 0.0 111.111 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -74.54 125.78 9.81 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.735 2.29 . . . . 0.0 111.93 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.936 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.8 mm? -58.66 155.35 12.76 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.391 179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.601 ' O ' HG12 ' A' ' 139' ' ' VAL . 71.8 t -139.87 141.69 33.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.961 0.41 . . . . 0.0 111.422 -179.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.636 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -121.84 118.69 29.59 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.761 179.73 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 31.4 p -57.63 127.98 34.75 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.058 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.43 -76.16 0.24 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.343 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.02 134.17 28.84 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 122.532 2.155 . . . . 0.0 112.076 179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 12.2 p80 -95.12 130.61 41.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.802 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.407 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 73.92 55.38 5.88 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.956 -179.504 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.487 HD21 ' CE1' ' A' ' 91' ' ' PHE . 16.8 tp -106.11 141.1 38.05 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.208 -0.293 . . . . 0.0 110.208 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 5.3 mtmt -139.51 103.73 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.992 0.425 . . . . 0.0 111.466 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.491 ' N ' ' O ' ' A' ' 130' ' ' ASP . 21.9 m-85 -79.26 166.41 22.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.997 179.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 5.0 mt -84.77 -22.08 29.74 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.721 178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 4.6 mtmt -139.22 150.3 64.0 Favored Pre-proline 0 C--N 1.332 -0.187 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.985 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.498 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 41.2 Cg_endo -68.35 136.38 36.82 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.431 2.088 . . . . 0.0 112.719 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 129' ' ' ILE . 26.8 m -99.39 134.86 37.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.641 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 7.2 tt0 -82.35 108.06 15.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.34 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.603 ' HB3' HG13 ' A' ' 127' ' ' VAL . 7.2 tt -97.41 130.11 44.57 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.153 179.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.466 ' HA ' ' O ' ' A' ' 125' ' ' VAL . 14.6 mtp180 -117.62 130.96 56.7 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.586 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.567 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -119.99 147.19 43.87 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.821 179.763 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.553 ' CD ' HG22 ' A' ' 38' ' ' VAL . 70.3 Cg_endo -75.26 95.78 1.0 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.762 2.308 . . . . 0.0 112.542 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.456 ' HB2' HG23 ' A' ' 125' ' ' VAL . 50.5 t-80 -112.26 128.74 56.35 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.523 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 7.3 m -99.74 171.83 7.64 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.011 -179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -72.3 163.54 66.6 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.826 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.42 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 34.3 Cg_endo -64.58 -13.08 36.78 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.61 2.206 . . . . 0.0 112.677 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.91 -42.25 63.74 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.842 0.353 . . . . 0.0 110.984 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.486 HG21 HD21 ' A' ' 119' ' ' LEU . 1.8 t -94.76 8.31 42.97 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.329 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.439 ' CD2' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.06 -28.22 1.13 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.869 -179.72 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.439 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 8.2 mt-30 -147.04 17.76 1.23 Allowed 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.708 0.262 . . . . 0.0 111.708 -179.636 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.456 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 3.8 t-20 -76.13 142.49 41.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.866 0.365 . . . . 0.0 110.933 179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.415 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -56.99 -22.0 35.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.195 179.855 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.513 ' C ' HD13 ' A' ' 112' ' ' LEU . 8.1 m 82.15 111.82 0.06 Allowed 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.118 -179.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.69 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.71 154.83 39.88 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.265 -179.244 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.93 -16.04 36.67 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.642 2.228 . . . . 0.0 112.281 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -59.78 -35.25 85.79 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.333 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.438 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 6.9 t0 -176.12 67.24 0.24 Allowed Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 120.773 0.32 . . . . 0.0 110.943 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.455 ' O ' HG21 ' A' ' 120' ' ' VAL . 89.7 Cg_endo -81.12 5.85 5.97 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.668 2.245 . . . . 0.0 112.879 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.464 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 7.4 m-80 -130.53 14.08 5.47 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.909 0.385 . . . . 0.0 111.007 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.08 -79.88 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.563 -179.698 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.688 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -90.36 -1.88 57.94 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.929 -179.694 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.464 ' CG2' ' HA ' ' A' ' 117' ' ' ASN . 70.4 t -51.46 -29.2 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.963 0.411 . . . . 0.0 110.673 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -117.36 -9.32 10.5 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.34 179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.512 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -76.44 -68.45 0.59 Allowed 'General case' 0 C--O 1.232 0.172 0 CA-C-O 120.835 0.35 . . . . 0.0 111.241 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -78.9 59.84 2.71 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.853 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 51.4 m -80.11 160.6 25.69 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.105 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 98' ' ' ARG . 5.0 t -95.59 147.44 5.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.563 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -132.29 129.65 39.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.065 0.459 . . . . 0.0 111.439 -179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.821 ' HB ' HD23 ' A' ' 5' ' ' LEU . 5.9 p -142.54 137.95 28.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.27 179.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.498 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 33.9 mt -101.85 122.83 44.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.031 0.444 . . . . 0.0 111.816 -178.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.955 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -117.38 112.32 38.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 CA-C-N 115.846 -0.616 . . . . 0.0 111.878 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.491 ' O ' ' N ' ' A' ' 91' ' ' PHE . 22.2 t0 -89.46 -37.4 14.81 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.55 132.13 30.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.261 178.527 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.955 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 9.4 m-85 -96.86 139.1 33.41 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.832 0.348 . . . . 0.0 110.575 179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.44 -167.3 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 116.0 -0.546 . . . . 0.0 113.497 -179.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.407 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 87.0 p -87.58 21.38 2.57 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.768 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.28 -154.12 1.18 Allowed Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.934 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.5 p 58.85 20.14 7.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.626 0.25 . . . . 0.0 111.429 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 167.72 -43.92 0.24 Allowed Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.525 -0.845 . . . . 0.0 112.304 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.768 HG22 ' HA2' ' A' ' 135' ' ' GLY . 11.9 m -59.85 121.22 7.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 111.031 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.636 HG12 ' HA ' ' A' ' 83' ' ' MET . 1.5 m -144.85 145.57 20.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.022 0.439 . . . . 0.0 111.379 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.765 ' HE2' HG21 ' A' ' 127' ' ' VAL . 21.6 m-85 -89.92 137.05 32.66 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.145 179.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -157.64 131.59 2.93 Favored Glycine 0 N--CA 1.45 -0.431 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.94 -179.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.48 HG11 ' N ' ' A' ' 79' ' ' SER . 6.8 p -64.6 152.47 8.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.738 0.304 . . . . 0.0 110.563 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.54 ' O ' HG13 ' A' ' 143' ' ' VAL . 10.7 p -126.88 115.82 42.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.519 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.81 ' CG ' HD11 ' A' ' 78' ' ' LEU . 0.7 OUTLIER -94.37 105.86 17.83 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.27 179.831 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.3 mmt180 -72.81 163.16 28.55 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.219 -179.512 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.209 -0.9 . . . . 0.0 110.814 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 120.915 0.388 . . . . 0.0 111.194 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -157.9 131.36 7.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.89 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 p -105.25 146.74 28.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.929 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.59 -170.29 28.28 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.716 -0.755 . . . . 0.0 112.248 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.872 HD13 ' N ' ' A' ' 6' ' ' GLU . 1.8 tm? -93.81 141.07 28.92 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.871 0.367 . . . . 0.0 110.954 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.872 ' N ' HD13 ' A' ' 5' ' ' LEU . 0.3 OUTLIER -149.75 144.41 26.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.904 179.932 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 26.7 t -94.88 107.4 19.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.982 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.771 HD23 ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -102.39 -179.52 4.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.976 -179.997 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.608 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -130.67 157.05 43.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.894 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.487 ' HG2' HG21 ' A' ' 139' ' ' VAL . 8.2 mt-30 -115.91 113.85 23.87 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -87.29 -69.38 1.31 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.277 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.97 -167.56 0.28 Allowed 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.576 2.184 . . . . 0.0 112.213 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.41 109.46 2.9 Favored Glycine 0 N--CA 1.453 -0.201 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 77.9 p -71.86 142.69 49.56 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.79 0.329 . . . . 0.0 110.947 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 58.1 m -91.98 98.83 11.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG22 ' SG ' ' A' ' 60' ' ' CYS . 82.5 t -83.98 110.53 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.227 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.136 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -105.17 -24.2 4.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.769 -179.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.938 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -135.81 143.02 44.94 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.696 -0.683 . . . . 0.0 110.553 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.846 HG23 ' HG3' ' A' ' 58' ' ' LYS . 37.6 m -140.64 107.88 5.51 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.001 0.429 . . . . 0.0 111.207 179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.457 ' CB ' ' CZ ' ' A' ' 57' ' ' PHE . . . -96.36 128.3 43.15 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.806 -0.634 . . . . 0.0 109.661 179.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.64 ' HG3' ' HB2' ' A' ' 56' ' ' TYR . 0.5 OUTLIER -140.35 138.61 34.99 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.04 0.447 . . . . 0.0 112.177 -178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -167.74 125.88 1.36 Allowed Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.552 178.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -74.66 120.34 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 179.327 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.623 ' HD2' HD12 ' A' ' 55' ' ' ILE . 4.6 m-85 -115.09 139.84 49.56 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.412 0.625 . . . . 0.0 111.813 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -115.87 167.68 10.73 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.626 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.403 ' HB3' ' O ' ' A' ' 48' ' ' PRO . 13.1 p -42.35 -28.22 0.19 Allowed 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.292 -179.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -53.94 -44.29 70.56 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.123 0.487 . . . . 0.0 109.765 178.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 100.2 -175.27 27.03 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.577 -0.738 . . . . 0.0 113.721 178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 147.64 -171.27 28.25 Favored Glycine 0 N--CA 1.45 -0.407 0 N-CA-C 111.43 -0.668 . . . . 0.0 111.43 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.23 157.34 43.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 117.22 0.51 . . . . 0.0 111.21 179.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.553 HD23 ' CE1' ' A' ' 57' ' ' PHE . 18.0 tp -123.44 106.38 10.59 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.905 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.12 144.85 25.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.047 -179.407 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 17.3 t -125.89 92.78 3.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.88 179.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.708 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.46 -27.12 41.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.527 -179.62 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.37 -23.44 24.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.262 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.041 HG21 HG11 ' A' ' 59' ' ' VAL . 76.0 p -135.59 -40.36 0.71 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.121 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.08 21.05 5.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.236 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.548 HG22 ' CD ' ' A' ' 100' ' ' PRO . 74.8 t -101.57 126.42 55.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.768 0.318 . . . . 0.0 111.029 -179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.436 ' HA ' ' O ' ' A' ' 31' ' ' LEU . 0.3 OUTLIER -126.95 134.18 50.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.995 179.98 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.63 HD12 ' CD1' ' A' ' 57' ' ' PHE . 56.1 mt -113.69 113.46 43.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.864 0.364 . . . . 0.0 111.077 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.625 HD12 ' N ' ' A' ' 41' ' ' ILE . 2.6 mp -95.77 127.07 48.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.676 179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG23 HG12 ' A' ' 95' ' ' VAL . 2.7 mp -113.32 118.09 44.34 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.446 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.93 139.79 58.11 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.433 2.088 . . . . 0.0 111.927 179.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -58.58 92.8 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.951 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.39 -22.02 0.74 Allowed Glycine 0 CA--C 1.518 0.234 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.743 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.471 ' HB1' ' HB3' ' A' ' 91' ' ' PHE . . . -57.25 -31.37 65.49 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.869 0.366 . . . . 0.0 111.293 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.562 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.6 mt -111.57 138.45 21.48 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.422 179.714 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.668 ' HG2' HG11 ' A' ' 51' ' ' VAL . 56.5 Cg_endo -71.72 152.02 58.35 Favored 'Trans proline' 0 N--CA 1.462 -0.375 0 C-N-CA 122.524 2.149 . . . . 0.0 111.852 179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -72.8 135.31 45.21 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.332 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.86 23.77 14.67 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.909 -0.662 . . . . 0.0 113.0 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.668 HG11 ' HG2' ' A' ' 48' ' ' PRO . 4.7 p -147.06 157.58 10.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-O 121.047 0.451 . . . . 0.0 111.44 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.479 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.5 OUTLIER -133.44 108.39 8.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.413 179.532 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 25.8 mm100 -103.13 122.8 45.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.485 -179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.449 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 3.9 tt0 -78.22 101.88 7.32 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.109 179.103 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.623 HD12 ' HD2' ' A' ' 24' ' ' PHE . 22.0 mt -100.67 117.19 45.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-O 120.954 0.407 . . . . 0.0 110.75 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.64 ' HB2' ' HG3' ' A' ' 21' ' ' ARG . 45.3 p90 -140.0 125.8 19.46 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.053 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.63 ' CD1' HD12 ' A' ' 40' ' ' ILE . 30.9 p90 -110.74 123.83 50.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.231 179.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.846 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.3 OUTLIER -97.34 122.34 40.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.189 -179.387 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.041 HG11 HG21 ' A' ' 36' ' ' THR . 65.4 t -89.28 124.57 42.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.246 179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.695 ' SG ' HG22 ' A' ' 16' ' ' VAL . 74.4 m -114.68 167.11 11.05 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.997 0.427 . . . . 0.0 111.315 -179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -78.0 170.7 16.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.554 179.705 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.7 p-10 -101.6 72.5 1.39 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.808 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -140.52 -46.47 0.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.044 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -105.0 68.69 0.83 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.877 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.75 HD13 HD11 ' A' ' 81' ' ' LEU . 10.2 pt -143.38 168.05 12.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.109 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.607 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.9 tt -107.53 77.36 0.59 Allowed Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.834 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.84 110.06 2.82 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.632 2.221 . . . . 0.0 112.411 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.771 ' HD2' HD23 ' A' ' 8' ' ' LEU . 52.8 Cg_endo -69.18 -18.32 39.81 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.478 2.118 . . . . 0.0 112.394 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.4 pp -58.34 175.41 0.23 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.958 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -117.7 104.96 11.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.893 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -67.23 -30.83 70.85 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.82 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.34 -36.12 68.38 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.916 -179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.38 -21.64 35.79 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.994 179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 118.26 15.38 6.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.499 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 23.3 mt-10 -82.12 161.06 22.98 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.629 0.252 . . . . 0.0 110.721 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.877 HG22 ' HD3' ' A' ' 144' ' ' ARG . 12.9 t -176.95 -171.85 0.38 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 111.78 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.645 HD23 ' O ' ' A' ' 79' ' ' SER . 0.2 OUTLIER -114.7 104.92 12.45 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.913 -179.882 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.65 HD21 ' HD2' ' A' ' 144' ' ' ARG . 3.2 mt -93.93 19.21 9.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.612 -179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.645 ' O ' HD23 ' A' ' 77' ' ' LEU . 52.7 p -138.26 155.4 74.14 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-O 120.605 0.24 . . . . 0.0 110.884 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -75.22 129.45 12.16 Favored 'Trans proline' 0 N--CA 1.463 -0.305 0 C-N-CA 122.499 2.132 . . . . 0.0 111.881 179.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.75 HD11 HD13 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -61.87 167.84 3.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.94 -179.603 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG22 ' A' ' 59' ' ' VAL . 69.9 t -155.91 149.65 11.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 -179.783 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.419 ' HG3' ' CG1' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -132.07 123.41 27.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.907 179.826 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 29.5 p -61.17 126.64 28.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.83 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.406 ' HA2' ' CE1' ' A' ' 56' ' ' TYR . . . -57.29 -78.49 0.12 Allowed Glycine 0 C--N 1.33 0.244 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.397 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.49 132.28 35.05 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.465 2.11 . . . . 0.0 111.975 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.454 ' N ' ' CD2' ' A' ' 87' ' ' HIS . 2.6 m170 -95.46 125.76 40.29 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.825 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.431 ' N ' ' HA ' ' A' ' 134' ' ' SER . . . 78.76 52.09 5.19 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.858 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.462 HD23 ' CZ ' ' A' ' 91' ' ' PHE . 50.2 tp -105.45 142.81 34.56 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 110.226 -0.287 . . . . 0.0 110.226 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.607 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.1 OUTLIER -136.27 105.57 6.04 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.159 0.504 . . . . 0.0 111.205 -179.896 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 130' ' ' ASP . 47.3 m-85 -76.95 144.45 38.8 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.476 -0.783 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 25.4 mt -65.27 -21.06 66.68 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.055 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -143.26 150.85 53.47 Favored Pre-proline 0 N--CA 1.455 -0.182 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.9 179.309 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 130' ' ' ASP . 38.2 Cg_endo -66.31 134.48 36.37 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.537 2.158 . . . . 0.0 112.72 -179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG12 HG23 ' A' ' 42' ' ' ILE . 26.8 m -98.66 139.91 19.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.641 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -86.24 129.58 34.8 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.991 0.424 . . . . 0.0 111.161 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.653 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.4 tt -122.58 127.14 49.04 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.098 179.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -118.55 121.68 40.82 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.284 -179.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.653 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.1 mt -105.92 148.34 36.35 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.746 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.548 ' CD ' HG22 ' A' ' 38' ' ' VAL . 80.5 Cg_endo -78.73 84.42 2.04 Favored 'Trans proline' 0 N--CA 1.462 -0.37 0 C-N-CA 122.784 2.323 . . . . 0.0 112.641 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 10.7 t-160 -101.29 100.02 10.47 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.478 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.573 ' SG ' HG23 ' A' ' 106' ' ' THR . 14.6 p -75.83 171.85 13.69 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.007 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.32 163.44 58.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.949 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.421 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.2 Cg_endo -66.21 -13.05 38.14 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.653 2.236 . . . . 0.0 112.608 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.0 mmtt -66.98 -42.35 85.23 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.958 0.409 . . . . 0.0 111.01 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.573 HG23 ' SG ' ' A' ' 102' ' ' CYS . 1.8 t -89.87 8.47 31.97 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.335 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.431 ' CG ' ' HG3' ' A' ' 108' ' ' GLN . 0.5 OUTLIER -46.08 -28.18 1.13 Allowed 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.654 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.431 ' HG3' ' CG ' ' A' ' 107' ' ' TRP . 12.9 mt-30 -150.45 21.61 0.83 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 111.71 0.263 . . . . 0.0 111.71 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.437 ' HB2' ' HA ' ' A' ' 106' ' ' THR . 2.8 t-20 -78.1 145.51 35.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.864 0.364 . . . . 0.0 110.999 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.429 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 73.4 mttt -58.64 -21.94 55.26 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.224 179.831 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.502 ' C ' HD13 ' A' ' 112' ' ' LEU . 0.6 OUTLIER 82.24 111.43 0.06 Allowed 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.953 0.406 . . . . 0.0 109.988 -179.381 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.694 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.82 153.66 39.99 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.263 -179.248 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.92 -14.35 35.48 Favored 'Trans proline' 0 N--CA 1.464 -0.234 0 C-N-CA 122.615 2.21 . . . . 0.0 112.111 179.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -58.77 -41.13 95.8 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.543 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.413 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 0.2 OUTLIER -174.03 74.41 0.35 Allowed Pre-proline 0 C--N 1.331 -0.209 0 CA-C-O 120.89 0.376 . . . . 0.0 111.188 -179.916 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.538 ' O ' HG21 ' A' ' 120' ' ' VAL . 83.0 Cg_endo -82.74 4.27 7.21 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.644 2.23 . . . . 0.0 112.484 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.452 ' HA ' ' CG2' ' A' ' 120' ' ' VAL . 10.7 m-80 -131.01 13.86 5.22 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.811 0.339 . . . . 0.0 111.007 179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.577 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.18 -80.02 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.383 -179.686 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.646 HD13 ' H ' ' A' ' 119' ' ' LEU . 0.0 OUTLIER -88.41 -5.15 58.45 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.731 -179.987 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.538 HG21 ' O ' ' A' ' 116' ' ' PRO . 94.9 t -51.52 -28.23 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.983 0.42 . . . . 0.0 110.756 -179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -115.22 -11.66 10.57 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.263 179.472 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.478 ' HB3' ' HA ' ' A' ' 119' ' ' LEU . . . -77.2 -58.7 3.13 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.921 0.391 . . . . 0.0 111.219 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.84 49.87 1.81 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.112 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.4 m -72.85 171.83 11.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.275 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.649 HG11 HD23 ' A' ' 5' ' ' LEU . 3.1 t -114.02 115.69 50.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.691 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 2.9 p -96.07 132.34 41.54 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.984 0.421 . . . . 0.0 111.62 -179.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.64 HG21 ' HE2' ' A' ' 140' ' ' TYR . 4.9 p -144.87 135.51 19.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.212 179.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.447 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 67.1 mt -101.86 124.0 46.75 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.979 0.418 . . . . 0.0 111.735 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.948 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.25 112.25 38.75 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.989 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.504 ' O ' ' N ' ' A' ' 91' ' ' PHE . 7.7 p-10 -85.65 -39.02 17.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.604 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.607 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -139.37 133.26 30.85 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.847 -1.069 . . . . 0.0 110.448 178.553 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.948 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 2.0 m-85 -96.82 134.62 39.89 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.895 0.378 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.73 -173.46 0.06 OUTLIER Glycine 0 C--N 1.332 0.311 0 C-N-CA 121.021 -0.609 . . . . 0.0 113.225 -179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.431 ' HA ' ' N ' ' A' ' 88' ' ' GLY . 1.5 p -102.54 50.38 0.83 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.834 0.349 . . . . 0.0 111.414 -179.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.829 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 46.47 -128.86 10.91 Favored Glycine 0 C--N 1.331 0.287 0 C-N-CA 120.818 -0.706 . . . . 0.0 113.024 179.524 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 66.73 10.5 7.55 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 133.65 -20.48 4.11 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.502 -0.856 . . . . 0.0 112.523 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.829 HG22 ' HA2' ' A' ' 135' ' ' GLY . 10.7 m -50.56 119.75 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.883 0.373 . . . . 0.0 111.28 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.487 HG21 ' HG2' ' A' ' 10' ' ' GLN . 2.6 m -145.64 156.21 12.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.269 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.64 ' HE2' HG21 ' A' ' 127' ' ' VAL . 11.1 m-85 -100.37 150.6 22.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.724 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -171.49 140.88 6.09 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.466 -0.873 . . . . 0.0 112.724 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.437 HG12 ' N ' ' A' ' 79' ' ' SER . 4.6 p -73.52 127.4 35.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.732 0.301 . . . . 0.0 110.507 179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.555 ' O ' HG13 ' A' ' 143' ' ' VAL . 14.9 p -98.58 115.47 39.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-O 121.001 0.429 . . . . 0.0 111.436 -179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.877 ' HD3' HG22 ' A' ' 76' ' ' THR . 11.9 ttt85 -95.2 108.29 20.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.986 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 5.1 mmm180 -73.78 163.06 28.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.142 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.249 1.033 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.487 1.395 0 CA-C-O 120.775 0.322 . . . . 0.0 111.215 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.6 p -115.91 129.5 56.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.924 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 p -89.93 154.08 20.12 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.825 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -160.07 175.91 36.83 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.571 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.958 HD23 HG11 ' A' ' 125' ' ' VAL . 1.8 tm? -86.65 135.47 33.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.846 0.355 . . . . 0.0 110.967 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.733 ' N ' HD13 ' A' ' 5' ' ' LEU . 3.2 mm-40 -149.71 144.08 25.86 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.816 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' VAL . 13.5 p -90.6 110.65 22.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.043 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 77' ' ' LEU . 2.8 mt -93.03 170.08 9.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.898 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.707 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 4.5 m-85 -125.1 123.6 40.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.773 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.486 ' HG2' HG21 ' A' ' 139' ' ' VAL . 7.8 mt-30 -84.09 142.64 30.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.036 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.93 -75.84 0.69 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.435 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.39 -167.73 0.3 Allowed 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.545 2.163 . . . . 0.0 112.259 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.12 103.64 0.82 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 90.1 p -66.01 145.97 55.24 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.792 0.329 . . . . 0.0 110.926 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.439 ' O ' ' HA ' ' A' ' 60' ' ' CYS . 77.2 m -93.52 98.51 11.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.025 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.504 HG22 ' SG ' ' A' ' 60' ' ' CYS . 85.6 t -85.11 110.41 19.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.022 0.439 . . . . 0.0 110.032 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.45 HG21 ' HD3' ' A' ' 61' ' ' ARG . 0.0 OUTLIER -105.96 -24.06 4.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.889 -179.605 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.872 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -133.88 139.39 46.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.382 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.661 HG23 ' HG3' ' A' ' 58' ' ' LYS . 59.7 m -136.31 107.42 6.75 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.975 0.417 . . . . 0.0 111.219 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.65 ' HB3' ' CE1' ' A' ' 57' ' ' PHE . . . -99.91 123.67 44.41 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.747 178.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.602 ' CB ' ' HB3' ' A' ' 56' ' ' TYR . 5.1 ptt180 -142.66 139.82 31.35 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -178.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -165.15 129.02 1.88 Allowed Glycine 0 N--CA 1.446 -0.651 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.251 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.483 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.2 mm -72.48 133.1 32.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.264 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.578 ' HD2' HD12 ' A' ' 55' ' ' ILE . 13.5 m-85 -128.44 142.73 51.01 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.559 0.695 . . . . 0.0 111.939 -178.483 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 52.6 p-10 -119.92 167.59 11.98 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.492 -178.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 2.2 t -42.46 -28.22 0.2 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.708 -0.223 . . . . 0.0 111.254 -179.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -52.74 -44.46 66.45 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.68 -179.63 27.85 Favored Glycine 0 N--CA 1.448 -0.56 0 CA-C-N 115.568 -0.742 . . . . 0.0 113.677 178.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 156.35 -163.84 32.19 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.623 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ILE . 0.8 OUTLIER -144.56 141.99 23.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 117.211 0.506 . . . . 0.0 111.087 179.429 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.532 HD23 ' CD2' ' A' ' 57' ' ' PHE . 27.2 tp -104.57 106.63 17.21 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.006 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 12.9 p -96.59 145.26 25.89 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.048 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.536 ' HB2' ' HB2' ' A' ' 20' ' ' ALA . 46.9 t -128.77 92.59 3.44 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.134 179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.673 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.7 -28.09 44.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.515 -179.796 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -56.18 -22.7 30.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.319 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.978 HG21 HG11 ' A' ' 59' ' ' VAL . 67.8 p -133.42 -40.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.303 -179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.09 18.39 6.35 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.85 -0.691 . . . . 0.0 112.321 -179.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.574 HG22 ' HD2' ' A' ' 100' ' ' PRO . 72.4 t -100.05 133.28 43.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.839 0.352 . . . . 0.0 111.085 -179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.23 130.02 36.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.927 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.608 HD12 ' CD2' ' A' ' 57' ' ' PHE . 45.0 mt -109.01 112.32 39.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.139 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.573 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -93.93 126.21 46.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.456 179.382 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.629 HG23 HG12 ' A' ' 95' ' ' VAL . 3.5 mt -110.66 117.52 50.55 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.661 -179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.91 139.94 58.77 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.409 2.073 . . . . 0.0 111.857 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.7 tm0? -57.05 93.75 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.086 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 150.23 -20.85 1.08 Allowed Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.825 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -57.75 -35.53 70.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.839 0.352 . . . . 0.0 111.342 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.581 HG23 ' HD2' ' A' ' 48' ' ' PRO . 10.3 mt -107.73 139.75 20.91 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.43 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.882 ' HG2' HG11 ' A' ' 51' ' ' VAL . 34.4 Cg_endo -66.58 170.82 11.72 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.454 2.103 . . . . 0.0 112.062 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 -83.96 161.3 20.83 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.536 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 56.24 37.57 73.56 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.678 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.882 HG11 ' HG2' ' A' ' 48' ' ' PRO . 9.3 p -146.99 157.89 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 120.934 0.397 . . . . 0.0 111.463 -179.749 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.498 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.0 OUTLIER -139.96 108.38 5.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.517 179.495 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 22.3 mm100 -105.45 123.42 47.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.375 -179.535 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 1.8 tt0 -77.37 101.75 6.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.191 179.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.578 HD12 ' HD2' ' A' ' 24' ' ' PHE . 24.4 mt -98.3 116.64 41.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 121.042 0.449 . . . . 0.0 109.95 179.539 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.602 ' HB3' ' CB ' ' A' ' 21' ' ' ARG . 33.2 p90 -137.35 125.96 23.72 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.173 -179.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.687 ' HB2' HG13 ' A' ' 82' ' ' VAL . 36.5 p90 -115.31 123.49 48.88 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.063 179.078 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.661 ' HG3' HG23 ' A' ' 19' ' ' THR . 0.5 OUTLIER -98.77 125.26 44.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.044 -0.525 . . . . 0.0 111.031 -179.338 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.978 HG11 HG21 ' A' ' 36' ' ' THR . 93.9 t -89.18 119.46 36.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.042 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . 0.504 ' SG ' HG22 ' A' ' 16' ' ' VAL . 69.8 m -105.39 166.4 10.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.612 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.45 ' HD3' HG21 ' A' ' 17' ' ' VAL . 5.0 mmm180 -76.62 160.63 29.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.464 179.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -91.99 40.79 1.05 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.424 -0.353 . . . . 0.0 111.588 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . 0.447 HD21 ' HB2' ' A' ' 61' ' ' ARG . 0.3 OUTLIER -122.3 -6.23 8.81 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 111.679 0.252 . . . . 0.0 111.679 179.554 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.7 p -134.05 60.01 1.72 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.938 0.399 . . . . 0.0 110.672 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.642 HG21 ' CD1' ' A' ' 81' ' ' LEU . 20.3 pt -143.53 169.62 10.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.067 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.722 ' O ' HD23 ' A' ' 66' ' ' LEU . 4.5 tt -110.35 80.43 1.95 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.955 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 65' ' ' ILE . 94.5 Cg_endo -82.71 111.2 1.97 Allowed 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.734 2.29 . . . . 0.0 112.447 -179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -62.23 -19.15 65.86 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.455 2.103 . . . . 0.0 112.52 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 pp -58.39 177.44 0.13 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.004 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -127.46 111.1 13.44 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 16.2 mttp -68.08 -29.6 68.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.006 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.46 -34.83 67.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.923 -179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.88 -24.55 33.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.777 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 125.49 0.78 7.88 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.622 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 144' ' ' ARG . 27.5 mt-10 -69.0 163.51 24.46 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 120.609 0.242 . . . . 0.0 110.691 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.829 HG22 ' HD2' ' A' ' 144' ' ' ARG . 15.2 t -177.83 -176.88 0.6 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.134 0.492 . . . . 0.0 112.022 179.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.64 HD11 HD11 ' A' ' 8' ' ' LEU . 0.1 OUTLIER -113.41 103.29 11.14 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.435 179.822 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.742 HD11 ' HG3' ' A' ' 144' ' ' ARG . 0.4 OUTLIER -96.39 19.45 12.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.836 -179.377 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.513 ' N ' HG12 ' A' ' 142' ' ' VAL . 41.3 t -137.1 132.7 18.21 Favored Pre-proline 0 C--N 1.33 -0.25 0 C-N-CA 121.14 -0.224 . . . . 0.0 111.178 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 79' ' ' SER . 39.8 Cg_exo -56.73 127.79 27.31 Favored 'Trans proline' 0 C--N 1.347 0.456 0 C-N-CA 122.381 2.054 . . . . 0.0 112.055 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.642 ' CD1' HG21 ' A' ' 65' ' ' ILE . 4.7 mt -58.58 169.72 0.88 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.703 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG13 ' HB2' ' A' ' 57' ' ' PHE . 53.3 t -153.41 134.3 4.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.441 ' HA ' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.31 111.46 20.14 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.589 179.747 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 13.4 p -54.63 124.11 15.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.056 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -53.41 -77.72 0.13 Allowed Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.42 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.16 135.35 22.69 Favored 'Trans proline' 0 N--CA 1.462 -0.357 0 C-N-CA 122.386 2.057 . . . . 0.0 112.058 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 11.3 p80 -90.49 135.81 33.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.788 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 134' ' ' SER . . . 65.16 55.8 19.48 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.007 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.502 HD21 ' CE1' ' A' ' 91' ' ' PHE . 46.5 tp -101.71 143.88 31.1 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.606 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 1.9 mtmt -138.65 106.79 5.74 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.168 0.509 . . . . 0.0 111.574 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.524 ' N ' ' O ' ' A' ' 130' ' ' ASP . 38.8 m-85 -81.45 157.52 24.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.861 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.13 -18.07 59.3 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.851 178.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 12.3 mtpp -145.84 151.28 45.35 Favored Pre-proline 0 C--N 1.332 -0.19 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.143 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.461 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 37.4 Cg_endo -66.43 136.19 42.28 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.543 2.162 . . . . 0.0 112.646 -179.554 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.629 HG12 HG23 ' A' ' 42' ' ' ILE . 35.8 m -101.73 136.42 33.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.605 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 41' ' ' ILE . 13.0 tt0 -82.2 130.68 35.15 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.066 -179.663 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.617 HD21 ' HG ' ' A' ' 99' ' ' LEU . 6.5 tt -124.35 127.42 47.56 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.128 179.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 8.1 mtp180 -118.07 125.96 51.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.938 0.399 . . . . 0.0 111.295 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.617 ' HG ' HD21 ' A' ' 97' ' ' LEU . 1.2 mp -112.08 148.1 38.33 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.774 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.574 ' HD2' HG22 ' A' ' 38' ' ' VAL . 56.1 Cg_endo -71.09 104.71 1.57 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 122.728 2.285 . . . . 0.0 112.534 -179.649 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . . . . . . . . . 53.7 t60 -132.08 114.66 14.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.604 179.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 12.8 m -87.93 171.87 10.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.289 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -71.33 163.53 65.08 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.022 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 44.3 Cg_endo -67.96 -12.63 35.89 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.606 2.204 . . . . 0.0 112.618 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 9.9 mmtt -66.1 -38.66 88.8 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.809 0.338 . . . . 0.0 110.869 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.7 t -89.27 8.17 31.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.268 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -46.54 -29.66 1.89 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-O 120.871 0.367 . . . . 0.0 111.532 -179.883 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -122.45 -28.91 4.19 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.225 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 12.2 t-20 -47.24 138.17 7.41 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 121.112 0.482 . . . . 0.0 111.453 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.439 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -68.41 -21.59 64.67 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.048 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.513 ' C ' HD13 ' A' ' 112' ' ' LEU . 10.6 m 84.69 113.24 0.05 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -179.022 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.725 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -94.6 149.53 36.66 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.461 -178.827 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.28 -11.45 28.7 Favored 'Trans proline' 0 N--CA 1.465 -0.193 0 C-N-CA 122.909 2.406 . . . . 0.0 112.21 179.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -68.96 -36.92 82.62 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.621 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.455 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 5.7 m-20 -156.37 65.12 3.86 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 120.711 0.291 . . . . 0.0 111.231 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.49 ' O ' HG21 ' A' ' 120' ' ' VAL . 86.8 Cg_endo -85.48 16.91 1.86 Allowed 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 122.728 2.285 . . . . 0.0 112.77 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -128.76 10.76 6.07 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.779 179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.474 ' CD1' ' N ' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -49.98 -25.2 3.1 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.612 -179.676 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.472 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -165.8 19.32 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 111.854 0.316 . . . . 0.0 111.854 179.894 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 116' ' ' PRO . 10.3 t -64.81 -26.22 39.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.913 0.387 . . . . 0.0 110.286 179.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -122.37 2.56 10.44 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.18 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -86.63 -45.26 11.19 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.902 0.382 . . . . 0.0 111.067 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -95.08 30.81 2.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.041 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 6.7 p -57.77 157.42 7.43 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.051 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.958 HG11 HD23 ' A' ' 5' ' ' LEU . 4.5 t -98.53 111.41 28.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.67 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -96.91 133.07 42.02 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.044 0.45 . . . . 0.0 111.708 -179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.587 HG13 ' HB3' ' A' ' 97' ' ' LEU . 5.4 p -146.71 135.02 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.31 179.371 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.461 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 65.5 mt -101.1 124.65 47.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.004 0.431 . . . . 0.0 111.731 -179.053 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.967 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.2 mt -118.82 112.4 37.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.386 0 CA-C-O 121.373 0.606 . . . . 0.0 112.203 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.524 ' O ' ' N ' ' A' ' 91' ' ' PHE . 19.6 t0 -87.99 -38.33 15.61 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 177.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.606 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.76 134.14 33.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 114.768 -1.105 . . . . 0.0 109.999 178.261 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.967 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 6.5 m-85 -96.78 118.87 34.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.892 0.377 . . . . 0.0 111.017 -179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -54.71 174.49 0.66 Allowed Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.885 -0.598 . . . . 0.0 113.191 -179.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.428 ' HB3' ' N ' ' A' ' 88' ' ' GLY . 7.5 p -140.59 108.11 5.59 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.792 0.33 . . . . 0.0 110.626 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . -142.12 -172.39 13.56 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.626 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -59.63 -27.43 66.34 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.804 0.335 . . . . 0.0 110.987 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . -172.74 48.19 0.17 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.56 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.707 HG12 ' CZ ' ' A' ' 9' ' ' PHE . 30.0 m -61.24 93.27 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.883 0.373 . . . . 0.0 111.025 179.866 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.486 HG21 ' HG2' ' A' ' 10' ' ' GLN . 4.0 m -114.41 166.9 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.312 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.505 ' HD2' HD11 ' A' ' 5' ' ' LEU . 32.5 m-85 -102.53 162.93 12.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.632 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.411 ' HA3' HD12 ' A' ' 8' ' ' LEU . . . 179.29 145.47 6.27 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.829 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.513 HG12 ' N ' ' A' ' 79' ' ' SER . 5.4 p -86.85 126.95 40.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.667 0.27 . . . . 0.0 110.349 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.552 ' O ' HG13 ' A' ' 143' ' ' VAL . 13.3 p -98.31 115.36 38.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.909 0.385 . . . . 0.0 111.425 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.829 ' HD2' HG22 ' A' ' 76' ' ' THR . 1.4 ttm180 -94.49 110.65 22.43 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.007 179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 11.0 mmt180 -73.81 163.15 28.33 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.259 -179.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.428 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.4 OUTLIER . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.256 -0.878 . . . . 0.0 110.924 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.6 m80 . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.785 0.326 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -159.79 179.45 8.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.882 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.435 ' HA ' ' O ' ' A' ' 143' ' ' VAL . 0.9 OUTLIER -138.24 153.93 49.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.887 -179.949 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.642 ' O ' HG12 ' A' ' 143' ' ' VAL . . . -169.11 160.64 34.11 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.745 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 1.055 HD23 HG11 ' A' ' 125' ' ' VAL . 2.4 tm? -70.67 135.61 48.47 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.745 0.307 . . . . 0.0 110.981 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLU . . . . . 0.714 ' N ' HD13 ' A' ' 5' ' ' LEU . 1.0 OUTLIER -144.11 146.38 32.76 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.781 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.32 100.33 9.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.006 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.504 HD23 ' CD ' ' A' ' 68' ' ' PRO . 1.1 mt -97.04 172.37 7.89 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.796 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.528 ' CZ ' HG12 ' A' ' 138' ' ' VAL . 9.6 m-85 -134.27 155.3 50.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.598 ' NE2' HG11 ' A' ' 139' ' ' VAL . 1.0 OUTLIER -101.45 171.53 7.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.984 -179.734 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.2 -71.03 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.279 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.08 -167.77 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.601 2.201 . . . . 0.0 112.192 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.39 97.84 0.22 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.543 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 28.2 p -64.92 145.28 56.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.899 0.38 . . . . 0.0 110.921 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 61' ' ' ARG . 96.7 m -103.16 98.59 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.13 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 60.3 t -84.76 110.3 18.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.135 0.493 . . . . 0.0 109.78 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -104.21 -22.11 4.98 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.061 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.839 ' HB3' ' HB ' ' A' ' 59' ' ' VAL . . . -138.19 141.4 40.04 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.567 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.82 HG23 ' HG3' ' A' ' 58' ' ' LYS . 56.2 m -139.21 107.69 5.85 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.002 0.429 . . . . 0.0 110.979 179.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 56' ' ' TYR . . . -97.19 117.68 31.93 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.378 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.466 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 0.6 OUTLIER -129.98 138.16 50.69 Favored 'General case' 0 C--N 1.332 -0.187 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.042 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -164.11 127.77 1.71 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.939 -0.648 . . . . 0.0 112.385 179.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.511 ' HA ' ' HA ' ' A' ' 54' ' ' GLU . 1.4 mm -76.07 123.81 32.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.517 ' CZ ' ' HB2' ' A' ' 31' ' ' LEU . 5.4 m-85 -121.01 141.18 50.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.549 0.69 . . . . 0.0 111.84 -178.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -117.45 167.75 11.0 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 114.849 -1.068 . . . . 0.0 110.387 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 48' ' ' PRO . 20.0 t -41.93 -27.4 0.12 Allowed 'General case' 0 N--CA 1.464 0.253 0 N-CA-C 111.823 0.305 . . . . 0.0 111.823 -178.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -53.93 -44.08 70.32 Favored 'General case' 0 N--CA 1.462 0.145 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 98.04 -176.93 31.03 Favored Glycine 0 N--CA 1.449 -0.463 0 CA-C-N 115.443 -0.799 . . . . 0.0 113.771 178.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 151.65 -169.97 31.14 Favored Glycine 0 N--CA 1.45 -0.401 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.408 ' CG1' HG13 ' A' ' 41' ' ' ILE . 0.7 OUTLIER -133.32 147.21 31.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 117.273 0.536 . . . . 0.0 111.215 179.51 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . 0.517 ' HB2' ' CZ ' ' A' ' 24' ' ' PHE . 17.4 tp -113.07 106.53 14.78 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.626 -0.715 . . . . 0.0 109.899 179.373 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' SER . . . . . . . . . . . . . 6.3 p -94.65 144.83 25.29 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 33.7 t -126.34 92.57 3.6 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 109.996 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.668 HD13 ' O ' ' A' ' 34' ' ' ILE . 0.0 OUTLIER -64.64 -29.53 47.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.399 -179.478 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -53.15 -24.57 10.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.417 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 1.103 HG21 HG11 ' A' ' 59' ' ' VAL . 75.1 p -134.26 -39.99 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.373 -179.731 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.28 20.73 5.44 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.242 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.552 HG22 ' HD2' ' A' ' 100' ' ' PRO . 70.4 t -101.35 127.4 54.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.902 0.382 . . . . 0.0 111.124 -179.22 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -127.63 132.01 49.81 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.973 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.53 HD12 ' CD1' ' A' ' 57' ' ' PHE . 20.2 mt -111.4 112.33 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.033 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 41' ' ' ILE . 3.2 mp -95.52 119.63 43.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.588 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.756 HG23 HG12 ' A' ' 95' ' ' VAL . 3.2 mt -105.58 117.15 58.74 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.5 -179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.4 139.98 61.72 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.35 2.033 . . . . 0.0 111.929 179.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 1.6 tm0? -58.82 93.38 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.066 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 152.39 -22.4 0.85 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.867 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -56.95 -29.91 63.57 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.312 . . . . 0.0 111.296 -179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.516 HG23 ' HD2' ' A' ' 48' ' ' PRO . 8.5 mt -112.48 137.21 21.55 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.424 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.79 ' HG2' HG11 ' A' ' 51' ' ' VAL . 47.8 Cg_endo -69.87 160.42 49.75 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.457 2.105 . . . . 0.0 111.89 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -77.54 143.72 38.17 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.408 -179.399 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.46 35.68 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.797 179.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.79 HG11 ' HG2' ' A' ' 48' ' ' PRO . 5.0 p -147.06 156.94 10.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.031 0.443 . . . . 0.0 111.508 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.478 ' N ' HG22 ' A' ' 51' ' ' VAL . 0.3 OUTLIER -137.07 108.23 6.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.417 179.581 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -106.81 119.25 38.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.368 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.511 ' HA ' ' HA ' ' A' ' 23' ' ' ILE . 2.5 tt0 -75.17 101.74 4.71 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 179.179 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.488 ' HB ' ' CE2' ' A' ' 24' ' ' PHE . 53.3 mt -98.11 116.89 41.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.203 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.466 ' HB3' ' HA ' ' A' ' 21' ' ' ARG . 30.8 p90 -137.76 127.44 25.25 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.203 -179.304 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' HG13 ' A' ' 82' ' ' VAL . 22.0 p90 -111.9 123.45 50.27 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.172 179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.82 ' HG3' HG23 ' A' ' 19' ' ' THR . 6.3 mttt -97.43 126.43 42.67 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.837 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 1.103 HG11 HG21 ' A' ' 36' ' ' THR . 89.5 t -89.19 119.96 37.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.358 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.67 165.59 10.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.23 -179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ARG . . . . . 0.422 ' HB2' ' HB ' ' A' ' 15' ' ' THR . 3.0 mmm180 -75.1 167.04 22.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.797 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -97.37 28.47 3.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.422 -0.353 . . . . 0.0 111.061 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.36 -15.4 12.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.585 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.27 59.61 1.25 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.984 0.421 . . . . 0.0 110.681 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.9 HG21 ' HG ' ' A' ' 81' ' ' LEU . 7.2 pt -140.08 169.65 15.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.139 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.706 ' O ' HD23 ' A' ' 66' ' ' LEU . 3.1 tt -109.96 77.79 1.18 Allowed Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.933 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -79.11 111.69 2.95 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.657 2.238 . . . . 0.0 112.454 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.504 ' CD ' HD23 ' A' ' 8' ' ' LEU . 23.2 Cg_exo -64.54 -17.47 59.69 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.619 2.212 . . . . 0.0 112.461 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.512 HD13 ' N ' ' A' ' 76' ' ' THR . 0.8 OUTLIER -58.5 177.5 0.13 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.86 0.362 . . . . 0.0 110.987 -179.845 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -122.39 107.35 11.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.949 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -68.01 -28.64 67.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.924 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -56.11 -34.59 66.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.86 -179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 16.6 mttm -83.98 -24.52 30.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.842 179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 126.74 -0.52 7.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.866 -0.683 . . . . 0.0 112.612 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 76' ' ' THR . 9.7 mt-10 -66.16 161.89 20.98 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.706 0.288 . . . . 0.0 110.823 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.585 HG22 ' CD ' ' A' ' 144' ' ' ARG . 14.8 t -177.4 -174.54 0.49 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.969 0.414 . . . . 0.0 111.569 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.657 HD13 ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.46 109.88 20.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.777 179.951 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.674 HD21 ' HD2' ' A' ' 144' ' ' ARG . 9.6 mt -97.47 13.87 28.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.752 -179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.446 ' HB2' HG12 ' A' ' 142' ' ' VAL . 68.9 m -136.49 155.79 76.79 Favored Pre-proline 0 C--N 1.331 -0.238 0 CA-C-O 120.639 0.257 . . . . 0.0 110.853 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . 0.44 ' HB2' HG13 ' A' ' 59' ' ' VAL . 71.7 Cg_endo -77.47 126.62 8.44 Favored 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.461 2.107 . . . . 0.0 112.523 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.9 ' HG ' HG21 ' A' ' 65' ' ' ILE . 3.3 mm? -59.52 169.87 1.18 Allowed 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.545 179.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.583 ' O ' HG12 ' A' ' 139' ' ' VAL . 84.2 t -148.98 148.7 15.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.812 0.339 . . . . 0.0 111.507 -179.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' MET . . . . . 0.513 ' HG2' HG12 ' A' ' 139' ' ' VAL . 0.0 OUTLIER -127.28 111.52 14.02 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.532 179.587 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 24.0 p -53.47 130.09 34.49 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.121 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.425 ' HA2' ' CE2' ' A' ' 56' ' ' TYR . . . -61.89 -83.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.386 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -68.47 131.83 24.05 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.221 1.947 . . . . 0.0 112.165 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.455 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 0.5 OUTLIER -91.77 128.55 37.64 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.942 -179.859 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 77.43 51.17 6.19 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.541 -0.837 . . . . 0.0 111.809 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.639 HD21 ' CE1' ' A' ' 91' ' ' PHE . 43.3 tp -106.08 139.88 39.91 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . 0.615 ' CG ' ' HB2' ' A' ' 131' ' ' HIS . 0.2 OUTLIER -136.56 108.79 7.27 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.996 0.427 . . . . 0.0 111.393 -179.593 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CE1' HD21 ' A' ' 89' ' ' LEU . 26.3 m-85 -82.15 163.1 22.19 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.943 179.702 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 11.4 mt -80.91 -18.68 46.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.789 178.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 10.6 mtpp -144.47 150.42 47.61 Favored Pre-proline 0 N--CA 1.456 -0.164 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.08 179.493 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.423 ' HB2' ' HB3' ' A' ' 128' ' ' LEU . 38.9 Cg_endo -66.91 134.63 35.19 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.513 2.142 . . . . 0.0 112.58 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.756 HG12 HG23 ' A' ' 42' ' ' ILE . 32.8 m -97.7 137.66 24.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.722 179.744 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.418 ' HB3' ' HB ' ' A' ' 41' ' ' ILE . 53.5 tt0 -77.66 133.91 38.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.088 0.47 . . . . 0.0 111.385 -179.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 98' ' ' ARG . 4.1 tt -120.37 130.02 54.21 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.179 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.76 ' N ' HD23 ' A' ' 97' ' ' LEU . 0.4 OUTLIER -123.11 119.59 30.74 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.842 0.353 . . . . 0.0 111.294 -179.722 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.569 ' CD1' HD22 ' A' ' 97' ' ' LEU . 1.6 mp -113.92 146.88 36.54 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.552 ' HD2' HG22 ' A' ' 38' ' ' VAL . 73.4 Cg_endo -75.19 96.68 1.04 Allowed 'Trans proline' 0 N--CA 1.464 -0.244 0 C-N-CA 122.874 2.382 . . . . 0.0 112.513 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' HIS . . . . . 0.747 ' CD2' HG21 ' A' ' 142' ' ' VAL . 47.1 t-80 -117.33 111.67 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.649 179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 87.8 m -94.73 171.87 8.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.953 -179.872 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -66.34 163.49 39.25 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.986 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.427 ' O ' ' CD1' ' A' ' 107' ' ' TRP . 38.7 Cg_endo -66.64 -11.65 32.68 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.551 2.167 . . . . 0.0 112.637 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' LYS . . . . . . . . . . . . . 6.8 mmpt? -67.42 -37.13 82.56 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 110.922 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 1.8 t -94.05 8.25 42.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.355 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' TRP . . . . . 0.427 ' CD1' ' O ' ' A' ' 104' ' ' PRO . 0.6 OUTLIER -46.21 -29.15 1.47 Allowed 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 120.723 0.296 . . . . 0.0 111.447 -179.884 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLN . . . . . 0.422 ' HG3' ' CD2' ' A' ' 107' ' ' TRP . 26.9 mt-30 -122.81 -29.72 3.94 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.332 -0.395 . . . . 0.0 111.219 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -50.15 138.43 16.11 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.997 0.427 . . . . 0.0 111.366 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.45 ' O ' ' CB ' ' A' ' 111' ' ' CYS . 2.2 mttp -69.61 -21.63 63.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.064 179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.463 ' C ' HD13 ' A' ' 112' ' ' LEU . 14.0 m 87.39 111.9 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.167 -0.47 . . . . 0.0 109.904 -179.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.687 ' N ' HD13 ' A' ' 112' ' ' LEU . 0.0 OUTLIER -92.61 154.12 42.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.27 -179.181 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.32 -15.05 34.93 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.67 2.246 . . . . 0.0 112.44 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -64.84 -29.17 74.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.407 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ASP . . . . . 0.464 ' O ' ' CD2' ' A' ' 118' ' ' TYR . 21.5 t0 -165.61 63.46 0.9 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 120.756 0.312 . . . . 0.0 111.039 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.524 ' O ' HG21 ' A' ' 120' ' ' VAL . 95.8 Cg_endo -86.24 12.84 2.9 Favored 'Trans proline' 0 N--CA 1.461 -0.425 0 C-N-CA 122.655 2.237 . . . . 0.0 112.831 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -131.55 13.31 4.97 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.867 0.365 . . . . 0.0 110.784 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' TYR . . . . . 0.664 ' CD1' HD13 ' A' ' 119' ' ' LEU . 0.0 OUTLIER -49.84 -26.55 4.12 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.505 -179.866 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.664 HD13 ' CD1' ' A' ' 118' ' ' TYR . 0.0 OUTLIER -160.12 16.54 0.14 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.523 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . 0.524 HG21 ' O ' ' A' ' 116' ' ' PRO . 5.5 t -62.95 -26.78 41.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.976 0.417 . . . . 0.0 110.318 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLY . . . . . . . . . . . . . . . -111.1 -18.82 7.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.01 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -65.96 -73.59 0.13 Allowed 'General case' 0 C--N 1.333 -0.148 0 CA-C-O 120.919 0.39 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -73.07 63.44 0.68 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.895 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' CYS . . . . . . . . . . . . . 2.6 m -86.21 133.69 33.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 1.055 HG11 HD23 ' A' ' 5' ' ' LEU . 19.1 t -84.18 111.34 19.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.695 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . 0.407 ' HA ' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -96.94 129.25 44.43 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.611 -179.496 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' VAL . . . . . 0.88 HG11 ' CE1' ' A' ' 140' ' ' TYR . 1.5 t -132.57 154.23 39.53 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.456 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' LEU . . . . . 0.423 ' HB3' ' HB2' ' A' ' 94' ' ' PRO . 52.1 mt -126.58 118.01 23.97 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.187 178.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.95 HD13 ' CZ ' ' A' ' 132' ' ' PHE . 2.3 mt -116.05 111.94 37.52 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 CA-C-O 121.303 0.573 . . . . 0.0 112.118 -179.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 91' ' ' PHE . 9.5 p-10 -87.5 -38.21 16.25 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 177.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' HIS . . . . . 0.615 ' HB2' ' CG ' ' A' ' 90' ' ' LYS . 0.0 OUTLIER -138.82 132.16 30.13 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.265 178.568 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.95 ' CZ ' HD13 ' A' ' 129' ' ' ILE . 5.4 m-85 -96.65 130.61 43.84 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.89 0.376 . . . . 0.0 110.697 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -53.34 -174.27 0.05 OUTLIER Glycine 0 C--N 1.331 0.262 0 C-N-CA 121.007 -0.616 . . . . 0.0 113.097 -179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.1 m -100.38 49.97 0.9 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.368 -179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.79 ' HA2' HG22 ' A' ' 138' ' ' VAL . . . 47.43 -132.44 15.12 Favored Glycine 0 CA--C 1.518 0.222 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.819 179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 67.26 9.86 7.28 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 138.08 -23.79 3.01 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.56 -0.829 . . . . 0.0 112.846 179.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' VAL . . . . . 0.79 HG22 ' HA2' ' A' ' 135' ' ' GLY . 14.9 m -49.29 118.21 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.745 0.307 . . . . 0.0 111.079 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.598 HG11 ' NE2' ' A' ' 10' ' ' GLN . 21.2 m -148.35 146.88 17.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.026 0.441 . . . . 0.0 111.77 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.88 ' CE1' HG11 ' A' ' 127' ' ' VAL . 23.5 m-85 -95.64 137.29 34.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.964 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -163.67 139.72 6.04 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.091 -1.052 . . . . 0.0 113.198 -179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.747 HG21 ' CD2' ' A' ' 101' ' ' HIS . 4.4 p -67.41 152.2 9.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.667 -0.267 . . . . 0.0 110.481 179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 4' ' ' GLY . 14.9 p -125.16 115.52 44.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 120.826 0.346 . . . . 0.0 110.975 179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' ARG . . . . . 0.674 ' HD2' HD21 ' A' ' 78' ' ' LEU . 26.4 ttt-85 -94.39 108.77 20.67 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.369 179.737 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ARG . . . . . . . . . . . . . 6.7 mmm180 -74.36 163.06 28.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.179 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' SER . . . . . 0.406 ' N ' ' HG2' ' A' ' 75' ' ' GLU . 0.5 OUTLIER . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.255 -0.879 . . . . 0.0 110.84 -179.958 . . . . . . . . 2 2 . 1 stop_ save_